,id,target,enzyme,pathway,smile,name,category
0,DB01296,P14780|Q00653|P01375|P01579|P33673,P33261|P05181,hsa:4318|hsa:4791|hsa:7124|hsa:3458,9|10|14|18|19|20|178|181|283|284|285|286|299|308|332|338|339|340|341|344|345|346|347|351|352|365|366|367|380|393|405|406|528|563|566|567|571|582|592|614|615|617|637|638|639|643|661|662|663|679|680|681|682|683|689|690|691|701|703,Glucosamine,"Amino Sugars| Antiinflammatory and Antirheumatic Products| Antiinflammatory and Antirheumatic Products, Non-Steroids| Carbohydrates| Hexosamines| Musculo-Skeletal System"
1,DB09230,Q02641,P08684,hsa:782,9|10|11|12|13|14|15|16|18|19|20|129|131|132|178|182|183|184|185|189|192|196|199|283|284|285|286|299|301|332|333|335|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|375|376|377|380|384|390|391|392|393|395|401|405|416|420|423|430|434|437|440|441|443|446|449|452|454|455|464|470|490|502|514|516|520|524|535|540|545|546|549|552|553|556|558|560|564|566|570|573|578|579|582|584|592|594|595|599|600|603|607|608|613|614|615|618|619|628|633|634|637|640|643|654|656|659|660|664|665|666|668|671|673|677|678|679|680|683|684|688|689|690|692|693|694|696|697|698|700|704|708|709|710|712|737|800,Azelnidipine,"Acids, Acyclic| Agents causing hyperkalemia| Amino Acids| Amino Acids, Cyclic| Amino Acids, Peptides, and Proteins| Antiarrhythmic agents| Azetidines| Azetines| Bradycardia-Causing Agents| Calcium Channel Blockers| Carboxylic Acids| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Imines| Imino Acids| Pyridines| Vasodilating Agents"
2,DB05812,P05093,P08684|Q06520|P10635|P10632|P05177|P33261|P11712,hsa:1586,9|10|11|12|14|18|143|147|178|179|182|183|184|185|186|192|199|283|284|285|286|308|332|333|334|335|339|341|344|345|346|351|352|355|356|358|365|366|370|371|372|373|374|376|384|387|390|396|403|406|416|418|430|434|435|441|442|445|446|447|449|453|464|470|472|482|490|491|495|502|506|516|520|521|523|524|530|538|539|540|545|546|549|552|555|556|564|570|571|576|577|578|582|584|585|592|595|599|600|603|607|608|613|617|618|628|633|634|637|640|641|656|657|660|664|665|668|677|678|679|680|683|688|689|696|697|698|699|708|709|710|711|712|776|777|797|818|839|860,Abiraterone,"Androstanes| Androstenes| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP1A2 Inhibitors (strong)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (moderate)| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (moderate)| Cytochrome P-450 CYP2C8 Inhibitors (weak)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (moderate)| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (moderate)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (moderate)| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Cytochrome P450 17A1 Inhibitors| Endocrine Therapy| Enzyme Inhibitors| Fused-Ring Compounds| Hormone Antagonists| Hormone Antagonists and Related Agents| Hormones, Hormone Substitutes, and Hormone Antagonists| Metabolic Side Effects of Drugs and Substances| OATP1B1/SLCO1B1 Inhibitors| P-glycoprotein inhibitors| Polycyclic Compounds| Steroid Synthesis Inhibitors| Steroids"
3,DB01195,Q14524|P35499|Q12809,P10635|P11712,hsa:6331|hsa:6329|hsa:3757,9|10|11|12|14|15|18|19|23|24|25|178|180|181|182|185|283|284|285|286|287|299|332|333|338|340|341|344|345|346|351|352|355|356|363|365|366|370|371|381|382|384|390|392|393|405|416|420|430|434|439|441|443|446|451|464|470|476|490|493|498|516|520|524|528|535|540|541|542|548|549|552|553|556|564|565|569|570|573|574|578|579|581|582|584|589|592|594|595|597|599|603|604|606|607|608|611|613|614|618|619|620|623|625|626|628|632|633|634|637|638|640|641|642|643|645|646|651|655|656|660|664|666|668|671|672|677|678|679|680|681|682|683|684|686|688|689|692|698|699|704|708|709|710|719|735|756|782|798|819,Flecainide,"Antiarrhythmic agents| Antiarrhythmics, Class I| Antiarrhythmics, Class Ic| Cardiac Therapy| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| MATE 1 Inhibitors| MATE 1 Substrates| MATE 1 Substrates with a Narrow Therapeutic Index| MATE inhibitors| MATE substrates| Membrane Transport Modulators| Moderate Risk QTc-Prolonging Agents| Narrow Therapeutic Index Drugs| Negative Inotrope| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Piperidines| QTc Prolonging Agents| Sodium Channel Blockers| Voltage-Gated Sodium Channel Blockers"
4,DB00201,P30542|P29274|Q07343|P21817|BE0004922|P78527|O00329|P42336|P42338|BE0004914|Q13315,P20815|P05177|P24462|P08684|P05181|P10632|P11712|P04798|Q16678|P10635,hsa:134|hsa:135|hsa:5142|hsa:6261|hsa:5591|hsa:5293|hsa:5290|hsa:5291|hsa:472,9|10|11|14|15|16|18|19|143|148|149|178|183|184|283|284|285|286|332|340|351|352|355|357|358|359|365|373|374|375|376|377|378|379|381|384|386|387|388|389|390|391|396|397|403|416|418|420|431|437|438|439|441|442|443|447|449|450|451|453|464|472|482|484|485|487|491|493|494|495|499|504|506|519|521|523|530|535|536|538|540|545|547|549|553|555|560|569|572|580|585|593|596|601|602|611|613|621|624|628|636|645|646|647|650|654|657|673|674,Caffeine,"Alkaloids| Anorexigenic Agents & Respiratory and CNS Stimulants| BCRP/ABCG2 Inhibitors| Caffeine and Caffeine Containing Products| Carboxylic Acids| Central Nervous System Agents| Central Nervous System Stimulants| Central Nervous System Stimulation| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (moderate)| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dermatologicals| Diagnostic Agents| Drugs for Obstructive Airway Diseases| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Nervous System| Neurotransmitter Agents| Phosphodiesterase Inhibitors| Psychoanaleptics| Psychostimulants, Agents Used for ADHD and Nootropics| Purinergic Agents| Purinergic Antagonists| Purines| Purinones| Respiratory and CNS Stimulants| Respiratory System| Tests for Gastric Secretion| Tricarboxylic Acids| Xanthine derivatives"
5,DB01020,P33402,P08684,hsa:2977,9|10|14|18|19|20|143|146|150|153|283|284|286|301|308|332|339|341|344|346|352|366|401|405|406|423|455|567|571|582|614|617|637|639|662|663|679|680|681|689|690|701,Isosorbidemononitrate,Alcohols| Antianginal Agents| Carbohydrates| Cardiac Therapy| Cardiovascular Agents| Cardiovascular System| Delayed-Action Preparations| Drugs that are Mainly Renally Excreted| Hypotensive Agents| Methemoglobinemia Associated Agents| Nitrate Vasodilator| Nitrates and Nitrites| Nitric Oxide Donors| Organic Nitrates| Sugar Alcohols| Vasodilating Agents| Vasodilation| Vasodilators Used in Cardiac Diseases
6,DB00278,P00734,P08684|P20815,hsa:2147,9|10|11|12|14|15|16|18|19|20|33|178|180|181|182|183|184|185|192|283|284|285|286|293|299|305|308|332|333|335|338|340|344|345|351|352|353|355|356|365|370|371|374|375|376|377|380|383|384|390|391|392|393|406|414|416|418|420|430|434|437|439|440|441|443|446|449|450|451|452|453|457|459|464|465|470|483|487|490|495|516|520|524|528|531|532|533|535|536|540|545|549|552|556|564|566|569|570|578|579|582|584|585|592|595|599|600|602|603|607|608|611|613|617|618|628|633|634|637|640|643|645|646|656|657|659|660|664|665|668|677|678|679|680|683|684|688|689|692|695|696|697|708|709|710|736|758|767|799|821|830,Argatroban,"Acids, Heterocyclic| Amides| Amino Acids| Amino Acids, Basic| Amino Acids, Diamino| Amino Acids, Essential| Amino Acids, Peptides, and Proteins| Anticoagulants| Antithrombins| Blood and Blood Forming Organs| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates (strength unknown)| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Substrates| Enzyme Inhibitors| Hematologic Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Narrow Therapeutic Index Drugs| Piperidines| Protease Inhibitors| Serine Protease Inhibitors| Sulfones| Sulfur Compounds| Thrombin Inhibitors"
7,DB01403,P14416|P21728|P21918|P35462|P21917|P28223|P28335|P35367|P11229|P08172|P20309|P08173|P08912|P35348|P35368|P25100|P08913|P18089|P18825,P10635|P05181|P05177,hsa:1813|hsa:1812|hsa:1816|hsa:1814|hsa:1815|hsa:3356|hsa:3358|hsa:3269|hsa:1128|hsa:1129|hsa:1131|hsa:1132|hsa:1133|hsa:148|hsa:147|hsa:146|hsa:150|hsa:151|hsa:152,9|10|11|12|14|15|18|33|178|182|183|184|185|189|192|283|284|285|286|293|332|333|335|340|341|344|345|351|352|353|355|365|366|370|371|374|376|377|381|382|383|384|390|391|405|412|416|434|437|441|446|449|464|470|476|490|495|498|500|502|507|516|520|524|531|532|533|540|541|542|545|546|548|549|552|556|564|565|570|573|574|577|578|582|584|585|586|589|592|593|594|595|599|600|603|604|606|607|608|613|618|619|626|628|633|634|637|638|640|641|651|652|655|656|657|658|660|664|665|666|668|677|678|679|680|683|689|691|702|703|720|742|767|783|805|830,Methotrimeprazine,"Adrenergic alpha-1 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Agents producing tachycardia| Agents that produce hypertension| Analgesics| Analgesics, Non-Narcotic| Anticholinergic Agents| Antidepressive Agents| Antipsychotic Agents| Antipsychotic Agents (First Generation [Typical])| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strong)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dopamine Agents| Dopamine Antagonists| Dopamine D2 Receptor Antagonists| Drugs causing inadvertant photosensitivity| Heterocyclic Compounds| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Histamine Antagonists| Histamine H1 Antagonists| Hyperglycemia-Associated Agents| Muscarinic Antagonists| Nervous System| Neurotoxic agents| Neurotransmitter Agents| Peripheral Nervous System Agents| Phenothiazines| Phenothiazines With Aliphatic Side-Chain| Photosensitizing Agents| Potential QTc-Prolonging Agents| Psycholeptics| Psychotropic Drugs| QTc Prolonging Agents| Sensory System Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin 5-HT2C Receptor Antagonists| Serotonin Agents| Serotonin Receptor Antagonists| Sulfur Compounds| Tranquilizing Agents"
8,DB00588,P04150|P06401|P47712|P08235,P08684|P20815|P24462,hsa:2908|hsa:5241|hsa:5321|hsa:4306,9|10|11|12|18|19|20|23|24|33|143|144|178|179|182|185|186|192|283|284|286|287|293|308|332|333|334|335|337|339|341|344|346|352|353|366|368|374|380|405|406|412|416|420|430|432|434|440|441|443|446|452|462|490|507|516|524|535|537|553|556|571|579|582|586|599|605|614|617|637|640|660|671|672|678|679|680|681|684|688|689|692|693|696|697|698|699|704|705|708|709|710|711|712|776|777|797|798|818|819|839|840|860|861,Fluticasonepropionate,"Adrenal Cortex Hormones| Adrenals| Agents to Treat Airway Disease| Androstadienes| Androstanes| Androstenes| Anti-Allergic Agents| Anti-Asthmatic Agents| Anti-Inflammatory Agents| Autonomic Agents| Bronchodilator Agents| Central Nervous System Depressants| Corticosteroids| Corticosteroids for inhalation use| Corticosteroids, Dermatological Preparations| Corticosteroids, Potent (Group III)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strong)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dermatologicals| Fused-Ring Compounds| Glucocorticoids| Immunosuppressive Agents| OATP1B1/SLCO1B1 Inhibitors| P-glycoprotein substrates| Peripheral Nervous System Agents| Polycyclic Compounds| Respiratory System Agents| Steroids| Thyroxine-binding globulin inhibitors"
9,DB00091,P49069|Q96LZ3|P62937|P30405,P24462|P20815|P08684|P33261|P10632|P11712|P10635,hsa:819|hsa:5535|hsa:5478|hsa:10105,9|10|11|12|13|14|15|16|17|18|19|20|21|283|284|285|286|299|308|332|333|335|338|339|340|341|344|345|346|351|352|365|366|374|390|391|392|393|406|416|420|434|439|441|443|446|451|490|516|524|528|535|536|540|556|566|569|571|579|581|582|592|599|602|611|613|617|637|638|640|642|643|645|646|656|659|660|678|679|683|684|692|708|709|710,Cyclosporine,"Agents causing hyperkalemia| Agents Causing Muscle Toxicity| Agents that produce hypertension| Agents that produce neuromuscular block (indirect)| Agents that reduce seizure threshold| Amino Acids, Peptides, and Proteins| Anti-Inflammatory Agents| Antirheumatic Agents| BCRP/ABCG2 Inhibitors| BSEP/ABCB11 Inhibitors| BSEP/ABCB11 Substrates| BSEP/ABCB11 Substrates with a Narrow Therapeutic Index| Calcineurin Inhibitor Immunosuppressant| Calcineurin Inhibitors| Cyclosporins| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (moderate)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (moderate)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dermatologicals| Enzyme Inhibitors| Immunologic Factors| Immunosuppressive Agents| Macrocyclic Compounds| Medications that reduce magnesium levels| Narrow Therapeutic Index Drugs| Nephrotoxic agents| Neurotoxic agents| NTCP Inhibitors| OAT1/SLC22A6 inhibitors| OAT1/SLC22A6 Substrates| OATP1B1/SLCO1B1 Inhibitors| OATP1B1/SLCO1B1 Substrates| OATP1B3 inhibitors| Ophthalmologicals| P-glycoprotein inhibitors| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Peptides| Peptides, Cyclic"
10,DB00915,P21430|Q8TCU5|P14416,P20711|P27338,hsa:116443|hsa:1813,9|10|11|14|178|179|185|186|192|193|283|284|285|299|332|333|335|336|340|344|351|393|582|592|643|679|683|688|696|697|708|709|710|797|800,Amantadine,"Adamantane Derivatives| Adamantanes| Analgesics| Analgesics, Non-Narcotic| Anti-Dyskinesia Agents| Anti-Infective Agents| Anti-Parkinson Drugs| Anticholinergic Agents| Antiviral Agents| Bridged Compounds| Bridged-Ring Compounds| Central Nervous System Agents| Dopamine Agents| Drugs that are Mainly Renally Excreted| Hydrocarbons| Hydrocarbons, Cyclic| Influenza A M2 Protein Inhibitor| M2 Protein Inhibitors| Nervous System| Neurotransmitter Agents| Nicotinic Antagonists| NMDA Receptor Antagonists| OCT1 inhibitors| OCT1 substrates| OCT2 Inhibitors| OCT2 Substrates| Peripheral Nervous System Agents| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Sensory System Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
11,DB00461,P35354|P23219,P05164|P05177,hsa:5743|hsa:5742,9|10|11|18|19|178|182|185|189|283|284|286|332|333|341|344|352|355|356|366|370|371|374|381|382|384|385|405|416|420|430|432|434|441|443|446|470|476|490|498|516|520|524|535|541|542|548|552|556|564|565|570|573|574|578|579|582|584|589|594|595|599|603|604|606|608|618|619|626|634|637|640|641|651|655|660|664|666|668|677|678|679|680|684|688|689|692|696|697|698|699|704|708|709|710|712|713|714|734|735|755|776|777|797|798|818,Nabumetone,"Agents causing hyperkalemia| Agents that produce hypertension| Analgesics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)| Antiinflammatory and Antirheumatic Products| Antiinflammatory and Antirheumatic Products, Non-Steroids| Antirheumatic Agents| Butanones| COX-2 Inhibitors| Cyclooxygenase Inhibitors| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Enzyme Inhibitors| Ketones| Musculo-Skeletal System| Nephrotoxic agents| Other Nonsteroidal Anti-inflammatory Agents| Photosensitizing Agents| Selective Cyclooxygenase 2 Inhibitors (NSAIDs)"
12,DB01223,Q14432|P30542|P0DMS8|Q92769,P05177|P05181|P08684,hsa:5139|hsa:134|hsa:140|hsa:3066,9|10|11|12|14|15|16|17|18|19|20|143|148|149|150|155|156|178|183|184|185|190|191|283|284|285|286|299|332|340|344|345|351|352|355|357|358|359|365|373|374|375|376|377|378|379|381|384|386|387|388|389|390|391|392|393|396|397|399|400|403|416|418|420|431|437|438|439|441|442|443|447|449|450|451|453|464|472|482|484|485|487|488|491|493|494|495|499|504|506|519|521|523|527|528|530|535|536|538|540|545|547|549|553|555|560|569|572|580|585|593|596|601|602|611|613|621|624|628|636|643|645|646|647|650|654|657|673|674,Aminophylline,"Agents that reduce seizure threshold| Amines| Anti-Asthmatic Agents| Autonomic Agents| Bronchodilator Agents| Cardiotonic Agents| Cardiovascular Agents| Compounds used in a research, industrial, or household setting| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Substrates| Diamines| Drug Combinations| Drugs for Obstructive Airway Diseases| Enzyme Inhibitors| Ethylenediamines| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Narrow Therapeutic Index Drugs| Neurotransmitter Agents| Peripheral Nervous System Agents| Pharmaceutical Preparations| Phosphodiesterase Inhibitors| Polyamines| Protective Agents| Purinergic Agents| Purinergic Antagonists| Purinergic P1 Receptor Antagonists| Purines| Purinones| Respiratory Smooth Muscle Relaxants| Respiratory System| Respiratory System Agents| Xanthine derivatives| Xanthines and Adrenergics"
13,DB00648,P15538|P10109|P03372|P06401|P10275,P08684,hsa:1584|hsa:2230|hsa:2099|hsa:5241|hsa:367,9|10|11|37|38|39|178|182|185|189|283|284|294|332|333|335|342|343|344|355|356|360|361|362|370|371|384|416|430|434|441|446|470|490|501|503|516|520|524|550|552|556|564|570|578|582|584|591|595|598|599|603|608|618|634|640|660|664|668|677|678|679|688|696|697|708|709|710|712|717|759|780|822,Mitotane,"Adrenal Cytotoxic Agents| Antineoplastic Agents| Antineoplastic Agents, Hormonal| Antineoplastic and Immunomodulating Agents| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inducers (strong)| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strong)| Cytochrome P-450 CYP3A5 Inducers| Cytochrome P-450 CYP3A5 Inducers (strong)| Cytochrome P-450 CYP3A7 Inducers| Cytochrome P-450 CYP3A7 Inducers (strong)| Cytochrome P-450 Enzyme Inducers| Hydrocarbons| Hydrocarbons, Chlorinated| Hydrocarbons, Halogenated| Narrow Therapeutic Index Drugs| P-glycoprotein inhibitors| Thyroxine-binding globulin inducers"
14,DB00783,P03372|Q92731|O75469|P43681|Q15596|Q99527|P00846|Q14457|P37059|P62508,P08684|P05177|P20815|P24462|P22309|P04798|Q16678|P33261|P10632|P11712,hsa:2099|hsa:2100|hsa:8856|hsa:1137|hsa:10499|hsa:2852|hsa:4508|hsa:8678|hsa:3294|hsa:2104,9|10|11|12|18|19|143|144|178|179|182|185|189|192|283|284|286|308|332|333|334|335|339|341|344|346|352|355|356|366|370|371|374|381|382|384|406|416|430|434|441|446|470|490|498|516|520|524|541|542|548|552|556|564|570|571|573|574|578|582|584|590|595|599|603|606|608|617|618|619|634|637|640|641|651|655|660|664|667|668|677|678|679|680|688|689|696|697|698|699|708|709|710|711|712|714|735|755|776|777|797|798|818|840|860|861,Estradiol,"Adrenal Cortex Hormones| Androgens and Estrogens| Anti-Gonadotropin-Releasing Hormones| Antiandrogens and Estrogens| BCRP/ABCG2 Inhibitors| COMT Substrates| Contraceptive Agents, Female| Contraceptives, Oral| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (weak)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Estradiol Congeners| Estradiol, agonists| Estranes| Estrenes| Estrogen Contraceptives| Estrogens| Estrogens, agonists| Fused-Ring Compounds| Genito Urinary System and Sex Hormones| Gonadal Hormones| Gonadal Steroid Hormones| Hormonal Contraceptives for Systemic Use| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Hyperglycemia-Associated Agents| Hypothalamic Hormones| Intravaginal Contraceptives| Medications that reduce magnesium levels| Natural and Semisynthetic Estrogens, Plain| OAT3/SLC22A8 Substrates| OATP1B1/SLCO1B1 Inhibitors| OCT2 Inhibitors| P-glycoprotein substrates| Pituitary and Hypothalamic Hormones and Analogues| Polycyclic Compounds| Progestogens and Estrogens, Sequential Preparations| Sex Hormones and Modulators of the Genital System| Steroids| Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins| Thyroxine-binding globulin inducers| UGT1A1 Substrates"
15,DB00631,P09884|P23921,P27707,hsa:5422|hsa:6240,9|10|11|14|15|16|18|19|23|37|143|146|148|149|150|178|183|184|283|284|285|286|287|294|299|308|332|339|340|341|344|345|346|351|352|355|357|358|359|365|366|373|375|376|377|378|379|384|386|387|388|389|390|391|393|396|397|403|405|406|416|418|431|437|438|441|442|447|449|450|453|464|472|482|484|485|487|491|495|499|504|506|519|521|523|530|538|540|545|547|549|555|560|567|569|571|572|582|585|592|593|596|601|611|612|613|614|617|621|628|636|637|638|639|654|656|657|662|663|674|680|682|683|690|691|702,Clofarabine,"Adenine Nucleotides| Antimetabolites| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Arabinonucleosides| BCRP/ABCG2 Substrates| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hypotensive Agents| Immunosuppressive Agents| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| Noxae| Nucleic Acid Synthesis Inhibitors| Nucleic Acids, Nucleotides, and Nucleosides| Nucleoside Metabolic Inhibitor| Nucleosides| Nucleotides| OAT3/SLC22A8 Substrates| OAT3/SLC22A8 Substrates with a Narrow Therapeutic Index| OCT2 Substrates with a Narrow Therapeutic Index| Purine Analogues| Purine Nucleotides| Purines| Ribonucleotides| Toxic Actions"
16,DB00933,P28223|P14416,P10635,hsa:3356|hsa:1813,9|10|11|12|14|15|18|33|34|178|180|181|182|183|184|185|189|192|199|283|284|285|293|332|338|340|344|345|351|353|355|365|368|370|371|374|376|377|383|384|390|391|412|414|416|434|437|441|446|449|457|464|465|470|490|495|500|502|507|516|520|524|531|532|533|540|545|546|549|552|556|564|570|577|578|582|584|585|586|592|593|595|599|600|603|607|608|613|618|628|629|633|634|640|656|657|658|660|664|665|668|677|678|679|683|688|724|746|767|787|809|830,Mesoridazine,"Antidepressive Agents| Antipsychotic Agents| Antipsychotic Agents (First Generation [Typical])| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Substrates| Dopamine Agents| Dopamine Antagonists| Dopamine D2 Receptor Antagonists| Heterocyclic Compounds| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Moderate Risk QTc-Prolonging Agents| Nervous System| Neurotoxic agents| Neurotransmitter Agents| Phenothiazines| Phenothiazines With Piperidine Structure| Psycholeptics| Psychotropic Drugs| QTc Prolonging Agents| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin Agents| Serotonin Receptor Antagonists| Sulfur Compounds| Tranquilizing Agents"
17,DB01219,P21817,P08684,hsa:6261,9|10|11|14|15|16|18|19|20|143|145|146|149|150|178|182|283|284|285|286|299|300|301|332|333|340|341|344|345|351|352|355|356|365|370|371|375|376|377|381|384|390|392|393|395|401|405|409|416|418|420|423|430|432|434|435|437|439|441|442|443|446|447|449|451|454|455|461|464|467|470|476|490|493|498|502|514|515|516|517|518|520|524|535|536|538|540|541|542|545|546|548|549|552|553|555|556|558|560|564|565|569|570|573|574|576|578|579|582|584|589|592|594|595|597|599|600|602|603|604|606|607|608|611|614|618|619|620|623|626|632|633|634|635|636|637|640|641|643|644|645|646|647|650|651|654|655|660|664|665|666|668|671|672|677|678|679|680|683|684|688|689|691|692|695|696|697|698|699|703|704|707|708|709|710|716|779,Dantrolene,"Agents causing hyperkalemia| Agents that produce neuromuscular block (indirect)| Azoles| Central Nervous System Agents| Central Nervous System Depressants| Dantrolene and Derivatives| Decreased Striated Muscle Contraction| Decreased Striated Muscle Tone| Direct-acting Skeletal Muscle Relaxants| Hepatotoxic Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hydantoins| Imidazoles| Imidazolidines| Muscle Relaxants| Muscle Relaxants, Centrally Acting Agents| Musculo-Skeletal System| Neuromuscular Agents| Peripheral Nervous System Agents| Thyroxine-binding globulin substrates"
18,DB00608,P09210|P01375|Q9NR96|Q8MU52,P08684|P10635|P04798|P10632|P20815,hsa:2939|hsa:7124|hsa:54106,9|10|11|12|14|15|37|178|182|183|184|185|283|284|285|294|299|332|333|338|340|342|344|345|351|355|356|357|358|362|365|370|371|372|373|374|376|377|384|385|386|387|390|391|392|393|396|403|416|418|430|431|434|435|437|441|442|445|446|447|449|453|464|470|472|482|490|491|495|501|502|503|506|516|520|521|523|524|528|530|538|539|540|545|546|549|550|552|555|556|564|570|576|577|578|582|584|585|591|592|593|595|598|599|600|601|603|607|608|613|618|621|628|633|634|640|643|656|657|660|664|665|668|677|678|679|683|688|696|708|709|710|717|750|758|780|813|821,Chloroquine,"Agents Causing Muscle Toxicity| Agents that produce neuromuscular block (indirect)| Agents that reduce seizure threshold| alpha-Galactosidase, antagonists & inhibitors| Amebicides| Aminoquinolines| Analgesics| Analgesics, Non-Narcotic| Anti-Infective Agents| Anti-Inflammatory Agents| Antimalarials| Antinematodal Agents| Antiparasitic Agents| Antiparasitic Products, Insecticides and Repellents| Antiprotozoals| Antirheumatic Agents| Biguanides| Central Nervous System Agents| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (moderate)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Drugs that are Mainly Renally Excreted| Experimental Unapproved Treatments for COVID-19| Filaricides| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Methemoglobinemia Associated Agents| Moderate Risk QTc-Prolonging Agents| P-glycoprotein inhibitors| P-glycoprotein substrates| Peripheral Nervous System Agents| Photosensitizing Agents| QTc Prolonging Agents| Quinolines| Sensory System Agents| Tumor Necrosis Factor Blockers"
19,DB01043,Q8TCU5|Q12879|Q13224|P46098|Q693P7|P14416|Q05586,P20813|P11509|P33261,hsa:116443|hsa:2903|hsa:2904|hsa:3359|hsa:1813|hsa:2902,9|10|11|14|178|179|185|186|192|193|283|284|285|299|332|333|334|335|336|340|344|351|374|393|582|592|643|679|683|688|696|697|708|709|710|711|797|800,Memantine,"Anti-Dementia Drugs| Anti-Dyskinesia Agents| Anti-Parkinson Drugs| Bridged Compounds| Bridged-Ring Compounds| Central Nervous System Agents| Cholinesterase Inhibitors| Cytochrome P-450 CYP2A6 Inhibitors| Cytochrome P-450 CYP2A6 Inhibitors (weak)| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strong)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (weak)| Cytochrome P-450 Enzyme Inhibitors| Dopamine Agents| Drugs that are Mainly Renally Excreted| Excitatory Amino Acid Antagonists| Hydrocarbons| Hydrocarbons, Cyclic| Macrocyclic Compounds| Miscellaneous Central Nervous System Agents| N-methyl-D-aspartate Receptor Antagonist| Nervous System| Neurotransmitter Agents| NMDA Receptor Antagonists| OCT2 Substrates| Psychoanaleptics"
20,DB01380,P04150,P08684,hsa:2908,9|10|11|12|18|19|20|143|144|178|179|182|185|186|192|283|284|286|308|332|333|334|335|337|341|344|346|352|366|374|380|405|406|416|420|430|432|434|440|441|443|446|452|462|490|524|535|537|553|556|579|582|599|605|614|617|637|639|640|660|671|678|679|680|684|686|688|689|692|694|696|697|698|699|704|706|708|709|710|711|712|776|797|818|839|840|860|861,Cortisoneacetate,"17-Hydroxycorticosteroids| Adrenal Cortex Hormones| Adrenals| Anti-Inflammatory Agents| Corticosteroids| Corticosteroids for Systemic Use| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inducers| Cytochrome P-450 CYP3A5 Inducers (strength unknown)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Fused-Ring Compounds| Glucocorticoids| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Hydroxycorticosteroids| Hyperglycemia-Associated Agents| Immunosuppressive Agents| OAT3/SLC22A8 Substrates| P-glycoprotein inducers| P-glycoprotein substrates| Polycyclic Compounds| Pregnanes| Pregnenes| Steroids"
21,DB11817,P23458|O60674|Q14289|P52333,P08684,hsa:3716|hsa:3717|hsa:2185|hsa:3718,9|10|11|12|14|15|16|18|19|33|129|131|132|143|148|149|150|155|156|178|183|184|283|284|285|293|299|300|305|332|333|336|340|344|345|349|351|353|355|356|357|358|359|365|368|370|371|372|373|374|375|376|378|379|384|385|387|388|389|390|392|393|396|399|400|403|414|416|418|419|422|429|430|431|434|435|437|438|441|442|445|446|447|449|450|453|457|459|464|465|467|470|472|477|482|484|487|488|490|491|495|496|502|504|506|515|516|519|520|521|523|524|527|528|530|538|539|540|545|546|549|552|555|556|560|564|568|569|570|572|576|577|578|582|584|585|592|593|595|596|599|600|601|603|607|608|611|613|616|618|621|628|633|634|636|640|643|644|654|656|657|660|664|665|668|674|676|677|678|679|683|708|709|710,Baricitinib,"Amides| Antineoplastic and Immunomodulating Agents| Antirheumatic Agents| Azetines| Azoles| BCRP/ABCG2 Inhibitors| BCRP/ABCG2 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Substrates| Disease-modifying Antirheumatic Agents| Drugs that are Mainly Renally Excreted| Experimental Unapproved Treatments for COVID-19| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Immunosuppressive Agents| Janus Kinase Inhibitor| Janus Kinase Inhibitors| MATE 2 Inhibitors| MATE 2 Substrates| MATE 2 Substrates with a Narrow Therapeutic Index| MATE inhibitors| MATE substrates| Narrow Therapeutic Index Drugs| OAT1/SLC22A6 inhibitors| OAT3/SLC22A8 Inhibitors| OAT3/SLC22A8 Substrates| OAT3/SLC22A8 Substrates with a Narrow Therapeutic Index| OATP1B3 inhibitors| OCT2 Inhibitors| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Selective Immunosuppressants| Sulfones| Sulfur Compounds"
22,DB01002,Q9Y5Y9,P08684|P05177,hsa:6336,9|10|11|12|14|15|18|178|180|181|182|185|283|284|285|286|299|332|333|338|340|344|345|351|352|355|356|365|370|371|374|376|377|384|390|391|392|393|416|420|430|434|437|439|441|443|446|449|451|464|470|490|495|516|520|524|535|536|540|545|549|552|556|564|569|570|578|579|582|584|585|592|595|599|600|602|603|607|608|611|613|618|628|633|634|640|643|645|656|657|660|664|665|668|677|678|679|683|684|688|692|697|708|709|710|734|758|797|821,Levobupivacaine,"Amides| Amines| Anesthetics| Anesthetics, Local| Anilides| Aniline Compounds| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Hypotensive Agents| Nervous System| Neuraxial Anesthetics| Peripheral Nervous System Agents| Sensory System Agents"
23,DB00928,P26358,P32320,hsa:1786,9|10|11|14|15|16|18|19|20|143|146|178|183|184|283|284|285|286|299|308|332|339|341|344|345|346|351|352|365|366|373|375|379|389|390|391|393|396|397|403|405|406|418|420|447|450|451|453|484|487|491|504|519|521|540|560|566|567|571|572|582|592|596|612|613|614|617|636|637|638|639|645|646|647|654|659|662|663|680|681|682|683|690|691|702,Azacitidine,"Antimetabolites| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Aza Compounds| Cytidine Deaminase Substrates| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Immunosuppressive Agents| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| Noxae| Nucleic Acid Synthesis Inhibitors| Nucleic Acids, Nucleotides, and Nucleosides| Nucleoside Metabolic Inhibitor| Nucleosides| Pyrimidine Analogues| Pyrimidine Nucleosides| Pyrimidines| Ribonucleosides| Toxic Actions"
24,DB00261,Q14432,P05177,hsa:5139,9|10|11|14|15|18|37|38|143|145|146|178|182|183|184|185|283|284|285|286|294|299|332|333|340|342|344|345|351|352|355|356|362|365|370|371|375|376|377|384|390|391|392|393|416|418|420|430|434|437|439|441|443|446|449|450|451|453|464|470|487|490|501|502|503|516|519|520|524|526|529|536|540|545|546|549|550|552|556|560|564|569|570|578|582|584|591|592|593|595|596|598|600|602|603|607|608|611|613|618|628|633|634|636|640|643|647|654|656|660|664|665|668|677|678|679|683|688|708|709|710|729|738|750|758|759|773|792|801|813|821|822|836,Anagrelide,"Agents producing tachycardia| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Antiplatelet agents| Cardiovascular Agents| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (weak)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Decreased Platelet Production| Hematologic Agents| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Highest Risk QTc-Prolonging Agents| Narrow Therapeutic Index Drugs| Phosphodiesterase 3 Inhibitors| Phosphodiesterase Inhibitors| Platelet-reducing Agents| QTc Prolonging Agents| Thrombocytosis"
25,DB08899,P10275,P10632|P08684|P11712|P33261|P20813|P10635|P20815,hsa:367,9|10|11|12|14|15|16|18|19|23|24|25|33|143|145|146|178|182|185|189|283|284|285|286|287|293|299|332|333|336|340|344|351|352|355|356|363|364|365|370|371|374|375|376|377|384|390|391|392|393|416|419|420|421|429|430|434|437|439|441|443|446|449|451|464|466|470|490|493|495|502|508|516|520|524|528|535|536|540|545|546|549|552|553|556|560|564|568|569|570|578|579|582|584|585|592|595|597|599|600|602|603|607|608|611|613|618|623|628|633|634|636|640|645|646|647|654|656|657|660|664|665|668|671|672|674|676|677|678|679|683|684|688|692|695|696|704|707|708|709|710|712|716|737|755|779|800|818,Enzalutamide,"Amides| Androgen Receptor Antagonists| Androgen Receptor Inhibitors| Antiandrogens| Antiandrogens, non-steroidal| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Azoles| Benzene Derivatives| Carboxylic Acids| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Inducers| Cytochrome P-450 CYP2C19 Inducers (moderate)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (moderate)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Inducers| Cytochrome P-450 CYP2C9 Inducers (moderate)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inducers (strong)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strong)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inducers| Cytochrome P-450 CYP3A5 Inducers (strong)| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Endocrine Therapy| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hormone Antagonists and Related Agents| Hydantoins| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Imidazoles| Imidazolidines| P-glycoprotein inhibitors| Thyroxine-binding globulin substrates"
26,DB00749,P35354|P23219|P19793,P11712|O60656|P35503|Q9HAW8|P16662,hsa:5743|hsa:5742|hsa:6256,9|10|11|12|14|18|19|143|148|149|178|182|184|185|283|284|285|286|299|308|332|333|337|340|341|344|346|351|352|355|356|357|358|366|370|371|374|376|377|380|384|385|386|387|390|392|393|396|399|400|403|405|406|416|418|420|430|431|434|437|440|441|442|443|446|449|452|453|461|464|470|472|482|490|495|506|516|520|523|524|527|530|535|538|545|548|549|552|555|556|564|566|570|573|574|576|577|578|579|581|582|584|585|592|594|595|599|600|603|604|607|608|613|614|615|617|618|619|628|633|634|637|639|640|641|642|655|656|657|659|660|664|665|666|668|677|678|679|680|682|683|684|685|688|689|691|692|696|697|698|699|702|703|704|708|709|710|712|734|758|797|821,Etodolac,"Acetic Acid Derivatives and Related Substances| Acids, Heterocyclic| Agents causing hyperkalemia| Agents that produce hypertension| Analgesics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)| Antiinflammatory and Antirheumatic Products| Antiinflammatory and Antirheumatic Products, Non-Steroids| Antirheumatic Agents| COX-2 Inhibitors| Cyclooxygenase Inhibitors| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Indoleacetic Acids| Indoles| Musculo-Skeletal System| Nephrotoxic agents| OAT1/SLC22A6 inhibitors| Other Nonsteroidal Anti-inflammatory Agents| Peripheral Nervous System Agents| Photosensitizing Agents| Selective Cyclooxygenase 2 Inhibitors (NSAIDs)| Sensory System Agents| UGT1A3 substrates| UGT1A9 Substrates| UGT2B7 substrates"
27,DB05381,P35367|P25021|Q9Y5N1|Q9H3N8|Q05940,P50135|P11712|P10635|P08684,hsa:3269|hsa:3274|hsa:11255|hsa:59340|hsa:6571,9|10|14|15|143|148|149|283|284|285|299|332|340|344|345|351|355|357|358|365|370|372|373|375|376|379|387|389|390|392|393|396|399|400|403|416|418|431|435|437|441|442|445|446|447|449|450|453|472|482|484|485|487|488|490|491|495|499|502|504|506|519|521|523|527|528|538|539|540|545|546|547|556|560|569|570|572|585|592|593|596|599|607|611|613|636|643|654|657|665|674,Histamine,"Adjuvants, Immunologic| Amines| Antineoplastic and Immunomodulating Agents| Autacoids| Azoles| Biogenic Amines| Biogenic Monoamines| Biological Factors| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 Enzyme Inhibitors| Diagnostic Agents| Ethylamines| Gastric Function| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Histamine Agents| Histamine Agonists| Imidazoles| Inflammation Mediators| Neurotransmitter Agents| OCT1 substrates| OCT2 Inhibitors| OCT2 Substrates| Other Diagnostics| Tests for Gastric Secretion"
28,DB01122,P22303,P06276,hsa:43,9|10|11|12|14|15|16|18|19|37|38|178|182|185|189|283|284|285|286|294|299|332|333|342|344|345|351|352|355|356|362|365|370|371|374|384|390|391|392|393|416|420|430|434|439|441|443|446|451|464|470|490|501|503|516|520|524|528|536|540|549|550|552|556|564|569|570|578|582|584|591|592|595|598|599|602|603|607|608|611|613|618|628|633|634|640|643|645|646|656|660|664|668|677|678|679|683|688|708|709|710|759|822,Ambenonium,Amines| Autonomic Agents| Benzylammonium Compounds| Cholinergic Agents| Cholinesterase Inhibitors| Enzyme Inhibitors| Nervous System| Neurotransmitter Agents| Onium Compounds| Parasympathomimetics| Peripheral Nervous System Agents| Quaternary Ammonium Compounds
29,DB00959,P04150,P08684,hsa:2908,9|10|11|12|18|19|20|143|144|178|179|182|185|186|192|283|284|286|308|332|333|334|335|337|339|341|344|346|352|366|374|406|416|420|430|432|434|441|443|446|462|490|516|524|535|537|553|556|571|579|582|599|617|637|639|640|660|671|672|678|679|680|681|684|688|689|692|693|696|697|698|699|704|705|708|709|710|711|712|776|777|797|798|818|819|839|840|860|861,Methylprednisolone,"Adrenal Cortex Hormones| Adrenals| Anti-Acne Preparations| Anti-Acne Preparations for Topical Use| Anti-Inflammatory Agents| Antiemetics| Antineoplastic Agents| Autonomic Agents| Central Nervous System Agents| Compounds used in a research, industrial, or household setting| Corticosteroid Hormone Receptor Agonists| Corticosteroids| Corticosteroids for Systemic Use| Corticosteroids for Systemic Use, Plain| Corticosteroids, Dermatological Preparations| Corticosteroids, Weak (Group I)| Cytochrome P-450 CYP2A6 Inducers| Cytochrome P-450 CYP2A6 Inducers (strength unknown)| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (strength unknown)| Cytochrome P-450 CYP2C19 Inducers| Cytochrome P-450 CYP2C19 Inducers (strength unknown)| Cytochrome P-450 CYP2C8 Inducers| Cytochrome P-450 CYP2C8 Inducers (strength unknown)| Cytochrome P-450 CYP2C9 Inducers| Cytochrome P-450 CYP2C9 Inducers (strength unknown)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Dermatologicals| Experimental Unapproved Treatments for COVID-19| Fused-Ring Compounds| Gastrointestinal Agents| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Hyperglycemia-Associated Agents| Immunosuppressive Agents| Neuroprotective Agents| Ophthalmological and Otological Preparations| Ophthalmologicals| P-glycoprotein inducers| P-glycoprotein substrates| Peripheral Nervous System Agents| Polycyclic Compounds| Pregnadienes| Pregnadienetriols| Pregnanes| Protective Agents| Sensory Organs| Steroids| Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"
30,DB01110,P10613|P29474|P35228|Q12791|Q16558|Q9Y691|Q9NPA1|Q86W47|O15554|Q92952|Q9H2S1|Q9UGI6|Q12809|Q9H252|Q9NS40|O75469,P08684|P10635|P11712|P15538|P11511|P05177|P11509|P20813|P33261|P05181,hsa:4846|hsa:4843|hsa:3778|hsa:3779|hsa:10242|hsa:27094|hsa:27345|hsa:3783|hsa:3780|hsa:3781|hsa:3782|hsa:3757|hsa:81033|hsa:90134|hsa:8856,9|10|11|12|14|15|18|37|38|39|143|148|149|178|182|185|189|283|284|285|286|294|332|333|339|341|342|344|345|346|351|352|355|356|358|362|365|366|370|371|372|373|375|376|379|384|387|389|390|391|396|397|403|405|416|418|430|434|435|441|442|445|446|447|449|450|453|470|472|482|484|485|487|490|491|495|499|501|502|503|504|506|516|519|520|521|524|539|540|546|547|548|550|552|556|560|564|566|569|570|572|573|574|578|582|584|591|592|594|595|596|598|599|603|604|607|608|611|613|614|615|618|619|634|636|637|640|641|654|655|656|659|660|664|666|668|674|677|678|679|680|683|688|689|696|698|708|709|710|717|752|759|780|815|822,Miconazole,"14-alpha Demethylase Inhibitors| Anti-Infective Agents| Antifungal Agents| Antifungal Agents (Vaginal)| Antifungals for Dermatological Use| Antifungals for Topical Use| Antiinfectives and Antiseptics for Local Oral Treatment| Azole Antifungals| Azoles| Chemically-Induced Disorders| Cytochrome P-450 CYP2A6 Inhibitors| Cytochrome P-450 CYP2A6 Inhibitors (strong)| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Inhibitors (strong)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (moderate)| Cytochrome P-450 CYP2C9 Inhibitors (strong)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strong)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (moderate)| Cytochrome P-450 Enzyme Inhibitors| Dermatologicals| Enzyme Inhibitors| Genito Urinary System and Sex Hormones| Gynecological Antiinfectives and Antiseptics| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hormone Antagonists| Hormones, Hormone Substitutes, and Hormone Antagonists| Imidazole and Triazole Derivatives| Imidazole Derivatives| Imidazoles| Intestinal Antiinfectives| Metabolic Side Effects of Drugs and Substances| Otologicals| P-glycoprotein inhibitors| Sensory Organs| Steroid Synthesis Inhibitors| Stomatological Preparations| Vaginal Creams, Foams, and Jellies"
31,DB01197,P12821|P08253|P14780|P09960|P46663,P10635,hsa:1636|hsa:4313|hsa:4318|hsa:4048|hsa:623,9|10|11|14|18|19|33|143|145|146|283|284|285|286|293|308|332|333|335|338|340|344|345|349|351|352|353|365|368|374|380|390|391|406|413|420|439|440|443|451|452|535|536|540|566|579|582|592|602|613|617|637|645|646|656|659|680|683|684|691|695|702,Captopril,"ACE Inhibitors and Diuretics| Agents Acting on the Renin-Angiotensin System| Agents causing angioedema| Agents causing hyperkalemia| Agents Causing Muscle Toxicity| Amino Acids| Amino Acids, Cyclic| Amino Acids, Peptides, and Proteins| Angiotensin-Converting Enzyme Inhibitors| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Cardiovascular Agents| Cardiovascular System| Drugs causing inadvertant photosensitivity| Enzyme Inhibitors| Hypotensive Agents| Imino Acids| OAT1/SLC22A6 inhibitors| OAT1/SLC22A6 Substrates| OAT3/SLC22A8 Substrates| P-glycoprotein inhibitors| Photosensitizing Agents| Protease Inhibitors"
32,DB00808,P51787|P15382,P08684,hsa:3784|hsa:3753,9|10|11|12|14|15|18|19|33|37|143|145|146|178|182|185|189|283|284|285|286|293|294|299|300|305|332|333|338|340|342|344|345|351|352|353|355|356|362|365|370|371|374|376|377|383|384|390|393|394|398|414|416|420|430|434|437|439|441|443|446|449|451|457|459|464|465|470|477|483|490|493|495|501|502|503|515|516|518|520|522|524|531|532|535|540|545|546|549|550|552|553|556|564|570|578|579|582|584|585|591|592|595|597|598|599|600|603|607|608|613|618|623|628|633|634|640|656|657|660|664|665|668|671|672|677|678|679|683|684|688|692|696|704|708|709|710|717|736|758|768|780|799|821|831,Indapamide,"Amides| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Diuretics| Drugs causing inadvertant photosensitivity| Drugs that are Mainly Renally Excreted| Genito Urinary System and Sex Hormones| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hyperglycemia-Associated Agents| Hypotensive Agents| Increased Diuresis| Indoles| Lipid Modifying Agents| Low-Ceiling Diuretics, Excl. Thiazides| Medications that reduce magnesium levels| Membrane Transport Modulators| Natriuretic Agents| Non Potassium Sparing Diuretics| Photosensitizing Agents| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Sodium Chloride Symporter Inhibitors| Sulfonamides| Sulfones| Sulfur Compounds| Thiazide-like Diuretic"
33,DB00918,P28222|P28221,P21397|P08684|P10635|P31513|P05177|P33261|P05181|P10632,hsa:3351|hsa:3352,9|10|11|12|14|15|18|19|33|143|145|146|148|149|150|178|182|283|284|285|293|299|305|332|333|340|344|345|349|351|353|355|356|357|358|365|368|370|371|372|373|374|376|377|384|385|386|387|390|391|392|393|396|399|400|403|414|416|418|430|431|434|435|437|441|442|445|446|447|449|453|457|459|464|465|470|472|482|490|491|495|502|506|516|520|521|523|524|527|528|530|538|539|540|545|546|549|552|555|556|564|570|576|577|578|582|584|585|592|595|599|600|603|607|608|613|618|628|633|634|640|643|656|657|660|664|665|668|677|678|679|683|688|696|697|708|709|710|712|716|734|758|779|797|821,Almotriptan,"Agents that produce hypertension| Amines| Analgesics| Antidepressive Agents| Antimigraine Preparations| Biogenic Amines| Biogenic Monoamines| Central Nervous System Depressants| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Indoles| Migraine Disorders| Monoamine Oxidase A Substrates| Nervous System| Neurotransmitter Agents| Selective Serotonin 5-HT1 Receptor Agonists| Selective Serotonin Agonists| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 1b Receptor Agonists| Serotonin 1d Receptor Agonists| Serotonin 5-HT1 Receptor Agonists| Serotonin Agents| Serotonin Modulators| Serotonin Receptor Agonists| Serotonin-1b and Serotonin-1d Receptor Agonist| Triptans"
34,DB01126,P31213|P18405,P08684|P20815,hsa:6716|hsa:6715,0|9|10|11|12|14|15|18|19|23|24|25|143|144|178|179|182|183|184|185|186|192|199|283|284|285|286|287|299|332|333|334|335|338|340|344|345|351|352|355|356|363|365|370|371|374|376|377|384|390|392|393|416|420|430|434|437|439|441|443|446|449|451|464|470|490|495|502|516|520|524|528|535|540|545|546|549|552|553|556|564|570|578|579|582|584|585|592|595|599|600|603|607|608|613|618|628|633|634|640|643|645|646|656|657|660|664|665|668|671|672|677|678|679|683|684|688|692|696|697|704|708|709|710|711|712|713|737|758|776|779|797|800|818|821|839|860,Dutasteride,"5-alpha Reductase Inhibitors| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Agents that produce hypertension| Azasteroids| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Substrates| Drugs Used in Benign Prostatic Hypertrophy| Enzyme Inhibitors| Fused-Ring Compounds| Genito Urinary System and Sex Hormones| Hormone Antagonists| Hormones, Hormone Substitutes, and Hormone Antagonists| Polycyclic Compounds| Steroid Synthesis Inhibitors| Steroids| Steroids, Heterocyclic| Urologicals"
35,DB01233,P14416|P11229|Q13639|P46098|P22303,P10635|P15538|P19099|P05093,hsa:1813|hsa:1128|hsa:3360|hsa:3359|hsa:43,9|10|11|14|15|18|19|37|178|182|283|284|285|286|294|299|332|333|340|341|342|344|345|351|352|355|356|362|365|366|370|371|374|376|377|381|382|384|390|391|392|393|405|416|420|430|434|437|439|441|443|446|449|451|464|470|476|490|493|498|501|502|503|520|524|528|535|540|541|542|545|546|548|549|550|552|553|556|564|565|569|570|573|574|578|579|581|582|584|589|591|592|594|595|597|598|600|603|604|606|607|608|611|613|618|619|623|625|626|628|633|634|637|638|640|641|642|643|645|646|651|652|655|656|660|664|665|666|668|671|672|677|678|679|680|683|684|688|689|691|692|695|698|703|704|707|708|709|710|716|722|738|742|756|771|779|785|801|805|819|834,Metoclopramide,"Acids, Carbocyclic| Agents Causing Muscle Toxicity| Agents that modify thyroid function| Alimentary Tract and Metabolism| Amides| Aminobenzoates| Antiemetics| Autonomic Agents| Benzamides and benzamide derivatives| Benzoates| Carboxylic Acids| Central Nervous System Agents| Central Nervous System Depressants| Chlorobenzoates| Cholinesterase Inhibitors| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dopamine Agents| Dopamine Antagonists| Dopamine D2 Receptor Antagonists| Drugs for Functional Gastrointestinal Disorders| Drugs that are Mainly Renally Excreted| Gastrointestinal Agents| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hydroxybenzoates| Methemoglobinemia Associated Agents| Neurotransmitter Agents| P-glycoprotein substrates| para-Aminobenzoates| Peripheral Nervous System Agents| Potential QTc-Prolonging Agents| Prokinetic Agents| Propulsives| QTc Prolonging Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
36,DB00694,P11388|Q02880,P08684|P20815|P05177|P04798|Q16678|P47989|P16435,hsa:7153|hsa:7155,9|10|11|12|14|18|19|20|21|178|181|182|185|189|192|196|199|203|206|283|284|285|286|299|308|332|333|337|338|339|340|341|344|345|346|347|351|352|355|356|365|366|367|370|371|374|380|381|382|384|393|405|406|416|420|430|432|434|441|443|446|462|470|476|490|493|498|516|520|524|528|535|537|541|542|548|552|553|556|563|564|565|566|567|570|571|573|574|575|578|579|581|582|584|589|590|592|594|595|597|599|603|604|606|608|610|614|617|618|619|623|625|626|634|637|638|639|640|641|642|643|651|655|660|661|662|663|664|666|667|668|671|672|677|678|679|680|681|684|686|687|688|689|690|692|693|696|697|698|699|700|701|704|705|708|709|710|712|713|719|734|735|755|756|776|777|782|797|798|803|818|819,Daunorubicin,"Anthracycline Topoisomerase Inhibitor| Anthracyclines| Anthracyclines and Related Substances| Antibiotics, Antineoplastic| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| BCRP/ABCG2 Substrates| BSEP/ABCB11 Substrates| BSEP/ABCB11 Substrates with a Narrow Therapeutic Index| Cardiotoxic antineoplastic agents| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A5 Inducers| Cytochrome P-450 CYP3A5 Inducers (strength unknown)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Cytotoxic Antibiotics and Related Substances| Enzyme Inhibitors| Glycosides| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Immunosuppressive Agents| Myelosuppressive Agents| Naphthacenes| Narrow Therapeutic Index Drugs| P-glycoprotein inducers| P-glycoprotein inhibitors| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Topoisomerase II Inhibitors| Topoisomerase Inhibitors"
37,DB00594,P37088|P51168|P51170|P51172|P19801|Q16515|P78348|P19634|P00749,P19801|Q9TRC7,hsa:6337|hsa:6338|hsa:6340|hsa:6339|hsa:26|hsa:40|hsa:41|hsa:6548|hsa:5328,9|10|14|15|16|18|37|178|183|184|284|285|286|294|299|332|340|342|351|352|355|357|358|362|375|376|378|379|387|390|393|396|403|416|418|420|431|437|438|439|441|442|443|449|450|451|453|464|472|482|484|485|487|493|494|495|499|506|523|535|536|538|545|547|549|553|560|569|577|580|585|593|602|609|611|613|624|654|656|657|673|674,Amiloride,"Acid Sensing Ion Channel Blockers| Agents causing hyperkalemia| Cardiovascular Agents| Cardiovascular System| Decreased Renal K+ Excretion| Diuretics| Epithelial Sodium Channel Blockers| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypotensive Agents| Increased Diuresis| Membrane Transport Modulators| Natriuretic Agents| OCT2 Inhibitors| Potassium-Sparing Diuretics| Pyrazines| Sodium Channel Blockers"
38,DB00788,P23219|Q51911|P35354,P11712|P05177|P10632|P22309|P16662,hsa:5742|hsa:5743,9|10|11|18|19|178|182|185|189|283|284|286|308|332|333|335|341|344|352|355|356|366|370|371|374|380|381|382|384|385|405|406|416|420|430|434|440|441|443|446|452|470|476|490|498|516|520|524|535|541|542|548|552|556|564|565|570|573|574|578|579|582|584|589|594|595|597|599|603|604|606|608|617|618|619|626|634|637|640|641|651|655|660|664|666|668|677|678|679|680|684|688|689|692|696|697|698|699|704|708|709|710|712|713|714|734|735|755|776|777|797|798|818,Naproxen,"Agents causing hyperkalemia| Agents that produce hypertension| Analgesics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)| Antigout Preparations| Antiinflammatory and Antirheumatic Products| Antiinflammatory and Antirheumatic Products, Non-Steroids| Antiinflammatory Preparations, Non-Steroids for Topical Use| Antiinflammatory Products for Vaginal Administration| Antirheumatic Agents| Arylpropionic acid NSAIDS| BSEP/ABCB11 Substrates| Central Nervous System Agents| Cyclooxygenase Inhibitors| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Enzyme Inhibitors| Genito Urinary System and Sex Hormones| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Musculo-Skeletal System| Naphthaleneacetic Acids| Naphthalenes| Nephrotoxic agents| Non COX-2 selective NSAIDS| OAT1/SLC22A6 inhibitors| Other Nonsteroidal Anti-inflammatory Agents| P-glycoprotein inhibitors| Peripheral Nervous System Agents| Photosensitizing Agents| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Propionates| Sensory System Agents| Topical Products for Joint and Muscular Pain| UGT1A1 Substrates| UGT1A3 substrates| UGT1A6 substrate| UGT1A9 Substrates| UGT2B7 substrates"
39,DB00690,P14867|P47869|P34903|P48169|P31644|Q16445|P18505|P47870|P28472|Q8N1C3|P18507|Q99928|O14764|P78334|O00591|P24046|P28476|A8MPY1|Q9UN88,P05181|P11509|P08684,hsa:2554|hsa:2555|hsa:2556|hsa:2557|hsa:2558|hsa:2559|hsa:2560|hsa:2561|hsa:2562|hsa:2565|hsa:2566|hsa:2567|hsa:2563|hsa:2564|hsa:2568|hsa:2569|hsa:2570|hsa:200959|hsa:55879,9|10|11|12|14|15|18|23|37|178|182|185|189|213|218|219|283|284|285|286|287|294|332|333|340|342|344|345|351|352|355|356|362|364|365|370|371|374|376|377|384|390|391|416|418|420|430|431|434|437|439|441|442|443|446|449|451|453|464|470|490|495|501|502|503|516|520|524|536|538|540|545|546|549|550|552|555|556|564|569|570|576|578|582|584|585|591|592|595|598|599|600|603|607|608|611|613|618|628|633|634|640|645|646|656|657|660|664|665|668|677|678|679|683|688|696|697|708|709|710|729|738|758|792|801|821,Flurazepam,"Anti-Anxiety Agents| Benzazepines| Benzodiazepines and benzodiazepine derivatives| Benzodiazepinones| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| GABA Agents| GABA Modulators| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hypnotics and Sedatives| Nervous System| Neurotransmitter Agents| OCT2 Inhibitors| P-glycoprotein inhibitors| Psycholeptics| Psychotropic Drugs| Tranquilizing Agents"
40,DB01275,Q16853|P13674,P08684,hsa:8639|hsa:5033,9|10|11|14|15|16|178|182|183|184|185|283|284|285|299|300|332|333|344|345|351|355|356|358|365|370|371|372|373|375|376|378|379|384|385|387|393|394|398|416|418|422|430|434|435|438|441|442|445|446|447|449|450|464|467|470|477|486|490|496|510|515|516|517|520|522|523|524|530|538|545|549|552|555|556|564|570|576|578|582|584|592|595|599|600|603|607|608|616|618|633|634|635|640|644|660|664|665|668|677|678|679|683|688|696|708|709|710|712|755|818,Hydralazine,"Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Arteriolar Smooth Muscle, Agents Acting On| Arteriolar Vasodilation| Arteriolar Vasodilator| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Direct Vasodilators| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hydrazinophthalazine Derivatives| Hydrazinophthalazine Derivatives and Diuretics| Hypotensive Agents| Medications that reduce magnesium levels| Phthalazines| Pyridazines| Vasodilating Agents"
41,DB00688,P20839|P12268,P22309|Q9HAW7|P19224|O60656|P16662|Q9HAW9|Q9HAW8|P23141|O00748|P08684|P20815|P10632,hsa:3614|hsa:3615,9|10|11|12|14|18|19|20|143|146|178|180|181|182|185|283|284|285|286|308|332|333|341|344|345|346|351|352|355|356|365|366|374|380|381|382|384|390|391|405|406|416|420|430|434|440|441|443|446|452|470|476|490|493|498|520|524|535|540|541|548|552|553|556|564|565|566|570|573|574|575|578|579|581|582|584|589|590|594|595|597|599|603|604|606|608|614|615|617|618|619|623|625|626|634|637|639|640|641|642|651|653|655|656|659|660|664|666|667|668|671|677|678|679|680|681|684|686|688|689|690|692|693|696|697|698|699|700|701|704|705|708|709|710|712|713|714|734|735|740|755|756|776|777|797|798|803|818|819,Mycophenolatemofetil,"Agents Causing Muscle Toxicity| Anti-Bacterial Agents| Anti-Infective Agents| Antibiotics, Antineoplastic| Antibiotics, Antitubercular| Antimetabolite Immunosuppressant| BCRP/ABCG2 Substrates| Carboxylic Acids| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Fatty Acids| Immunologic Factors| Immunosuppressive Agents| IMP Dehydrogenase, antagonists & inhibitors| Lipids| Mycophenolic Acid and Prodrugs| OATP1B1/SLCO1B1 Substrates| OATP1B3 substrates| P-glycoprotein substrates| UGT1A1 Substrates| UGT1A6 substrate| UGT1A9 Substrates| UGT2B7 substrates"
42,DB00276,P11388|Q12809|P02763|P02768,P10635,hsa:7153|hsa:3757|hsa:5004|hsa:213,9|10|11|12|14|15|18|19|33|178|182|183|184|185|189|192|196|199|283|284|285|286|293|299|305|332|333|340|341|344|351|352|355|356|357|358|366|368|370|371|374|376|377|381|382|384|385|386|387|390|392|393|396|403|405|414|416|418|430|431|434|437|441|442|446|449|453|457|459|464|470|472|476|482|490|495|498|502|506|516|520|523|524|530|538|539|541|542|543|545|546|548|549|552|555|556|564|565|566|570|573|574|576|577|578|582|584|585|589|592|593|594|595|599|600|601|603|604|606|607|608|613|615|618|619|621|626|628|633|634|637|638|640|641|643|651|652|655|656|657|659|660|664|665|666|668|677|678|679|680|683|688|689|691|696|697|703|708|709|710|728|742|758|763|791|805|821|826,Amsacrine,"Acridines| Aminoacridines| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Cardiotoxic antineoplastic agents| Compounds used in a research, industrial, or household setting| Heterocyclic Compounds| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Immunosuppressive Agents| Indicators and Reagents| Intercalating Agents| Laboratory Chemicals| Medications that reduce magnesium levels| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| P-glycoprotein inhibitors"
43,DB00188,P28074|P20618,P08684|P33261|P10635|P05177|P11712,hsa:5693|hsa:5689,6|9|10|11|12|14|15|16|18|19|20|178|182|183|184|185|274|276|283|284|285|286|299|308|332|333|335|338|340|344|345|351|352|355|356|357|358|365|370|371|372|373|374|376|384|387|390|392|393|396|403|416|418|420|430|431|434|435|437|439|441|442|443|445|446|447|449|451|453|464|470|472|482|485|490|491|493|494|495|499|502|506|516|520|521|523|524|528|535|536|538|539|540|545|546|547|549|552|553|556|564|569|570|577|578|579|580|582|584|585|592|593|595|599|602|603|607|608|611|613|618|624|628|634|640|643|645|646|656|657|660|664|668|672|673|677|678|679|683|684|688|692|696|704|708|709|710,Bortezomib,"Acids| Acids, Noncarboxylic| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Boron Compounds| Boronic Acids| Cardiotoxic antineoplastic agents| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (moderate)| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (weak)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Hepatotoxic Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypotensive Agents| Immunosuppressive Agents| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| OATP1B3 inhibitors| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Potential QTc-Prolonging Agents| Proteasome Inhibitors| Pyrazines| QTc Prolonging Agents"
44,DB00934,P23975|P35367|P11229|P08172|P20309|P08173|P08912|BE0004863|P28223|P28335|P34969|P14416|BE0004864,P10635|P05177,hsa:6530|hsa:3269|hsa:1128|hsa:1129|hsa:1131|hsa:1132|hsa:1133|hsa:3356|hsa:3358|hsa:3363|hsa:1813,9|10|11|12|14|178|179|182|185|186|189|192|199|283|284|285|299|332|333|334|335|344|345|351|355|356|365|370|371|374|384|390|392|393|416|430|434|441|446|470|490|516|520|524|528|540|552|556|564|570|578|582|584|592|595|599|603|608|613|618|634|640|643|660|664|668|677|678|679|683|688|696|697|708|709|710|711|712|755|776|797|818,Maprotiline,"Adrenergic Agents| Adrenergic Uptake Inhibitors| Agents producing tachycardia| Agents that reduce seizure threshold| Anthracenes| Anticholinergic Agents| Antidepressive Agents| Antidepressive Agents Indicated for Depression| Antidepressive Agents, Second-Generation| Antidepressive Agents, Tetracyclic| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Histamine Antagonists| Histamine H1 Antagonists| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Membrane Transport Modulators| Muscarinic Antagonists| Nervous System| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| Non-Selective Monoamine Reuptake Inhibitors| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Potential QTc-Prolonging Agents| Psychoanaleptics| Psychotropic Drugs| QTc Prolonging Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin Agents| Serotonin Modulators| Tricyclics and Other Norepinephrine-reuptake Inhibitors"
45,DB00711,P09917|P23219,P06276,hsa:240|hsa:5742,9|10|11|14|15|18|178|180|181|283|284|285|286|344|345|351|365|374|375|390|391|420|451|540|560|569|611|636|645|646|654|656,Diethylcarbamazine,"Acids, Acyclic| Anthelmintics| Anti-Infective Agents| Antihelminthic| Antinematodal Agents| Antiparasitic Agents| Antiparasitic Products, Insecticides and Repellents| Carbamates| Carboxylic Acids| Cholinesterase Inhibitors| Enzyme Inhibitors| Filaricides| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Lipoxygenase Inhibitors| Piperazine and Derivatives| Piperazines"
46,DB11737,P00533,P08684|P05177,hsa:1956,9|10|11|12|14|15|18|19|20|178|182|183|184|185|189|192|283|284|285|286|299|332|333|340|341|344|346|351|352|355|356|357|358|365|366|370|371|373|375|376|377|378|379|381|382|384|385|386|387|389|390|392|393|396|403|405|416|417|418|427|428|430|431|434|437|438|441|442|446|447|449|450|453|460|464|470|472|476|482|484|487|490|491|495|498|502|504|506|516|519|520|521|523|524|530|538|539|540|541|542|544|545|546|548|549|552|555|556|560|564|565|567|570|572|573|574|576|577|578|582|584|585|589|592|593|594|595|596|599|600|601|603|604|606|607|608|613|614|618|619|620|621|626|628|630|632|633|634|636|637|638|640|641|643|651|652|654|655|656|657|660|662|664|665|666|668|674|677|678|679|680|682|683|688|689|691|699|702|703|708|709|710|714|721|735|737|742|758|761|777|784|798|800|805|821|824,Icotinib,"Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Crown Compounds| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inducers| Cytochrome P-450 CYP3A5 Inducers (moderate)| Cytochrome P-450 CYP3A5 Inducers (weak)| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors| Ethers| Ethers, Cyclic| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Macrocyclic Compounds| Polycyclic Compounds| Protein Kinase Inhibitors| Tyrosine Kinase Inhibitors"
47,DB00977,P03372|O75469|P04278,P08684|P10632,hsa:2099|hsa:8856|hsa:6462,9|10|11|12|18|19|143|144|178|179|182|185|189|192|283|284|286|308|332|333|334|335|337|341|344|352|355|356|370|371|374|381|382|384|406|416|417|427|428|430|434|441|446|460|470|490|498|516|520|524|541|542|548|552|556|564|570|573|574|578|582|584|590|595|599|603|606|608|617|618|619|634|637|640|641|651|655|660|664|667|668|677|678|679|680|688|689|696|697|698|699|708|709|710|711|712|714|735|755|776|777|797|798|818|839|840|860|861,Ethinylestradiol,"Adrenal Cortex Hormones| Antineoplastic and Immunomodulating Agents| BSEP/ABCB11 inducers| BSEP/ABCB11 Inhibitors| COMT Substrates| Contraceptive Agents, Female| Contraceptive Agents, Hormonal| Contraceptives, Oral| Contraceptives, Oral, Hormonal| Contraceptives, Postcoital| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Endocrine Therapy| Estradiol Congeners| Estrogen Contraceptives| Estrogenic Steroids, Alkylated| Estrogens| Fused-Ring Compounds| Genito Urinary System and Sex Hormones| Gonadal Hormones| Gonadal Steroid Hormones| Hormonal Contraceptives for Systemic Use| Hormones| Hormones and Related Agents| Hormones, Hormone Substitutes, and Hormone Antagonists| Hyperglycemia-Associated Agents| Natural and Semisynthetic Estrogens, Plain| Norpregnanes| Norpregnatrienes| Norsteroids| P-glycoprotein substrates| Polycyclic Compounds| Progestogens and Estrogens, Sequential Preparations| Reproductive Control Agents| Sex Hormones and Modulators of the Genital System| Steroids| Thyroxine-binding globulin inducers| UGT1A1 Inducers| UGT1A1 Substrates| UGT1A4 substrates| UGT1A9 Substrates| UGT2B7 substrates"
48,DB00502,P14416|P21728|Q13224|P28223|P35462|Q99705|Q05940,P20815|P24462|P05177|P10635|P08684|P16152|O60656|P04798|P33261|P11712,hsa:1813|hsa:1812|hsa:2904|hsa:3356|hsa:1814|hsa:2847|hsa:6571,9|10|11|12|14|18|19|23|37|178|180|181|182|185|189|192|283|284|285|286|287|294|308|332|333|337|341|342|344|345|351|352|355|356|362|364|365|370|371|384|390|391|406|416|420|430|432|434|441|443|446|470|490|493|501|503|516|520|524|535|540|548|550|552|553|556|564|570|573|574|578|579|582|584|591|592|595|597|598|599|603|608|613|617|618|619|623|634|637|638|640|641|655|656|660|664|667|668|671|672|677|678|679|680|683|684|685|688|689|692|696|697|698|704|708|709|710|712|717|780,Haloperidol,Agents that reduce seizure threshold| Anti-Dyskinesia Agents| Antiemetics| Antipsychotic Agents| Antipsychotic Agents (First Generation [Typical])| Autonomic Agents| Butyrophenone Derivatives| Butyrophenones| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (moderate)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dopamine Agents| Dopamine Antagonists| Dopamine D2 Receptor Antagonists| Drugs causing inadvertant photosensitivity| Drugs that are Mainly Renally Excreted| Gastrointestinal Agents| Hyperglycemia-Associated Agents| Ketones| Moderate Risk QTc-Prolonging Agents| Nervous System| Neurotoxic agents| Neurotransmitter Agents| NMDA Receptor Antagonists| P-glycoprotein inhibitors| P-glycoprotein substrates| Peripheral Nervous System Agents| Photosensitizing Agents| Psycholeptics| Psychotropic Drugs| QTc Prolonging Agents| Tranquilizing Agents| UGT1A9 Substrates
49,DB01142,P35367|P25021|P23975|P31645|P28223|P41595|P28335|P11229|P08172|P20309|P08173|P08912|P35348|P35368|P25100|P08908|P08913|P18089|P18825|P14416|P50406|Q9H3N8|Q12809,P10635|P33261|P11712|P05177|P08684,hsa:3269|hsa:3274|hsa:6530|hsa:6532|hsa:3356|hsa:3357|hsa:3358|hsa:1128|hsa:1129|hsa:1131|hsa:1132|hsa:1133|hsa:148|hsa:147|hsa:146|hsa:3350|hsa:150|hsa:151|hsa:152|hsa:1813|hsa:3362|hsa:59340|hsa:3757,9|10|11|12|14|18|178|182|185|189|213|216|283|284|285|286|332|333|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|391|405|416|430|434|441|446|470|476|490|498|516|520|524|540|541|542|548|552|556|564|565|570|573|574|578|582|584|589|594|595|599|603|604|606|608|613|614|618|619|620|626|632|634|637|640|641|651|655|660|664|666|668|677|678|679|680|688|689|696|697|698|699|708|709|710|712|755|756|818|819,Doxepin,"Acid Reducers| Adrenergic alpha-1 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Agents producing tachycardia| Agents that produce hypertension| Agents that reduce seizure threshold| Anticholinergic Agents| Antidepressive Agents| Antidepressive Agents Indicated for Depression| Antidepressive Agents, Tricyclic| Antipruritics and Local Anesthetics| Antipruritics, Incl. Antihistamines, Anesthetics, Etc.| Central Nervous System Agents| Central Nervous System Depressants| Combined Inhibitors of Serotonin/Norepinephrine Reuptake| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dermatologicals| Dibenzoxepins| Drugs that are Mainly Renally Excreted| Ethers, Cyclic| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, Fused-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Histamine H2 Antagonists| Hypnotics and Sedatives| Muscarinic Antagonists| Nervous System| Neurotoxic agents| Neurotransmitter Agents| Non-Selective Monoamine Reuptake Inhibitors| P-glycoprotein substrates| Polycyclic Compounds| Potential QTc-Prolonging Agents| Psychoanaleptics| Psychotropic Drugs| QTc Prolonging Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT1 Receptor Antagonists| Serotonin 5-HT1A Receptor Antagonists| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin 5-HT2C Receptor Antagonists| Serotonin Agents| Serotonin Modulators| Serotonin Receptor Antagonists| Sleep Aids, Pharmaceutical| Tertiary amine tricyclic antidepressants| Tricyclics and Other Norepinephrine-reuptake Inhibitors"
50,DB00950,P35367,P10635,hsa:3269,9|10|11|12|13|14|18|19|20|178|180|181|182|185|189|192|196|199|283|284|285|286|308|332|333|334|335|337|339|341|344|345|346|351|352|355|356|365|366|370|371|374|380|384|390|391|406|416|420|430|434|440|441|443|446|452|470|490|516|520|524|535|540|548|552|556|564|570|571|573|574|578|579|582|584|592|595|597|599|603|608|613|617|618|619|634|637|640|641|655|656|660|664|667|668|677|678|679|680|682|683|684|688|689|692|696|697|698|699|704|708|709|710|711|712|713|776,Fexofenadine,"Anti-Allergic Agents| Antihistamines for Systemic Use| Benzene Derivatives| Benzhydryl Compounds| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Histamine H1 Antagonists, Non-Sedating| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Neurotransmitter Agents| OAT3/SLC22A8 Substrates| OATP1B1/SLCO1B1 Substrates| OATP1B3 substrates| OATP2B1/SLCO2B1 substrates| P-glycoprotein substrates| Piperidines| Respiratory System"
51,DB01406,P03372|P10275|P06401|P30968|Q96P88|P13500,P11511|P08684,hsa:2099|hsa:367|hsa:5241|hsa:2798|hsa:6347,9|10|11|12|14|18|19|143|144|148|149|150|178|179|182|185|186|192|283|284|285|286|301|308|332|333|334|335|337|341|344|345|351|352|355|356|358|365|370|372|373|374|376|381|384|387|395|406|416|417|418|420|423|427|428|430|432|434|435|441|442|443|445|446|447|449|454|460|464|470|490|493|498|514|520|523|524|530|535|538|541|545|548|549|553|555|556|558|564|570|573|579|580|582|584|592|595|599|600|606|608|617|619|624|633|634|637|638|640|652|660|664|665|668|671|672|673|677|678|679|680|683|684|688|689|692|696|697|698|699|704|708|709|710|711|712|776|797|818|839|840|860|861,Danazol,"Androgens| Antigonadotropins and Similar Agents| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (moderate)| Cytochrome P-450 CYP3A4 Inhibitors (strong)| Cytochrome P-450 Enzyme Inhibitors| Estrogen Antagonists| Fused-Ring Compounds| Genito Urinary System and Sex Hormones| Hormone Antagonists| Hormones, Hormone Substitutes, and Hormone Antagonists| Hyperglycemia-Associated Agents| Polycyclic Compounds| Pregnadienes| Pregnanes| Sex Hormones and Modulators of the Genital System| Steroids| Thyroxine-binding globulin inhibitors"
52,DB00537,P43702|P43700|P11388|Q12809|P0AES4|P0C1U9|Q59192|P05653|C3T8E2|B4YQT9|P20831,P08684|P20815|P24462|P05177,hsa:7153|hsa:3757,9|10|11|12|14|15|18|19|23|115|116|178|180|181|182|183|184|185|192|283|284|285|286|287|299|308|332|333|338|340|341|344|345|351|352|355|356|357|358|364|365|370|371|372|373|376|377|380|381|382|384|385|386|387|390|391|392|393|396|397|403|406|416|418|420|430|431|432|434|435|437|440|441|442|443|445|446|447|449|452|453|464|470|472|482|490|491|493|495|502|506|520|521|523|524|528|530|535|538|539|540|545|546|548|549|552|553|555|556|564|569|570|573|574|576|577|578|579|580|581|582|584|585|588|592|593|595|597|600|601|603|607|608|611|613|617|618|619|621|623|624|628|633|634|637|638|640|641|642|643|655|656|657|660|664|665|667|668|671|672|673|677|678|679|680|683|684|688|689|691|692|695|696|697|698|702|703|704|707|708|709|710|716|749|758|779|812|821,Ciprofloxacin,"Agents Causing Muscle Toxicity| Anti-Bacterial Agents| Anti-Infective Agents| Antibacterials for Systemic Use| Antiinfectives for Systemic Use| Chemically-Induced Disorders| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strong)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (moderate)| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (moderate)| Cytochrome P-450 CYP3A7 Inhibitors| Cytochrome P-450 CYP3A7 Inhibitors (moderate)| Cytochrome P-450 Enzyme Inhibitors| Drug-Related Side Effects and Adverse Reactions| Drugs causing inadvertant photosensitivity| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Fluoroquinolone Antibacterial| Fluoroquinolones| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| MATE 1 Inhibitors| MATE 1 Substrates| MATE 2 Inhibitors| MATE inhibitors| MATE substrates| Medications that reduce magnesium levels| Metabolic Side Effects of Drugs and Substances| Moderate Risk QTc-Prolonging Agents| Ophthalmological and Otological Preparations| Ophthalmologicals| Otologicals| P-glycoprotein substrates| Photosensitizing Agents| QTc Prolonging Agents| Quinolines| Quinolone Antimicrobial| Quinolones| Sensory Organs| Topoisomerase II Inhibitors| Topoisomerase Inhibitors"
53,DB06689,BMOL0000014|P00748,P05181,hsa:2161,9|10|11|12|14|18|19|283|284|285|286|299|308|332|344|345|346|351|352|365|366|374|380|393|406|416|420|434|440|441|443|446|452|490|516|524|528|535|556|566|571|579|582|599|617|637|640|643|660|678|679|680|684|688|689|692|696|698|704,Ethanolamineoleate,"Antivaricose Therapy| Cardiovascular Agents| Cardiovascular System| Compounds used in a research, industrial, or household setting| Fatty Acids| Fatty Acids, Monounsaturated| Fatty Acids, Unsaturated| Lipids| Pharmaceutical Preparations| Pharmaceutical Solutions| Sclerosing Agents for Local Injection| Sclerosing Solutions| Solutions| Vasoprotectives"
54,DB08820,P13569,P08684|P20815,hsa:1080,9|10|11|12|14|15|18|19|178|182|183|184|185|189|192|283|284|285|286|299|308|332|333|334|340|341|344|345|351|352|355|356|357|358|365|370|371|372|373|374|376|377|381|382|384|385|386|387|390|392|393|396|399|400|403|406|416|418|420|430|431|432|434|435|437|439|441|442|443|445|446|447|449|451|453|464|470|472|482|490|491|493|495|498|502|506|516|520|521|523|524|527|528|530|535|538|539|540|541|542|545|546|548|549|552|553|555|556|564|570|573|574|576|577|578|579|580|582|584|585|588|590|592|593|595|597|599|600|603|606|607|608|613|617|618|619|623|624|628|633|634|637|638|640|641|643|645|651|652|655|656|657|660|664|665|667|668|671|672|673|677|678|679|680|683|684|688|689|691|692|695|696|697|698|699|702|703|704|707|708|709|710|711|712|714|716|734|742|756|758|777|779|797|805|819|821,Ivacaftor,"Amines| Aniline Compounds| Benzene Derivatives| Chloride Channel Activation Potentiators| Chloride Channel Agonists| Cystic Fibrosis Transmembrane Conductance Regulator Potentiators| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (weak)| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Membrane Transport Modulators| P-glycoprotein inhibitors| Phenols| Quinolines| Respiratory System"
55,DB01095,P04035,P04798|P05177|P08684|P20815|P20813|P10632|P11712|P33261|P10635|P22309|P35503|P16662,hsa:3156,9|10|11|12|14|18|19|20|23|143|148|149|178|182|185|189|283|284|285|286|287|308|332|333|338|339|340|341|344|345|346|351|352|355|356|357|358|364|365|366|370|371|374|376|377|380|384|385|386|387|390|391|396|397|403|406|416|418|420|430|431|434|437|440|441|442|443|446|449|452|453|464|470|472|482|490|495|502|506|516|520|521|523|524|530|535|538|539|540|545|546|549|552|555|556|564|570|571|573|576|577|578|579|581|582|584|585|592|595|599|600|603|607|608|613|617|618|619|628|633|634|637|639|640|642|656|657|660|664|665|667|668|677|678|679|680|683|684|688|689|690|692|693|696|697|701|705|708|709|710|712|758|821,Fluvastatin,"Agents Causing Muscle Toxicity| Cardiovascular System| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (strength unknown)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (moderate)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Fatty Acids| Heptanoic Acids| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hydroxymethylglutaryl-CoA Reductase Inhibitors| Hypolipidemic Agents| Hypolipidemic Agents Indicated for Hyperlipidemia| Indoles| Lipid Modifying Agents| Lipid Modifying Agents, Plain| Lipid Regulating Agents| Lipids| OATP1B1/SLCO1B1 Inhibitors| OATP1B1/SLCO1B1 Substrates| OATP1B3 substrates| UGT1A1 Substrates| UGT1A3 substrates| UGT2B7 substrates"
56,DB01120,Q09428|P15692,P11712|P33261,hsa:6833|hsa:7422,9|10|11|14|15|18|19|33|143|144|145|146|150|178|182|283|284|285|286|293|299|300|305|332|333|335|344|345|351|353|355|356|365|370|371|374|375|383|384|390|393|394|398|414|416|420|430|434|441|446|451|457|459|465|470|483|490|515|516|517|518|520|522|524|531|532|540|552|556|564|570|578|582|584|592|595|599|603|608|613|618|634|635|640|656|660|664|668|677|678|679|683|688|708|709|710|712|715|778|860,Gliclazide,"Alimentary Tract and Metabolism| Amides| Benzene Derivatives| Benzenesulfonamides| Blood Glucose Lowering Agents| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 Substrates| Drugs Used in Diabetes| Genito Urinary System and Sex Hormones| Gynecological Antiinfectives and Antiseptics| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hypoglycemia-Associated Agents| Insulin Secretagogues| Oral Hypoglycemics| Sulfonamides| Sulfones| Sulfonylureas| Sulfur Compounds"
57,DB00371,P14867|P47869|P34903|P48169|P31644|Q16445|BE0004797,P33261|P05181,hsa:2554|hsa:2555|hsa:2556|hsa:2557|hsa:2558|hsa:2559,9|10|11|14|15|18|19|20|283|284|285|286|299|332|333|334|344|346|352|366|374|380|393|405|420|451|452|559|582|612|637|639|680|708|709|711,Meprobamate,"Acids, Acyclic| Anti-Anxiety Agents| Carbamates| Carboxylic Acids| Central Nervous System Agents| Central Nervous System Depressants| Hypnotics and Sedatives| Muscle Relaxants| Muscle Relaxants, Centrally Acting Agents| Nervous System| Peripheral Nervous System Agents| Psycholeptics| Psychotropic Drugs| Tranquilizing Agents"
58,DB00227,P04035|P20701|Q92769,P08684|P20815|P24462|Q15166|P10632|P11712|P33261|P10635|P22309|P35503|P16662,hsa:3156|hsa:3683|hsa:3066,9|10|11|12|18|19|20|178|181|182|185|189|192|283|284|286|308|332|333|335|339|341|344|346|352|366|374|380|405|406|416|420|430|434|440|441|443|446|452|490|516|524|535|556|564|571|579|581|582|599|614|617|637|639|640|641|642|660|664|678|679|680|684|688|689|692|693|696|697|698|699|704|705|708|709|710|712|798|818,Lovastatin,"Agents Causing Muscle Toxicity| Agents that modify thyroid function| Anticholesteremic Agents| BSEP/ABCB11 Substrates| Cardiovascular System| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (moderate)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (moderate)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Enzyme Inhibitors| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hydroxymethylglutaryl-CoA Reductase Inhibitors| Hypolipidemic Agents| Hypolipidemic Agents Indicated for Hyperlipidemia| Lipid Modifying Agents| Lipid Regulating Agents| OATP1B1/SLCO1B1 Inhibitors| OATP1B1/SLCO1B1 Substrates| P-glycoprotein inhibitors| Photosensitizing Agents| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| UGT1A1 Substrates| UGT1A3 substrates| UGT2B7 substrates"
59,DB01206,Q9H169,P08684|P10635,hsa:81551,9|10|11|14|15|18|19|37|178|179|283|284|285|286|294|299|300|301|332|338|340|342|343|344|345|351|361|365|375|390|392|393|420|423|451|515|517|518|528|540|560|582|592|609|613|635|636|643|645|646|654|679|683,Lomustine,"Alkylating Activity| Alkylating Drugs| Amides| Antineoplastic Agents| Antineoplastic Agents, Alkylating| Antineoplastic and Immunomodulating Agents| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Immunosuppressive Agents| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| Nitroso Compounds| Nitrosourea Compounds| Nitrosoureas| Noxae| Toxic Actions"
60,DB00199,O43193|Q12809|P02768,P08684|P24462|P05177|P20813,hsa:2862|hsa:3757|hsa:213,9|10|11|12|13|14|18|19|20|21|178|181|185|188|283|284|285|286|308|332|333|335|337|338|339|340|341|344|345|346|347|351|352|365|366|367|374|380|390|391|405|406|420|432|440|443|452|535|540|563|566|567|571|579|581|582|592|610|613|614|617|637|638|639|642|659|661|662|663|679|680|681|684|686|688|689|690|692|693|696|697|698|699|700|701|704|705|708|709|710,Erythromycin,"Anti-Acne Preparations| Anti-Acne Preparations for Topical Use| Anti-Bacterial Agents| Anti-Infective Agents| Antibacterials for Systemic Use| Antiinfectives for Systemic Use| Antiinfectives for Treatment of Acne| BSEP/ABCB11 Inhibitors| BSEP/ABCB11 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (moderate)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (moderate)| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Inhibitors| Cytochrome P-450 CYP3A7 Inhibitors (moderate)| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dermatologicals| Enzyme Inhibitors| Erythromycin and similars| Erythromycins| Gastrointestinal Agents| Lactones| Macrocyclic Compounds| Macrolide Antimicrobial| Macrolides| Macrolides, Lincosamides and Streptogramins| Moderate Risk QTc-Prolonging Agents| OATP1B1/SLCO1B1 Inhibitors| OATP1B1/SLCO1B1 Substrates| OATP1B3 inhibitors| OATP1B3 substrates| Ophthalmologicals| P-glycoprotein inhibitors| P-glycoprotein substrates| Polycyclic Compounds| Protein Synthesis Inhibitors| QTc Prolonging Agents"
61,DB00683,P14867|P47869|P34903|P48169|P31644|P18505|P28472|P47870|Q16445|Q8N1C3|P18507|Q99928|O14764|P78334|O00591|P24046|P28476|A8MPY1|Q9UN88,P08684|P20815|P24462|P20813|P13584|P22310|P05181,hsa:2554|hsa:2555|hsa:2556|hsa:2557|hsa:2558|hsa:2560|hsa:2562|hsa:2561|hsa:2559|hsa:2565|hsa:2566|hsa:2567|hsa:2563|hsa:2564|hsa:2568|hsa:2569|hsa:2570|hsa:200959|hsa:55879,9|10|11|12|14|15|23|37|143|148|149|178|182|185|189|213|218|219|283|284|285|287|294|332|333|340|342|344|345|351|355|356|357|358|359|362|364|365|370|371|372|373|374|375|376|377|379|384|387|389|390|391|396|397|403|416|418|430|431|434|435|437|438|441|442|445|446|447|449|450|453|464|470|472|482|484|485|487|490|491|495|499|501|502|503|504|506|516|519|520|521|523|524|538|539|540|545|546|547|549|550|552|555|556|560|564|569|570|572|576|577|578|582|584|585|591|592|593|595|596|598|599|600|603|607|608|611|613|618|628|633|634|636|640|654|656|657|660|664|665|668|674|677|678|679|683|688|696|697|708|709|710|729|738|758|792|801|821,Midazolam,"Adjuvants, Anesthesia| Anesthetics| Anti-Anxiety Agents| Benzodiazepine hypnotics and sedatives| Benzodiazepines and benzodiazepine derivatives| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| GABA Agents| GABA Modulators| Heterocyclic Compounds| Heterocyclic Compounds, Fused-Ring| Hypnotics and Sedatives| Nervous System| Neurotransmitter Agents| P-glycoprotein substrates| Psycholeptics| Psychotropic Drugs| Tranquilizing Agents| Triazolobenzodiazepines| UGT1A4 substrates| UGT2B7 substrates"
62,DB00590,P35348|P35368|P25100|Q12809|Q9H252|Q9NS40,P33261|P10635,hsa:148|hsa:147|hsa:146|hsa:3757|hsa:81033|hsa:90134,9|10|11|12|14|15|16|18|19|20|178|180|181|182|183|184|185|188|189|192|199|206|283|284|285|286|299|332|333|339|340|341|344|345|346|351|352|355|356|357|358|365|366|370|371|374|375|376|377|378|379|381|382|384|385|386|387|389|390|391|393|396|403|405|416|418|420|430|431|434|437|438|439|441|442|443|446|449|450|451|453|462|464|470|472|476|482|484|487|490|495|498|502|504|506|516|519|520|523|524|530|535|537|538|539|540|541|542|544|545|546|548|549|552|555|556|560|564|565|566|567|569|570|572|573|574|576|578|581|582|584|585|589|592|593|594|595|596|599|600|601|603|604|605|606|607|608|611|613|614|615|618|619|620|621|626|628|630|632|633|634|636|637|638|640|641|642|645|646|651|652|654|655|656|657|659|660|662|664|665|666|668|674|677|678|679|680|682|683|688|689|691|699|702|703|708|709|710|714|721|735|742|758|761|777|784|798|805|821|824,Doxazosin,"Adrenergic Agents| Adrenergic alpha-1 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Antiadrenergic Agents, Peripherally Acting| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates (strength unknown)| Cytochrome P-450 Substrates| Drugs Used in Benign Prostatic Hypertrophy| Genito Urinary System and Sex Hormones| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hypotensive Agents| Neurotransmitter Agents| OCT1 inhibitors| P-glycoprotein inhibitors| Peripheral alpha-1 blockers| Quinazolines| Urologicals"
63,DB00270,Q13936|P54289|Q08289|O95180|Q9NY47|Q01668|Q13698,P08684,hsa:775|hsa:781|hsa:783|hsa:8912|hsa:9254|hsa:776|hsa:779,9|10|11|12|14|15|18|19|20|143|148|149|178|182|183|184|185|283|284|285|286|299|301|332|333|335|339|340|341|344|346|351|352|355|356|357|358|366|370|371|374|376|377|380|384|386|387|390|392|393|395|405|416|418|420|423|430|431|434|437|440|441|442|443|446|449|452|454|464|470|485|490|499|502|514|516|520|523|524|530|535|538|539|545|546|547|549|552|553|555|556|558|564|569|570|573|576|578|579|582|584|592|594|595|599|600|603|607|608|614|618|619|633|634|637|640|643|648|656|660|664|665|666|668|671|673|677|678|679|680|683|684|688|689|690|691|692|693|694|695|696|697|698|700|703|704|707|708|709|710|712|737|758|770|800|821|833,Isradipine,"Agents causing hyperkalemia| Antiarrhythmic agents| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Bradycardia-Causing Agents| BSEP/ABCB11 Substrates| Calcium Channel Blockers| Calcium Channel Blockers (Dihydropyridine)| Calcium-Regulating Hormones and Agents| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (moderate)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dihydropyridine Derivatives| Dihydropyridines| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypotensive Agents| Membrane Transport Modulators| P-glycoprotein inhibitors| Potential QTc-Prolonging Agents| Pyridines| QTc Prolonging Agents| Selective Calcium Channel Blockers With Mainly Vascular Effects| Vasodilating Agents"
64,DB00951,P9WIE5|P9WGR1|P10632|P05177|P08684|P33261|P9WNX1,P08684|P05181|P11712|P05177|P10635|P33261|P11245|P9WJI5|P11509|P10632,hsa:1558|hsa:1544|hsa:1576|hsa:1557,9|10|14|15|18|178|183|184|283|284|285|286|299|300|332|333|344|345|351|352|355|356|358|365|370|371|372|373|376|384|387|390|393|394|396|398|403|416|418|420|430|434|435|439|441|442|443|445|446|447|449|451|453|464|470|472|482|490|491|493|495|502|506|510|515|516|518|520|521|522|523|524|530|535|538|539|540|545|546|549|552|553|555|556|564|570|577|578|579|582|584|585|592|595|597|599|600|603|607|608|613|618|623|628|633|634|640|656|657|660|664|665|668|671|672|677|678|683|685|708|710,Isoniazid,"Acids, Heterocyclic| Agents Causing Muscle Toxicity| Agents that reduce seizure threshold| Anti-Bacterial Agents| Anti-Infective Agents| Antiinfectives for Systemic Use| Antimycobacterials| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP2A6 Inhibitors| Cytochrome P-450 CYP2A6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (strong)| Cytochrome P-450 CYP2C19 Inhibitors (weak)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP2E1 Inducers| Cytochrome P-450 CYP2E1 Inducers (strength unknown)| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (moderate)| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (moderate)| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs for Treatment of Tuberculosis| Drugs that are Mainly Renally Excreted| Fatty Acid Synthesis Inhibitors| Hepatotoxic Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hydrazides| Hydrazines| Hyperglycemia-Associated Agents| Hypolipidemic Agents| Isonicotinic Acids| Pyridines| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
65,DB01196,P11137|P78559|P03372|Q92731,P08684,hsa:4133|hsa:4130|hsa:2099|hsa:2100,9|10|11|12|14|18|19|37|38|143|144|178|179|182|185|186|192|283|284|285|286|294|308|332|333|334|335|339|341|342|343|344|345|346|351|352|355|356|361|365|366|370|371|374|380|381|382|384|390|391|405|406|416|420|430|434|441|446|451|452|470|476|490|498|516|520|524|540|541|542|548|552|556|564|565|570|571|573|574|578|582|584|589|594|595|599|603|604|606|608|609|612|617|618|619|622|626|634|637|640|641|645|646|651|655|656|660|664|666|668|677|678|679|680|688|689|696|697|698|699|708|709|710|711|712|714|735|755|776|777|797|798|818|840|860|861,Estramustine,"Alkylating Activity| Alkylating Drugs| Antineoplastic Agents| Antineoplastic Agents, Alkylating| Antineoplastic Agents, Hormonal| Antineoplastic and Immunomodulating Agents| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Estradiol Congeners| Estranes| Estrenes| Fused-Ring Compounds| Hydrocarbons| Hydrocarbons, Halogenated| Immunosuppressive Agents| Mustard Compounds| Nitrogen Mustard Compounds| Noxae| P-glycoprotein inhibitors| Polycyclic Compounds| Steroids| Toxic Actions"
66,DB00366,P35367|P11229|Q14994,Q14097,hsa:3269|hsa:1128|hsa:9970,9|10|11|12|14|15|18|178|182|183|184|185|283|284|285|286|332|333|337|340|341|344|345|346|351|352|355|356|357|358|365|366|370|371|372|373|374|376|384|387|390|391|396|403|405|416|418|430|431|434|435|437|441|442|445|446|447|449|453|461|464|470|472|482|490|491|495|502|506|516|520|521|523|524|530|538|539|540|545|546|548|549|552|555|556|564|566|570|573|574|576|577|578|582|584|585|592|594|595|599|600|603|604|607|608|613|614|615|618|619|628|633|634|637|640|641|655|656|657|659|660|664|665|666|668|677|678|679|680|683|688|689|696|697|698|708|709|710|712,Doxylamine,"Agents producing tachycardia| Aminoalkyl Ethers| Anticholinergic Agents| Antiemetics| Antihistamines for Systemic Use| Autonomic Agents| Central Nervous System Agents| Central Nervous System Depressants| Ethanolamine Derivatives| Gastrointestinal Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Histamine Receptor Antagonists| Muscarinic Antagonists| Neurotransmitter Agents| Peripheral Nervous System Agents| Potential QTc-Prolonging Agents| Pyridines| QTc Prolonging Agents| Respiratory System"
67,DB01577,Q01959|P31645|P23975|Q05940|P54219|Q96RJ0|P08913|P18089|P18825|P21397|P27338,P10635,hsa:6531|hsa:6532|hsa:6530|hsa:6571|hsa:6570|hsa:134864|hsa:150|hsa:151|hsa:152|hsa:4128|hsa:4129,9|10|11|14|178|182|283|284|285|299|332|333|338|340|344|345|351|355|356|365|370|371|374|384|390|392|393|416|430|434|441|446|470|490|516|520|524|528|540|552|556|564|570|578|582|584|592|595|599|603|607|608|613|618|634|640|643|660|664|668|677|678|679|683|688|696|708|709|710,Methamphetamine,"Adrenergic Agents| Adrenergic Agonists| Adrenergic alpha-2 Receptor Agonists| Adrenergic alpha-Agonists| Adrenergic Uptake Inhibitors| Agents producing tachycardia| Agents that produce hypertension| Amines| Amphetamine Anorectic| Amphetamines| Antidepressive Agents| Appetite Suppression| Autonomic Agents| Central Nervous System Agents| Central Nervous System Depressants| Central Nervous System Stimulants| Central Nervous System Stimulation| Centrally Acting Sympathomimetics| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Substrates| Dopamine Agents| Dopamine Uptake Inhibitors| Drugs that are Mainly Renally Excreted| Ethylamines| Increased Sympathetic Activity| Membrane Transport Modulators| Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates| Nervous System| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| Peripheral Nervous System Agents| Phenethylamines| Psychoanaleptics| Psychostimulants, Agents Used for ADHD and Nootropics| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Sympathomimetics"
68,DB01215,P14867|P47869|P34903|P31644|Q8N1C3|P18507|Q99928|P18505|P47870|P28472|O14764|P78334|O00591|P24046|P28476|A8MPY1|BE0004797,P08684,hsa:2554|hsa:2555|hsa:2556|hsa:2558|hsa:2565|hsa:2566|hsa:2567|hsa:2560|hsa:2561|hsa:2562|hsa:2563|hsa:2564|hsa:2568|hsa:2569|hsa:2570|hsa:200959,9|10|11|12|14|15|16|37|143|148|149|178|182|185|189|213|218|219|283|284|285|294|300|332|333|340|342|344|345|351|355|356|358|359|362|365|370|371|373|375|376|377|379|384|389|390|391|396|397|403|416|418|422|430|431|434|437|438|441|442|446|447|449|450|453|464|467|470|472|482|484|486|487|490|491|495|496|501|502|503|504|506|515|516|517|519|520|521|524|538|539|540|545|546|549|550|552|555|556|560|564|569|570|572|576|578|582|584|585|591|592|595|596|598|599|600|603|607|608|611|613|618|628|633|634|640|644|654|656|657|660|664|665|668|674|677|678|679|683|688|696|697|708|709|710|729|738|758|792|801|821,Estazolam,"Anti-Anxiety Agents| Anticonvulsants| Benzazepines| Benzodiazepine hypnotics and sedatives| Benzodiazepines and benzodiazepine derivatives| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Drugs that are Mainly Renally Excreted| GABA Agents| GABA Modulators| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hypnotics and Sedatives| Nervous System| Neurotransmitter Agents| Photosensitizing Agents| Psycholeptics| Psychotropic Drugs| Tranquilizing Agents| Triazolobenzodiazepines"
69,DB01364,P23975|P35348|Q05940|P22303,P06276,hsa:6530|hsa:148|hsa:6571|hsa:43,9|10|11|14|18|178|182|283|284|285|286|299|308|332|333|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|384|390|392|393|406|416|430|434|441|446|470|490|516|520|524|528|540|548|552|556|564|566|570|571|573|574|578|582|584|592|595|599|603|607|608|613|617|618|619|634|637|640|641|643|655|659|660|664|667|668|677|678|679|680|683|688|689|696|698|708|709|710,Ephedrine,"Adrenergic Agents| Adrenergic Agonists| Adrenergic alpha-Agonists| Adrenergic and Dopaminergic Agents| Adrenergic beta-Agonists| Adrenergics for Systemic Use| Agents producing tachycardia| Agents that produce hypertension| Alcohols| Alimentary Tract and Metabolism| Alpha-and Beta-adrenergic Agonists| Amines| Amino Alcohols| Antiobesity Preparations, Excl. Diet Products| Autonomic Agents| Cardiac Stimulants Excl. Cardiac Glycosides| Cardiac Therapy| Cardiovascular Agents| Cardiovascular System| Central Nervous System Agents| Central Nervous System Stimulants| Centrally Acting Antiobesity Products| Cholinesterase substrates| Drugs for Obstructive Airway Diseases| Epinephrine and similars| Ethylamines| Herbs and Natural Products| Increased Norepinephrine Activity| Mydriatics and Cycloplegics| Nasal Preparations| Neurotransmitter Agents| Norepinephrine Releasing Agents| Ophthalmologicals| Peripheral Nervous System Agents| Phenethylamines| Propanolamines| Propanols| Respiratory System| Sensory Organs| Sympathomimetic (Adrenergic) Agents| Sympathomimetics| Sympathomimetics Excl. Antiglaucoma Preparations| Sympathomimetics, Plain| Vasoconstrictor Agents"
70,DB00763,P07202,P05177|P11509|P20813|P33261|P11712|P10635|P05181|P08684,hsa:7173,9|10|14|15|33|143|148|149|283|284|285|293|299|344|345|351|358|365|370|372|373|374|375|376|379|387|389|390|391|392|393|396|397|399|400|403|416|418|421|435|442|445|446|447|449|450|453|472|482|484|485|487|488|491|495|499|502|504|506|508|511|516|519|521|527|528|539|540|546|547|560|569|572|596|611|636|643|654|674,Methimazole,"Antithyroid agents| Azoles| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP2A6 Inhibitors| Cytochrome P-450 CYP2A6 Inhibitors (weak)| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strong)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (weak)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strong)| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 Enzyme Inhibitors| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hormone Antagonists| Hormones, Hormone Substitutes, and Hormone Antagonists| Imidazoles| Immunosuppressive Agents| Myelosuppressive Agents| Sulfur Compounds| Sulfur-Containing Imidazole Derivatives| Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins| Thyroid Hormone Synthesis Inhibitor| Thyroid Hormone Synthesis Inhibitors| Thyroid Products"
71,DB00764,P04150|P06401,P10632,hsa:2908|hsa:5241,9|10|11|12|18|19|20|37|38|143|144|178|179|182|185|186|192|283|284|286|294|308|332|333|334|335|337|339|341|342|343|344|346|352|361|366|374|406|416|420|430|432|434|441|443|446|462|490|516|524|535|537|550|551|553|556|561|571|579|582|591|599|617|637|640|660|671|672|678|679|680|681|684|688|689|692|693|696|697|698|699|704|705|708|709|710|711|712|776|777|780|797|798|801|818|819|822|827|839|840|860|861,Mometasone,"Adrenal Cortex Hormones| Adrenals| Anti-Allergic Agents| Anti-Inflammatory Agents| Corticosteroid Hormone Receptor Agonists| Corticosteroids| Corticosteroids for inhalation use| Corticosteroids, Dermatological Preparations| Corticosteroids, Potent (Group III)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inducers| Cytochrome P-450 CYP3A5 Inducers (strength unknown)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dermatologicals| Drugs for Obstructive Airway Diseases| Fused-Ring Compounds| Glucocorticoids| Hyperglycemia-Associated Agents| Immunosuppressive Agents| Nasal Preparations| Polycyclic Compounds| Pregnadienediols| Pregnadienes| Pregnanes| Respiratory System| Steroids| Thyroxine-binding globulin inhibitors"
72,DB00736,P20648,P33261|P08684,hsa:495,9|10|11|12|14|15|18|19|33|143|148|149|178|182|183|184|185|283|284|285|286|293|299|332|333|340|341|344|345|349|351|352|353|355|356|357|358|365|366|368|370|371|372|373|374|375|376|377|379|381|382|384|386|387|389|390|392|393|396|399|400|403|405|412|414|416|418|430|431|434|435|437|441|442|445|446|447|449|450|453|457|464|465|468|470|472|473|475|476|478|482|484|485|487|488|489|490|491|495|498|499|502|504|506|507|516|519|520|521|523|524|527|530|538|539|540|541|542|545|546|547|548|549|552|555|556|560|564|565|569|570|572|573|574|576|577|578|582|584|585|586|589|592|594|595|596|599|600|603|604|606|607|608|611|613|618|619|626|628|633|634|636|637|638|640|641|643|651|652|654|655|656|657|660|664|665|666|668|674|677|678|679|680|682|683|689|691|702|703|708|709|710|721|742|770|784|805|833,Esomeprazole,"2-Pyridinylmethylsulfinylbenzimidazoles| Acid Reducers| Alimentary Tract and Metabolism| Anti-Ulcer Agents| Antiinflammatory and Antirheumatic Products| Antiinflammatory and Antirheumatic Products, Non-Steroids| Benzimidazoles| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (weak)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Drugs for Acid Related Disorders| Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)| Enzyme Inhibitors| Gastric Acid Lowering Agents| Gastrointestinal Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Medications that reduce magnesium levels| Musculo-Skeletal System| OAT3/SLC22A8 Inhibitors| Omeprazole and enantiomer| P-glycoprotein inhibitors| P-glycoprotein substrates| Photosensitizing Agents| Propionates| Proton Pump Inhibitors| Proton-pump Inhibitors| Pyridines| Sulfoxides| Sulfur Compounds"
73,DB00266,Q9BQB6|P15559|Q08257,P11712,hsa:79001|hsa:1728|hsa:1429,9|10|11|12|18|19|20|178|182|184|185|189|191|192|199|283|284|286|308|332|333|341|344|352|355|356|370|371|380|381|382|384|385|405|406|409|416|420|430|432|434|440|441|443|446|452|470|476|490|493|498|516|520|524|535|541|542|548|552|553|556|564|565|570|573|574|575|578|579|581|582|584|589|590|594|595|597|599|603|604|606|608|614|617|618|619|620|622|623|625|626|632|634|637|639|640|641|642|651|653|655|660|664|666|667|668|671|672|677|678|679|680|684|688|689|690|692|693|694|696|697|698|700|701|704|705|706|708|709|710|756|819,Dicoumarol,"4-Hydroxycoumarins| Anticoagulants| Benzopyrans| Blood and Blood Forming Organs| Coumarins| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Substrates| Enzyme Inhibitors| Fibrinolytic Agents| Hematologic Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Narrow Therapeutic Index Drugs| Pyrans| Uncoupling Agents| Vitamin K Antagonists"
74,DB01590,P42345,P08684,hsa:2475,0|9|10|11|12|13|14|18|19|20|21|178|179|180|181|185|188|192|283|284|285|286|308|332|333|335|338|339|340|341|344|345|346|351|352|365|366|374|380|390|391|405|406|416|420|430|432|434|439|440|441|443|446|451|452|462|490|516|524|535|536|537|540|556|563|564|566|567|571|573|579|581|582|592|594|599|602|605|613|614|615|617|619|637|638|639|640|641|642|645|646|656|659|660|661|662|663|664|666|667|678|679|680|683|684|688|689|690|692|696|697|698|699|701|704|708|709|710|777|798|824,Everolimus,Anti-Bacterial Agents| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Cancer immunotherapy| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Decreased Immunologic Activity| Enzyme Inhibitors| Hyperglycemia-Associated Agents| Immunologic Factors| Immunosuppressive Agents| Immunotherapy| Kinase Inhibitor| Lactones| Macrolides| Mammalian target of rapamycin (mTOR) kinase inhibitors| mTOR Inhibitor Immunosuppressant| mTOR Inhibitors| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| OATP1B1/SLCO1B1 Inhibitors| OATP1B3 inhibitors| P-glycoprotein inhibitors| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Polyketides| Protein Kinase Inhibitors| Selective Immunosuppressants
75,DB01169,O14920|Q16881|P05412|P24385|P27361|P28482|P31749|P38936|Q13547|P29590,P04798|Q16678|P08684,hsa:3551|hsa:7296|hsa:3725|hsa:595|hsa:5595|hsa:5594|hsa:207|hsa:1026|hsa:3065|hsa:5371,18|19|65,Arsenictrioxide,Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Arsenicals| Cardiotoxic antineoplastic agents| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Drugs that are Mainly Renally Excreted| Highest Risk QTc-Prolonging Agents| Hyperglycemia-Associated Agents| Hypotensive Agents| Immunosuppressive Agents| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| Oxides| Oxygen Compounds| P-glycoprotein inhibitors| QTc Prolonging Agents
76,DB01583,P10827|P10828,P10632,hsa:7067|hsa:7068,9|10|11|12|14|15|18|19|20|21|26|27|46|47|48|178|182|185|189|192|196|199|203|283|284|285|286|298|299|308|332|333|338|340|341|344|345|350|351|352|355|356|365|370|371|380|381|382|384|393|405|406|416|420|430|434|440|441|443|446|452|470|476|490|498|516|520|524|528|535|536|541|542|548|552|556|564|565|566|570|573|574|578|579|582|584|589|590|592|594|595|599|603|604|606|607|608|614|617|618|619|620|626|632|634|637|640|641|643|651|655|660|664|666|667|668|677|678|679|680|681|683|684|688|689|692|696|698|704|708|709|710|714|719|777|782,Liotrix,"Agents used to treat hypothyroidism| Amino Acids| Amino Acids, Aromatic| Amino Acids, Cyclic| Amino Acids, Peptides, and Proteins| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| l-Triiodothyronine| OAT3/SLC22A8 Inhibitors| OATP1B1/SLCO1B1 Substrates| OATP1B3 substrates| P-glycoprotein inducers| Pharmaceutical Preparations| Thyroid Products| Thyronines| Thyroxine-binding globulin substrates"
77,DB01245,Q15822|P22303|P43681|P17787,P06276,hsa:1135|hsa:43|hsa:1137|hsa:1141,9|10|11|12|14|15|283|284|285|332|344|345|351|365|374|390|391|540|582|592|613|679|683|688|696,Decamethonium,Amines| Bis-Trimethylammonium Compounds| Central Nervous System Depressants| Cholinesterase Inhibitors| Neuromuscular Agents| Neuromuscular Blocking Agents| Neuromuscular Depolarizing Agents| Neurotoxic agents| Onium Compounds| Peripheral Nervous System Agents| Quaternary Ammonium Compounds
78,DB00458,P23975|P31645|P28223|P35367|P35348|P25100|P11229|P08172|P20309|P08173|P08912|Q9NZV8|Q9UK17|P28335|P35368|P34969|BE0004889|P14416|Q12809|Q01959|P08908|P50406|O95259|P19652,P10635|P33261|P05177|P08684|P24462|P20813|P33260|P05181,hsa:6530|hsa:6532|hsa:3356|hsa:3269|hsa:148|hsa:146|hsa:1128|hsa:1129|hsa:1131|hsa:1132|hsa:1133|hsa:3751|hsa:3752|hsa:3358|hsa:147|hsa:3363|hsa:1813|hsa:3757|hsa:6531|hsa:3350|hsa:3362|hsa:3756|hsa:5005,9|10|11|12|14|15|178|182|185|189|213|215|216|283|284|285|332|333|340|344|345|351|355|356|365|370|371|374|376|377|384|390|391|416|430|434|437|441|446|449|464|470|490|495|502|516|520|524|540|545|546|549|552|556|564|570|577|578|582|584|585|592|593|595|599|600|603|607|608|613|618|628|633|634|640|656|657|660|664|665|668|677|678|679|683|688|696|697|708|709|710|758|821,Imipramine,"Adrenergic Agents| Adrenergic alpha-1 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Adrenergic Uptake Inhibitors| Agents producing tachycardia| Agents that produce hypertension| Agents that reduce seizure threshold| Anticholinergic Agents| Antidepressive Agents| Antidepressive Agents Indicated for Depression| Antidepressive Agents, Tricyclic| Central Nervous System Agents| Central Nervous System Depressants| Combined Inhibitors of Serotonin/Norepinephrine Reuptake| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (moderate)| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C18 Substrates| Cytochrome P-450 CYP2C18 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Inhibitors (strong)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (moderate)| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dibenzazepines| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Histamine Antagonists| Histamine H1 Antagonists| Hypotensive Agents| Membrane Transport Modulators| Moderate Risk QTc-Prolonging Agents| Muscarinic Antagonists| Narrow Therapeutic Index Drugs| Nervous System| Neurotoxic agents| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| Non-Selective Monoamine Reuptake Inhibitors| OCT2 Inhibitors| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Psychoanaleptics| Psychotropic Drugs| QTc Prolonging Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin 5-HT2C Receptor Antagonists| Serotonin Agents| Serotonin Modulators| Serotonin Receptor Antagonists| Tertiary amine tricyclic antidepressants| Tricyclics and Other Norepinephrine-reuptake Inhibitors"
79,DB00668,P35348|P35368|P08588|P07550|P08913|P18089|P25100|P00439|P18825|P13945|P01375|P00441,P05177|P11712|P08684,hsa:148|hsa:147|hsa:153|hsa:154|hsa:150|hsa:151|hsa:146|hsa:5053|hsa:152|hsa:155|hsa:7124|hsa:6647,9|10|11|14|18|19|178|182|283|284|285|286|299|308|332|333|339|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|392|393|406|416|430|434|441|446|470|490|498|516|520|524|528|540|541|542|544|548|552|556|564|566|567|570|571|573|574|578|582|584|590|592|595|599|603|606|607|608|613|617|618|619|631|634|637|640|641|643|651|655|659|660|663|664|667|668|677|678|679|680|681|683|688|689|690|691|696|698|699|701|702|708|709|710|714|735|761|777|798|824,Epinephrine,"Adrenergic Agents| Adrenergic Agonists| Adrenergic alpha-1 Receptor Agonists| Adrenergic alpha-2 Receptor Agonists| Adrenergic alpha-Agonists| Adrenergic and Dopaminergic Agents| Adrenergic beta-1 Receptor Agonists| Adrenergic beta-2 Receptor Agonists| Adrenergic beta-3 Receptor Agonists| Adrenergic beta-Agonists| Adrenergics, Inhalants| Agents producing tachycardia| Agents that produce hypertension| Alpha-and Beta-adrenergic Agonists| Amines| Anti-Asthmatic Agents| Antiglaucoma Preparations and Miotics| Autonomic Agents| Benzene Derivatives| Biogenic Amines| Biogenic Monoamines| Bronchodilator Agents| Cardiac Stimulants Excl. Cardiac Glycosides| Cardiac Therapy| Cardiovascular Agents| Cardiovascular System| Catecholamines| Catechols| COMT Substrates| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Dental Agents| Drugs for Obstructive Airway Diseases| Epinephrine and similars| Hemostatics| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hyperglycemia-Associated Agents| Local Hemostatics| Mydriatics| Nasal Preparations| Neurotransmitter Agents| OCT1 substrates| OCT2 Inhibitors| OCT2 Substrates| Ophthalmologicals| Peripheral Nervous System Agents| Phenols| Respiratory System| Respiratory System Agents| Stomatological Preparations| Sympathomimetic (Adrenergic) Agents| Sympathomimetics| Sympathomimetics in Glaucoma Therapy| Sympathomimetics, Plain| Vasoconstrictor Agents"
80,DB00307,P19793|P28702|P48443,P08684|P11712,hsa:6256|hsa:6257|hsa:6258,9|10|11|12|18|19|178|182|185|189|192|196|283|284|286|308|332|333|334|344|352|355|356|370|371|374|380|384|406|416|420|430|434|440|441|443|446|452|470|490|493|516|520|524|535|548|552|553|556|564|570|573|574|578|579|582|584|595|597|599|603|608|617|618|619|623|634|637|640|641|655|660|664|667|668|671|672|677|678|679|680|684|688|689|692|696|697|698|699|704|708|709|710|711|712|713|734|755|776|797|818,Bexarotene,"Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Compounds used in a research, industrial, or household setting| Cyclohexanes| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (moderate)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (moderate)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Immunosuppressive Agents| Myelosuppressive Agents| Naphthalenes| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Retinoids| Retinoids for cancer treatment| Tetrahydronaphthalenes"
81,DB00422,Q01959|P23975|P31645,P10635|Q6LAP9,hsa:6531|hsa:6530|hsa:6532,9|10|11|14|18|19|178|180|181|182|185|283|284|285|286|299|332|333|335|338|340|344|345|351|352|355|356|365|366|370|371|374|380|384|390|392|393|405|416|420|430|434|440|441|443|446|452|470|490|516|520|524|528|535|540|552|556|564|570|578|579|580|582|584|592|595|597|599|603|607|608|613|618|634|637|638|640|641|643|655|656|660|664|668|677|678|679|680|683|684|688|689|692|696|697|698|704|708|709|710|712,Methylphenidate,"Acids, Carbocyclic| Agents that produce hypertension| Agents that reduce seizure threshold| Carboxylic Acids| Central Nervous System Agents| Central Nervous System Stimulants| Central Nervous System Stimulation| Centrally Acting Sympathomimetics| Dopamine Agents| Dopamine Uptake Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Medications that reduce magnesium levels| Membrane Transport Modulators| Methylphenidate and isomer| Nervous System| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| Phenylacetates| Piperidines| Psychoanaleptics| Psychostimulants, Agents Used for ADHD and Nootropics| Respiratory and CNS Stimulants"
82,DB00324,P04150,P08684,hsa:2908,9|10|11|12|18|19|20|23|143|144|178|179|182|185|186|192|283|284|286|287|308|332|333|334|335|337|339|341|344|346|352|366|374|406|416|420|430|432|434|441|443|446|462|490|516|524|535|537|553|556|571|579|582|599|617|637|640|660|671|672|678|679|680|681|684|688|689|692|693|696|697|698|699|704|705|708|709|710|711|712|776|777|797|798|818|819|839|840|860|861,Fluorometholone,"Adrenal Cortex Hormones| Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use| Anti-Acne Preparations| Anti-Acne Preparations for Topical Use| Anti-Allergic Agents| Anti-Inflammatory Agents| Cardiovascular System| Corticosteroid Hormone Receptor Agonists| Corticosteroids| Corticosteroids, Dermatological Preparations| Corticosteroids, Moderately Potent (Group II)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inducers| Cytochrome P-450 CYP3A5 Inducers (strength unknown)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Dermatologicals| Fused-Ring Compounds| Glucocorticoids| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Hyperglycemia-Associated Agents| Immunosuppressive Agents| Ophthalmologicals| Polycyclic Compounds| Pregnadienediols| Pregnadienes| Pregnanes| Sensory Organs| Steroids| Steroids, Fluorinated| Thyroxine-binding globulin inhibitors| Vasoprotectives"
83,DB00186,BE0004797|P30536,P54855,hsa:706,9|10|11|14|15|18|19|37|38|178|182|185|189|213|218|219|283|284|285|286|294|299|308|332|333|340|342|344|345|346|351|352|355|356|362|365|366|370|371|376|377|384|390|392|393|406|416|418|420|430|431|434|437|439|441|442|443|446|449|451|453|462|464|470|490|495|501|502|503|516|520|524|536|537|538|545|546|549|550|552|555|556|564|566|569|570|571|576|578|582|584|585|591|592|595|598|599|600|603|607|608|611|613|618|628|633|634|640|643|645|656|657|659|660|664|665|668|677|678|679|683|688|696|697|708|709|710|729|738|758|759|792|801|821|822,Lorazepam,"Anti-Anxiety Agents| Anticonvulsants| Antiemetics| Autonomic Agents| Benzazepines| Benzodiazepine hypnotics and sedatives| Benzodiazepines and benzodiazepine derivatives| Benzodiazepinones| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates (strength unknown)| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| GABA Agents| GABA Modulators| Gastrointestinal Agents| Heterocyclic Compounds| Heterocyclic Compounds, Fused-Ring| Hypnotics and Sedatives| Muscle Relaxants| Muscle Relaxants, Centrally Acting Agents| Nervous System| Neurotransmitter Agents| Peripheral Nervous System Agents| Psycholeptics| Psychotropic Drugs| Tranquilizing Agents"
84,DB01175,P31645|Q01959|P23975|P35348|P11229|P35367,P08684|P33261|P10635,hsa:6532|hsa:6531|hsa:6530|hsa:148|hsa:1128|hsa:3269,9|10|11|12|14|15|18|23|143|149|178|182|185|189|283|284|285|286|287|332|333|337|341|344|345|346|351|352|355|356|364|365|366|370|371|374|384|390|391|405|416|419|429|430|434|441|446|466|470|490|516|520|524|540|548|552|556|564|568|570|573|574|578|582|584|592|594|595|599|603|604|608|613|614|618|619|634|637|640|641|655|660|664|666|668|676|677|678|679|680|682|683|688|689|696|697|698|699|708|709|710|712|713|734|755|776|797|818,Escitalopram,"Amines| Anticholinergic Agents| Antidepressive Agents| Antidepressive Agents Indicated for Depression| Antidepressive Agents, Second-Generation| Benzofurans| Central Nervous System Agents| Central Nervous System Depressants| Combined Inhibitors of Serotonin/Norepinephrine Reuptake| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Highest Risk QTc-Prolonging Agents| Hypoglycemia-Associated Agents| Membrane Transport Modulators| Monoamine Oxidase A Substrates| Muscarinic Antagonists| Nervous System| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| Nitriles| P-glycoprotein substrates| Photosensitizing Agents| Propylamines| Psychoanaleptics| Psychotropic Drugs| QTc Prolonging Agents| Selective Serotonin Reuptake Inhibitors| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin Agents| Serotonin Modulators"
85,DB00719,P35367,P08684,hsa:3269,9|10|11|12|14|15|178|180|181|182|183|184|185|192|213|217|283|284|285|332|333|340|344|345|351|355|356|357|358|365|370|371|372|373|374|376|384|387|390|391|396|403|416|418|430|431|434|435|437|441|442|445|446|447|449|453|464|470|472|482|490|491|495|502|506|516|520|521|523|524|530|538|539|540|545|546|549|552|555|556|564|570|576|577|578|582|584|585|592|595|599|600|603|607|608|613|618|628|633|634|640|656|657|660|664|665|668|677|678|679|683|688|696|697|708|709|710|712|755|818,Azatadine,"Agents that reduce seizure threshold| Anticholinergic Agents| Antihistamines for Systemic Use| Benzocycloheptenes| Cholinergic Agents| Dibenzocycloheptenes| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Neurotransmitter Agents| Piperidines| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Respiratory System"
86,DB04908,P08908|P28223|P21917,P08684,hsa:3350|hsa:3356|hsa:1815,9|10|11|12|14|15|16|18|23|24|143|145|146|178|180|181|182|185|189|192|283|284|285|286|287|299|332|333|340|344|345|351|355|356|357|358|363|365|370|371|375|376|377|379|384|386|387|389|390|391|392|393|396|397|399|400|403|416|418|420|430|431|434|437|441|442|446|449|450|451|453|464|470|472|482|484|485|487|488|490|495|499|502|504|506|516|519|520|521|523|524|527|530|538|539|540|545|546|547|549|552|555|556|560|564|569|570|572|576|578|582|584|585|592|595|596|599|600|603|607|608|611|613|618|628|633|634|636|640|643|645|646|654|656|657|660|664|665|668|674|677|678|679|683|688|708|709|710|737|770|800|833,Flibanserin,"Agents that produce hypertension| Antidepressive Agents| Central Nervous System Depressants| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Genito Urinary System and Sex Hormones| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Miscellaneous Central Nervous System Agents| P-glycoprotein inhibitors| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT1 Receptor Agonists| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin Agents| Serotonin Modulators| Serotonin Receptor Agonists| Serotonin Receptor Antagonists"
87,DB00988,P14416|P21728|P21918|P35462|P21917|Q01959|P09172|P08908|P34969|BE0004889|P23975|P31645|P46098|O95264|P00441|Q05940,P21397|P27338|P21964|P09172|P05177|P33261|P11712|P10635,hsa:1813|hsa:1812|hsa:1816|hsa:1814|hsa:1815|hsa:6531|hsa:1621|hsa:3350|hsa:3363|hsa:6530|hsa:6532|hsa:3359|hsa:9177|hsa:6647|hsa:6571,9|10|11|14|18|19|178|182|283|284|285|286|299|308|332|333|341|344|345|351|352|355|356|365|370|371|381|382|384|393|406|416|430|434|441|446|470|490|498|516|520|524|528|541|542|544|548|552|556|564|567|570|573|574|578|582|584|590|592|595|599|603|606|607|608|617|618|619|631|634|637|640|641|643|651|655|660|663|664|667|668|677|678|679|680|683|688|689|691|696|698|699|708|709|710|714|735|761|777|798|824,Dopamine,"Adrenergic and Dopaminergic Agents| Agents producing tachycardia| Agents that produce hypertension| Amines| Autonomic Agents| Benzene Derivatives| Biogenic Amines| Biogenic Monoamines| Cardiac Stimulants Excl. Cardiac Glycosides| Cardiac Therapy| Cardiotonic Agents| Cardiovascular Agents| Cardiovascular System| Catecholamines| Catechols| Compounds used in a research, industrial, or household setting| COMT Substrates| Dopamine Agents| Dopamine, metabolism| Drugs that are Mainly Renally Excreted| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Monoamine Oxidase A Substrates| Neurotransmitter Agents| OCT1 substrates| OCT2 Inhibitors| OCT2 Substrates| Peripheral Nervous System Agents| Phenols| Protective Agents| Selective Beta 1-adrenergic Agonists| Sympathomimetics"
88,DB06237,O76074,P08684,hsa:8654,9|10|11|12|14|15|16|18|19|37|143|145|146|178|182|183|184|185|190|191|192|283|284|285|286|294|299|308|332|333|338|340|341|342|344|345|346|351|352|355|356|358|359|362|365|366|370|371|372|373|374|375|376|378|379|381|382|384|387|389|390|391|392|393|396|403|405|406|416|418|420|430|434|435|438|439|441|442|443|445|446|447|449|450|451|453|464|470|472|476|482|484|487|490|491|493|495|498|501|502|503|504|505|506|516|519|520|521|523|524|528|530|535|538|539|540|541|542|545|546|548|549|550|551|552|553|555|556|560|564|565|566|569|570|571|572|573|574|576|578|580|582|583|584|585|589|591|592|593|594|595|596|598|599|601|603|604|606|607|608|611|613|617|618|619|621|624|626|628|633|634|636|637|640|641|645|646|651|654|655|656|657|659|660|664|666|668|672|673|674|677|678|679|680|683|688|689|691|702|708|709|710|714|738|764|777|801|827,Avanafil,"BCRP/ABCG2 Inhibitors| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs Used in Erectile Dysfunction| Genito Urinary System and Sex Hormones| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| P-glycoprotein substrates| Phosphodiesterase 5 Inhibitors| Phosphodiesterase Inhibitors| Urologicals| Vasodilating Agents"
89,DB08918,P31645|P23975,P08684|P10632|P33261|P10635|P51589,hsa:6532|hsa:6530,9|10|11|14|15|18|115|116|178|182|283|284|285|286|299|332|333|334|335|344|345|351|352|355|356|365|370|371|374|384|390|391|393|416|420|430|434|439|441|443|446|451|470|490|516|520|524|528|535|540|552|556|564|570|578|579|582|584|592|595|597|599|603|607|608|613|618|634|640|643|645|646|656|660|664|668|677|678|679|683|684|685|688|692|695|696|697|704|708|709|710|711|712,Levomilnacipran,"Adrenergic Uptake Inhibitors| Agents producing tachycardia| Antidepressive Agents| Antidepressive Agents Indicated for Depression| Central Nervous System Agents| Central Nervous System Depressants| Combined Inhibitors of Serotonin/Norepinephrine Reuptake| Cycloparaffins| Cyclopropanes| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Hydrocarbons| Hydrocarbons, Alicyclic| Hydrocarbons, Cyclic| Hypoglycemia-Associated Agents| Membrane Transport Modulators| Milnacipran and enantiomer| Miscellaneous Antidepressants| Nervous System| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| Norepinephrine Uptake Inhibitors| P-glycoprotein substrates| Psychoanaleptics| Psychotropic Drugs| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin Agents| Serotonin and Noradrenaline Reuptake Inhibitors| Serotonin Modulators"
90,DB03756,Q07869|P37231|P19793|P28702|P48443|P36956,P11712,hsa:5465|hsa:5468|hsa:6256|hsa:6257|hsa:6258|hsa:6720,9|10|11|12|18|19|283|284|286|308|332|344|352|374|380|406|416|420|434|440|441|443|446|452|490|516|524|535|556|579|599|617|637|640|660|678,Doconexent,"Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dietary Fats| Dietary Fats, Unsaturated| Fats| Fatty Acids| Fatty Acids, Omega-3| Fatty Acids, Unsaturated| Fish Oils| Lipids| Oils"
91,DB00283,P35367,P10635|P08684,hsa:3269,9|10|11|12|14|18|37|143|145|146|178|182|185|189|283|284|285|286|294|332|333|337|338|340|341|342|344|345|346|351|352|355|356|362|365|366|370|371|374|384|390|391|405|416|430|434|441|446|470|490|501|503|516|520|524|540|548|550|552|556|564|570|573|574|578|582|584|591|592|594|595|598|599|603|604|608|613|614|618|619|634|637|638|640|641|655|656|660|664|666|668|677|678|679|680|683|688|689|696|697|698|708|709|710|712|717|780,Clemastine,"Aminoalkyl Ethers| Anti-Allergic Agents| Antihistamines for Systemic Use| Antihistamines for Topical Use| Antipruritics| Antipruritics, Incl. Antihistamines, Anesthetics, Etc.| Central Nervous System Depressants| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Dermatologicals| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Highest Risk QTc-Prolonging Agents| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Neurotransmitter Agents| Pyrrolidines| QTc Prolonging Agents| Respiratory System"
92,DB00584,P12821,P08684,hsa:1636,9|10|11|12|14|15|18|19|20|143|145|146|178|182|283|284|285|286|299|308|332|333|338|340|344|345|346|351|352|355|356|365|366|370|371|374|380|384|390|391|392|393|405|406|416|420|430|434|439|440|441|443|446|451|452|470|490|516|520|524|528|535|536|540|552|556|564|566|569|570|578|579|582|584|592|595|599|602|603|608|611|613|614|615|617|618|634|637|640|643|645|646|656|659|660|664|668|677|678|679|680|683|684|688|689|691|692|695|696|698|699|702|704|708|709|710,Enalapril,"ACE Inhibitors and Calcium Channel Blockers| ACE Inhibitors and Diuretics| Agents Acting on the Renin-Angiotensin System| Agents causing angioedema| Agents causing hyperkalemia| Agents Causing Muscle Toxicity| Amino Acids, Peptides, and Proteins| Angiotensin-Converting Enzyme Inhibitors| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Cardiovascular Agents| Cardiovascular System| Decreased Blood Pressure| Dipeptides| Drugs causing inadvertant photosensitivity| Enzyme Inhibitors| Hypotensive Agents| OAT1/SLC22A6 inhibitors| OAT3/SLC22A8 Inhibitors| OATP1B1/SLCO1B1 Substrates| Oligopeptides| P-glycoprotein inhibitors| Peptides| Photosensitizing Agents| Protease Inhibitors"
93,DB00158,P14207|P41439|P15328,P05181|Q92820|P42898,hsa:2350|hsa:2352|hsa:2348,9|10|11|12|14|15|16|18|19|20|178|182|183|184|185|190|191|192|283|284|285|286|299|308|332|333|338|340|344|345|351|352|355|356|357|358|359|365|370|371|372|373|375|376|377|378|379|380|381|384|386|387|388|389|390|392|393|396|399|400|403|406|416|418|420|430|431|434|435|437|438|439|440|441|442|443|445|446|447|449|450|451|452|453|464|470|472|482|484|485|487|488|490|491|493|494|495|499|502|504|506|516|519|520|521|523|524|527|528|530|535|536|538|539|540|545|546|547|549|552|553|555|556|560|564|566|569|570|572|577|578|579|580|582|584|585|592|593|595|596|597|599|600|601|602|603|607|608|611|613|617|618|621|623|624|628|633|634|636|637|640|643|645|646|647|654|656|657|659|660|664|665|668|671|672|673|674|677|678|679|680|682|683|684|685|688|690|692|693|694|695|704|707|708|709|710|716|779,Folicacid,"Antianemic Preparations| Autacoids| BCRP/ABCG2 Substrates| Biological Factors| Diagnostic Agents| Diet, Food, and Nutrition| Dietary Supplements| Drugs that are Mainly Renally Excreted| Folic Acid and Derivatives| Food| Growth Substances| Hematinics| Hematologic Agents| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Micronutrients| OAT1/SLC22A6 inhibitors| Pteridines| Pterins| Supplements| Vitamin B Complex| Vitamin B12 and Folic Acid| Vitamins"
94,DB00530,P00533|O75469,P08684|P20815|P05177|P04798|P10635|P10632|Q16678|P22309,hsa:1956|hsa:8856,9|10|11|12|14|15|18|19|20|178|182|183|184|185|189|192|283|284|285|286|299|332|333|340|341|344|346|351|352|355|356|357|358|365|366|370|371|373|374|375|376|377|378|379|381|382|384|385|386|387|389|390|392|393|396|403|405|416|417|418|427|428|430|431|434|437|438|441|442|446|447|449|450|453|460|464|470|472|476|482|484|487|490|491|495|498|502|504|506|516|519|520|521|523|524|530|538|539|540|541|542|544|545|546|548|549|552|555|556|560|564|565|567|570|572|573|574|576|577|578|582|584|585|589|592|593|594|595|596|599|600|601|603|604|606|607|608|613|614|618|619|620|621|626|628|630|632|633|634|636|637|638|640|641|643|651|652|654|655|656|657|660|662|664|665|666|668|674|677|678|679|680|682|683|688|689|691|699|702|703|708|709|710|714|721|735|737|742|758|761|777|784|798|800|805|821|824,Erlotinib,"Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| BCRP/ABCG2 Inhibitors| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strong)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Enzyme Inhibitors| Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Highest Risk QTc-Prolonging Agents| Kinase Inhibitor| Narrow Therapeutic Index Drugs| Organic Anion Transporting Polypeptide 2B1 Inhibitors| P-glycoprotein inhibitors| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Protein Kinase Inhibitors| QTc Prolonging Agents| Quinazolines| Tyrosine Kinase Inhibitors| UGT1A1 Inhibitors"
95,DB00262,P00390,P05177,hsa:2936,9|10|14|15|18|19|37|38|283|284|285|286|294|299|300|301|342|343|344|345|351|361|365|375|390|392|393|420|423|451|515|517|518|528|540|560|609|635|636|643|645|646|654,Carmustine,"Alkylating Activity| Alkylating Drugs| Amides| Antineoplastic Agents| Antineoplastic Agents, Alkylating| Antineoplastic and Immunomodulating Agents| Cardiotoxic antineoplastic agents| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Immunosuppressive Agents| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| Nitroso Compounds| Nitrosourea Compounds| Nitrosoureas| Noxae| Toxic Actions"
96,DB00623,P14416|P21728|P0DP23|P10275|P28223|P28335,P10635|P05177|P05181,"hsa:1813|hsa:1812|hsa:801,hsa:805,hsa:808|hsa:367|hsa:3356|hsa:3358",9|10|11|12|14|15|18|23|24|33|178|180|181|182|183|184|185|189|192|199|283|284|285|286|287|293|308|332|333|340|344|345|346|351|352|353|355|356|363|365|366|370|371|376|377|383|384|390|391|406|412|416|430|434|437|441|446|449|464|470|490|495|500|502|507|516|520|524|531|532|533|540|545|546|549|552|556|564|566|569|570|571|577|578|582|584|585|586|592|593|595|599|600|603|607|608|611|613|618|628|633|634|640|656|657|658|659|660|664|665|668|677|678|679|683|688|708|709|710|715|737|767|778|800|830,Fluphenazine,"Agents that reduce seizure threshold| Antipsychotic Agents| Antipsychotic Agents (First Generation [Typical])| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (weak)| Cytochrome P-450 Enzyme Inhibitors| Delayed-Action Preparations| Dopamine Agents| Dopamine Antagonists| Dopamine D2 Receptor Antagonists| Drugs causing inadvertant photosensitivity| Heterocyclic Compounds| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Nervous System| Neurotoxic agents| Neurotransmitter Agents| P-glycoprotein inhibitors| Phenothiazines| Phenothiazines With Piperazine Structure| Photosensitizing Agents| Psycholeptics| Psychotropic Drugs| Sulfur Compounds| Tranquilizing Agents"
97,DB00882,P03372|P04278,P05108|P11511|P04798|P05177|P11509|P05181|P08684,hsa:2099|hsa:6462,9|10|11|12|14|18|37|178|182|185|189|192|196|283|284|285|286|294|332|333|341|342|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|391|405|416|430|434|441|446|470|476|490|498|516|520|524|540|541|542|548|550|552|556|564|565|566|570|573|574|578|582|584|589|591|594|595|599|603|604|606|608|614|615|618|619|620|626|632|634|637|640|641|651|655|656|659|660|664|666|668|677|678|679|680|688|689|696|697|698|708|709|710|714|777,Clomifene,"Benzene Derivatives| Benzylidene Compounds| Clomiphene| Estrogen Agonist-antagonists| Estrogen Agonist/Antagonist| Estrogen Antagonists| Estrogen Receptor Modulators| Fertility Agents| Fertility Agents, Female| Genito Urinary System and Sex Hormones| Hormone Antagonists| Hormones, Hormone Substitutes, and Hormone Antagonists| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Ovulation Stimulants, Synthetic| P-glycoprotein substrates| Reproductive Control Agents| Selective Estrogen Receptor Modulators| Sex Hormones and Modulators of the Genital System| Stilbenes"
98,DB09166,P14867|P47869|P34903|P18507|P25105,P08684|P33260|P33261,hsa:2554|hsa:2555|hsa:2556|hsa:2566|hsa:5724,9|10|11|12|14|15|16|33|37|143|148|149|150|156|178|182|213|218|219|283|284|285|293|294|300|332|333|340|342|344|345|351|353|355|356|358|359|362|365|370|371|374|375|376|379|383|384|389|390|391|396|397|403|412|416|418|421|422|430|431|434|438|441|442|446|449|450|453|464|467|470|471|472|480|482|484|486|487|489|490|495|500|501|503|504|506|507|508|513|515|516|517|519|520|524|531|532|538|539|545|549|550|552|555|556|560|564|569|570|572|576|578|582|584|585|586|591|592|595|596|598|599|600|603|607|608|611|613|618|628|633|634|640|644|654|656|657|658|660|664|665|668|674|677|678|679|683|688|696|697|708|709|710|759|822,Etizolam,"Anti-Anxiety Agents| Benzazepines| Benzodiazepine hypnotics and sedatives| Benzodiazepines and benzodiazepine derivatives| Benzodiazepinones| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2C18 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hypnotics and Sedatives| Muscle Relaxants| Muscle Relaxants, Centrally Acting Agents| Nervous System| Psycholeptics| Psychotropic Drugs| Tranquilizing Agents"
99,DB04871,P28335,P05177|P11509|P20813|P33261|P10635|P08684|Q01740|P04798,hsa:3358,9|10|11|14|37|178|182|213|215|216|283|284|285|294|299|332|333|335|342|344|345|351|355|356|362|365|370|371|374|384|390|392|393|416|430|434|441|446|470|490|501|503|516|520|524|528|540|550|552|556|564|570|578|582|584|591|592|595|598|599|603|607|608|613|618|634|640|643|656|660|664|668|677|678|679|683|688|696|697|708|709|710|712|717|738|755|780|801|818,Lorcaserin,"Alimentary Tract and Metabolism| Antidepressive Agents| Antiobesity Preparations, Excl. Diet Products| Central Nervous System Depressants| Centrally Acting Antiobesity Products| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (moderate)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 2c Receptor Agonists| Serotonin 5-HT2 Receptor Agonists| Serotonin 5-HT2C Receptor Agonists| Serotonin Agents| Serotonin Modulators| Serotonin Receptor Agonists"
100,DB00182,Q05940|Q01959|Q16568|Q96RJ0|P23975|BE0004888|BE0004872|P14416|P27338|P31645|BE0004909|Q99870,P10635|P11509,hsa:6571|hsa:6531|hsa:9607|hsa:134864|hsa:6530|hsa:1813|hsa:4129|hsa:6532,9|10|11|14|178|182|283|284|285|299|332|333|338|340|344|345|351|355|356|365|370|371|374|384|393|416|430|434|441|446|470|490|516|520|524|528|552|556|564|570|578|582|584|592|595|599|603|607|608|618|634|640|643|660|664|668|677|678|679|683|688|696|708|709|710,Amphetamine,"Adrenergic Agents| Agents producing tachycardia| Agents that produce hypertension| Agents that reduce seizure threshold| Amines| Amphetamines| Autonomic Agents| Benzene Derivatives| Biogenic Amines| Biogenic Monoamines| Catechols| Central Nervous System Agents| Central Nervous System Stimulants| Central Nervous System Stimulation| Centrally Acting Sympathomimetics| Cytochrome P-450 CYP2A6 Inhibitors| Cytochrome P-450 CYP2A6 Inhibitors (weak)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dopamine Agents| Dopamine Uptake Inhibitors| Drugs that are Mainly Renally Excreted| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Membrane Transport Modulators| Nervous System| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| Peripheral Nervous System Agents| Phenethylamines| Phenols| Psychoanaleptics| Psychostimulants, Agents Used for ADHD and Nootropics| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Sympathomimetics"
101,DB01355,P14867|P47869|P34903|P48169|P31644|Q16445|P43681|P36544|P42262|Q13002,P33261|P11712|P23219|P05181|P05177|P08684,hsa:2554|hsa:2555|hsa:2556|hsa:2557|hsa:2558|hsa:2559|hsa:1137|hsa:1139|hsa:2891|hsa:2898,9|10|11|14|15|18|19|178|180|181|182|185|283|284|285|286|299|332|333|334|344|351|352|365|374|375|390|391|392|393|416|420|430|434|439|441|443|446|451|490|524|535|540|556|560|579|580|582|588|592|593|599|613|636|640|645|646|647|650|654|660|678|679|683|684|688|692|696|697|704|708|709|711,Hexobarbital,"Adjuvants| Anesthetics| Anesthetics, General| Anticholinergic Agents| Anticonvulsants| Barbiturates| Barbiturates, Plain| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 Substrates| GABA Agents| GABA Modulators| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypnotics and Sedatives| Nervous System| Neurotransmitter Agents| Nicotinic Antagonists| Psycholeptics| Pyrimidines| Pyrimidinones"
102,DB01204,P11388,P05181|Q16678|P08684,hsa:7153,9|10|11|12|14|15|16|18|19|20|178|179|182|185|189|192|283|284|285|286|299|308|332|333|340|341|344|345|346|351|352|355|356|365|366|370|371|376|377|381|382|384|390|392|393|406|416|420|430|432|434|437|441|443|446|449|464|470|490|493|495|498|502|516|520|524|528|535|540|541|542|545|546|548|549|552|553|556|564|566|569|570|571|573|574|578|579|580|581|582|584|585|590|592|595|597|600|603|606|607|608|611|613|617|618|619|623|624|625|628|633|634|637|640|641|642|643|651|655|656|657|659|660|664|665|667|668|671|673|677|678|679|680|681|683|684|685|686|687|688|689|691|692|696|697|698|699|702|703|704|708|709|710|712|719|728|735|737|755|756|758|776|782|791|797|798|800|818|819|821,Mitoxantrone,"Analgesics| Anthracenes| Anthracyclines and Related Substances| Anthraquinones| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| BCRP/ABCG2 Substrates| Cardiotoxic antineoplastic agents| Central Nervous System Agents| Cytochrome P-450 CYP2E1 Inducers| Cytochrome P-450 CYP2E1 Inducers (strength unknown)| Cytochrome P-450 CYP2E1 Inducers (weak)| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Cytotoxic Antibiotics and Related Substances| Enzyme Inhibitors| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Immunosuppressive Agents| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| P-glycoprotein inducers| P-glycoprotein inhibitors| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Peripheral Nervous System Agents| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Quinones| Sensory System Agents| Topoisomerase II Inhibitors| Topoisomerase Inhibitors"
103,DB13956,P03372|O75469|Q92731|P43681|Q15596|Q99527|P00846|Q14457|P37059|P62508,P05177|P22309|P08684|P20815|P24462|P04798|Q16678|P33261|P10632|P11712,hsa:2099|hsa:8856|hsa:2100|hsa:1137|hsa:10499|hsa:2852|hsa:4508|hsa:8678|hsa:3294|hsa:2104,9|10|11|12|18|19|143|144|178|179|182|185|189|192|283|284|286|308|332|333|334|335|339|341|344|346|352|355|356|366|370|371|374|380|381|382|384|405|406|416|420|430|434|440|441|443|446|452|470|490|498|516|520|524|535|541|542|548|552|556|564|570|573|574|578|579|582|584|590|595|599|603|606|608|614|617|618|619|634|637|640|641|651|655|660|664|667|668|677|678|679|680|684|688|689|696|697|698|699|708|709|710|711|712|714|735|755|776|777|797|798|818|840|860|861,Estradiolvalerate,"Adrenal Cortex Hormones| BCRP/ABCG2 Inhibitors| Contraceptive Agents, Female| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP1A2 Inhibitors (weak)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Estradiol Congeners| Estradiol, agonists| Estranes| Estrenes| Estrogen Contraceptives| Estrogens| Fused-Ring Compounds| Gonadal Hormones| Gonadal Steroid Hormones| Hormonal Contraceptives for Systemic Use| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| OATP1B1/SLCO1B1 Inhibitors| OCT1 inhibitors| OCT2 Inhibitors| Organic Anion Transporting Polypeptide 2B1 Inhibitors| P-glycoprotein substrates| Polycyclic Compounds| Steroids| Thyroxine-binding globulin inducers| UGT1A1 Substrates"
104,DB00476,P31645|P23975|Q01959,P05177|P10635,hsa:6532|hsa:6530|hsa:6531,9|10|11|12|14|18|33|143|149|178|182|185|189|283|284|285|286|293|299|332|333|339|341|344|345|346|349|351|352|353|355|356|365|366|368|370|371|374|381|382|383|384|385|390|392|393|405|412|416|421|430|434|441|446|470|471|476|480|490|498|500|507|513|516|520|524|528|531|532|540|541|542|548|552|556|564|565|570|573|574|578|582|584|586|589|592|594|595|599|603|604|606|608|613|614|618|619|620|626|632|634|637|638|640|641|643|651|655|658|660|664|666|668|677|678|679|680|683|688|689|696|698|699|708|709|710|712|735|755|756|798|818|819,Duloxetine,"Agents producing tachycardia| Analgesics| Antidepressive Agents| Antidepressive Agents Indicated for Depression| Central Nervous System Agents| Central Nervous System Depressants| Combined Inhibitors of Serotonin/Norepinephrine Reuptake| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (moderate)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypoglycemia-Associated Agents| Membrane Transport Modulators| Nervous System| Neurotransmitter Uptake Inhibitors| Norepinephrine Uptake Inhibitors| P-glycoprotein inhibitors| Peripheral Nervous System Agents| Psychoanaleptics| Psychotropic Drugs| Selective Serotonin Reuptake Inhibitors| Sensory System Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin Agents| Serotonin and Noradrenaline Reuptake Inhibitors| Serotonin Modulators| Sulfur Compounds| Thiophenes"
105,DB06702,P20309|P08173|P11229|P08172|P08912,P08684|P10635,hsa:1131|hsa:1132|hsa:1128|hsa:1129|hsa:1133,9|10|11|12|14|18|19|178|182|185|189|283|284|285|286|308|332|333|335|338|340|341|344|345|346|351|352|355|356|365|366|370|371|374|380|381|382|384|390|391|405|406|416|420|430|434|440|441|443|446|452|470|476|490|498|516|520|524|535|540|541|542|548|552|556|564|565|570|571|573|574|578|582|584|589|592|594|595|599|603|604|606|608|613|614|617|618|619|620|622|626|632|634|637|640|641|651|655|656|660|664|666|667|668|677|678|679|680|683|688|689|690|691|696|697|698|699|700|701|702|708|709|710|712|714|734|756|777|797|819,Fesoterodine,"Agents producing tachycardia| Anticholinergic Agents| Benzene Derivatives| Cholinergic Agents| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs for Urinary Frequency and Incontinence| Drugs that are Mainly Renally Excreted| Genito Urinary System and Sex Hormones| Genitourinary Agents| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Muscarinic Antagonists| Neurotransmitter Agents| P-glycoprotein substrates| Urological Agents| Urologicals"
106,DB00215,P31645|P35367|P35348|P11229|P28335,P08684|P33261|P10635|P05181|P05177|P20813,hsa:6532|hsa:3269|hsa:148|hsa:1128|hsa:3358,9|10|11|12|14|15|18|23|143|149|178|182|185|189|283|284|285|286|287|332|333|337|341|344|345|346|351|352|355|356|364|365|366|370|371|374|384|390|391|405|416|419|429|430|434|441|446|466|470|490|516|520|524|540|548|552|556|564|568|570|573|574|578|582|584|592|594|595|599|603|604|608|613|614|618|619|634|637|640|641|655|660|664|666|668|676|677|678|679|680|682|683|688|689|696|697|698|699|708|709|710|712|713|734|755|776|797|818,Citalopram,"Amines| Antidepressive Agents| Antidepressive Agents Indicated for Depression| Antidepressive Agents, Second-Generation| Benzofurans| Central Nervous System Agents| Central Nervous System Depressants| Combined Inhibitors of Serotonin/Norepinephrine Reuptake| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (weak)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (weak)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Heterocyclic Compounds, Fused-Ring| Highest Risk QTc-Prolonging Agents| Hypoglycemia-Associated Agents| Monoamine Oxidase A Substrates| Nervous System| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| Nitriles| P-glycoprotein inhibitors| P-glycoprotein substrates| Propylamines| Psychoanaleptics| Psychotropic Drugs| QTc Prolonging Agents| Selective Serotonin Reuptake Inhibitors| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT2 Receptor Antagonists| Serotonin Agents| Serotonin Modulators| Serotonin Receptor Antagonists| Vasodilating Agents"
107,DB00264,P08588|P07550,P10635|P33261,hsa:153|hsa:154,9|10|11|14|18|19|178|182|283|284|285|286|299|308|332|333|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|392|393|405|406|416|430|434|441|446|470|476|490|498|516|520|524|528|540|541|542|548|552|556|564|565|566|567|570|571|573|574|578|582|584|589|594|595|599|603|604|606|608|613|614|618|619|620|626|632|634|637|638|640|641|643|651|655|656|659|660|662|663|664|666|668|677|678|679|680|688|689|696|698|708|709|710|714|777,Metoprolol,"Adrenergic Agents| Adrenergic Antagonists| Adrenergic beta-1 Receptor Antagonists| Adrenergic beta-Antagonists| Agents causing hyperkalemia| Alcohols| Amines| Amino Alcohols| Antiarrhythmic agents| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Beta blocking agents and calcium channel blockers| Beta Blocking Agents and Thiazides| Beta Blocking Agents, Selective| Beta Blocking Agents, Selective, and Thiazides| Beta-Blockers (Beta1 Selective)| Bradycardia-Causing Agents| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (moderate)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Drugs that are Mainly Renally Excreted| Hypotensive Agents| OCT2 Inhibitors| Photosensitizing Agents| Propanolamines"
108,DB00390,P05023,P05108|P08684,hsa:476,9|10|11|12|13|18|19|20|21|143|144|149|150|178|179|181|185|186|188|192|193|195|199|206|283|284|286|308|332|333|334|335|337|339|341|344|346|347|352|366|367|374|380|405|406|416|420|430|434|440|441|443|446|452|490|524|553|556|563|567|571|573|582|594|599|610|614|617|619|637|639|640|660|661|662|663|666|671|678|679|680|681|688|689|690|696|697|698|699|700|701|708|709|710|711|712|776|777|797|798|803|818|819|839|840|860|861,Digoxin,"Agents causing hyperkalemia| Antiarrhythmic agents| Bradycardia-Causing Agents| BSEP/ABCB11 Substrates| BSEP/ABCB11 Substrates with a Narrow Therapeutic Index| Carbohydrates| Cardanolides| Cardenolides| Cardiac Glycosides| Cardiac Therapy| Cardiotonic Agents| Cardiovascular Agents| Cardiovascular System| Compounds used in a research, industrial, or household setting| Digitalis Glycosides| Digoxin and derivatives| Digoxin, immunology| Drugs that are Mainly Renally Excreted| Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index| Fused-Ring Compounds| Glycosides| Medications that reduce magnesium levels| Narrow Therapeutic Index Drugs| OATP1B1/SLCO1B1 Inhibitors| OATP1B1/SLCO1B1 Substrates| P-glycoprotein inducers| P-glycoprotein inhibitors| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Polycyclic Compounds| Potential QTc-Prolonging Agents| Protective Agents| QTc Prolonging Agents"
109,DB00924,P28223,P05177|P08684|P10635,hsa:3356,9|10|11|12|14|178|182|185|189|213|217|283|284|285|332|333|344|345|351|355|356|365|370|371|374|384|390|391|416|430|434|441|446|470|490|516|520|524|540|552|556|564|570|578|582|584|595|599|603|608|613|618|634|640|660|664|668|677|678|679|688|696|697|708|709|710|712|755|818,Cyclobenzaprine,"Agents that reduce seizure threshold| Antidepressive Agents| Benzocycloheptenes| Central Nervous System Agents| Central Nervous System Depressants| Centrally-mediated Muscle Relaxation| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Dibenzocycloheptenes| Drugs causing inadvertant photosensitivity| Muscle Relaxants| Muscle Relaxants, Centrally Acting Agents| Musculo-Skeletal System| Neurotoxic agents| Photosensitizing Agents| Polycyclic Compounds| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin 5-HT2C Receptor Antagonists| Serotonin Agents| Serotonin Receptor Antagonists| Tranquilizing Agents| UGT1A4 substrates"
110,DB00544,P04818,P11712|P05177|P19971|Q12882|Q16831|O95045|P11509|P10632|P42898|P04818|P11172|Q06203,hsa:7298,9|10|14|15|18|19|23|178|183|184|283|284|285|286|287|299|332|344|345|351|352|355|358|364|365|370|372|373|375|376|379|381|384|387|389|390|392|393|396|399|400|403|416|418|420|435|439|441|442|443|445|446|447|449|450|451|453|464|472|482|484|487|488|491|493|495|504|506|519|521|523|527|528|530|535|538|540|545|549|553|555|560|572|576|580|585|593|596|601|613|621|624|628|636|645|646|647|650|654|657|672|673|674,Fluorouracil,"Antimetabolites| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| BCRP/ABCG2 Substrates| Cardiotoxic antineoplastic agents| CMF chemotherapy regimen| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Fluoropyrimidines| Fluorouracil and prodrugs| FOLFIRI chemotherapy regimen| FOLFOX chemotherapy regimen| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Immunologic Factors| Immunosuppressive Agents| Misc. Skin and Mucous Membrane Agents| Moderate Risk QTc-Prolonging Agents| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| Noxae| Nucleic Acid Synthesis Inhibitors| Nucleoside Metabolic Inhibitor| Photosensitizing Agents| Pyrimidine Analogues| Pyrimidines| Pyrimidinones| QTc Prolonging Agents| Thyroxine-binding globulin inducers| Toxic Actions"
111,DB00280,Q14524|P11229|P08172|P20309|Q9NZV8|Q9UK17|Q12809|P19652,P08684,hsa:6331|hsa:1128|hsa:1129|hsa:1131|hsa:3751|hsa:3752|hsa:3757|hsa:5005,9|10|11|12|14|15|18|178|182|183|184|185|283|284|285|286|299|332|333|334|338|340|344|345|351|352|355|356|357|358|365|370|371|372|373|374|376|384|387|390|391|393|396|403|416|418|420|430|431|434|435|437|439|441|442|443|445|446|447|449|451|453|464|470|472|482|490|491|495|502|506|516|520|521|523|524|530|535|538|539|540|545|546|549|552|555|556|564|570|576|577|578|579|580|582|584|585|592|593|595|597|599|600|603|607|608|613|618|628|633|634|640|656|657|660|664|665|668|677|678|679|683|684|685|688|692|696|697|704|708|709|710|711|712,Disopyramide,"Agents producing tachycardia| Antiarrhythmic agents| Antiarrhythmics, Class I| Antiarrhythmics, Class Ia| Anticholinergic Agents| Blood Glucose Lowering Agents| Cardiac Therapy| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Highest Risk QTc-Prolonging Agents| Hypoglycemia-Associated Agents| Membrane Transport Modulators| Muscarinic Antagonists| Negative Inotrope| OCT1 inhibitors| OCT2 Inhibitors| Pyridines| QTc Prolonging Agents| Sodium Channel Blockers| Voltage-Gated Sodium Channel Blockers"
112,DB00333,P35372|Q8TCU5|Q9GZZ6|P41143|P46098|Q9Y6Y9|P19652,P08684|P33261|P20815|P24462|P10635|P20813|P10632|P11511|P05177|P33260|P11712,hsa:4988|hsa:116443|hsa:57053|hsa:4985|hsa:3359|hsa:23643|hsa:5005,9|10|11|12|14|18|178|182|185|189|283|284|285|286|332|333|334|338|340|341|344|345|351|352|355|356|365|370|371|374|384|390|391|416|420|430|432|434|441|443|446|470|490|516|520|524|535|540|552|556|564|570|578|579|582|584|592|595|597|599|603|608|613|618|634|640|660|664|668|677|678|679|683|684|685|688|692|696|697|704|708|709|710|711|712,Methadone,Analgesics| Anticholinergic Agents| Antidepressive Agents| Antitussive Agents| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (strength unknown)| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C18 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Diphenylheptane opioids| Diphenylpropylamine Derivatives| Drugs that are Mainly Renally Excreted| Drugs Used in Addictive Disorders| Drugs Used in Opioid Dependence| High-risk opioids| Ketones| Moderate Risk QTc-Prolonging Agents| Narcotics| Nervous System| Nicotinic Antagonists| NMDA Receptor Antagonists| Opiate Agonists| Opioid Agonist| Opioids| P-glycoprotein inhibitors| Peripheral Nervous System Agents| QTc Prolonging Agents| Respiratory System Agents| Sensory System Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin Agents| Serotonin Modulators| Thyroxine-binding globulin inducers
113,DB00574,P31645|P41595|P28335|P28223,P10635,hsa:6532|hsa:3357|hsa:3358|hsa:3356,9|10|11|14|23|24|178|182|283|284|285|287|299|332|333|338|340|344|345|351|355|356|363|365|370|371|374|384|390|392|393|416|430|434|441|446|470|490|516|520|524|528|540|552|556|564|570|578|582|584|592|595|599|603|607|608|613|618|634|640|643|656|660|664|668|677|678|679|683|688|696|697|708|709|710|734|797,Fenfluramine,"Alimentary Tract and Metabolism| Amines| Anticonvulsants| Antidepressive Agents| Antiobesity Preparations, Excl. Diet Products| Central Nervous System Depressants| Centrally Acting Antiobesity Products| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Ethylamines| Membrane Transport Modulators| Nervous System| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| Phenethylamines| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT2 Receptor Agonists| Serotonin Agents| Serotonin Receptor Agonists| Stimulants"
114,DB01026,P10613|P10275|P08686|P11511|Q12809|O75469|Q14994,P08684|P10635|P11712|P33261|P20815|P24462|P10632|P05177|P04798|P05108|P15538|Q16678|O43174|P11509|P20813|Q16850,hsa:367|hsa:1589|hsa:1588|hsa:3757|hsa:8856|hsa:9970,9|10|11|12|14|15|16|18|19|20|37|38|143|146|148|149|150|178|180|181|182|185|189|192|283|284|285|286|294|332|333|339|340|341|342|344|345|346|351|352|355|356|358|362|365|366|370|371|372|373|374|375|376|377|379|380|381|382|384|387|389|390|391|396|397|403|405|416|418|420|430|434|435|437|439|441|442|443|445|446|447|449|450|451|453|464|470|472|476|482|484|485|487|490|491|495|498|499|501|502|503|504|506|516|519|520|521|524|539|540|541|542|545|546|547|548|549|550|552|556|560|563|564|565|566|567|569|570|572|573|574|578|582|584|585|589|591|592|594|595|596|598|599|600|603|604|606|607|608|610|611|613|614|615|618|619|620|626|628|632|633|634|636|637|639|640|641|645|646|651|654|655|656|657|659|660|661|662|664|665|666|668|674|677|678|679|680|682|683|688|689|696|698|708|709|710|717|721|752|759|780|784|815|822,Ketoconazole,"14-alpha Demethylase Inhibitors| Agents causing hyperkalemia| Anti-Infective Agents| Antiadrenal Preparations| Anticorticosteroids| Antifungal Agents| Antifungals for Dermatological Use| Antifungals for Topical Use| Antiinfectives for Systemic Use| Antimycotics for Systemic Use| Azole Antifungals| Azoles| BSEP/ABCB11 Inhibitors| BSEP/ABCB11 Substrates| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (moderate)| Cytochrome P-450 CYP2A6 Inhibitors| Cytochrome P-450 CYP2A6 Inhibitors (moderate)| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (moderate)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (moderate)| Cytochrome P-450 CYP2C8 Inhibitors (strong)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (moderate)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (moderate)| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strong)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (strong)| Cytochrome P-450 CYP3A7 Inhibitors| Cytochrome P-450 CYP3A7 Inhibitors (strong)| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dermatologicals| Drugs causing inadvertant photosensitivity| Enzyme Inhibitors| Gynecological Antiinfectives and Antiseptics| Hepatotoxic Agents| Heterocyclic Compounds| Imidazole and Triazole Derivatives| Imidazole Derivatives| Metabolic Side Effects of Drugs and Substances| OATP1B1/SLCO1B1 Inhibitors| P-glycoprotein inhibitors| P-glycoprotein substrates| Photosensitizing Agents| Piperazines| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Steroid Synthesis Inhibitors| Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins| UGT1A1 Inhibitors| UGT2B7 Inhibitors"
115,DB00332,P11229|P08172|P20309,P10635|P08684,hsa:1128|hsa:1129|hsa:1131,6|9|10|11|12|14|18|19|143|145|146|178|180|181|182|185|283|284|285|286|308|332|333|335|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|380|384|390|391|405|406|416|420|430|434|440|441|443|446|452|470|490|516|520|524|535|540|552|556|564|570|571|578|579|581|582|584|592|595|597|599|603|608|613|614|617|618|634|637|638|639|640|641|642|655|656|660|664|668|677|678|679|680|683|684|688|689|692|696|697|698|704|708|709|710|712,Ipratropiumbromide,"Adrenergics, Inhalants| Agents producing tachycardia| Agents to Treat Airway Disease| Alkaloids| Anti-Asthmatic Agents| Anticholinergic Agents| Antimuscarinics Antispasmodics| Atropine Derivatives| Autonomic Agents| Aza Compounds| Azabicyclo Compounds| Belladonna Alkaloids| Bicyclo Compounds| Bicyclo Compounds, Heterocyclic| Bridged Compounds| Bronchodilator Agents| Cholinergic Agents| Drugs for Obstructive Airway Diseases| Heterocyclic Compounds| Heterocyclic Compounds, Bridged-Ring| Hydrocarbons| Hydrocarbons, Cyclic| Muscarinic Antagonists| Nasal Preparations| Neurotransmitter Agents| Peripheral Nervous System Agents| Polycyclic Compounds| Respiratory System| Respiratory System Agents| Solanaceous Alkaloids| Tropanes"
116,DB01170,P23975,P08684,hsa:6530,9|10|11|14|15|16|227|229|230|283|284|285|299|332|344|345|351|365|375|390|391|393|418|450|453|487|540|569|582|592|611|613|656|679|683|688,Guanethidine,"Adrenergic Agents| Adrenergic Antagonists| Amidines| Antiadrenergic Agents, Peripherally Acting| Antiglaucoma Preparations and Miotics| Antihypertensive Agents| Autonomic Agents| Cardiovascular Agents| Cardiovascular System| Catecholamine-depleting Sympatholytic| Drugs that are Mainly Renally Excreted| Gastrointestinal Acidifying Agents| Guanidine Derivatives| Guanidine Derivatives and Diuretics| Guanidines| Neurotransmitter Agents| Ophthalmologicals| Peripheral Nervous System Agents| Sensory Organs| Sympatholytics"
117,DB09555,P35367,P10635|P08684,hsa:3269,9|10|11|12|14|15|18|19|20|37|178|182|183|184|185|283|284|285|286|294|308|332|333|335|340|342|344|345|351|352|355|356|357|358|362|365|370|371|372|373|374|376|380|384|387|390|391|396|403|406|416|418|420|430|431|434|435|437|440|441|442|443|445|446|447|449|452|453|464|470|472|482|490|491|495|501|502|503|506|516|520|521|523|524|530|538|539|540|545|546|549|550|552|553|555|556|564|570|573|576|577|578|582|584|585|591|592|595|598|599|600|603|607|608|613|618|619|628|633|634|640|656|657|660|664|665|667|668|671|672|677|678|679|683|688|696|697|708|709|710|712|717|780,Dexchlorpheniraminemaleate,"Agents that reduce seizure threshold| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Moderate Risk QTc-Prolonging Agents| Neurotransmitter Agents| OCT1 inhibitors| OCT1 substrates| OCT2 Inhibitors| Pyridines| QTc Prolonging Agents| Stereoisomerism"
118,DB08868,Q9H228|Q13547,P78329|Q9NYA1|P10635|P05181|P08684|Q9HCS2,hsa:53637|hsa:3065,9|10|11|12|14|18|19|178|182|283|284|285|286|299|308|332|333|336|340|344|346|351|352|355|356|366|370|371|374|384|393|406|416|430|434|441|446|470|490|516|520|524|552|556|564|566|570|571|578|582|584|592|595|599|603|608|617|618|634|637|639|640|643|660|664|668|677|678|679|680|683|688|689|696|697|698|699|708|709|710|713|776,Fingolimod,Alcohols| Amines| Amino Alcohols| Antineoplastic and Immunomodulating Agents| Bradycardia-Causing Agents| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 Substrates| Experimental Unapproved Treatments for COVID-19| Glycols| Immunologic Factors| Immunomodulatory Agents| Immunosuppressive Agents| P-glycoprotein inducers| P-glycoprotein inhibitors| Propylene Glycols| Selective Immunosuppressants| Sphingosine 1 Phosphate Receptor Modulators| Sphingosine 1-phosphate Receptor Modulator
119,DB06262,P35348|P35368|P25100|P08913|P18089|P18825|P08588|P07550|P13945|P00439,P20711,hsa:148|hsa:147|hsa:146|hsa:150|hsa:151|hsa:152|hsa:153|hsa:154|hsa:155|hsa:5053,9|10|11|14|18|19|20|178|182|283|284|285|286|299|308|332|333|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|380|381|382|384|393|406|416|420|430|434|440|441|443|446|452|470|490|498|516|520|524|528|535|536|541|542|544|548|552|556|564|566|567|570|571|573|574|578|579|581|582|584|590|592|595|599|603|606|607|608|617|618|619|631|634|637|639|640|641|642|643|651|655|660|663|664|667|668|677|678|679|680|681|683|684|688|689|690|691|692|696|698|699|701|703|704|708|709|710|714|735|761|777|798|824,Droxidopa,"Adrenergic Agonists| Adrenergic alpha-1 Receptor Agonists| Adrenergic alpha-2 Receptor Agonists| Adrenergic alpha-Agonists| Adrenergic and Dopaminergic Agents| Adrenergic beta-1 Receptor Agonists| Adrenergic beta-2 Receptor Agonists| Adrenergic beta-3 Receptor Agonists| Adrenergic beta-Agonists| Agents producing tachycardia| Agents that produce hypertension| Amines| Amino Acids| Amino Acids, Neutral| Amino Acids, Peptides, and Proteins| Anti-Dyskinesia Agents| Benzene Derivatives| Cardiac Stimulants Excl. Cardiac Glycosides| Cardiac Therapy| Cardiovascular System| Catecholamines| Catechols| Central Nervous System Agents| Drugs that are Mainly Renally Excreted| Epinephrine and similars| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Increased Blood Pressure| Phenols"
120,DB00320,P28221|P28222|P08913|P41595,P08684,hsa:3352|hsa:3351|hsa:150|hsa:3357,9|10|11|12|13|14|15|16|18|19|20|143|145|146|148|149|150|152|153|157|178|180|181|182|185|187|188|189|192|196|199|206|283|284|285|286|299|308|332|333|335|338|340|341|344|345|351|352|355|356|357|358|365|370|371|372|373|374|376|377|380|384|385|386|387|390|391|392|393|396|399|400|403|405|406|416|418|420|430|431|434|435|437|439|441|442|443|445|446|447|449|451|453|462|464|470|472|482|490|491|495|502|506|516|520|521|523|524|527|528|530|535|536|537|538|539|540|545|546|549|552|555|556|559|563|564|566|569|570|576|577|578|579|580|582|584|585|592|593|595|599|600|602|603|605|607|608|611|612|613|614|615|617|618|628|633|634|637|640|643|645|646|656|657|659|660|661|664|665|668|677|678|679|680|683|684|688|691|692|695|696|697|702|704|707|708|709|710|712|737|755|758|776|779|797|800|818|821,Dihydroergotamine,"Adrenergic alpha-1 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Agents that produce hypertension| Alkaloids| Analgesics| Antidepressive Agents| Antimigraine Preparations| Cardiovascular Agents| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dopamine Agents| Dopamine Agonists| Ergot Alkaloids and Derivatives| Ergot-derivative Dopamine Receptor Agonists| Ergotamine Derivative| Ergotamines| Heterocyclic Compounds| Heterocyclic Compounds with 4 or More Rings| Heterocyclic Compounds, Fused-Ring| Narrow Therapeutic Index Drugs| Nervous System| Neurotransmitter Agents| P-glycoprotein inhibitors| Peripheral Nervous System Agents| Sensory System Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT1 Receptor Agonists| Serotonin 5-HT2 Receptor Agonists| Serotonin Agents| Serotonin Modulators| Serotonin Receptor Agonists| Sympatholytic (Adrenergic Blocking) Agents| Vasoconstrictor Agents"
121,DB01253,P35348,P08684,hsa:148,9|10|11|12|14|15|18|19|143|148|149|178|182|183|184|185|189|192|283|284|285|286|299|308|332|333|335|338|340|344|345|346|351|352|355|356|357|358|365|366|370|371|372|373|374|376|377|384|385|386|387|390|391|392|393|396|399|400|403|406|416|418|420|430|431|434|435|437|439|441|442|443|445|446|447|449|451|453|464|470|472|482|490|491|495|502|506|516|520|521|523|524|527|528|530|535|538|539|540|545|546|549|552|555|556|564|566|570|571|576|577|578|580|582|584|585|592|593|595|599|600|603|607|608|613|617|618|628|633|634|640|643|645|646|656|657|659|660|664|665|668|677|678|679|683|688|696|697|708|709|710|712|737|755|758|779|797|800|818|821,Ergonovine,"Adrenergic Agonists| Adrenergic alpha-1 Receptor Agonists| Adrenergic alpha-Agonists| Agents producing tachycardia| Agents that produce hypertension| Alkaloids| Antidepressive Agents| Central Nervous System Depressants| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Ergolines| Ergot Alkaloids and Derivatives| Genito Urinary System and Sex Hormones| Heterocyclic Compounds| Heterocyclic Compounds with 4 or More Rings| Heterocyclic Compounds, Fused-Ring| P-glycoprotein inhibitors| Reproductive Control Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin Agents| Serotonin Modulators| Uterotonic agents"
122,DB00115,Q99707|P22033|Q9UBK8|Q8IVH4|Q9Y4U1|P42898,Q96EY8|P22033|Q99707|Q05599,hsa:4548|hsa:4594|hsa:4552|HAS:166875|hsa:25974|hsa:4524,9|10|11|12|13|14|15|16|17|18|19|20|21|30|59|143|145|146|148|149|150|152|153|155|156|157|160|162|163|164|169|170|171|178|182|183|184|185|190|191|192|197|198|199|283|284|285|286|299|308|314|332|333|334|335|336|338|339|340|341|344|345|346|351|352|355|356|357|358|365|366|370|371|373|374|375|376|377|379|384|386|387|389|390|391|392|393|396|397|403|405|406|407|411|416|418|419|420|425|430|431|434|437|439|441|442|443|446|447|449|450|451|453|456|464|470|472|482|484|485|487|490|491|495|499|502|504|506|519|520|521|523|524|528|530|535|538|539|540|545|546|547|549|552|555|556|560|564|566|567|569|570|571|572|576|578|579|582|584|585|592|595|596|599|600|603|607|608|611|612|613|614|617|618|628|633|634|636|637|638|639|640|643|645|646|654|656|657|659|660|662|663|664|665|668|674|677|678|679|680|681|682|683|684|685|688|690|691|692|695|696|697|702|704|707|708|709|710|711|712|716|737|755|770|779|800|818|833,Cyanocobalamin,"Antianemic Preparations| Blood and Blood Forming Organs| Corrinoids| Diet, Food, and Nutrition| Drugs that are Mainly Renally Excreted| Food| Growth Substances| Heterocyclic Compounds| Heterocyclic Compounds with 4 or More Rings| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, Fused-Ring| Macrocyclic Compounds| Micronutrients| Polycyclic Compounds| Pyrroles| Tetrapyrroles| Vitamin B 12, biosynthesis| Vitamin B Complex| Vitamin B12 and Folic Acid| Vitamins"
123,DB01086,Q9Y5Y9,P23141,hsa:6336,9|10|11|14|18|19|178|182|283|284|285|286|299|332|333|340|344|346|351|352|355|356|366|370|371|374|376|377|380|384|393|405|416|420|430|434|437|440|441|443|446|449|452|464|470|490|493|502|516|520|524|535|545|546|548|549|552|553|556|564|570|573|574|578|579|582|584|592|594|595|597|599|600|603|604|607|608|614|618|619|623|633|634|637|640|641|643|655|660|664|665|666|668|671|672|677|678|679|680|683|684|688|689|691|692|695|698|703|704|707|708|709|710|716|779,Benzocaine,"Acids, Carbocyclic| Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use| Aminobenzoates| Anesthetics| Anesthetics for Topical Use| Anesthetics, Local| Antipruritics and Local Anesthetics| Antipruritics, Incl. Antihistamines, Anesthetics, Etc.| Benzene Derivatives| Benzoates| Carboxylic Acids| Cardiovascular System| Cell-mediated Immunity| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 Substrates| Dermatologicals| Esters of Aminobenzoic Acid| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Increased Histamine Release| Local Anesthetics (Ester)| Methemoglobinemia Associated Agents| Nervous System| P-glycoprotein inhibitors| para-Aminobenzoates| Peripheral Nervous System Agents| Respiratory System| Sensory System Agents| Standardized Chemical Allergen| Throat Preparations| Vasoprotectives"
124,DB00531,O75469,P20813|P11712|P08684|P33261|P11509|P33260|P10632|P10635|P24462|P20815,hsa:8856,9|10|14|15|18|19|30|37|38|178|180|181|283|284|285|286|294|299|304|314|332|342|343|344|345|346|351|352|361|365|366|390|393|407|411|425|456|528|540|609|638|643|656,Cyclophosphamide,"Alkylating Activity| Alkylating Drugs| Antineoplastic Agents| Antineoplastic Agents, Alkylating| Antineoplastic and Immunomodulating Agents| Antirheumatic Agents| BEACOPP chemotherapy regimen| Cardiotoxic antineoplastic agents| CHOP chemotherapy regimen| CHOP-R chemotherapy regimen| CMF chemotherapy regimen| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (strength unknown)| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C18 Substrates| Cytochrome P-450 CYP2C18 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C8 Inducers| Cytochrome P-450 CYP2C8 Inducers (strength unknown)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Hydrocarbons| Hydrocarbons, Halogenated| Immunologic Factors| Immunosuppressive Agents| Methemoglobinemia Associated Agents| Mustard Compounds| Mutagens| Myeloablative Agonists| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| Neurotoxic agents| Nitrogen Mustard Analogues| Nitrogen Mustard Compounds| Noxae| Organophosphorus Compounds| Phosphoramide Mustards| Phosphoramides| Toxic Actions"
125,DB00987,P06746,P32320|P08684|P27707|P21589|P32321,hsa:5423,9|10|11|14|15|18|19|20|143|146|178|183|184|283|284|285|286|299|308|332|339|341|344|345|346|351|352|355|358|365|366|370|371|372|373|375|376|378|379|384|387|389|390|391|393|396|397|403|405|406|416|418|420|434|435|438|441|442|445|446|447|449|450|451|453|464|472|482|484|487|491|495|502|504|506|516|519|521|523|530|538|539|540|545|546|549|555|560|566|567|571|572|576|582|585|592|593|596|601|612|613|614|617|621|628|636|637|638|639|643|645|646|647|654|656|657|659|662|663|674|680|681|682|683|690|691|702,Cytarabine,"Agents Causing Muscle Toxicity| Anti-Infective Agents| Antimetabolites| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Arabinonucleosides| Cardiotoxic antineoplastic agents| Cytidine Deaminase Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Immunologic Factors| Immunosuppressive Agents| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| Noxae| Nucleic Acid Synthesis Inhibitors| Nucleic Acids, Nucleotides, and Nucleosides| Nucleoside Metabolic Inhibitor| Nucleosides| OCT1 substrates| Pyrimidine Analogues| Pyrimidine Nucleosides| Pyrimidines| Toxic Actions"
126,DB01167,P50859|Q16850,P20815|P24462|P08684|P10635|P20813|P04798|P05181,hsa:1595,9|10|11|12|13|14|15|16|17|18|19|20|37|38|143|146|148|149|150|155|156|157|178|180|181|182|185|189|192|196|199|283|284|285|286|294|300|332|333|338|339|340|341|342|344|345|346|351|352|355|356|362|365|366|370|371|373|374|375|376|377|379|380|381|382|384|389|390|391|396|397|403|405|416|418|420|422|430|434|437|441|446|447|449|450|451|453|464|467|470|476|482|484|486|487|490|491|495|496|498|501|502|503|504|515|516|517|518|519|520|521|524|540|541|542|545|546|548|549|550|552|556|560|563|564|565|566|567|569|570|572|573|574|578|582|584|585|589|591|592|594|595|596|598|599|600|603|604|606|607|608|610|611|613|614|615|618|619|620|626|628|632|633|634|636|637|639|640|641|645|646|647|651|654|655|656|657|659|660|661|662|664|665|666|668|674|677|678|679|680|682|683|688|689|696|698|708|709|710|717|721|728|752|759|780|784|791|815|822,Itraconazole,"14-alpha Demethylase Inhibitors| Agents causing hyperkalemia| Anti-Infective Agents| Antifungal Agents| Antiinfectives for Systemic Use| Antimycotics for Systemic Use| Azole Antifungals| Azoles| BCRP/ABCG2 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strong)| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (weak)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strong)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (strong)| Cytochrome P-450 CYP3A7 Inhibitors| Cytochrome P-450 CYP3A7 Inhibitors (strong)| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Metabolic Side Effects of Drugs and Substances| Organic Anion Transporting Polypeptide 2B1 Inhibitors| P-glycoprotein inhibitors| Photosensitizing Agents| Piperazines| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Steroid Synthesis Inhibitors| Triazole and tetrazole derivatives| Triazole Derivatives| Triazoles"
127,DB01628,P35354,P08684|P11712|P10635|P05177|P33261|P05181,hsa:5743,9|10|11|12|14|15|18|19|33|37|178|182|183|184|185|190|191|192|283|284|285|293|294|332|333|340|342|344|345|351|353|355|356|357|358|362|365|368|370|371|372|373|374|376|383|384|387|390|396|403|412|414|416|418|430|431|434|435|437|441|442|445|446|447|449|453|457|459|464|465|470|472|482|490|491|495|500|501|502|503|506|507|516|520|521|523|524|530|531|532|538|539|540|545|546|549|550|552|555|556|564|570|576|577|578|582|584|585|586|591|592|593|595|598|599|600|603|607|608|609|613|618|628|633|634|640|656|657|660|664|665|668|677|678|679|683|688|696|697|708|709|710|712|715|778,Etoricoxib,"Agents causing hyperkalemia| Agents that produce hypertension| Analgesics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Antiinflammatory and Antirheumatic Products| Antiinflammatory and Antirheumatic Products, Non-Steroids| Antirheumatic Agents| COX-2 Inhibitors| Cyclooxygenase Inhibitors| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (weak)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (weak)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Musculo-Skeletal System| Nephrotoxic agents| Peripheral Nervous System Agents| Pyridines| Selective Cyclooxygenase 2 Inhibitors (NSAIDs)| Sensory System Agents| Sulfones| Sulfur Compounds"
128,DB00835,P35367|P11229|P08172|P20309|P08173|P08912,P20813|P33261|P10632|P11712|P10635|P05181|P08684,hsa:3269|hsa:1128|hsa:1129|hsa:1131|hsa:1132|hsa:1133,6|9|10|11|12|14|15|178|182|183|184|185|272|274|283|284|285|332|333|335|340|344|345|351|355|356|357|358|365|370|371|372|373|374|376|384|387|390|391|396|403|416|418|430|431|434|435|437|441|442|445|446|447|449|453|464|470|472|482|490|491|495|502|506|516|520|521|523|524|530|538|539|540|545|546|549|552|555|556|564|570|576|577|578|582|584|585|592|595|599|600|603|607|608|613|618|628|633|634|640|656|657|660|664|665|668|677|678|679|683|688|696|697|708|709|710|712,Brompheniramine,"Agents producing tachycardia| Anti-Allergic Agents| Anticholinergic Agents| Antihistamines for Systemic Use| Central Nervous System Depressants| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Muscarinic Antagonists| Neurotransmitter Agents| Potential QTc-Prolonging Agents| Propylamine Derivatives| Pyridines| QTc Prolonging Agents| Respiratory System| Substituted Alkylamines"
129,DB00619,A9UF02|P10721|O43519|P04629|P07333|P16234|Q08345|P00519|P09619,P08684|P20815|P24462|P05177|P11712|P10635|P33261|P23219,hsa:3815|hsa:4914|hsa:1436|hsa:5156|hsa:780|hsa:25|hsa:5159,9|10|11|12|14|15|16|18|178|180|181|182|183|184|185|189|190|191|192|199|206|283|284|285|286|299|332|333|340|344|345|351|352|355|356|357|358|365|370|371|372|373|374|375|376|377|379|384|387|389|390|391|392|393|396|403|416|418|420|430|431|434|435|437|439|441|442|443|445|446|447|449|450|451|453|464|470|472|482|484|487|490|491|493|495|502|504|506|516|519|520|521|523|524|530|535|538|539|540|545|546|549|552|553|555|556|560|564|569|570|572|576|577|578|579|582|584|585|592|593|595|596|597|599|600|601|603|607|608|611|613|618|621|623|628|633|634|636|640|643|645|654|656|657|660|664|665|668|671|672|674|677|678|679|683|684|688|692|704|708|709|710|713|716|749|758|776|779|812|821,Imatinib,"Amides| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Bcr-Abl Tyrosine Kinase Inhibitors| BCRP/ABCG2 Inhibitors| BCRP/ABCG2 Substrates| Benzamides and benzamide derivatives| Benzene Derivatives| BSEP/ABCB11 Substrates| Cancer immunotherapy| Carboxylic Acids| Cardiotoxic antineoplastic agents| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (moderate)| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Inhibitors| Cytochrome P-450 CYP3A7 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Highest Risk QTc-Prolonging Agents| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Immunosuppressive Agents| Immunotherapy| Kinase Inhibitor| Myelosuppressive Agents| OATP1B3 substrates| OCT1 substrates| OCT2 Inhibitors| P-glycoprotein inhibitors| P-glycoprotein substrates| Photosensitizing Agents| Piperazines| Protein Kinase Inhibitors| Pyrimidines| QTc Prolonging Agents| Tyrosine Kinase Inhibitors| UDP Glucuronosyltransferases Inhibitors| UGT2B17 Inhibitors"
130,DB01396,P05023,P08684|P05108,hsa:476,9|10|11|12|13|18|19|20|21|143|144|149|150|178|179|181|185|186|188|192|193|195|199|206|283|284|286|308|332|333|334|335|337|339|341|344|346|347|352|366|367|374|380|405|406|416|420|430|434|440|441|443|446|452|490|524|553|556|563|567|571|573|582|594|599|610|614|617|619|637|639|640|660|661|662|663|666|671|678|679|680|681|688|689|690|696|697|698|699|700|701|708|709|710|711|712|776|777|797|798|818|819|839|840|860|861,Digitoxin,"Antiarrhythmic agents| Carbohydrates| Cardanolides| Cardenolides| Cardiac Glycosides| Cardiac Therapy| Cardiotonic Agents| Cardiovascular Agents| Cardiovascular System| Compounds used in a research, industrial, or household setting| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Substrates| Digitalis Glycosides| Enzyme Inhibitors| Fused-Ring Compounds| Glycosides| Narrow Therapeutic Index Drugs| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Polycyclic Compounds| Potential QTc-Prolonging Agents| Protective Agents| QTc Prolonging Agents| Steroids"
131,DB01611,Q9NYK1|Q9NR96,P10635,hsa:51284|hsa:54106,9|10|11|12|14|15|18|37|178|182|183|184|185|283|284|285|286|294|299|308|332|333|338|340|342|344|345|346|351|352|355|356|357|358|362|365|366|370|371|372|373|374|376|377|384|385|386|387|390|391|392|393|396|403|406|416|418|430|431|434|435|437|441|442|445|446|447|449|453|464|470|472|482|490|491|495|501|502|503|506|516|520|521|523|524|528|530|538|539|540|545|546|549|550|552|555|556|564|566|570|571|576|577|578|582|584|585|591|592|593|595|598|599|600|601|603|607|608|613|618|621|628|633|634|640|643|656|657|659|660|664|665|668|677|678|679|683|688|696|708|709|710|717|750|758|780|813|821,Hydroxychloroquine,"Aminoquinolines| Anti-Infective Agents| Antimalarials| Antiparasitic Agents| Antiparasitic Products, Insecticides and Repellents| Antiprotozoals| Antirheumatic Agents| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Immunosuppressive Agents| P-glycoprotein inhibitors| Photosensitizing Agents| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Quinolines"
132,DB06605,P00742,P08684|P05177|P10632|P11712|P33261|P51589|P20815,hsa:2159,9|10|11|12|14|15|16|18|19|20|143|148|149|178|180|181|182|183|184|185|189|192|199|283|284|285|286|299|300|332|333|340|341|344|345|351|352|355|356|357|358|365|366|370|371|374|376|377|381|382|384|387|390|391|393|396|405|416|418|420|422|430|431|434|437|439|441|442|443|446|449|451|453|464|467|470|476|477|482|490|493|494|495|498|502|515|516|520|523|524|530|535|536|538|540|541|542|545|546|548|549|552|553|555|556|564|565|569|570|573|574|577|578|579|582|584|585|589|592|593|594|595|597|599|600|601|602|603|604|606|607|608|611|613|616|618|619|621|623|626|628|633|634|637|640|641|644|645|646|651|655|656|657|660|664|665|666|668|671|677|678|679|680|682|683|684|685|689|694|695|708|710|721|728|784|791,Apixaban,"Anticoagulants| Antithrombins| Azoles| BCRP/ABCG2 Substrates| Blood and Blood Forming Organs| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Substrates| Direct factor Xa inhibitors| Enzyme Inhibitors| Factor Xa Inhibitors| Hematologic Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| P-glycoprotein substrates| Protease Inhibitors| Pyridines| Serine Protease Inhibitors"
133,DB01242,P31645|P28223|P41595|P28335|P23975|P09211,P10635|P33261|P05177|P08684,hsa:6532|hsa:3356|hsa:3357|hsa:3358|hsa:6530|hsa:2950,9|10|11|12|14|15|37|178|182|185|189|213|218|219|283|284|285|294|332|333|340|342|344|345|351|355|356|362|365|370|371|374|376|377|384|390|391|416|430|434|437|441|446|449|464|470|490|495|501|502|503|516|520|524|540|545|546|549|550|552|556|564|570|577|578|582|584|585|591|592|593|595|598|599|600|603|607|608|613|618|628|633|634|640|656|657|660|664|665|668|677|678|679|683|688|696|697|708|709|710|717|750|758|780|813|821,Clomipramine,"Agents that produce hypertension| Agents that reduce seizure threshold| Antidepressive Agents| Antidepressive Agents Indicated for Depression| Antidepressive Agents, Tricyclic| Central Nervous System Agents| Central Nervous System Depressants| Combined Inhibitors of Serotonin/Norepinephrine Reuptake| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (strong)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dibenzazepines| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Hypotensive Agents| Membrane Transport Modulators| Moderate Risk QTc-Prolonging Agents| Narrow Therapeutic Index Drugs| Nervous System| Neurotoxic agents| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| Non-Selective Monoamine Reuptake Inhibitors| P-glycoprotein inhibitors| Psychoanaleptics| Psychotropic Drugs| QTc Prolonging Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin 5-HT2C Receptor Antagonists| Serotonin Agents| Serotonin Modulators| Serotonin Receptor Antagonists| Tertiary amine tricyclic antidepressants| Tricyclics and Other Norepinephrine-reuptake Inhibitors"
134,DB00290,P18858|P49916,Q13867,hsa:3978|hsa:3980,9|10|11|12|13|14|15|16|17|18|19|20|21|22|33|34|143|148|149|150|155|156|157|162|163|178|181|183|184|185|188|192|283|284|285|286|293|299|308|332|333|335|338|339|340|341|344|345|346|347|349|351|352|353|355|356|357|358|359|365|366|367|368|370|372|373|374|375|376|378|379|380|383|384|387|389|390|392|393|396|399|400|403|405|406|412|416|418|420|421|430|431|435|437|438|439|441|442|443|445|446|447|449|450|451|452|453|461|464|472|473|474|475|480|482|484|485|487|488|489|490|491|493|494|495|499|500|502|504|506|507|508|519|521|523|524|527|528|530|531|533|535|536|538|539|540|545|546|547|548|549|553|555|556|559|560|563|566|567|569|570|571|572|573|576|579|580|581|582|585|586|592|593|594|595|596|597|599|600|601|602|604|607|608|610|611|612|613|614|615|617|621|623|628|633|636|637|638|639|640|642|643|645|646|654|656|657|658|659|661|662|663|665|666|671|672|674|679|680|681|683|684|685|689|690|695|700|701|708|709,Bleomycin,"ABVD chemotherapy regimen| Amino Acids, Peptides, and Proteins| Antibiotics, Antineoplastic| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| BEACOPP chemotherapy regimen| Carbohydrates| Cardiotoxic antineoplastic agents| Cytoprotective Agent| Cytotoxic Antibiotics and Related Substances| Drugs that are Mainly Renally Excreted| Glycoconjugates| Glycopeptides| Immunosuppressive Agents| Narrow Therapeutic Index Drugs| Peptides"
135,DB00875,P14416|P28223|P21728|P35348|P11229,P20711,hsa:1813|hsa:3356|hsa:1812|hsa:148|hsa:1128,9|10|11|12|14|15|18|23|24|33|178|180|181|182|184|185|189|192|199|283|284|285|286|287|293|308|332|333|344|345|346|351|352|353|355|356|363|365|366|370|371|383|384|390|391|406|412|416|430|434|441|446|470|490|500|507|516|520|524|531|532|540|552|556|564|566|569|570|571|578|582|584|586|595|599|603|608|611|613|618|634|640|656|658|659|660|664|668|677|678|679|688|696|697|708|709|710|715|734|757|778|797|820,Flupentixol,"Adrenergic alpha-1 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Agents producing tachycardia| Agents that produce hypertension| Anticholinergic Agents| Antidepressive Agents| Antipsychotic Agents| Antipsychotic Agents (First Generation [Typical])| Central Nervous System Agents| Central Nervous System Depressants| Dopamine Agents| Dopamine Antagonists| Dopamine D2 Receptor Antagonists| Drugs causing inadvertant photosensitivity| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Highest Risk QTc-Prolonging Agents| Muscarinic Antagonists| Nervous System| Neurotoxic agents| Neurotransmitter Agents| P-glycoprotein inhibitors| Photosensitizing Agents| Piperazines| Psycholeptics| Psychotropic Drugs| QTc Prolonging Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin 5-HT2C Receptor Antagonists| Serotonin Agents| Serotonin Receptor Antagonists| Sulfur Compounds| Thioxanthene Derivatives| Thioxanthenes| Tranquilizing Agents| Xanthenes"
136,DB09049,P35372,P08684|P10635|P33261,hsa:4988,9|10|11|12|13|14|18|19|20|21|143|149|178|179|180|181|182|185|186|192|199|283|284|285|286|308|332|333|334|337|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|391|405|406|416|430|434|441|446|464|470|476|490|498|516|520|524|540|541|542|544|548|552|556|564|565|566|567|570|573|574|578|582|584|589|590|592|594|595|599|603|604|606|607|608|613|614|617|618|619|620|626|630|631|632|634|637|639|640|641|651|655|656|659|660|662|663|664|666|667|668|677|678|679|680|681|682|683|688|689|690|691|696|697|698|699|700|701|702|703|708|709|710|711|712|714|735|755|756|761|776|777|779|782|797|798|800|803|818|819|821|824|826,Naloxegol,"Alcohols| Alimentary Tract and Metabolism| Alkaloids| Central Nervous System Agents| Compounds used in a research, industrial, or household setting| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (weak)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs for Constipation| Ethylene Glycols| Glycols| Heterocyclic Compounds| Heterocyclic Compounds with 4 or More Rings| Heterocyclic Compounds, Bridged-Ring| Heterocyclic Compounds, Fused-Ring| Macromolecular Substances| Manufactured Materials| Miscellaneous GI Drugs| Opiate Alkaloids| Opioid Antagonists| Opioids| Peripheral Nervous System Agents| Peripheral Opioid Receptor Antagonists| Phenanthrene opioids| Phenanthrenes| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Polymers| Sensory System Agents"
137,DB00712,P23219|P35354,P11712|P16662|P22309|P35503|O60656|P06133,hsa:5742|hsa:5743,9|10|11|18|19|23|178|182|185|189|283|284|286|287|308|332|333|335|344|352|355|356|364|370|371|374|380|384|406|416|420|430|434|440|441|443|446|452|470|490|516|520|524|535|552|556|564|570|578|579|582|584|595|597|599|603|608|617|618|634|637|640|641|655|660|664|668|677|678|679|680|684|688|689|692|696|697|698|704|708|709|710|712|713|776,Flurbiprofen,"Acids, Acyclic| Agents causing hyperkalemia| Agents that produce hypertension| Analgesics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)| Antiinflammatory and Antirheumatic Products| Antiinflammatory and Antirheumatic Products, Non-Steroids| Antiinflammatory Preparations, Non-Steroids for Topical Use| Antirheumatic Agents| Arylpropionic acid NSAIDS| Benzene Derivatives| Biphenyl Compounds| Carboxylic Acids| Central Nervous System Agents| Cyclooxygenase Inhibitors| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Musculo-Skeletal System| Nephrotoxic agents| Non COX-2 selective NSAIDS| OAT1/SLC22A6 inhibitors| Ophthalmologicals| Other Nonsteroidal Anti-inflammatory Agents| Peripheral Nervous System Agents| Photosensitizing Agents| Propionates| Respiratory System| Sensory Organs| Sensory System Agents| Throat Preparations| Topical Products for Joint and Muscular Pain| UGT1A1 Inhibitors| UGT1A1 Substrates| UGT1A3 substrates| UGT1A9 Substrates| UGT2B7 substrates"
138,DB01171,P21397|BE0004909|P27338,P21397|P27338|P33261|P10635|P05177|P11712,hsa:4128|hsa:4129,9|10|11|14|15|18|19|37|178|180|181|182|185|283|284|285|286|294|299|332|333|342|344|345|346|351|352|355|356|362|365|366|370|371|384|390|391|392|393|405|416|420|430|434|439|441|443|446|451|464|470|490|493|501|503|516|520|524|528|535|540|549|550|552|553|556|564|566|569|570|578|579|582|584|591|592|595|597|598|599|603|607|608|611|613|614|615|618|623|628|633|634|640|643|645|646|656|659|660|664|668|671|672|677|678|679|683|684|688|692|704|708|709|710|717|780,Moclobemide,"Acids, Carbocyclic| Agents that produce hypertension| Agents that reduce seizure threshold| Amides| Antidepressive Agents| Antidepressive Agents Indicated for Depression| Benzamides and benzamide derivatives| Benzene Derivatives| Benzoates| Carboxylic Acids| Central Nervous System Agents| Central Nervous System Depressants| Chlorobenzoates| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Enzyme Inhibitors| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Monoamine Oxidase A Inhibitors| Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates| Monoamine Oxidase Inhibitors| Nervous System| Psychoanaleptics| Psychotropic Drugs| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin Agents| Serotonin Modulators"
139,DB00969,P46098,P11712|P08684|P05177|P05181,hsa:3359,9|10|11|12|14|15|16|18|143|148|149|150|155|156|178|182|183|184|185|283|284|285|286|299|332|333|340|344|345|351|352|355|356|357|358|365|370|371|373|374|375|376|377|379|384|385|386|387|389|390|391|392|393|396|397|399|400|403|416|418|420|430|431|434|437|439|441|442|443|446|447|449|450|451|453|464|470|472|482|484|485|487|488|490|491|493|495|499|502|504|506|516|519|520|521|523|524|527|528|530|535|538|539|540|545|546|547|549|552|553|555|556|560|564|569|570|572|576|577|578|579|580|582|584|585|592|593|595|596|597|599|600|603|607|608|611|613|618|623|624|628|633|634|636|640|643|645|646|654|656|657|660|664|665|668|671|673|674|677|678|679|683|684|685|688|692|695|696|697|704|708|709|710|712|758|821,Alosetron,"Alimentary Tract and Metabolism| Antidepressive Agents| Antiemetic Serotonin 5-HT3 Receptor Antagonists| Antiemetics| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (moderate)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (moderate)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs for Functional Gastrointestinal Disorders| Gastrointestinal Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Indole Alkaloids| Indoles| Neurotransmitter Agents| Pyridines| Serotonin 3 Receptor Antagonists| Serotonin 5-HT3 Receptor Antagonists| Serotonin Agents| Serotonin Receptor Antagonists"
140,DB01576,Q05940|P23975|Q01959|Q96RJ0|P35348|P35368,P10635,hsa:6571|hsa:6530|hsa:6531|hsa:134864|hsa:148|hsa:147,9|10|11|14|178|182|283|284|285|299|332|333|338|340|344|345|351|355|356|365|370|371|374|384|393|416|430|434|441|446|470|490|516|520|524|528|552|556|564|570|578|582|584|592|595|599|603|607|608|618|634|640|643|660|664|668|677|678|679|683|688|696|708|709|710,Dextroamphetamine,"Agents producing tachycardia| Agents that produce hypertension| Amines| Amphetamines| Central Nervous System Agents| Central Nervous System Stimulants| Central Nervous System Stimulation| Centrally Acting Sympathomimetics| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Substrates| Dopamine Agents| Dopamine Uptake Inhibitors| Ethylamines| Membrane Transport Modulators| Nervous System| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| Phenethylamines| Psychoanaleptics| Psychostimulants, Agents Used for ADHD and Nootropics| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Sympathomimetics"
141,DB09031,P08183,Q13393,hsa:5243,9|10|11|12|14|18|19|20|30|283|284|285|286|314|332|344|345|346|351|352|365|366|374|390|391|407|411|425|456|540|566|582|637|659|679|680|688|689|696|698,Miltefosine,"Agents Against Leishmaniasis and Trypanosomiasis| Amines| Anti-Infective Agents| Antifungal Agents| Antileishmanial| Antineoplastic Agents| Antiparasitic Agents| Antiparasitic Products, Insecticides and Repellents| Antiprotozoals| Onium Compounds| Quaternary Ammonium Compounds| Trimethyl Ammonium Compounds"
142,DB01016,BE0008670|P48544|O60706|O95342|O95477|P13569|BE0004923|P50416,P33261|P08684|P11712,hsa:3762|hsa:10060|hsa:8647|hsa:19|hsa:1080|hsa:1374,9|10|11|12|14|15|18|19|20|33|37|178|179|182|185|189|192|283|284|285|286|293|294|299|305|332|333|338|340|341|342|344|345|351|352|353|355|356|362|365|366|370|371|374|375|381|382|383|384|390|392|393|405|414|416|420|430|434|439|441|443|446|451|457|459|464|465|470|476|483|490|493|498|501|503|516|520|524|528|531|532|535|540|541|542|548|549|550|552|553|556|560|564|565|570|573|574|578|579|581|582|584|589|591|592|594|595|597|598|599|603|604|606|607|608|613|618|619|623|625|626|628|633|634|637|638|640|641|642|643|645|646|651|654|655|656|660|664|666|668|671|672|677|678|679|680|683|684|688|689|692|696|698|704|708|709|710|715|722|738|756|778|785|801|819,Glyburide,Alimentary Tract and Metabolism| Amides| BCRP/ABCG2 Substrates| Blood Glucose Lowering Agents| BSEP/ABCB11 Inhibitors| BSEP/ABCB11 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Drugs Used in Diabetes| Hypoglycemia-Associated Agents| Insulin Secretagogues| OAT1/SLC22A6 inhibitors| OATP2B1/SLCO2B1 substrates| Oral Hypoglycemics| P-glycoprotein inhibitors| Photosensitizing Agents| Sulfones| Sulfonylureas| Sulfur Compounds
143,DB01320,Q14524,P11712|P10632|P33261|P08684|P20813,hsa:6331,9|10|11|12|14|15|18|19|20|30|143|145|146|178|182|185|189|283|284|285|286|299|308|314|332|333|336|340|344|351|352|355|356|365|366|370|371|375|384|390|391|392|393|407|411|416|420|425|430|434|439|441|443|446|451|456|464|470|490|516|520|524|535|536|540|549|552|556|560|564|569|570|578|579|582|584|592|595|597|599|602|603|607|608|611|613|618|628|633|634|636|640|645|646|647|650|654|660|664|668|677|678|679|683|684|688|692|696|697|704|708|709|710|712,Fosphenytoin,"Anti-epileptic Agent| Anticonvulsants| Azoles| Cardiovascular Agents| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Inducers| Cytochrome P-450 CYP1A2 Inducers (strength unknown)| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (strong)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C9 Inducers| Cytochrome P-450 CYP2C9 Inducers (strength unknown)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inducers (strong)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strong)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates (strength unknown)| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Decreased Central Nervous System Disorganized Electrical Activity| Enzyme Inducing Antiepileptic Drugs| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hydantoins| Imidazoles| Imidazolidines| Membrane Transport Modulators| Narrow Therapeutic Index Drugs| Nervous System| Phenytoin and Prodrugs| Prodrugs| Sodium Channel Blockers| Thyroxine-binding globulin substrates| UGT1A6 Inhibitors| UGT1A9 Inhibitors"
144,DB14011,P21554|P34972|P47775|P23415|BE0004857|O75311|Q14330|Q9Y2T6|P08908|P28223|P36544|P41143|P35372|P37231|Q8NER1|O43497|O95180|Q9P0X4|O75762|Q7Z2W7|Q9Y5S1|Q8NET8|Q9HBA0|P21796,P11712|P33261|P10635|P08684|P20815|P24752|F1T0I5|P04040|P23219|P35354|P24462|P04798|P05177|Q16678|F5GY58|O00519|P00390|P07203|P04035|P14902|P09917|P16050|Q02083|Q08257|Q6IQ20|P04054|P05093|P00441|P17405,hsa:1268|hsa:1269|hsa:2835|hsa:2741|hsa:8001|hsa:2841|hsa:9290|hsa:3350|hsa:3356|hsa:1139|hsa:4985|hsa:4988|hsa:5468|hsa:7442|hsa:8913|hsa:8912|hsa:8911|hsa:8989|hsa:79054|hsa:51393|hsa:162514|hsa:59341|hsa:7416,0|9|10|11|12|13|18|19|20|178|181|182|185|189|192|196|199|203|206|283|284|286|308|332|333|335|337|341|344|352|355|356|370|371|374|381|382|384|405|406|416|430|434|441|446|470|476|490|498|520|524|541|542|548|552|556|564|565|570|573|574|575|578|582|584|589|590|594|595|599|603|604|606|608|614|617|618|619|620|626|632|634|637|639|640|641|651|653|655|660|664|666|667|668|677|678|679|680|688|689|690|696|697|698|699|700|701|708|709|710|712|713|735|740|756|776|798|803|819,Nabiximols,Agents producing tachycardia| Analgesics| BCRP/ABCG2 Inhibitors| Cannabinoid Receptor Agonists| Cannabinoids and similars| Central Nervous System Agents| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Inhibitors| Cytochrome P-450 CYP3A7 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Hydrocarbons| Peripheral Nervous System Agents| Pharmaceutical Preparations| Sensory System Agents| Terpenes
145,DB00998,P28221|P28222,P05177,hsa:3352|hsa:3351,9|10|11|14|15|18|143|148|149|178|182|185|189|283|284|285|286|299|332|333|338|340|344|345|351|352|355|356|357|358|365|370|371|374|376|377|384|385|386|387|390|392|393|396|399|400|403|416|418|420|430|431|434|437|439|441|442|443|446|449|451|453|464|470|472|482|490|493|495|502|506|516|520|523|524|527|528|530|535|538|539|540|545|546|549|552|553|555|556|564|570|576|577|578|579|582|584|585|592|595|597|599|600|603|607|608|613|618|623|628|633|634|640|643|656|657|660|664|665|668|671|672|677|678|679|683|684|688|692|695|696|697|704|707|708|709|710|712|716|734|758|779|791|797|800|821,Frovatriptan,"Agents that produce hypertension| Amines| Analgesics| Antidepressive Agents| Antimigraine Preparations| Biogenic Amines| Biogenic Monoamines| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Indoles| Migraine Disorders| Nervous System| Neurotransmitter Agents| Selective Serotonin 5-HT1 Receptor Agonists| Selective Serotonin Agonists| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 1b Receptor Agonists| Serotonin 1d Receptor Agonists| Serotonin 5-HT1 Receptor Agonists| Serotonin Agents| Serotonin Modulators| Serotonin Receptor Agonists| Serotonin-1b and Serotonin-1d Receptor Agonist| Triptans"
146,DB00176,P31645|Q12809,P10635|P05177|P05181|P04798|P08684|P20815|P24462|P11712|P33261|P20813,hsa:6532|hsa:3757,9|10|11|14|15|18|19|23|24|178|182|283|284|285|286|287|299|301|332|333|340|344|345|346|351|352|355|356|363|365|366|370|371|374|384|393|395|405|416|418|430|431|434|441|442|446|470|490|516|520|524|528|538|539|552|555|556|564|566|570|576|578|582|584|595|599|603|608|618|634|637|640|643|660|664|668|677|678|679|680|688|689|696|697|698|708|709|710|713|776,Fluvoxamine,"Amines| Anti-Anxiety Agents| Antidepressive Agents| Antidepressive Agents Indicated for Depression| Antidepressive Agents, Second-Generation| BSEP/ABCB11 Substrates| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strong)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (strong)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (moderate)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (moderate)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (moderate)| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A7 Inhibitors| Cytochrome P-450 CYP3A7 Inhibitors (moderate)| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Hydroxylamines| Hypoglycemia-Associated Agents| Membrane Transport Modulators| Metabolic Side Effects of Drugs and Substances| Nervous System| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| Oximes| P-glycoprotein inhibitors| Psychoanaleptics| Psychotropic Drugs| Selective Serotonin Reuptake Inhibitors| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin Agents| Serotonin Modulators| Tranquilizing Agents"
147,DB00603,P06401|P03372,P08684|P10632|P26439|P11712,hsa:5241|hsa:2099,9|10|11|12|18|19|20|143|144|178|179|182|185|186|192|283|284|286|332|333|334|335|337|341|344|352|374|380|405|416|420|430|432|434|440|441|443|446|452|462|490|524|535|537|553|556|579|582|599|605|614|637|640|660|671|678|679|680|684|688|689|692|696|697|698|699|704|708|709|710|711|712|776|797|818|839|840|860|861,Medroxyprogesteroneacetate,"Adrenal Cortex Hormones| Antineoplastic Agents| Antineoplastic Agents, Hormonal| Antineoplastic and Immunomodulating Agents| Combination Contraceptives (with Estrogen and derivatives)| Contraceptive Agents, Female| Contraceptive Agents, Hormonal| Contraceptive Agents, Male| Contraceptives, Oral| Contraceptives, Oral, Hormonal| Contraceptives, Oral, Synthetic| Corpus Luteum Hormones| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (moderate)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Endocrine Therapy| Fused-Ring Compounds| Genito Urinary System and Sex Hormones| Gonadal Hormones| Gonadal Steroid Hormones| Hormonal Contraceptives for Systemic Use| Hormones| Hormones and Related Agents| Hormones, Hormone Substitutes, and Hormone Antagonists| Hydroxyprogesterones| Hyperglycemia-Associated Agents| P-glycoprotein inhibitors| Polycyclic Compounds| Pregnanes| Pregnen (4) Derivatives| Pregnenediones| Pregnenes| Progesterone and Derivatives| Progesterone Congeners| Progestin Contraceptives| Progestins| Progestogens and Estrogens, Sequential Preparations| Reproductive Control Agents| Sex Hormones and Modulators of the Genital System| Steroids"
148,DB01407,P07550|P08588|P13945|P01138|P01375,P04798|P05177,hsa:154|hsa:153|hsa:155|hsa:4803|hsa:7124,9|10|11|14|15|18|37|38|178|182|283|284|285|286|294|299|308|332|333|336|339|340|341|342|344|345|346|351|352|355|356|362|365|366|370|371|374|376|377|384|390|392|393|406|416|430|434|437|441|446|449|464|470|490|501|503|520|524|528|540|545|548|549|550|552|556|564|566|570|571|573|574|578|582|584|591|592|595|598|599|600|603|607|608|613|617|618|619|633|634|637|640|641|643|655|656|659|660|664|665|667|668|677|678|679|680|683|688|689|691|696|698|703|708|709|710|716|738|752|771|779|801|815|834,Clenbuterol,"Adrenergic Agents| Adrenergic Agonists| Adrenergic beta-2 Receptor Agonists| Adrenergic beta-Agonists| Adrenergics for Systemic Use| Adrenergics, Inhalants| Agents producing tachycardia| Agents that produce hypertension| Agents to Treat Airway Disease| Alcohols| Amines| Amino Alcohols| Anti-Asthmatic Agents| Autonomic Agents| Bronchodilator Agents| Drugs for Obstructive Airway Diseases| Ethanolamines| Long-acting beta-adrenoceptor agonists| Neurotransmitter Agents| Peripheral Nervous System Agents| Respiratory System| Respiratory System Agents| Selective Beta 2-adrenergic Agonists| Sympathomimetics"
149,DB00673,P25103,P08684|P20815|P24462|P05177|P33261|P11712,hsa:6869,9|10|11|12|14|15|16|18|19|23|24|25|143|148|149|178|180|181|182|185|189|192|283|284|285|286|287|299|300|332|333|338|339|340|341|344|345|346|347|351|352|355|356|358|359|363|364|365|366|367|370|371|374|375|379|380|384|389|390|391|392|393|394|396|398|399|400|403|405|416|418|420|422|430|434|438|441|442|446|450|451|453|464|467|470|472|484|486|487|488|490|504|506|515|516|517|518|519|520|522|524|539|540|548|549|552|556|560|563|564|566|569|570|572|573|574|578|582|584|592|594|595|596|599|603|604|607|608|610|611|613|614|615|618|619|628|633|634|635|637|640|641|643|644|645|647|654|655|656|659|660|661|664|666|668|677|678|679|680|683|688|689|696|697|698|708|709|710|734|797,Aprepitant,"Alimentary Tract and Metabolism| Antiemetics| Antiemetics and Antinauseants| Aprepitant and Prodrugs| Autonomic Agents| Central Nervous System Agents| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (weak)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Inducers| Cytochrome P-450 CYP2C9 Inducers (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors (weak)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (moderate)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Inhibitors| Cytochrome P-450 CYP3A7 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Gastrointestinal Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Morpholines| Neurokinin 1 Antagonists| Neurokinin-1 Receptor Antagonists| Neurotransmitter Agents| Oxazines| Peripheral Nervous System Agents| Substance P/Neurokinin-1 Receptor Antagonist"
150,DB13955,P03372|O75469|Q92731|P43681|Q15596|Q99527|P00846|Q14457|P37059|P62508,P05177|P22309|P08684|P20815|P24462|P04798|Q16678|P33261|P10632|P11712,hsa:2099|hsa:8856|hsa:2100|hsa:1137|hsa:10499|hsa:2852|hsa:4508|hsa:8678|hsa:3294|hsa:2104,9|10|11|12|13|18|19|20|143|144|178|179|182|185|186|192|283|284|286|332|333|334|335|339|341|344|346|352|355|356|366|370|371|374|380|381|382|384|405|416|420|430|434|440|441|443|446|452|470|476|490|498|516|520|524|535|541|542|548|552|556|564|565|570|573|574|578|579|582|584|589|594|595|599|603|604|606|608|614|618|619|620|622|626|632|634|637|640|641|651|655|660|664|666|668|677|678|679|680|684|688|689|692|696|697|698|699|704|708|709|710|711|712|714|735|755|776|777|797|798|818|840|860|861,Estradioldienanthate,"BCRP/ABCG2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP1A2 Inhibitors (weak)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Estradiol Congeners| Estranes| Estrenes| Fused-Ring Compounds| Gonadal Hormones| Gonadal Steroid Hormones| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| OATP1B1/SLCO1B1 Inhibitors| OCT1 inhibitors| OCT2 Inhibitors| Organic Anion Transporting Polypeptide 2B1 Inhibitors| P-glycoprotein substrates| Polycyclic Compounds| Steroids| UGT1A1 Substrates"
151,DB01183,P35372|P41143|P41145|P16220|P03372|O00206|P23141,P10632|P08684,hsa:4988|hsa:4985|hsa:4986|hsa:1385|hsa:2099|hsa:7099|hsa:1066,9|10|11|12|14|18|19|20|143|149|178|179|180|181|182|185|186|192|199|283|284|285|286|308|332|333|334|337|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|381|382|384|390|391|405|406|416|420|430|432|434|441|443|446|462|464|470|476|490|498|516|520|524|535|537|540|541|542|544|548|552|556|564|565|566|567|570|573|574|578|579|582|584|589|590|592|594|595|599|603|604|605|606|607|608|613|614|617|618|619|620|626|630|631|632|634|637|639|640|641|651|655|656|659|660|662|663|664|666|667|668|677|678|679|680|681|682|683|684|686|688|689|690|691|692|693|695|696|697|698|699|700|701|702|703|704|705|707|708|709|710|711|712|714|735|755|756|761|776|777|779|797|798|800|803|818|819|821|824|826,Naloxone,"Alimentary Tract and Metabolism| Alkaloids| Analgesics| Antidotes| Central Nervous System Agents| Cytochrome P-450 CYP2C18 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors (strong)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs for Constipation| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds with 4 or More Rings| Heterocyclic Compounds, Bridged-Ring| Heterocyclic Compounds, Fused-Ring| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Morphinans| Natural Opium Alkaloids| Nervous System| Opiate Alkaloids| Opiate Antagonists| Opioid Antagonists| P-glycoprotein substrates| Peripheral Nervous System Agents| Peripheral Opioid Receptor Antagonists| Phenanthrenes| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Sensory System Agents| UGT1A1 Substrates"
152,DB00945,P23219|P35354|Q04828|Q13131|P25101|O14920|P04637|P11021|P51812|P25963|Q00653,P33261|P10632|P11712,hsa:5742|hsa:5743|hsa:1645|hsa:5562|hsa:1909|hsa:3551|hsa:7157|hsa:3309|hsa:6197|hsa:4792|hsa:4791,9|10|11|18|19|20|178|182|283|284|286|308|332|333|341|344|352|355|356|370|371|374|380|381|382|384|405|406|416|420|430|434|440|441|443|446|452|470|476|490|493|498|516|520|524|535|541|542|548|552|553|556|564|565|570|573|574|575|578|579|581|582|584|589|594|595|597|599|603|604|606|608|614|617|618|619|620|622|623|625|626|632|634|637|639|640|641|642|651|655|660|664|666|667|668|671|672|677|678|679|680|684|688|689|692|698|704|708|709|710|756|819,Acetylsalicylicacid,"Acids, Carbocyclic| Agents causing angioedema| Agents causing hyperkalemia| Agents that produce hypertension| Alimentary Tract and Metabolism| Analgesics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)| Antiinflammatory and Antirheumatic Products| Antiplatelet agents| Antipyretics| Benzene Derivatives| Blood and Blood Forming Organs| Carboxylic Acids| Cardiovascular Agents| Cardiovascular System| Cyclooxygenase Inhibitors| Cytochrome P-450 CYP2C19 Inducers| Cytochrome P-450 CYP2C19 Inducers (strength unknown)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Decreased Platelet Aggregation| Decreased Prostaglandin Production| Drugs that are Mainly Renally Excreted| Hematologic Agents| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hydroxybenzoates| Musculo-Skeletal System| Nephrotoxic agents| Non COX-2 selective NSAIDS| OAT1/SLC22A6 inhibitors| OAT3/SLC22A8 Inhibitors| P-glycoprotein inducers| P-glycoprotein substrates| Peripheral Nervous System Agents| Platelet Aggregation Inhibitors Excl. Heparin| Salicylates| Salicylic Acid and Derivatives| Sensory System Agents| Stomatological Preparations| UGT1A6 substrate"
153,DB06263,P11388,P16435|P16152,hsa:7153,9|10|11|12|14|18|19|20|21|178|179|181|182|185|189|192|196|199|206|283|284|285|286|299|308|332|333|336|339|340|341|344|346|347|351|352|355|356|366|367|370|371|374|380|381|382|384|393|405|406|416|420|430|432|434|441|443|446|470|490|493|498|516|520|524|535|536|541|548|552|553|556|563|564|567|570|571|573|574|575|578|579|581|582|584|590|592|594|595|597|599|603|604|606|607|608|610|614|617|618|619|623|625|634|637|638|639|640|641|642|643|651|655|660|661|662|663|664|666|667|668|671|672|677|678|679|680|681|682|683|684|686|687|688|689|690|691|692|693|696|697|698|699|700|703|704|705|708|709|710|712|713|719|734|735|755|756|776|779|782|797|798|800|805|818|819,Amrubicin,"Anthracyclines and Related Substances| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Carbohydrates| Cytotoxic Antibiotics and Related Substances| Glycosides| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Naphthacenes| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic"
154,DB00695,Q13621|P00918,P52209,hsa:6557|hsa:760,9|10|11|14|15|18|19|20|33|37|143|149|178|182|283|284|285|286|293|294|299|305|308|332|333|340|341|342|344|345|346|351|352|353|355|356|362|365|366|370|371|376|377|380|381|383|384|390|392|393|405|406|409|414|416|420|430|432|434|436|437|440|441|443|446|448|449|452|457|459|464|465|470|476|483|490|493|495|498|501|502|503|516|520|524|528|531|532|535|536|540|541|542|545|546|548|549|550|552|553|556|564|565|566|570|573|574|578|579|580|582|584|585|589|591|592|594|595|597|598|599|600|602|603|604|606|607|608|613|614|615|617|618|619|620|623|624|626|628|632|633|634|637|638|640|641|643|651|655|656|657|659|660|664|665|666|667|668|671|672|673|677|678|679|680|683|684|688|689|691|692|695|698|702|704|708|709|710|717|725|736|750|758|768|780|788|799|813|821|831,Furosemide,"Acids, Carbocyclic| Amides| Amines| Aminobenzoates| Aniline Compounds| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Benzene Derivatives| Benzoates| Carboxylic Acids| Cardiovascular Agents| Cardiovascular System| Diuretics| Drugs causing inadvertant photosensitivity| Drugs that are Mainly Renally Excreted| High-Ceiling Diuretics| High-Ceiling Diuretics and Potassium-Sparing Agents| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hyperglycemia-Associated Agents| Hypotensive Agents| Increased Diuresis at Loop of Henle| Medications that reduce magnesium levels| Membrane Transport Modulators| Natriuretic Agents| Nephrotoxic agents| Non Potassium Sparing Diuretics| OAT1/SLC22A6 Inducers| OAT1/SLC22A6 inhibitors| OAT3/SLC22A8 Inhibitors| Ototoxic agents| Photosensitizing Agents| Sodium Potassium Chloride Symporter Inhibitors| Sulfanilamides| Sulfonamides| Sulfones| Sulfur Compounds| Thyroxine-binding globulin substrates| UGT1A1 Substrates"
155,DB09282,P33402,P33402|O76074,hsa:2977,9|10|11|14|15|16|18|19|20|143|148|149|178|180|181|283|284|285|286|300|301|344|345|346|351|352|358|365|366|370|372|373|374|376|380|381|387|390|405|416|418|420|422|423|435|439|442|443|445|446|447|449|451|452|461|467|477|494|495|496|497|499|502|515|536|540|542|543|546|547|566|569|611|612|614|615|644|645|650|656|659,Molsidomine,"Azoles| Cardiac Therapy| Cardiovascular Agents| Cardiovascular System| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Morpholines| Nitric Oxide Donors| Oxadiazoles| Oxazines| Oxazoles| Sydnones| Vasodilating Agents| Vasodilators Used in Cardiac Diseases"
156,DB00494,P21964,P21964|O60656|P05177|P10635,hsa:1312,9|10|11|14|15|18|19|20|178|182|283|284|285|286|301|308|332|333|340|341|344|345|351|352|355|356|365|370|371|374|376|377|381|382|384|390|391|395|401|406|416|419|420|423|429|430|434|437|439|441|443|446|449|451|454|455|464|466|470|490|498|502|514|520|524|535|540|541|542|543|544|545|546|548|549|552|553|556|558|564|566|567|568|570|573|574|578|582|584|587|590|592|595|599|600|603|606|607|608|613|617|618|619|631|633|634|637|638|640|641|645|646|649|651|652|655|656|660|663|664|665|667|668|671|672|677|678|679|680|683|688|689|691|699|703|708|709|710|714|735|737|742|761|763|777|798|800|805|824|826,Entacapone,"Anti-Dyskinesia Agents| Anti-Parkinson Drugs| Benzene Derivatives| Central Nervous System Agents| Central Nervous System Depressants| COMT Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 Enzyme Inhibitors| Dopamine Agents| Enzyme Inhibitors| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Nervous System| Phenols| UGT1A9 Substrates"
157,DB01068,BE0004797|P30536|O75469,P08684|P05181|P11245,hsa:706|hsa:8856,9|10|11|14|15|18|19|37|178|182|185|189|213|218|219|283|284|285|286|294|299|301|332|333|340|342|344|345|351|352|355|356|362|365|370|371|376|377|384|390|392|393|395|401|416|418|420|423|430|431|434|437|439|441|442|443|446|449|451|453|454|455|464|470|490|495|501|502|503|514|516|520|524|536|538|545|546|549|550|552|555|556|558|564|569|570|576|578|582|584|585|591|592|595|598|599|600|603|607|608|611|613|618|628|633|634|640|643|645|656|657|660|664|665|668|677|678|679|683|688|696|697|708|709|710|728|737|758|759|791|800|821|822,Clonazepam,"Anticonvulsants| Benzazepines| Benzodiazepines and benzodiazepine derivatives| Benzodiazepinones| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| GABA Agents| GABA Modulators| Heterocyclic Compounds| Heterocyclic Compounds, Fused-Ring| Muscle Relaxants| Muscle Relaxants, Centrally Acting Agents| Nervous System"
158,DB00572,P11229|P08172|P20309|P08173|P08912|P23415|P43681|P17787,P05177,hsa:1128|hsa:1129|hsa:1131|hsa:1132|hsa:1133|hsa:2741|hsa:1137|hsa:1141,9|10|11|12|14|18|19|143|145|146|178|180|181|182|185|283|284|285|286|308|332|333|335|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|380|384|390|391|405|406|416|420|430|434|440|441|443|446|452|470|490|516|520|524|535|540|552|556|564|570|571|578|579|581|582|584|592|595|597|599|603|608|613|614|617|618|634|637|638|639|640|641|642|655|656|660|664|668|677|678|679|680|683|684|688|689|692|696|697|698|704|708|709|710|712,Atropine,"Adjuvants, Anesthesia| Agents producing tachycardia| Agents that produce hypertension| Alimentary Tract and Metabolism| Alkaloids| Anti-Asthmatic Agents| Antiarrhythmic agents| Anticholinergic Agents| Antimuscarinics Antispasmodics| Autonomic Agents| Aza Compounds| Azabicyclo Compounds| Belladonna Alkaloids| Belladonna Alkaloids, Tertiary Amines| Belladonna and Derivatives, Plain| Bicyclo Compounds, Heterocyclic| Bronchodilator Agents| BSEP/ABCB11 Substrates| Cardiovascular Agents| Central Nervous System Agents| Cholinergic Agents| Drugs for Functional Gastrointestinal Disorders| Heterocyclic Compounds| Heterocyclic Compounds, Bridged-Ring| Moderate Risk QTc-Prolonging Agents| Muscarinic Antagonists| Mydriatics| Mydriatics and Cycloplegics| Neurotransmitter Agents| Ophthalmologicals| Parasympatholytics| Peripheral Nervous System Agents| QTc Prolonging Agents| Respiratory System Agents| Sensory Organs| Solanaceous Alkaloids| Tropanes"
159,DB00499,P10275|P35869|O75469,P08684|P05177|P04798|Q16678|P33261|P20815,hsa:367|hsa:196|hsa:8856,9|10|11|14|15|18|19|23|24|178|182|283|284|285|286|287|299|301|332|333|335|340|344|351|352|355|356|363|370|371|374|376|377|384|390|392|393|395|401|416|420|423|430|434|437|439|441|443|446|449|451|454|455|464|470|490|495|502|514|516|520|524|535|545|546|549|552|556|558|564|570|578|582|584|585|592|595|599|600|603|607|608|613|618|628|633|634|640|643|645|656|657|660|664|665|668|677|678|679|683|688|708|709|710|728|737|758|791|800|821,Flutamide,"Amides| Amines| Androgen Receptor Antagonists| Androgen Receptor Inhibitors| Anilides| Aniline Compounds| Antiandrogens| Antiandrogens, non-steroidal| Antineoplastic Agents| Antineoplastic Agents, Hormonal| Antineoplastic and Immunomodulating Agents| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Endocrine Therapy| Hormone Antagonists| Hormone Antagonists and Related Agents| Hormones, Hormone Substitutes, and Hormone Antagonists| Methemoglobinemia Associated Agents"
160,DB00358,P69905|P29274,P08684|P06276|P11511|P10635|P22303,"hsa:3039,hsa:3040|hsa:135",9|10|11|12|14|15|18|23|24|25|178|180|181|182|183|184|185|192|283|284|285|286|287|299|308|332|333|338|339|340|341|344|345|346|351|352|355|356|357|358|363|365|366|370|371|376|377|384|385|386|387|390|392|393|396|403|406|416|418|430|431|434|437|441|442|446|449|453|464|470|472|482|490|495|502|506|516|520|523|524|528|530|538|539|540|545|546|548|549|552|555|556|564|566|570|571|573|574|576|577|578|582|584|585|592|595|599|600|603|607|608|613|617|618|619|628|633|634|637|640|641|643|655|656|657|659|660|664|665|667|668|677|678|679|680|682|683|688|689|696|697|698|699|708|709|710|712|734|758|797|821,Mefloquine,"Agents Causing Muscle Toxicity| Agents that reduce seizure threshold| Aminoquinolines| Anti-Infective Agents| Antimalarial methanolquinolines| Antimalarials| Antiparasitic Agents| Antiparasitic Products, Insecticides and Repellents| Antiprotozoals| Cholinesterase Inhibitors| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| P-glycoprotein inhibitors| P-glycoprotein substrates| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Quinolines"
161,DB01151,P23975|P31645|P28223|P07550|P08588|P17405|P35367|BE0004863|P11229|P08172|P20309|P08173|P08912|P08908|P28335|P14416|BE0004864,P10635|P33261|P33260|P05177|P08684|P11509|P20813|P05181,hsa:6530|hsa:6532|hsa:3356|hsa:154|hsa:153|hsa:6609|hsa:3269|hsa:1128|hsa:1129|hsa:1131|hsa:1132|hsa:1133|hsa:3350|hsa:3358|hsa:1813,9|10|11|12|14|15|178|182|185|189|213|215|216|283|284|285|299|332|333|340|344|345|351|355|356|365|370|371|374|376|377|384|390|391|392|393|416|430|434|437|441|446|449|464|470|490|495|502|516|520|524|528|540|545|546|549|552|556|564|570|577|578|582|584|585|592|593|595|599|600|603|607|608|613|618|628|633|634|640|643|656|657|660|664|665|668|677|678|679|683|688|696|697|708|709|710|758|821,Desipramine,"Adrenergic Agents| Adrenergic Uptake Inhibitors| Agents producing tachycardia| Agents that produce hypertension| Agents that reduce seizure threshold| Anticholinergic Agents| Antidepressive Agents| Antidepressive Agents Indicated for Depression| Antidepressive Agents, Tricyclic| Central Nervous System Agents| Central Nervous System Depressants| Combined Inhibitors of Serotonin/Norepinephrine Reuptake| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (moderate)| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 CYP2E1 Inhibitors (weak)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dibenzazepines| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Histamine Antagonists| Histamine H1 Antagonists| Membrane Transport Modulators| Muscarinic Antagonists| Narrow Therapeutic Index Drugs| Nervous System| Neurotoxic agents| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| Non-Selective Monoamine Reuptake Inhibitors| OCT1 inhibitors| OCT2 Inhibitors| P-glycoprotein inhibitors| Potential QTc-Prolonging Agents| Psychoanaleptics| Psychotropic Drugs| QTc Prolonging Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin Agents| Serotonin Modulators| Serotonin Receptor Antagonists| Tricyclics and Other Norepinephrine-reuptake Inhibitors"
162,DB00486,P34972|P21554,P05181|P08684|P10632|P11712,hsa:1269|hsa:1268,9|10|11|12|18|19|178|179|181|182|185|192|283|284|286|308|332|333|334|335|337|341|344|352|355|356|370|371|374|381|382|384|405|406|416|420|430|432|434|441|443|446|470|476|490|498|520|524|535|541|542|548|552|556|564|565|570|573|574|575|578|579|582|584|589|590|594|595|599|603|604|606|608|614|617|618|619|620|626|632|634|637|639|640|641|651|653|655|660|664|666|667|668|677|678|679|680|684|688|689|690|692|693|696|697|698|699|700|701|704|705|708|709|710|711|712|713|735|740|756|776|798|803|818|819,Nabilone,Agents producing tachycardia| Alimentary Tract and Metabolism| Antiemetics| Antiemetics and Antinauseants| Autonomic Agents| Cannabinoids and similars| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (moderate)| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (moderate)| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (weak)| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Gastrointestinal Agents| Hydrocarbons| Hypotensive Agents| Miscellaneous Antiemetics| Peripheral Nervous System Agents| Photosensitizing Agents| Psychotropic Drugs| Terpenes| Tranquilizing Agents
163,DB01410,P04150,P08684|P10635|P23141,hsa:2908,0|9|10|11|12|13|18|19|20|143|144|146|150|178|179|182|185|186|192|193|199|283|284|286|308|332|333|334|335|337|339|341|344|346|347|352|366|367|374|380|405|406|416|420|430|432|434|440|441|443|446|452|462|490|516|524|535|537|553|556|563|567|571|579|581|582|599|605|610|614|617|637|639|640|642|660|661|662|671|672|678|679|680|681|684|688|689|690|692|693|696|697|698|699|700|701|704|705|708|709|710|711|712|776|777|797|798|818|819|839|840|860|861|866,Ciclesonide,"Adrenal Cortex Hormones| Adrenals| Agents to Treat Airway Disease| Anti-Allergic Agents| Corticosteroids| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs for Obstructive Airway Diseases| Fused-Ring Compounds| Glucocorticoids| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Hyperglycemia-Associated Agents| Immunosuppressive Agents| Nasal Preparations| Polycyclic Compounds| Pregnanes| Pregnenes| Respiratory System| Steroids| Thyroxine-binding globulin inhibitors"
164,DB00804,P11229|P08172,P04798,hsa:1128|hsa:1129,9|10|11|12|14|18|19|178|179|185|186|283|284|285|286|332|333|334|335|344|345|346|351|352|365|366|374|380|390|391|405|420|440|443|452|535|540|566|579|582|614|615|637|656|659|679|680|684|688|689|692|696|697|698|704|708|709|710|711|712,Dicyclomine,"Acids, Carbocyclic| Agents producing tachycardia| Alimentary Tract and Metabolism| Anticholinergic Agents| Antimuscarinics Antispasmodics| Autonomic Agents| Carboxylic Acids| Cholinergic Agents| Cyclohexanecarboxylic Acids| Cyclohexanes| Cycloparaffins| Drugs for Functional Gastrointestinal Disorders| Drugs that are Mainly Renally Excreted| Hydrocarbons| Hydrocarbons, Alicyclic| Hydrocarbons, Cyclic| Macrocyclic Compounds| Muscarinic Antagonists| Neurotransmitter Agents| Parasympatholytics| Peripheral Nervous System Agents| Polycyclic Compounds| Synthetic Anticholinergics, Esters With Tertiary Amino Group"
165,DB00451,P10827|P10828,P10632|P08684,hsa:7067|hsa:7068,9|10|11|14|18|19|20|46|47|48|178|182|185|189|283|284|285|286|298|299|308|332|333|338|340|341|344|345|350|351|352|355|356|365|370|371|380|381|382|384|393|405|406|416|420|430|434|440|441|443|446|452|470|476|490|498|520|524|528|535|536|541|542|548|552|556|564|565|566|570|573|574|578|579|582|584|589|590|592|594|595|599|603|604|606|607|608|614|617|618|619|620|626|632|634|637|640|641|643|651|655|660|664|666|667|668|677|678|679|680|681|683|684|688|689|692|696|698|704|708|709|710|714|719|777|782,Levothyroxine,"Agents used to treat hypothyroidism| Amino Acids| Amino Acids, Aromatic| Amino Acids, Cyclic| Amino Acids, Peptides, and Proteins| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (moderate)| Cytochrome P-450 Enzyme Inhibitors| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Narrow Therapeutic Index Drugs| OATP1B1/SLCO1B1 Inhibitors| OATP1B3 inhibitors| Organic Anion Transporting Polypeptide 2B1 Inhibitors| P-glycoprotein inducers| Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins| Thyroid Products| Thyroxine-binding globulin substrates| UGT1A1 Substrates| UGT1A1 Substrates with a Narrow Therapeutic Index"
166,DB06230,P35372|P41145|P41143,P16662|P35503|Q9HAW9,hsa:4988|hsa:4986|hsa:4985,9|10|11|12|14|18|19|115|116|143|146|178|179|180|181|182|185|189|192|199|283|284|285|286|308|332|333|334|335|337|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|381|382|384|390|391|405|406|416|430|434|441|446|470|476|490|498|516|520|524|540|541|542|544|548|552|556|564|565|566|567|570|573|574|578|582|584|589|590|592|594|595|599|603|604|606|607|608|613|614|617|618|619|620|626|630|631|632|634|637|639|640|641|651|655|656|659|660|662|663|664|666|667|668|677|678|679|680|681|682|683|688|689|690|691|696|697|698|699|700|701|702|703|708|709|710|711|712|714|735|755|756|761|776|777|779|797|798|800|803|818|819|821|824|826,Nalmefene,"Alkaloids| Antidotes| Antipruritics| Central Nervous System Agents| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Drugs Used in Addictive Disorders| Drugs Used in Alcohol Dependence| Heterocyclic Compounds| Heterocyclic Compounds with 4 or More Rings| Heterocyclic Compounds, Bridged-Ring| Heterocyclic Compounds, Fused-Ring| Morphinans| Nervous System| Opiate Alkaloids| Opioid Antagonists| Peripheral Nervous System Agents| Phenanthrenes| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Sensory System Agents| UGT1A3 substrates| UGT2B7 substrates"
167,DB00643,Q71U36|P68371,P08684|P04798,hsa:7846|hsa:10383,9|10|11|12|14|15|18|19|143|148|149|178|182|185|189|283|284|285|286|299|332|333|340|341|344|351|352|355|356|357|358|366|370|371|374|375|376|377|379|380|384|386|387|389|390|392|393|396|399|400|403|405|416|418|420|430|431|432|434|437|441|442|443|446|449|450|451|452|453|464|470|472|482|484|485|487|488|490|493|495|499|502|504|506|516|519|520|523|524|527|530|535|538|539|545|546|547|549|552|553|555|556|559|560|564|569|570|572|576|578|579|582|584|585|592|595|596|597|599|600|603|607|608|611|613|618|623|628|633|634|636|640|643|647|654|657|660|664|665|668|671|672|674|677|678|679|683|684|685|688|692|695|696|697|704|707|708|709|710|716|737|770|779|800|833,Mebendazole,"Acids, Acyclic| Anthelmintics| Anti-Infective Agents| Antihelminthic| Antimitotic Agents| Antinematodal Agents| Antiparasitic Agents| Antiparasitic Products, Insecticides and Repellents| Benzimidazole Derivatives| Benzimidazoles| Carbamates| Carboxylic Acids| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Mitosis Modulators| Tubulin Modulators"
168,DB00865,Q05940|P08913|P35348|Q01959,P08684|P20813|P16435,hsa:6571|hsa:150|hsa:148|hsa:6531,9|10|11|12|14|178|182|185|189|283|284|285|332|333|338|340|344|345|351|355|356|365|370|371|374|384|390|391|416|430|434|441|446|464|470|490|516|520|524|540|549|552|556|564|570|578|582|584|592|595|599|603|607|608|613|618|628|633|634|640|656|660|664|668|677|678|679|683|688|696|708|709|710,Benzphetamine,Adrenergic Agents| Adrenergic Agonists| Adrenergic alpha-1 Receptor Agonists| Adrenergic alpha-Agonists| Adrenergic Uptake Inhibitors| Agents producing tachycardia| Agents that produce hypertension| Amines| Amphetamines| Antidepressive Agents| Appetite Suppression| Autonomic Agents| Central Nervous System Agents| Central Nervous System Depressants| Central Nervous System Stimulants| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Dopamine Agents| Dopamine Uptake Inhibitors| Ethylamines| Increased Sympathetic Activity| Membrane Transport Modulators| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| Peripheral Nervous System Agents| Phenethylamines| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Sympathomimetic Amine Anorectic| Sympathomimetics
169,DB00819,P00915|P00918|P22748|O43570|Q9ULX7|P07451|P43166|P29972,P08684,hsa:759|hsa:760|hsa:762|hsa:771|hsa:23632|hsa:761|hsa:766|hsa:358,9|10|14|15|16|18|19|33|34|143|148|149|283|284|285|286|293|299|300|305|344|351|352|374|375|379|390|392|393|412|414|418|420|421|422|439|443|450|451|457|459|467|468|479|486|489|508|511|517|519|560|596|635|643|647|654,Acetazolamide,"Anticonvulsants| Antiglaucoma Agents| Antiglaucoma Preparations and Miotics| Azoles| Carbonic Anhydrase Inhibitors| Cardiovascular Agents| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Diuretics| Drugs causing inadvertant photosensitivity| Enzyme Inhibitors| Genito Urinary System and Sex Hormones| Gynecological Antiinfectives and Antiseptics| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Natriuretic Agents| OAT1/SLC22A6 inhibitors| Ophthalmologicals| Photosensitizing Agents| Sensory Organs| Sulfonamides| Sulfur Compounds| Thiadiazoles| Thiazoles"
170,DB04841,O43497|O95180|Q9P0X4|P35367|P0DP23,P10635|P20813|P11712|P04798|P05177|P11509,"hsa:8913|hsa:8912|hsa:8911|hsa:3269|hsa:801,hsa:805,hsa:808",9|10|11|12|14|15|23|24|178|180|181|182|185|189|192|196|199|283|284|285|287|332|333|338|340|344|345|351|355|356|364|365|370|371|384|390|391|416|430|434|441|446|464|470|490|516|520|524|540|549|552|556|564|569|570|578|582|584|592|595|599|603|607|608|611|613|618|628|633|634|640|656|660|664|668|677|678|679|683|688|696|697|708|709|710,Flunarizine,"Agents causing hyperkalemia| Antiarrhythmic agents| Anticonvulsants| Antimigraine Agents, Miscellaneous| Antivertigo Preparations| Bradycardia-Causing Agents| Calcium Channel Blockers| Calcium-Regulating Hormones and Agents| Cardiovascular Agents| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Membrane Transport Modulators| Nervous System| Neurotransmitter Agents| Piperazine Derivatives| Piperazines| Vasodilating Agents"
171,DB00185,P20309|P11229,P10635|P08684|Q01740,hsa:1131|hsa:1128,9|10|11|14|18|33|143|146|178|180|181|185|187|188|283|284|285|286|293|332|333|335|337|341|344|345|346|349|351|352|353|365|366|368|374|390|391|405|412|507|540|566|582|586|592|613|614|615|637|656|658|659|682|683|708|709|710|712,Cevimeline,"Autonomic Agents| Cholinergic Agents| Cholinergic Agonists| Cholinergic Receptor Agonist| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, Bridged-Ring| Muscarinic Agonists| Nervous System| Neurotransmitter Agents| Parasympathomimetics| Peripheral Nervous System Agents| Sulfur Compounds"
172,DB00439,P04035,P08684|P20815|P24462|P10632|P10635|P33261|P11712|P20813,hsa:3156,9|10|11|12|14|18|19|20|23|178|182|183|184|185|283|284|285|286|287|308|332|333|335|339|340|341|344|346|351|352|355|356|357|358|364|366|370|371|374|376|380|384|387|390|396|403|405|406|416|418|420|430|431|434|437|440|441|442|443|446|449|452|453|464|470|472|482|490|495|506|516|520|523|524|530|535|538|539|545|548|549|552|555|556|564|570|571|573|574|577|578|579|581|582|584|585|592|594|595|599|600|603|604|607|608|613|617|618|619|628|633|634|637|638|639|640|641|642|655|656|657|660|664|665|666|667|668|677|678|679|680|683|684|688|689|690|691|692|693|696|697|698|701|702|703|705|708|709|710|712,Cerivastatin,"Agents Causing Muscle Toxicity| Anticholesteremic Agents| BCRP/ABCG2 Substrates| BSEP/ABCB11 Substrates| Cardiovascular System| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (strength unknown)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hydroxymethylglutaryl-CoA Reductase Inhibitors| Hypolipidemic Agents| Hypolipidemic Agents Indicated for Hyperlipidemia| Lipid Modifying Agents| Lipid Modifying Agents, Plain| Lipid Regulating Agents| OATP1B1/SLCO1B1 Inhibitors| OATP1B1/SLCO1B1 Substrates| P-glycoprotein substrates| UGT1A1 Substrates"
173,DB01544,P30536|P47869|P48169|P31644|Q16445|P34903|P14867|P28472|P18507,P33261|P16662|P05177|P11509|P20813|P11712|P08684|P05181|P22309|P35503,hsa:706|hsa:2555|hsa:2557|hsa:2558|hsa:2559|hsa:2556|hsa:2554|hsa:2562|hsa:2566,9|10|11|12|14|15|18|19|23|178|182|185|189|213|218|219|283|284|285|286|287|301|332|333|340|344|345|351|352|355|356|364|365|370|371|374|376|377|384|390|391|395|401|416|418|420|423|430|431|434|437|439|441|442|443|446|449|451|453|454|455|464|470|490|495|502|514|516|520|524|536|538|540|545|546|549|552|555|556|558|564|569|570|576|578|582|584|585|592|595|599|600|603|607|608|611|613|618|628|633|634|640|645|646|656|657|660|664|665|668|677|678|679|683|688|696|697|708|709|710|728|737|758|791|800|821,Flunitrazepam,"Anti-Anxiety Agents| Benzazepines| Benzodiazepine hypnotics and sedatives| Benzodiazepines and benzodiazepine derivatives| Benzodiazepinones| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| GABA Agents| GABA Modulators| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hypnotics and Sedatives| Muscle Relaxants| Muscle Relaxants, Centrally Acting Agents| Nervous System| Neurotransmitter Agents| Psycholeptics| Psychotropic Drugs| Tranquilizing Agents| UGT1A1 Inhibitors| UGT1A3 Inhibitors| UGT2B7 Inhibitors"
174,DB09078,P17948|P35968|P35916|P11362|P21802|P22607|P22455|P10721,P08684|Q06278,hsa:2321|hsa:3791|hsa:2324|hsa:2260|hsa:2263|hsa:2261|hsa:2264|hsa:3815,9|10|11|12|14|15|16|18|19|20|37|115|116|178|182|183|184|185|189|192|283|284|285|286|294|299|308|332|333|338|340|341|342|344|345|351|352|355|356|357|358|362|365|366|370|371|372|373|374|375|376|377|381|382|384|385|386|387|390|392|393|396|403|405|406|416|418|430|431|434|435|437|441|442|445|446|447|449|450|453|464|470|472|476|482|487|490|491|495|498|501|502|503|506|516|519|520|521|523|524|530|538|539|540|541|542|545|546|548|549|550|552|555|556|559|564|565|570|573|574|575|576|577|578|582|584|585|589|591|592|594|595|596|598|599|600|603|604|606|607|608|609|613|614|617|618|619|620|626|628|632|633|634|637|638|639|640|641|643|651|652|655|656|657|660|664|665|666|667|668|677|678|679|680|682|683|688|689|690|691|696|697|698|700|701|702|703|708|709|710|714|716|721|734|742|743|756|758|771|777|779|784|797|805|806|819|821|834,Lenvatinib,"Amides| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| BCRP/ABCG2 Substrates| Benzene Derivatives| BSEP/ABCB11 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (moderate)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (weak)| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Kinase Inhibitor| Moderate Risk QTc-Prolonging Agents| OAT1/SLC22A6 inhibitors| OAT3/SLC22A8 Inhibitors| OATP1B1/SLCO1B1 Inhibitors| OATP1B3 inhibitors| OCT2 Inhibitors| P-glycoprotein inhibitors| P-glycoprotein substrates| Protein Kinase Inhibitors| QTc Prolonging Agents| Receptor Tyrosine Kinase Inhibitors| Tyrosine Kinase Inhibitors"
175,DB01357,P03372,P11712|P05177,hsa:2099,9|10|11|12|18|19|143|144|178|179|182|185|189|192|283|284|286|308|332|333|334|335|337|341|344|352|355|356|366|370|371|374|381|382|384|405|406|416|417|427|428|430|434|441|446|460|470|476|490|498|516|520|524|541|542|548|552|556|564|565|570|573|574|578|582|584|589|594|595|599|603|604|606|608|617|618|619|626|634|637|640|641|651|655|660|664|666|668|677|678|679|680|688|689|696|697|698|699|708|709|710|711|712|714|735|755|776|777|797|798|818|839|840|860|861,Mestranol,"Adrenal Cortex Hormones| Contraceptive Agents, Female| Contraceptive Agents, Hormonal| Contraceptives, Oral| Contraceptives, Oral, Hormonal| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Estradiol Congeners| Estrogen Contraceptives| Estrogenic Steroids, Alkylated| Estrogens| Ethinyl Estradiol| Fused-Ring Compounds| Gonadal Hormones| Gonadal Steroid Hormones| Hormonal Contraceptives for Systemic Use| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Hyperglycemia-Associated Agents| Norpregnanes| Norpregnatrienes| Norsteroids| Polycyclic Compounds| Reproductive Control Agents| Steroids| Thyroxine-binding globulin inducers"
176,DB00528,Q06432,P24462|P08684|P20815|P10635,hsa:786,9|10|11|12|13|14|15|18|19|20|178|182|183|184|185|189|192|196|199|283|284|285|286|299|301|332|333|335|337|340|341|344|345|351|352|355|356|365|366|370|371|374|376|377|380|384|390|391|392|393|395|401|405|416|420|423|430|434|437|440|441|443|446|449|452|454|455|464|470|490|502|514|516|520|524|535|540|545|546|549|552|553|556|558|564|566|570|573|578|579|582|584|592|594|595|599|600|603|607|608|613|614|615|618|619|633|634|637|640|643|656|659|660|664|665|666|668|671|673|677|678|679|680|683|684|688|689|690|692|693|694|696|697|698|700|704|708|709|710|712|737|800,Lercanidipine,"ACE Inhibitors and Calcium Channel Blockers| Agents causing hyperkalemia| Agents Causing Muscle Toxicity| Angiotensin II receptor blockers (ARBs) and calcium channel blockers| Antiarrhythmic agents| Antihypertensive Agents| Bradycardia-Causing Agents| Calcium Channel Blockers| Calcium-Regulating Hormones and Agents| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (moderate)| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dihydropyridine Derivatives| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypotensive Agents| Membrane Transport Modulators| Pyridines| Selective Calcium Channel Blockers With Mainly Vascular Effects| Vasodilating Agents"
177,DB09285,P09917|P35354|Q15722|P21731,P09917|P35354,hsa:240|hsa:5743|hsa:1241|hsa:6915,9|10|11|12|14|15|18|19|23|24|178|180|181|182|183|184|185|192|283|284|285|286|287|299|332|333|340|344|345|346|351|352|355|356|358|363|365|366|370|371|372|373|375|376|377|378|379|380|384|387|390|391|392|393|396|403|405|416|418|420|430|434|435|437|438|440|441|442|443|445|446|447|449|450|452|453|464|470|472|482|484|487|490|491|493|495|502|506|516|519|520|521|523|524|530|535|538|539|540|545|546|548|549|552|553|555|556|560|564|566|570|573|574|576|577|578|579|580|582|584|585|592|594|595|596|597|599|600|603|604|607|608|613|614|615|618|619|623|624|628|633|634|636|637|638|640|641|643|654|655|656|657|659|660|664|665|666|668|671|672|673|674|677|678|679|680|683|684|688|691|695|702|708|709|710|737|800,Morniflumate,"Acids, Carbocyclic| Acids, Heterocyclic| Agents causing hyperkalemia| Agents that produce hypertension| Aminobenzoates| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Antiinflammatory and Antirheumatic Products| Antiinflammatory and Antirheumatic Products, Non-Steroids| Benzene Derivatives| Benzoates| Carboxylic Acids| Fenamates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Musculo-Skeletal System| Nephrotoxic agents| Nicotinic Acids| ortho-Aminobenzoates| Pyridines| UGT1A9 Inhibitors"
178,DB00876,P30556,P11712,hsa:185,9|10|11|12|14|15|18|19|20|33|143|148|149|150|156|178|182|283|284|285|286|293|308|332|333|340|344|345|349|351|352|353|355|356|357|358|359|365|368|370|371|372|373|374|375|376|379|380|383|384|387|389|390|391|396|397|403|406|412|416|418|420|421|430|431|434|435|437|438|440|441|442|443|445|446|447|449|450|452|453|464|470|471|472|480|482|484|485|487|490|491|493|495|499|500|502|504|506|507|513|516|519|520|521|523|524|531|532|535|538|539|540|545|546|547|548|549|552|553|555|556|560|564|569|570|572|573|574|578|579|582|584|585|586|592|595|596|597|599|603|607|608|611|613|617|618|619|623|628|633|634|636|637|640|641|654|655|656|657|658|660|664|667|668|671|672|674|677|678|679|680|683|684|688|689|692|698|699|704|708|709|710|713|776,Eprosartan,"Acids, Acyclic| Agents Acting on the Renin-Angiotensin System| Agents causing angioedema| Agents causing hyperkalemia| Agents Causing Muscle Toxicity| Angiotensin 2 Receptor Blocker| Angiotensin II receptor antagonists| Angiotensin II receptor blockers (ARBs) and diuretics| Angiotensin II receptor blockers (ARBs), plain| Angiotensin II Type 1 Receptor Blockers| Angiotensin Receptor Antagonists| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Azoles| Carboxylic Acids| Cardiovascular Agents| Cardiovascular System| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypotensive Agents| Sulfur Compounds"
179,DB06594,P28335|P48039|P49286,P05177|P11712,hsa:3358|hsa:4543|hsa:4544,9|10|11|14|18|19|178|182|185|189|283|284|285|286|299|332|333|341|344|345|351|352|355|356|365|366|370|371|374|381|382|384|385|390|392|393|405|416|420|430|434|439|441|443|446|451|470|476|490|498|516|520|524|528|540|541|542|548|552|556|564|565|570|573|574|578|582|584|589|592|594|595|599|603|604|606|607|608|613|618|619|626|634|637|640|641|643|645|646|651|655|656|660|664|666|668|677|678|679|680|683|688|689|696|697|698|699|708|709|710|712|714|734|735|755|777|797|798|818,Agomelatine,"Acetates| Acids, Acyclic| Amides| Antidepressive Agents| Carboxylic Acids| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Melatonin, agonists| Nervous System| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Psychoanaleptics| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2C Receptor Antagonists| Serotonin Agents| Serotonin Receptor Antagonists"
180,DB00170,P38435|Q9BQB6|Q8N0U8|P00734|P08709|P00740|P00742|P04070|P07225|P22891|P16083|P15559|P02818,P47989|Q06278|P05181|P42898|P04798|P05177|P11509,hsa:2677|hsa:79001|hsa:154807|hsa:2147|hsa:2155|hsa:2158|hsa:2159|hsa:5624|hsa:5627|hsa:8858|hsa:4835|hsa:1728|hsa:632,9|10|11|18|19|178|182|185|189|283|284|286|332|333|341|344|352|355|356|370|371|374|384|416|420|430|432|434|441|443|446|470|490|493|516|520|524|535|552|553|556|564|570|578|579|582|584|595|597|599|603|608|618|623|634|640|660|664|668|671|672|677|678|679|684|687|688|692|696|704|708|709|710|712|755|776|797|818,Menadione,"Antifibrinolytic Agents| Blood and Blood Forming Organs| Coagulants| Cytochrome P-450 CYP1A2 Inducers| Cytochrome P-450 CYP1A2 Inducers (strength unknown)| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP2A6 Inhibitors| Cytochrome P-450 CYP2A6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A7 Inhibitors| Cytochrome P-450 CYP3A7 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Diet, Food, and Nutrition| Dietary Supplements| Diterpenes| Fibrin Modulating Agents| Food| Hematologic Agents| Hemostatics| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Micronutrients| Naphthalenes| Naphthoquinones| Physiological Phenomena| Phytol| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Quinones| Supplements| Terpenes| Vitamin K| Vitamins| Vitamins (Fat Soluble)"
181,DB01327,P02918|P02919|P76577|P0AD65|P0AD68|P27169|P40933|P60568,P51580,hsa:5444|hsa:3600|hsa:3558,9|10|11|14|15|16|17|18|19|20|33|34|129|131|132|143|148|149|150|155|156|178|183|184|283|284|285|286|293|299|300|308|332|333|338|340|344|345|349|351|352|353|358|365|368|373|374|375|379|380|389|390|391|392|393|396|406|412|416|418|420|421|422|430|437|439|440|441|442|443|447|449|450|451|452|453|467|479|480|486|487|489|491|496|504|507|515|517|519|521|524|528|535|536|539|540|553|560|566|569|573|580|586|596|602|611|613|619|643|644|645|646|654|656|658|659|667|671,Cefazolin,"Amides| Anti-Bacterial Agents| Anti-Infective Agents| Antibacterials for Systemic Use| Antiinfectives for Systemic Use| beta-Lactams| Cephalosporins| First-Generation Cephalosporins| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Lactams| Nephrotoxic agents| OAT1/SLC22A6 inhibitors| OAT1/SLC22A6 Substrates| OAT3/SLC22A8 Inhibitors| OAT3/SLC22A8 Substrates| Sulfur Compounds| Thiazines"
182,DB06700,P31645|P23975,P08684,hsa:6532|hsa:6530,9|10|11|12|14|18|19|178|179|182|185|283|284|285|286|308|332|333|335|337|341|344|345|351|352|355|356|365|370|371|374|381|382|384|390|391|406|416|430|434|441|446|470|490|498|516|520|524|540|541|542|548|552|556|564|570|573|574|578|582|584|590|592|595|599|603|606|607|608|613|617|618|619|634|637|638|640|641|651|655|660|664|667|668|677|678|679|680|683|688|689|696|697|698|699|708|709|710|712|714|777,Desvenlafaxine,"Agents producing tachycardia| Agents that reduce seizure threshold| Alcohols| Antidepressive Agents| Antidepressive Agents Indicated for Depression| Benzene Derivatives| Central Nervous System Agents| Central Nervous System Depressants| Combined Inhibitors of Serotonin/Norepinephrine Reuptake| Cyclohexanes| Cyclohexanols| Cycloparaffins| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (moderate)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Fatty Alcohols| Hexanols| Hydrocarbons| Hydrocarbons, Alicyclic| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hypoglycemia-Associated Agents| Lipids| Membrane Transport Modulators| Nervous System| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| Norepinephrine Uptake Inhibitors| Phenols| Psychoanaleptics| Psychotropic Drugs| Selective Serotonin Reuptake Inhibitors| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin Agents| Serotonin and Noradrenaline Reuptake Inhibitors| Serotonin Modulators| UGT1A1 Substrates| UGT1A3 substrates| UGT2B17 substrates"
183,DB00612,P08588|P07550,P08684|P10635,hsa:153|hsa:154,9|10|11|12|14|18|19|20|178|182|283|284|285|286|299|308|332|333|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|392|393|405|406|416|430|434|441|446|470|476|490|498|516|520|524|528|540|541|542|548|552|556|564|565|566|567|570|571|573|574|578|582|584|589|594|595|599|603|604|606|608|613|614|618|619|620|626|632|634|637|638|640|641|643|651|655|656|659|660|662|663|664|666|668|677|678|679|680|688|689|690|698|700|701|708|709|710|714|777,Bisoprolol,"Adrenergic Agents| Adrenergic Antagonists| Adrenergic beta-1 Receptor Antagonists| Adrenergic beta-Antagonists| Agents causing hyperkalemia| Alcohols| Amines| Amino Alcohols| Antiarrhythmic agents| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Autonomic Agents| Beta blocking agents and calcium channel blockers| Beta Blocking Agents and Thiazides| Beta Blocking Agents, Selective| Beta Blocking Agents, Selective, and Thiazides| Beta-Blockers (Beta1 Selective)| Bradycardia-Causing Agents| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Hypotensive Agents| Neurotransmitter Agents| P-glycoprotein inhibitors| P-glycoprotein substrates| Peripheral Nervous System Agents| Phenoxypropanolamines| Propanolamines| Propanols| Sympatholytics"
184,DB00593,O43497,P05181|P08684|Q9HB55|P20815|P24462,hsa:8913,9|10|14|18|19|143|145|146|283|284|285|286|299|332|333|334|344|351|352|374|390|392|393|420|439|443|451|535|579|582|592|613|643|645|650|656|683|684|685|687|708|710|711,Ethosuximide,"Agents causing hyperkalemia| Anti-epileptic Agent| Antiarrhythmic agents| Anticonvulsants| Bradycardia-Causing Agents| Calcium Channel Blockers| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Decreased Central Nervous System Disorganized Electrical Activity| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Imides| Nervous System| Potential QTc-Prolonging Agents| Pyrrolidines| Pyrrolidinones| QTc Prolonging Agents| Succinimide Derivatives| Succinimides"
185,DB01259,P00533|P04626,P08684|P20815|P10632|P33261,hsa:1956|hsa:2064,9|10|11|12|14|15|16|18|19|20|23|33|37|143|149|178|182|183|184|185|189|192|196|199|283|284|285|286|287|293|294|299|332|333|340|341|342|344|345|346|349|351|352|353|355|356|357|358|362|364|365|366|368|370|371|373|374|375|376|377|378|379|381|382|384|385|386|387|389|390|392|393|396|403|405|409|412|414|416|418|420|430|431|432|434|437|438|441|442|443|446|447|449|450|453|457|459|464|465|470|472|476|482|484|487|490|491|493|495|498|501|502|503|504|505|506|507|516|519|520|521|523|524|528|530|535|536|538|539|540|541|542|545|546|548|549|550|551|552|553|555|556|560|564|565|566|570|572|573|574|576|577|578|579|582|583|584|585|589|591|592|593|594|595|596|597|598|599|600|601|602|603|604|606|607|608|613|614|615|618|619|620|621|623|626|628|632|633|634|636|637|640|641|643|651|654|655|656|657|659|660|664|665|666|668|671|672|674|677|678|679|680|682|683|684|688|689|691|692|695|696|697|698|699|702|703|704|707|708|709|710|716|721|734|750|758|764|779|784|797|813|821|827,Lapatinib,"Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Enzyme Inhibitors| Hepatotoxic Agents| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors| Kinase Inhibitor| P-glycoprotein inhibitors| Potential QTc-Prolonging Agents| Protein Kinase Inhibitors| QTc Prolonging Agents| Quinazolines| Tyrosine Kinase Inhibitors"
186,DB01176,P35367|P49888,P11712,hsa:3269|hsa:6783,9|10|11|12|14|15|178|180|181|182|185|189|192|283|284|285|332|333|338|340|344|345|351|355|356|365|370|371|374|384|390|391|416|430|434|441|446|464|470|490|516|520|524|540|549|552|556|564|569|570|578|582|584|592|595|599|603|607|608|611|613|618|628|633|634|640|656|660|664|668|677|678|679|683|688|696|697|708|709|710,Cyclizine,"Antiemetics| Antihistamines for Systemic Use| Autonomic Agents| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Gastrointestinal Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Neurotransmitter Agents| Peripheral Nervous System Agents| Piperazine Derivatives| Piperazines| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Respiratory System"
187,DB00395,P14867|P47870|P18507,P33261,hsa:2554|hsa:2561|hsa:2566,9|10|11|14|15|18|19|20|283|284|285|286|299|332|333|334|338|340|344|345|346|351|352|365|366|374|380|390|392|393|405|420|451|452|528|540|559|582|612|637|639|643|645|646|680|708|709|711,Carisoprodol,"Carbamates| Carbamic Acid Esters| Carboxylic Acids| Central Nervous System Agents| Central Nervous System Depressants| Centrally-mediated Muscle Relaxation| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 Substrates| Muscle Relaxants| Muscle Relaxants, Centrally Acting Agents| Musculo-Skeletal System"
188,DB00521,P07550|P08588,P10635,hsa:154|hsa:153,9|10|11|12|14|15|18|19|178|182|183|184|185|283|284|285|286|299|308|332|333|336|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|376|377|381|382|384|390|392|393|405|406|416|420|430|434|437|439|441|443|446|449|451|464|470|476|490|495|498|502|516|520|524|528|535|540|541|542|545|546|548|549|552|556|564|565|566|567|570|571|573|574|578|579|582|584|585|589|592|594|595|599|600|603|604|606|607|608|613|614|618|619|620|626|628|632|633|634|637|638|640|641|643|645|651|652|655|656|657|659|660|662|663|664|665|666|668|677|678|679|680|683|684|688|689|691|692|693|695|696|698|702|703|704|705|707|708|709|710|742|756|758|805|819|821,Carteolol,"Adrenergic Agents| Adrenergic Antagonists| Adrenergic beta-Antagonists| Agents causing hyperkalemia| Alcohols| Amines| Amino Alcohols| Antiarrhythmic agents| Antiglaucoma Preparations and Miotics| Antihypertensive Agents| Autonomic Agents| Beta Blocking Agents, Non-Selective| Bradycardia-Causing Agents| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hypotensive Agents| Negative Inotrope| Neurotransmitter Agents| Ophthalmologicals| Peripheral Nervous System Agents| Phenoxypropanolamines| Potential QTc-Prolonging Agents| Propanolamines| Propanols| QTc Prolonging Agents| Quinolines| Quinolones| Sensory Organs| Sympatholytics"
189,DB00292,P14867|P18089|BE0004797,P15538|P19099|P11511,hsa:2554|hsa:151,9|10|11|14|15|18|19|143|148|149|178|182|283|284|285|286|332|333|338|340|344|345|346|351|352|355|356|357|358|365|366|370|371|372|373|374|375|376|379|380|384|387|389|390|391|396|397|403|405|416|418|420|430|431|434|435|437|440|441|442|443|445|446|447|449|450|452|453|461|464|470|472|482|484|485|487|490|491|493|494|495|499|502|504|506|516|519|520|521|523|524|535|536|538|539|540|545|546|547|548|549|552|553|556|560|564|566|569|570|572|573|578|580|582|584|585|592|594|595|596|599|602|603|604|607|608|611|613|614|615|618|624|628|633|634|636|638|640|654|656|657|659|660|664|666|668|672|673|674|677|678|679|683|688|696|708|709|710,Etomidate,"Adrenergic Agonists| Adrenergic alpha-2 Receptor Agonists| Adrenergic alpha-Agonists| Agents producing tachycardia| Agents that produce hypertension| Anesthetics| Anesthetics, General| Anesthetics, Intravenous| Azoles| Central Nervous System Agents| Central Nervous System Depressants| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypnotics and Sedatives| Imidazoles| Nervous System"
190,DB00242,P23921|P31350|Q7LG56|P09884|Q07864|P56282|Q9NRF9|Q9NR33|P00491,P27707,hsa:6240|hsa:6241|hsa:50484|hsa:5422|hsa:5426|hsa:5427|hsa:54107|hsa:56655|hsa:4860,9|10|11|14|15|16|18|19|37|143|146|148|149|150|178|183|184|283|284|285|286|294|299|308|332|339|340|341|344|345|346|351|352|355|357|358|359|365|366|373|375|376|377|378|379|384|386|387|388|389|390|391|393|396|397|403|405|406|416|418|431|437|438|441|442|447|449|450|453|464|472|482|484|485|487|491|495|499|504|506|519|521|523|530|538|540|545|547|549|555|560|567|569|571|572|582|585|592|593|596|601|611|612|613|614|617|621|628|636|637|638|639|654|656|657|662|663|674|680|682|683|690|691|702,Cladribine,"2-Chloroadenosine| Agents Causing Muscle Toxicity| Antimetabolites| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| BCRP/ABCG2 Substrates| Cardiotoxic antineoplastic agents| Deoxyadenosines| Deoxyribonucleosides| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Immunologic Factors| Immunosuppressive Agents| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| Nucleic Acids, Nucleotides, and Nucleosides| Nucleosides| Purine Analogues| Purine Antimetabolite| Purine Nucleosides| Purines| Ribonucleosides| Selective Immunosuppressants"
191,DB11148,Q06432|BE0004905,P06276,hsa:786,9|10|11|14|18|19|178|182|283|284|285|286|299|332|333|340|344|346|351|352|355|356|366|370|371|374|376|377|380|384|393|405|416|420|430|434|437|440|441|443|446|449|452|464|470|490|493|502|516|520|524|535|545|546|548|549|552|553|556|564|570|573|574|578|579|582|584|592|594|595|597|599|600|603|604|607|608|614|618|619|623|633|634|637|640|641|643|655|660|664|665|666|668|671|672|677|678|679|680|683|684|688|689|691|692|695|698|703|704|707|708|709|710|716|779,Butamben,"Acids, Carbocyclic| Aminobenzoates| Anesthetics| Anesthetics, Local| Benzene Derivatives| Benzoates| Carboxylic Acids| Central Nervous System Agents| Central Nervous System Depressants| Cholinesterase substrates| Drugs that are Mainly Renally Excreted| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| para-Aminobenzoates| Peripheral Nervous System Agents| Sensory System Agents"
192,DB00392,P11229|Q8TCU5|P08172,P06276,hsa:1128|hsa:116443|hsa:1129,9|10|11|12|14|15|33|178|180|181|182|185|189|192|283|284|285|293|332|338|340|344|345|351|353|355|365|370|371|374|376|377|383|384|390|391|412|416|434|437|441|446|449|464|470|490|495|500|502|507|516|520|524|531|532|533|540|545|546|549|552|556|564|569|570|577|578|582|584|585|586|592|595|599|600|603|607|608|611|613|618|628|633|634|640|656|657|658|660|664|665|668|677|678|679|683|767|830,Ethopropazine,"Adrenergic Agents| Adrenergic Antagonists| Agents producing tachycardia| Anti-Parkinson Drugs| Anticholinergic Agents| Cholinergic Agents| Cholinesterase Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Histamine Agents| Muscarinic Antagonists| Nervous System| Neurotransmitter Agents| NMDA Receptor Antagonists| Sulfur Compounds| Tertiary Amines"
193,DB08907,P31639|P13866,O60656|P06133|P08684,hsa:6524|hsa:6523,9|10|11|12|18|19|20|23|33|143|149|178|181|182|185|189|192|283|284|286|287|293|308|332|333|339|341|344|346|352|353|355|356|364|366|370|371|374|383|384|405|406|412|416|421|430|434|441|446|470|471|480|490|500|507|513|516|520|524|531|532|548|552|556|564|567|570|571|573|574|578|582|584|586|594|595|599|603|604|608|614|617|618|619|634|637|639|640|641|655|658|660|662|663|664|666|668|677|678|679|680|681|688|689|690|696|697|698|699|701|708|709|710|712|713|734|755|776|797|818,Canagliflozin,"Agents causing hyperkalemia| Alimentary Tract and Metabolism| Blood Glucose Lowering Agents| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Diuretics| Drugs that are Mainly Renally Excreted| Drugs Used in Diabetes| Glucosides| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypotensive Agents| Oral Hypoglycemics| P-glycoprotein inhibitors| P-glycoprotein substrates| Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors| Sulfur Compounds| Thiophenes| UGT1A9 Substrates"
194,DB06701,Q01959|P23975|P31645,P10635,hsa:6531|hsa:6530|hsa:6532,9|10|11|14|18|19|178|180|181|182|185|283|284|285|286|299|332|333|335|338|340|344|345|351|352|355|356|365|366|370|371|374|380|384|390|392|393|405|416|420|430|434|440|441|443|446|452|470|490|516|520|524|528|535|540|552|556|564|570|578|579|580|582|584|592|595|597|599|603|607|608|613|618|634|637|638|640|641|643|655|656|660|664|668|677|678|679|680|683|684|688|689|692|696|697|698|704|708|709|710|712,Dexmethylphenidate,"Agents that produce hypertension| Antidepressive Agents| Central Nervous System Agents| Central Nervous System Depressants| Central Nervous System Stimulants| Central Nervous System Stimulation| Centrally Acting Sympathomimetics| Combined Inhibitors of Serotonin/Norepinephrine Reuptake| Dopamine Agents| Dopamine Uptake Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Membrane Transport Modulators| Methylphenidate and isomer| Nervous System| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| Phenylacetates| Piperidines| Psychoanaleptics| Psychostimulants, Agents Used for ADHD and Nootropics| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin Agents| Serotonin Modulators"
195,DB00586,P35354|P23219|P09917|P35499|P78348|O43526|O43525|P14555,P11712|P33261|P05177|P10632|P22309|P16662|P23219|P08684|P04798|P20813|P33260|P05181,hsa:5743|hsa:5742|hsa:240|hsa:6329|hsa:41|hsa:3785|hsa:3786|hsa:5320,9|10|11|14|18|19|37|38|178|182|185|189|283|284|285|286|294|299|308|332|333|340|342|344|351|352|355|356|362|370|371|376|377|380|384|390|392|393|406|416|420|430|434|437|440|441|443|446|449|452|464|470|490|495|501|502|503|516|520|524|535|545|546|549|550|552|556|564|570|577|578|579|582|584|585|591|592|595|597|598|599|600|603|607|608|609|613|617|618|628|633|634|637|640|641|643|655|656|657|660|664|665|668|677|678|679|680|682|683|684|685|688|689|692|696|698|704|708|709|710|752|758|771|815|821|834,Diclofenac,"Acetic Acid Derivatives and Related Substances| Acids, Carbocyclic| Agents causing angioedema| Agents causing hyperkalemia| Agents that produce hypertension| Amines| Analgesics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)| Antiinflammatory and Antirheumatic Products| Antiinflammatory and Antirheumatic Products, Non-Steroids| Antiinflammatory Preparations, Non-Steroids for Topical Use| Antimigraine Agents, Miscellaneous| Antirheumatic Agents| BSEP/ABCB11 Substrates| Carboxylic Acids| Central Nervous System Agents| Cyclooxygenase Inhibitors| Cyclooxygenase-2 (COX-2) Inhibitors| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C18 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Decreased Prostaglandin Production| Dermatologicals| Drugs causing inadvertant photosensitivity| Enzyme Inhibitors| Ethylamines| Heteroaryl acetic acid NSAIDS| Musculo-Skeletal System| Nephrotoxic agents| Non COX-2 selective NSAIDS| OAT1/SLC22A6 inhibitors| OAT3/SLC22A8 Inhibitors| OATP1B1/SLCO1B1 Inhibitors| Ophthalmologicals| Other Nonsteroidal Anti-inflammatory Agents| P-glycoprotein inducers| Peripheral Nervous System Agents| Phenylacetates| Photosensitizing Agents| Sensory Organs| Sensory System Agents| Topical Products for Joint and Muscular Pain| UDP Glucuronosyltransferases Inhibitors| UGT1A1 Substrates| UGT1A3 substrates| UGT1A9 Substrates| UGT2B17 Inhibitors| UGT2B7 substrates"
196,DB00317,P00533,P08684|P10635|P20815|P04798|P11712|P33261,hsa:1956,9|10|11|12|14|15|16|18|19|23|37|178|180|181|182|183|184|185|189|192|199|283|284|285|286|287|294|299|332|333|340|341|342|344|345|346|351|352|355|356|357|358|362|364|365|366|370|371|373|374|375|376|377|378|379|381|382|384|385|386|387|389|390|391|392|393|396|403|405|416|418|430|431|434|437|438|441|442|446|447|449|450|453|464|470|472|476|482|484|487|490|491|495|498|501|502|503|504|506|516|519|520|521|523|524|530|538|539|540|541|542|544|545|546|548|549|550|552|555|556|560|564|565|566|567|570|572|573|574|576|577|578|582|584|585|589|591|592|593|594|595|596|598|599|600|601|603|604|606|607|608|613|614|615|618|619|620|621|626|628|630|632|633|634|636|637|638|640|641|643|651|652|654|655|656|657|659|660|662|664|665|666|668|674|677|678|679|680|682|683|688|689|691|699|702|703|708|709|710|714|721|735|742|750|758|761|777|784|798|805|813|821|824,Gefitinib,"Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| BCRP/ABCG2 Inhibitors| BCRP/ABCG2 Substrates| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Enzyme Inhibitors| Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Kinase Inhibitor| P-glycoprotein inhibitors| P-glycoprotein substrates| Protein Kinase Inhibitors| Quinazolines| Tyrosine Kinase Inhibitors"
197,DB01212,P0A3M6|Q9NSA0|Q4U2R8|Q8TCC7|P46059,P15104,hsa:55867|hsa:9356|hsa:9376|hsa:6564,9|10|11|12|14|15|16|17|18|19|20|33|34|129|131|132|143|148|149|178|183|184|185|190|191|283|284|285|286|293|299|300|301|308|332|333|338|340|344|345|349|351|352|353|355|357|358|365|366|368|370|374|375|376|379|380|381|383|387|389|390|391|392|393|394|395|396|398|399|403|406|412|416|418|420|421|422|430|431|437|439|440|441|442|443|446|449|450|451|452|453|467|472|473|474|475|477|480|482|484|485|486|487|489|490|494|495|496|499|500|502|504|506|507|508|511|515|517|518|519|521|522|524|527|528|531|533|535|536|538|539|540|546|547|553|555|556|560|566|569|570|572|573|576|579|580|586|592|593|596|597|602|607|611|613|616|619|636|643|644|645|646|647|654|656|658|659|667|671|674,Ceftriaxone,"Amides| Anti-Bacterial Agents| Anti-Infective Agents| Antibacterials for Systemic Use| Antiinfectives for Systemic Use| beta Lactam Antibiotics| beta-Lactams| Cephacetrile| Cephalosporins| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Lactams| Nephrotoxic agents| OAT1/SLC22A6 inhibitors| OAT3/SLC22A8 Inhibitors| P-glycoprotein inhibitors| Sulfur Compounds| Thiazines| Third-Generation Cephalosporins"
198,DB12267,Q9UM73|P00533|P00519|P08069|P36888|P06213|P08581|Q15303|P04626,P10632|P08684,hsa:238|hsa:1956|hsa:25|hsa:3480|hsa:2322|hsa:3643|hsa:4233|hsa:2066|hsa:2064,9|10|11|12|14|15|16|18|19|30|37|178|180|181|182|183|184|185|187|188|189|192|199|206|283|284|285|286|292|294|299|314|332|338|340|341|342|344|345|351|352|355|358|362|365|366|370|371|372|373|374|375|376|377|378|379|381|382|384|387|389|390|391|392|393|396|403|405|410|416|418|425|434|435|437|438|441|442|445|446|447|449|450|453|464|470|472|476|482|484|487|490|491|495|498|502|503|504|506|516|519|520|521|523|524|530|538|540|541|542|543|545|546|548|549|552|555|556|560|564|565|566|569|570|572|573|574|576|577|578|582|584|585|589|592|593|594|595|596|599|600|601|603|604|606|607|608|609|611|613|615|618|619|621|626|628|633|634|636|637|638|640|641|643|651|652|654|655|656|657|659|660|664|665|666|668|674|677|678|679|680|683|689|691|702|703|728|742|763|791|805|826,Brigatinib,"Anaplastic lymphoma kinase (ALK) inhibitors| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| BCRP/ABCG2 Inhibitors| BCRP/ABCG2 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Kinase Inhibitor| MATE 1 Inhibitors| MATE 2 Inhibitors| MATE inhibitors| Narrow Therapeutic Index Drugs| Protein Kinase Inhibitors| Tyrosine Kinase Inhibitors"
199,DB01097,Q02127|P35869|Q14289,P11712|P05177,hsa:1723|hsa:196|hsa:2185,9|10|11|14|15|18|19|23|24|143|148|149|178|182|283|284|285|286|287|299|301|332|333|340|341|344|345|351|352|355|356|358|363|365|370|371|372|373|374|376|377|381|384|387|390|392|393|395|416|418|420|423|430|432|434|435|437|439|441|442|443|445|446|447|449|451|454|464|470|490|493|495|498|502|514|516|520|523|524|530|535|538|541|545|546|548|549|552|553|555|556|558|564|570|573|578|579|580|581|582|584|585|588|592|593|595|599|600|603|607|608|613|618|623|624|625|628|633|634|638|640|642|643|645|652|656|657|660|664|665|668|671|672|673|677|678|679|683|688|708|709|710|716|779,Leflunomide,"Adjuvants| Agents Causing Muscle Toxicity| Antineoplastic and Immunomodulating Agents| Antirheumatic Agents| Azoles| BCRP/ABCG2 Substrates| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Disease-modifying Antirheumatic Agents| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Immunologic Factors| Immunosuppressive Agents| Isoxazoles| Leflunomide and metabolite| Selective Immunosuppressants"
200,DB00228,BE0004797|BE0004857|O15554|Q09470|P98194|P42261|P30049,P05181,hsa:3783|hsa:3736|hsa:27032|hsa:2890|hsa:513,9|18|23|24|25|37|283|284|286|287|294|342|343|344|352|361|363|366|405|551,Enflurane,"Agents that reduce seizure threshold| Anesthetics| Anesthetics, General| Anesthetics, Inhalation| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 Substrates| Ethers| Methyl Ethers| Nervous System"
201,DB00367,P06401|P18405|P03372|P10275|P04278,P08684|P11511,hsa:5241|hsa:6715|hsa:2099|hsa:367|hsa:6462,0|9|10|11|12|18|19|143|144|178|179|182|185|186|192|283|284|286|308|332|333|334|335|337|341|344|352|374|406|416|417|420|427|428|430|432|434|441|443|446|460|490|524|535|553|556|579|582|599|617|637|640|660|671|678|679|680|684|688|689|692|696|697|698|699|704|708|709|710|711|712|776|797|818|839|840|860|861,Levonorgestrel,"Adrenal Cortex Hormones| Combination Contraceptives (with Estrogen and derivatives)| Contraceptive Agents, Female| Contraceptive Agents, Hormonal| Contraceptives, Oral| Contraceptives, Oral, Synthetic| Contraceptives, Postcoital| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Substrates| Fused-Ring Compounds| Genito Urinary System and Sex Hormones| Hormonal Contraceptives for Systemic Use| Hyperglycemia-Associated Agents| Inhibit Ovum Fertilization| Norpregnanes| Norpregnenes| Norsteroids| Polycyclic Compounds| Progestin Contraceptives| Progestin-containing Intrauterine Device| Progestins| Progestogens and Estrogens, Sequential Preparations| Reproductive Control Agents| Sex Hormones and Modulators of the Genital System| Steroids"
202,DB00917,P43116|P34995|P43115|P35408|Q9Y5Y4,P05108|P11511|P05177,hsa:5732|hsa:5731|hsa:5733|hsa:5734|hsa:11251,9|10|11|12|18|19|20|143|144|283|284|286|308|332|333|335|339|341|344|346|352|366|374|380|406|416|420|432|434|440|441|443|446|452|490|516|524|535|556|571|573|579|581|582|599|617|619|637|640|641|642|660|667|678|679|680|684|686|688|689|692|696|704|708|709|710|712|840|860|861,Dinoprostone,"Autacoids| Biological Factors| Dinoprostone, antagonists & inhibitors| Eicosanoids| Fatty Acids| Fatty Acids, Unsaturated| Genito Urinary System and Sex Hormones| Inflammation Mediators| Lipids| OAT1/SLC22A6 inhibitors| OAT1/SLC22A6 Substrates| OAT3/SLC22A8 Inhibitors| OAT3/SLC22A8 Substrates| OATP1B1/SLCO1B1 Substrates| OATP2B1/SLCO2B1 substrates| OCT1 inhibitors| OCT2 Inhibitors| Prostaglandins| Prostaglandins E| Prostaglandins, Synthetic| Reproductive Control Agents| Uterotonic agents"
203,DB00254,P0A7X3|P0A7V8|Q9UM07|P61769,P08684,hsa:23569|hsa:567,9|10|11|12|14|15|18|19|20|21|178|182|185|189|192|196|199|203|283|284|285|286|299|308|332|333|335|337|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|391|393|406|416|420|430|432|434|439|441|443|446|451|462|464|470|490|493|498|516|520|524|535|537|540|541|542|548|552|553|556|564|566|567|570|571|573|574|578|579|580|581|582|584|588|590|592|595|597|599|603|606|608|613|617|618|619|623|625|634|637|638|639|640|641|642|651|655|659|660|663|664|667|668|671|677|678|679|680|681|682|683|684|685|686|688|689|690|691|692|693|696|697|698|699|704|708|709|710|712|735|755|756|776|782|797|798|818|819|824|826,Doxycycline,"Agents that produce neuromuscular block (indirect)| Alimentary Tract and Metabolism| Anti-Bacterial Agents| Anti-Infective Agents| Antibacterials for Systemic Use| Antiinfectives and Antiseptics for Local Oral Treatment| Antiinfectives for Systemic Use| Antiparasitic Agents| Antiprotozoals| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Drugs causing inadvertant photosensitivity| Drugs that are Mainly Renally Excreted| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Medications that reduce magnesium levels| Naphthacenes| OAT1/SLC22A6 inhibitors| Photosensitizing Agents| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Stomatological Preparations| Tetracyclines"
204,DB01218,Q12809|P46925,P10635|P08684|P20815|P10632,hsa:3757,9|10|11|12|14|18|23|24|37|38|178|182|185|189|192|196|283|284|285|286|287|294|308|332|333|339|341|342|344|345|346|351|352|355|356|362|363|365|366|370|371|374|384|385|390|391|406|416|430|434|441|446|470|490|501|503|516|520|524|540|548|550|552|556|564|570|571|573|574|578|582|584|591|592|595|598|599|603|608|613|617|618|619|634|637|638|640|641|655|656|660|664|667|668|677|678|679|680|683|688|689|696|697|698|699|708|709|710|712|713|717|734|738|752|755|759|776|780|797|801|815|818|822,Halofantrine,"Agents that reduce seizure threshold| Anti-Infective Agents| Antimalarials| Antiparasitic Agents| Antiparasitic Products, Insecticides and Repellents| Antiprotozoals| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strong)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Highest Risk QTc-Prolonging Agents| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| QTc Prolonging Agents"
205,DB08827,P55157,P08684,hsa:4547,9|10|11|12|13|14|15|18|19|23|24|25|143|144|178|180|181|182|185|189|192|196|199|203|206|283|284|285|286|287|299|332|333|334|338|340|344|345|351|352|355|356|363|365|370|371|384|390|391|392|393|416|420|430|434|439|441|443|446|451|464|470|490|493|516|520|524|528|535|540|549|552|553|556|564|570|578|579|582|584|592|593|595|597|599|603|607|608|613|618|623|628|633|634|640|643|645|646|656|660|664|668|671|672|677|678|679|683|684|688|692|696|697|704|708|709|710|711|712|713|755|776|818|839|860,Lomitapide,"Cardiovascular System| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates (strength unknown)| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Hepatotoxic Agents| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hypolipidemic Agents| Hypolipidemic Agents Indicated for Hyperlipidemia| Lipid Modifying Agents| Lipid Modifying Agents, Plain| Microsomal Triglyceride Transfer Protein Inhibitor| Microsomal Triglyceride Transfer Protein Inhibitors| Narrow Therapeutic Index Drugs| Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia| P-glycoprotein inhibitors"
206,DB01024,P20839|P12268,P22309|O60656|P16662|Q9HAW7|P19224,hsa:3614|hsa:3615,9|10|11|12|18|19|20|143|146|178|182|283|284|286|308|332|333|341|344|346|352|355|356|366|374|380|381|382|384|405|406|416|420|430|434|440|441|443|446|452|470|476|490|493|498|520|524|535|541|548|552|553|556|564|565|570|573|574|575|578|579|581|582|584|589|590|594|595|597|599|603|604|606|608|614|617|618|619|623|625|626|634|637|639|640|641|642|651|653|655|660|664|666|667|668|671|677|678|679|680|681|684|686|688|689|690|692|693|696|697|698|699|700|701|704|705|708|709|710|712|713|714|734|735|740|755|756|776|777|797|798|803|818|819,Mycophenolicacid,"Acids, Acyclic| Anti-Bacterial Agents| Anti-Infective Agents| Antibiotics, Antineoplastic| Antimetabolite Immunosuppressant| Antineoplastic and Immunomodulating Agents| Caproates| Carboxylic Acids| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Fatty Acids| Immunosuppressive Agents| Mycophenolic Acid and Prodrugs| Narrow Therapeutic Index Drugs| Selective Immunosuppressants| UGT1A1 Substrates| UGT1A1 Substrates with a Narrow Therapeutic Index| UGT1A6 substrate| UGT1A6 Substrates with a Narrow Therapeutic Index| UGT1A9 Substrates| UGT1A9 Substrates with a Narrow Therapeutic Index| UGT2B7 substrates| UGT2B7 Substrates with a Narrow Therapeutic Index"
207,DB12364,P00742,P00734,hsa:2159,9|10|11|12|14|15|16|18|19|37|178|182|183|184|185|189|192|283|284|285|286|294|299|332|333|340|341|342|344|345|351|352|355|356|358|362|365|366|370|371|372|373|374|375|376|377|378|379|381|382|384|387|390|391|392|393|396|403|405|416|418|420|430|434|435|437|438|439|441|442|443|445|446|447|449|450|451|453|464|470|472|476|482|484|487|488|490|491|493|495|498|501|502|503|506|516|519|520|521|523|524|530|535|538|539|540|541|542|545|546|548|549|550|552|553|555|556|560|564|565|570|573|574|576|577|578|579|580|582|584|585|589|591|592|593|594|595|596|597|598|599|600|603|604|606|607|608|609|613|618|619|623|624|626|628|633|634|636|637|640|641|643|645|647|651|654|655|656|657|660|664|665|666|668|671|672|673|674|677|678|679|680|682|683|684|686|688|689|692|699|704|708|709|710|713|721|735|758|776|784|798|821,Betrixaban,"Acids, Carbocyclic| Amides| Anticoagulants| Antithrombins| Benzene Derivatives| Benzoates| Blood and Blood Forming Organs| Carboxylic Acids| Direct factor Xa inhibitors| Enzyme Inhibitors| Factor Xa Inhibitors| Hematologic Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| P-glycoprotein substrates| Protease Inhibitors| Serine Protease Inhibitors"
208,DB00035,P30518|P37288|P47901,P23219|P35354,hsa:554|hsa:552|hsa:553,9|10|11|12|13|14|15|16|17|18|19|20|21|33|34|143|145|146|178|182|185|189|283|284|285|286|293|299|308|332|333|338|340|341|344|345|349|351|352|353|355|356|365|368|370|371|375|381|382|384|390|391|392|393|406|416|418|420|430|434|439|441|443|446|450|451|470|488|490|498|516|519|520|524|528|535|536|540|541|542|548|552|556|560|564|569|570|573|574|578|579|580|582|584|590|592|593|595|596|599|602|603|606|607|608|611|613|617|618|619|634|637|640|641|643|645|646|651|654|655|656|660|664|667|668|677|678|679|680|683|684|685|687|688|689|692|694|695|696|698|704|708|709|710|714|777,Desmopressin,"Agents that produce hypertension| Amino Acids, Peptides, and Proteins| Antidiuretic Agents| Arginine Vasopressin| Cardiovascular Agents| Coagulants| Drugs that are Mainly Renally Excreted| Factor VIII Activator| Hematologic Agents| Hemostatics| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Increased Coagulation Factor VIII Activity| Increased Coagulation Factor VIII Concentration| Natriuretic Agents| Nerve Tissue Proteins| Neuropeptides| Oligopeptides| Peptide Hormones| Peptides| Pituitary| Pituitary and Hypothalamic Hormones and Analogues| Pituitary Hormones| Pituitary Hormones, Posterior| Posterior Pituitary Lobe Hormones| Proteins| Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins| Vasopressin Analog| Vasopressin and Analogues| Vasopressins"
209,DB00470,P21554|P34972,P08684|P11712|P33261|P23219|P04798|P11509,hsa:1268|hsa:1269,9|10|11|12|18|19|178|182|184|185|189|192|283|284|286|308|332|333|335|337|341|344|352|355|356|370|371|374|381|382|384|405|406|416|430|434|441|446|470|476|490|498|520|524|541|542|548|552|556|564|565|570|573|574|575|578|582|584|589|590|594|595|599|603|604|606|608|614|617|618|619|620|626|632|634|637|639|640|641|651|653|655|660|664|666|667|668|677|678|679|680|688|689|690|696|697|698|699|700|701|708|709|710|712|713|735|740|756|776|798|803|819,Dronabinol,"Agents producing tachycardia| Alimentary Tract and Metabolism| Analgesics| Analgesics, Non-Narcotic| Antiemetics and Antinauseants| BCRP/ABCG2 Inhibitors| Cannabinoid Receptor Agonists| Cannabinoids and similars| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP2A6 Inhibitors| Cytochrome P-450 CYP2A6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Inducers| Cytochrome P-450 CYP2C9 Inducers (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (weak)| Cytochrome P-450 CYP3A7 Inhibitors| Cytochrome P-450 CYP3A7 Inhibitors (weak)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Hallucinogens| Hormones, Hormone Substitutes, and Hormone Antagonists| Hydrocarbons| Miscellaneous Antiemetics| Neurotransmitter Agents| P-glycoprotein inhibitors| Peripheral Nervous System Agents| Psychotropic Drugs| Sensory System Agents| Terpenes| UGT1A1 Substrates| UGT1A3 substrates| UGT1A9 Substrates"
210,DB00564,Q14524|P43681|P17787|O75469,P08684|P10632|P05177|P11712|P33261|P20813|P20815|P24462|P16662,hsa:6331|hsa:1137|hsa:1141|hsa:8856,9|10|11|14|15|18|178|182|185|189|213|218|219|283|284|285|286|299|332|333|340|344|351|355|356|370|371|375|376|377|384|390|391|393|416|420|430|434|437|441|446|449|451|464|470|490|495|502|516|520|524|545|546|549|552|556|560|564|570|577|578|582|584|585|592|595|599|600|603|607|608|613|618|628|633|634|640|645|654|656|657|660|664|665|668|674|677|678|679|683|688|708|709|710|758|821,Carbamazepine,"Analgesics| Analgesics, Non-Narcotic| Anticonvulsants| Antimanic Agents| Carboxamide Derivatives| Cardiovascular Agents| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Inducers| Cytochrome P-450 CYP1A2 Inducers (strong)| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (strong)| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C19 Inducers| Cytochrome P-450 CYP2C19 Inducers (moderate)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Inducers| Cytochrome P-450 CYP2C8 Inducers (strength unknown)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C9 Inducers| Cytochrome P-450 CYP2C9 Inducers (strength unknown)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inducers (strong)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strong)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A5 Inducers| Cytochrome P-450 CYP3A5 Inducers (strength unknown)| Cytochrome P-450 CYP3A5 Inducers (strong)| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Decreased Central Nervous System Disorganized Electrical Activity| Dibenzazepines| Drugs that are Mainly Renally Excreted| Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index| Enzyme Inducing Antiepileptic Drugs| Heterocyclic Compounds| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Immunosuppressive Agents| Inducers of Drug Clearance| Membrane Transport Modulators| Miscellaneous Anticonvulsants| Mood Stabilizer| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| P-glycoprotein inducers| P-glycoprotein substrates| Peripheral Nervous System Agents| Psychotropic Drugs| Sensory System Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Sodium Channel Blockers| Thyroxine-binding globulin substrates| UGT1A1 Inducers| UGT1A6 inducer| UGT2B7 substrates| UGT2B7 Substrates with a Narrow Therapeutic Index"
211,DB00598,P08588|P07550|BE0004863,P10635,hsa:153|hsa:154,9|10|11|12|14|15|18|19|178|182|185|189|283|284|285|286|299|308|332|333|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|392|393|406|416|420|430|434|439|441|443|446|451|464|470|490|493|498|516|520|524|528|535|540|541|542|548|549|552|553|556|564|566|570|571|573|574|578|579|581|582|584|590|592|595|597|599|603|606|607|608|613|617|618|619|623|625|633|634|637|638|640|641|642|643|651|655|656|659|660|664|667|668|671|672|677|678|679|680|683|684|688|689|690|691|692|693|696|697|698|701|704|705|708|709|710|714|734|756|777|797|819,Labetalol,Adrenergic Agents| Adrenergic alpha-1 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Adrenergic beta-Antagonists| Agents causing hyperkalemia| Agents producing tachycardia| Alcohols| Alpha and Beta Blocking Agents| Alpha and Beta Blocking Agents and Thiazides| Amides| Amines| Amino Alcohols| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Autonomic Agents| Beta Blocking Agents and Thiazides| Bradycardia-Causing Agents| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Ethanolamines| Hypotensive Agents| Negative Inotrope| Neurotransmitter Agents| Peripheral alpha-1 blockers| Peripheral Nervous System Agents| Salicylamides| Sympathomimetics| UGT1A1 Substrates| UGT1A9 Substrates| UGT2B7 substrates| Vasodilating Agents
212,DB06216,P14416|P28223|P08908|P28222|P41595|P28335|P47898|P50406|P34969|P08913|P18089|P18825|P35348|P21728|P35462|P21917|P35367|P25021|P08588|P07550,P05177|P10635|P22310|P08684,hsa:1813|hsa:3356|hsa:3350|hsa:3351|hsa:3357|hsa:3358|hsa:3361|hsa:3362|hsa:3363|hsa:150|hsa:151|hsa:152|hsa:148|hsa:1812|hsa:1814|hsa:1815|hsa:3269|hsa:3274|hsa:153|hsa:154,9|10|11|12|14|18|19|20|37|143|145|146|178|182|185|189|213|219|283|284|285|286|294|308|332|333|335|341|342|344|345|351|352|355|356|362|365|370|371|374|380|381|382|384|390|391|405|406|416|420|430|434|440|441|443|446|452|470|476|490|498|501|503|516|520|524|540|541|542|548|550|552|553|556|564|565|570|573|574|578|582|584|589|591|592|594|595|598|599|603|604|606|607|608|613|614|618|619|620|626|632|634|637|640|641|651|655|656|660|664|666|667|668|671|672|677|678|679|680|682|683|688|689|691|696|697|698|699|702|708|709|710|712|722|738|756|785|801|819,Asenapine,"Acid Reducers| Adrenergic alpha-1 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Agents that produce hypertension| Antidepressive Agents| Antipsychotic Agents| Antipsychotic Agents (Second Generation [Atypical])| Benzocycloheptenes| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Diazepines, Oxazepines, Thiazepines and Oxepines| Dopamine Antagonists| Dopamine D2 Receptor Antagonists| Heterocyclic Compounds, Fused-Ring| Highest Risk QTc-Prolonging Agents| Histamine Antagonists| Histamine H1 Antagonists| Histamine H2 Antagonists| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hyperglycemia-Associated Agents| Nervous System| Neurotoxic agents| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Psycholeptics| Psychotropic Drugs| QTc Prolonging Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT1 Receptor Antagonists| Serotonin 5-HT1A Receptor Antagonists| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin 5-HT2C Receptor Antagonists| Serotonin Agents| Serotonin Receptor Agonists| Serotonin Receptor Antagonists| Tranquilizing Agents| UGT1A4 substrates"
213,DB00773,P11388|Q02880,P08684|P05177|P10632|P05181|P20815|P22309|P30711|P09211|P35354|P23219,hsa:7153|hsa:7155,0|9|10|11|12|18|19|20|21|143|146|149|150|178|179|181|182|185|188|189|192|199|206|283|284|286|308|332|333|335|339|341|344|346|347|352|355|356|366|367|370|371|374|380|381|382|384|405|406|416|420|430|434|440|441|443|446|452|470|476|490|498|520|524|535|541|542|544|548|552|556|563|564|565|567|570|571|573|574|575|578|579|582|584|589|590|594|595|599|603|604|606|608|610|614|617|618|619|626|630|631|634|637|639|640|641|651|653|655|660|661|662|663|664|666|667|668|677|678|679|680|681|684|686|688|689|690|692|696|697|698|699|700|701|704|708|709|710|712|714|735|740|755|761|776|777|797|798|803|818|819|824,Etoposide,"Antineoplastic Agents| Antineoplastic Agents, Phytogenic| Antineoplastic and Immunomodulating Agents| BCRP/ABCG2 Substrates| BEACOPP chemotherapy regimen| Carbohydrates| Cardiotoxic antineoplastic agents| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Enzyme Inhibitors| Glucosides| Glycosides| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Immunosuppressive Agents| Myelosuppressive Agents| Naphthalenes| Narrow Therapeutic Index Drugs| P-glycoprotein inhibitors| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Podophyllotoxin| Podophyllotoxin Derivatives| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Tetrahydronaphthalenes| Topoisomerase II Inhibitors| Topoisomerase Inhibitors| UGT1A1 Substrates| UGT1A1 Substrates with a Narrow Therapeutic Index"
214,DB05351,P20648|P51164,P33261|P08684,hsa:495|hsa:496,9|10|11|12|14|15|18|19|23|24|33|143|148|149|178|182|183|184|185|283|284|285|286|287|293|299|332|333|340|341|344|345|346|349|351|352|353|355|356|357|358|363|365|366|368|370|371|372|373|374|375|376|377|379|381|382|384|386|387|389|390|392|393|396|399|400|403|405|412|414|416|418|430|431|434|435|437|441|442|445|446|447|449|450|453|457|464|465|468|470|472|473|475|476|478|482|484|485|487|488|489|490|491|495|498|499|502|504|506|507|516|519|520|521|523|524|527|530|538|539|540|541|542|545|546|547|548|549|552|555|556|560|564|565|569|570|572|573|574|576|577|578|582|584|585|586|589|592|594|595|596|599|600|603|604|606|607|608|611|613|614|618|619|620|626|628|632|633|634|636|637|638|640|643|651|652|654|656|657|660|664|665|666|668|674|677|678|679|683|708|709|710|770|833,Dexlansoprazole,"2-Pyridinylmethylsulfinylbenzimidazoles| Acid Reducers| Alimentary Tract and Metabolism| Anti-Ulcer Agents| Benzimidazoles| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (weak)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs for Acid Related Disorders| Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)| Enzyme Inhibitors| Gastric Acid Lowering Agents| Gastrointestinal Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Proton Pump Inhibitors| Proton-pump Inhibitors| Pyridines| Sulfoxides| Sulfur Compounds"
215,DB01149,P28223|P28335|P31645|P08908|P23975|Q01959|P35368|P08913|P35348|Q12809,P20815|P24462|P08684|Q14097|P10635|P05177,hsa:3356|hsa:3358|hsa:6532|hsa:3350|hsa:6530|hsa:6531|hsa:147|hsa:150|hsa:148|hsa:3757,9|10|11|12|14|15|16|18|19|37|143|148|149|178|180|181|182|185|189|192|283|284|285|286|294|300|332|340|341|342|344|345|346|351|352|355|358|359|362|365|366|370|371|374|375|376|377|379|381|382|384|389|390|391|396|397|403|405|416|418|420|422|434|437|438|441|442|446|449|450|451|453|464|467|470|472|476|484|486|487|490|495|496|498|501|502|503|504|506|515|516|517|518|519|520|521|524|538|539|540|541|542|545|546|548|549|550|552|556|560|564|565|566|569|570|572|573|574|578|582|584|585|589|591|592|593|594|595|596|598|599|600|603|604|606|607|608|611|613|614|615|618|619|620|626|628|632|633|634|636|637|640|641|644|645|646|647|651|654|655|656|657|659|660|664|665|666|668|677|678|679|680|683|689|750|813,Nefazodone,"Adrenergic alpha-1 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Agents that produce hypertension| Analgesics| Antidepressive Agents| Antidepressive Agents Indicated for Depression| Antidepressive Agents, Second-Generation| Antidepressive Agents, Triazolopyridine| Azoles| BSEP/ABCB11 Substrates| Central Nervous System Agents| Central Nervous System Depressants| Combined Inhibitors of Serotonin/Norepinephrine Reuptake| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strong)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypoglycemia-Associated Agents| Membrane Transport Modulators| Nervous System| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| OATP1B3 inhibitors| Organic Anion Transporting Polypeptide 2B1 Inhibitors| P-glycoprotein inducers| P-glycoprotein inhibitors| Psychoanaleptics| Psychotropic Drugs| Selective Serotonin Reuptake Inhibitors| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT1 Receptor Antagonists| Serotonin 5-HT1A Receptor Antagonists| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin 5-HT2C Receptor Antagonists| Serotonin Agents| Serotonin and Noradrenaline Reuptake Inhibitors| Serotonin antagonist and reuptake inhibitors (SARIs)| Serotonin Modulators| Serotonin Receptor Antagonists"
216,DB00903,P05023|Q13621|Q9UJU2|P09211,P09210,hsa:476|hsa:6557|hsa:51176|hsa:2950,9|10|11|18|19|20|37|38|178|182|283|284|286|294|308|332|333|341|342|344|346|352|355|356|362|366|370|371|374|380|381|382|384|405|406|416|420|430|432|434|440|441|443|446|452|462|470|476|490|493|498|501|505|516|520|524|526|529|535|537|541|542|548|550|551|552|553|556|564|565|567|570|573|574|578|579|582|583|584|589|591|594|595|597|598|599|603|604|605|606|608|614|618|619|620|623|626|632|634|637|640|641|651|655|660|662|663|664|666|668|669|671|672|677|678|679|680|684|688|689|692|693|696|698|704|705|708|709|710|714|738|743|759|764|773|777|801|806|822|827|836,Etacrynicacid,"Acetates| Acids, Acyclic| Agents that produce neuromuscular block (indirect)| Aryloxyacetic Acid Derivatives| Carboxylic Acids| Cardiovascular System| Diuretics| Enzyme Inhibitors| Glycolates| High-Ceiling Diuretics| Hydroxy Acids| Hyperglycemia-Associated Agents| Hypotensive Agents| Increased Diuresis at Loop of Henle| Medications that reduce magnesium levels| Natriuretic Agents| Nephrotoxic agents| Non Potassium Sparing Diuretics| OAT1/SLC22A6 inhibitors| Ototoxic agents| Phenoxyacetates| Sodium Potassium Chloride Symporter Inhibitors"
217,DB09063,Q9UM73,P08684|P11712,hsa:238,9|10|11|12|14|15|16|18|19|33|37|178|180|181|182|183|184|185|189|192|199|283|284|285|286|293|294|299|332|333|335|339|340|341|342|344|345|346|349|351|352|353|355|356|358|362|365|366|368|370|371|372|373|374|375|376|377|378|379|381|382|383|384|387|389|390|392|393|396|403|405|412|414|416|418|430|434|435|437|438|441|442|445|446|447|449|450|453|457|459|464|465|470|472|476|482|484|487|490|491|495|498|500|502|503|504|506|507|516|519|520|521|523|524|528|530|531|532|533|538|540|541|542|543|545|546|548|549|552|555|556|560|564|565|566|570|572|573|574|576|577|578|582|584|585|586|589|592|593|594|595|596|599|600|601|603|604|606|607|608|609|613|614|615|618|619|620|621|626|628|632|633|634|636|637|640|641|643|651|654|655|656|657|658|659|660|664|665|666|668|674|677|678|679|680|683|688|689|696|697|698|699|708|709|710|712|714|716|735|737|755|763|767|777|779|798|800|818|826|830,Ceritinib,"Anaplastic lymphoma kinase (ALK) inhibitors| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Bradycardia-Causing Agents| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates (strength unknown)| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hyperglycemia-Associated Agents| Kinase Inhibitor| Moderate Risk QTc-Prolonging Agents| Narrow Therapeutic Index Drugs| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Protein Kinase Inhibitors| QTc Prolonging Agents| Receptor Protein-Tyrosine Kinases, antagonists & inhibitors| ROS1 tyrosine kinase inhibitors| Sulfur Compounds| Tyrosine Kinase Inhibitors"
218,DB13074,Q92847,P08684,hsa:2693,9|10|11|12|14|15|16|18|19|143|148|149|150|155|156|178|182|185|189|283|284|285|286|299|332|333|336|338|340|344|345|351|352|355|356|357|358|365|366|370|371|372|373|374|375|376|377|384|385|386|387|390|392|393|396|399|400|403|416|418|420|430|431|434|435|437|439|441|442|443|445|446|447|448|449|451|453|464|470|472|482|490|491|495|502|506|516|520|521|523|524|527|528|530|535|536|538|539|540|545|546|549|552|555|556|560|564|569|570|576|577|578|579|582|584|585|592|595|599|600|602|603|607|608|611|613|618|628|633|634|636|640|643|645|646|647|654|656|657|660|664|665|668|677|678|679|683|684|688|692|695|696|697|704|708|709|710|712|758|821,Macimorelin,"Amino Acids| Amino Acids, Aromatic| Amino Acids, Cyclic| Amino Acids, Peptides, and Proteins| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Diagnostic Agents| Growth Hormone Secretagogue Receptor Agonist| Growth Hormone Secretagogue Receptor Agonists| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Highest Risk QTc-Prolonging Agents| QTc Prolonging Agents| Tests for Pituitary Function"
219,DB06730,Q6QNK2,P20815|P24462,hsa:283383,9|10|11|12|18|19|143|147|178|179|182|185|186|192|283|284|286|308|332|333|334|335|337|341|344|352|374|406|416|417|420|427|428|430|432|434|441|443|446|460|490|516|524|535|553|556|573|579|582|599|617|619|637|640|660|667|671|678|679|680|684|688|689|692|696|697|698|699|704|708|709|710|711|712|776|797|818,Gestodene,"Adrenal Cortex Hormones| Combination Contraceptives (with Estrogen and derivatives)| Contraceptive Agents, Female| Contraceptive Agents, Hormonal| Contraceptives, Oral| Contraceptives, Oral, Hormonal| Contraceptives, Oral, Synthetic| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A7 Inhibitors| Cytochrome P-450 CYP3A7 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Fused-Ring Compounds| Genito Urinary System and Sex Hormones| Hormonal Contraceptives for Systemic Use| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Norpregnanes| Norsteroids| Polycyclic Compounds| Progestin Contraceptives| Progestins| Progestogens and Estrogens, Sequential Preparations| Reproductive Control Agents| Sex Hormones and Modulators of the Genital System| Steroids"
220,DB00724,Q9NYK1|Q9NR97,P05177|P08684,hsa:51284|hsa:51311,9|10|11|14|15|16|143|148|149|178|182|183|184|185|283|284|285|299|332|333|335|340|344|345|351|355|356|357|358|365|370|371|373|374|375|376|377|378|379|384|385|386|387|389|390|391|393|396|397|403|416|418|430|431|434|437|438|441|442|446|447|449|450|453|464|470|472|482|484|485|487|490|491|495|499|502|504|506|516|519|520|521|523|524|530|538|539|540|545|546|547|549|552|555|556|560|564|569|570|572|576|577|578|582|584|585|592|593|595|596|599|600|601|603|607|608|611|613|618|621|628|633|634|636|640|654|656|657|660|664|665|668|674|677|678|679|683|688|696|708|709|710|758|821,Imiquimod,"Adjuvants, Immunologic| Aminoquinolines| Antineoplastic Agents| Cancer immunotherapy| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Dermatologicals| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Immune Response Modifiers| Immunologic Factors| Immunomodulatory Agents| Immunosuppressive Agents| Immunotherapy| Increased Cytokine Activity| Increased Cytokine Production| Interferon Inducers| Misc. Skin and Mucous Membrane Agents| Quinolines| Toll-Like Receptor Agonists"
221,DB01137,P43702|P43700|P11388,P05177|P08684,hsa:7153,9|10|11|12|14|15|18|19|20|23|178|180|181|182|183|184|185|190|191|192|199|283|284|285|286|287|308|332|333|338|340|341|344|345|346|351|352|355|356|357|358|364|365|366|370|371|372|373|374|376|377|380|381|382|384|385|386|387|390|391|396|397|403|405|406|416|418|420|430|431|432|434|435|437|440|441|442|443|445|446|447|449|452|453|461|464|470|472|476|482|490|491|493|495|497|498|506|520|521|523|524|530|535|538|540|541|543|545|548|549|552|553|555|556|564|565|566|569|570|573|574|576|577|578|579|580|581|582|584|585|588|589|592|593|594|595|597|600|601|603|604|606|607|608|611|613|614|615|617|618|619|620|621|623|624|626|628|632|633|634|637|638|640|641|642|651|655|656|657|659|660|664|665|666|667|668|671|672|673|677|678|679|680|683|684|686|688|689|691|692|695|696|697|698|699|702|703|704|707|708|709|710|716|735|749|758|763|779|798|812|821|826,Levofloxacin,"Alimentary Tract and Metabolism| Anti-Bacterial Agents| Anti-Infective Agents| Anti-Infective Agents, Urinary| Antibacterials for Systemic Use| Antiinfectives for Systemic Use| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Drugs causing inadvertant photosensitivity| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Fluoroquinolone Antibacterial| Fluoroquinolones| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| MATE 1 Inhibitors| MATE 1 Substrates| MATE 2 Inhibitors| MATE inhibitors| MATE substrates| Medications that reduce magnesium levels| Metabolic Side Effects of Drugs and Substances| Moderate Risk QTc-Prolonging Agents| OAT1/SLC22A6 Substrates| OCT1 inhibitors| OCT2 Inhibitors| Ophthalmologicals| P-glycoprotein inhibitors| P-glycoprotein substrates| Photosensitizing Agents| QTc Prolonging Agents| Quinolines| Quinolone Antimicrobial| Quinolones| Renal Agents| Sensory Organs| Topoisomerase II Inhibitors| Topoisomerase Inhibitors"
222,DB06282,P35367,P08684,hsa:3269,9|10|11|12|14|15|18|19|37|178|180|181|182|185|189|192|283|284|285|286|294|308|332|333|338|340|342|344|345|346|351|352|355|356|362|365|366|370|371|380|384|390|391|405|406|416|420|430|434|440|441|443|446|452|462|464|470|490|501|503|516|520|524|537|540|549|550|552|556|564|566|567|569|570|578|582|584|591|592|595|598|599|603|605|607|608|611|613|614|615|618|628|633|634|640|656|659|660|662|663|664|668|677|678|679|683|688|696|697|708|709|710|717|780,Levocetirizine,"Antihistamines for Systemic Use| Central Nervous System Depressants| Cetirizine and isomer| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Histamine H1 Antagonists, Non-Sedating| Neurotransmitter Agents| Piperazine Derivatives| Piperazines| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Respiratory System"
223,DB13139,P07550,P08684|P10635,hsa:154,9|10|11|14|18|19|178|182|283|284|285|286|299|308|332|333|336|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|392|393|406|416|430|434|441|446|470|490|498|516|520|524|528|540|541|542|548|552|556|564|566|570|571|573|574|575|578|582|584|590|592|595|599|603|606|607|608|613|617|618|619|634|637|639|640|641|643|651|655|656|659|660|664|667|668|677|678|679|680|683|688|689|690|696|697|698|701|708|709|710|714|734|756|777|797|819,Levosalbutamol,Adrenergic Agonists| Adrenergic beta-2 Receptor Agonists| Adrenergic beta-Agonists| Agents producing tachycardia| Agents that produce hypertension| Agents to Treat Airway Disease| Alcohols| Amines| Amino Alcohols| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 Enzyme Inhibitors| Drugs that are Mainly Renally Excreted| Ethanolamines| Ethylamines| OATP1B1/SLCO1B1 Substrates| OATP1B3 substrates| Phenethylamines
224,DB01166,Q14432,P20815|P24462|P33261|P08684|P05177|P10635,hsa:5139,9|10|11|12|14|15|16|18|19|143|148|149|178|179|182|183|184|185|192|283|284|285|286|299|300|332|333|338|340|341|344|345|346|351|352|355|356|358|359|365|366|370|371|375|376|377|379|381|382|384|389|390|392|393|396|405|416|418|420|422|430|434|437|438|439|441|442|443|446|449|450|451|453|464|470|476|486|487|490|495|496|498|502|504|515|516|517|519|520|521|524|535|538|539|540|541|542|545|546|548|549|552|556|560|564|565|570|573|574|578|579|582|584|585|589|592|594|595|596|599|600|603|604|606|607|608|613|614|618|619|620|626|628|632|633|634|637|640|641|643|645|651|654|655|656|657|660|664|665|666|668|677|678|679|680|682|683|684|688|689|691|692|695|696|698|699|702|704|707|708|709|710|721|735|758|784|798|821,Cilostazol,"Agents producing tachycardia| Anti-Asthmatic Agents| Antiplatelet agents| Autonomic Agents| Azoles| Blood and Blood Forming Organs| Bronchodilator Agents| Cardiovascular Agents| Central Nervous System Agents| Compounds used in a research, industrial, or household setting| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Fibrin Modulating Agents| Hematologic Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Neuroprotective Agents| Peripheral Nervous System Agents| Phosphodiesterase 3 Inhibitors| Phosphodiesterase Inhibitors| Platelet Aggregation Inhibitors Excl. Heparin| Potential QTc-Prolonging Agents| Protective Agents| QTc Prolonging Agents| Quinolines| Respiratory System Agents| Tetrazoles| Vasodilating Agents"
225,DB09026,P00797,P08684,hsa:5972,9|10|11|12|14|15|18|19|20|178|182|283|284|285|286|299|308|332|333|334|335|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|392|393|405|406|416|420|430|434|439|441|443|446|451|470|476|490|498|516|520|524|528|535|540|541|542|544|548|552|556|564|565|566|567|570|571|573|574|578|579|580|582|584|589|592|593|594|595|599|603|604|606|608|613|614|617|618|619|620|626|630|632|634|637|639|640|641|643|645|646|651|655|656|660|662|664|666|668|677|678|679|680|682|683|684|686|688|689|692|695|696|697|698|699|704|707|708|709|710|712|714|735|761|777|798|824,Aliskiren,"Acids, Acyclic| Agents Acting on the Renin-Angiotensin System| Agents causing hyperkalemia| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Benzene Derivatives| Carboxylic Acids| Cardiovascular System| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Dicarboxylic Acids| Enzyme Inhibitors| Ethers| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hypotensive Agents| Methyl Ethers| P-glycoprotein substrates| Protease Inhibitors| Renin Inhibitors"
226,DB00678,P30556,P11712|P08684|P20815|P10632|P33261|P05177|P22309|P35503|Q9HAW8|P16662|O75795,hsa:185,9|10|11|12|14|15|16|18|37|143|148|149|150|155|156|178|182|185|189|283|284|285|286|294|299|300|308|332|333|340|342|344|345|346|351|352|355|356|357|358|359|362|365|366|370|371|374|375|376|379|384|387|389|390|391|396|397|398|403|406|416|418|422|430|431|434|437|438|441|442|446|449|450|453|461|464|470|472|482|484|485|486|487|490|495|499|501|504|506|515|516|517|519|520|521|522|523|524|530|538|539|540|545|547|548|549|550|552|555|556|560|564|566|569|570|571|572|573|576|578|582|584|585|592|595|596|599|603|607|608|609|611|613|617|618|628|633|634|636|638|640|654|656|657|659|660|664|667|668|674|677|678|679|683|688|696|697|708|709|710|712|713|755|776|818,Losartan,"Agents Acting on the Renin-Angiotensin System| Agents causing angioedema| Agents causing hyperkalemia| Angiotensin 2 Receptor Blocker| Angiotensin II receptor antagonists| Angiotensin II receptor blockers (ARBs) and calcium channel blockers| Angiotensin II receptor blockers (ARBs) and diuretics| Angiotensin II receptor blockers (ARBs), plain| Angiotensin II Type 1 Receptor Blockers| Angiotensin II Type 2 Receptor Blockers| Angiotensin Receptor Antagonists| Antiarrhythmic agents| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Azoles| Benzene Derivatives| Biphenyl Compounds| BSEP/ABCB11 Substrates| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hypotensive Agents| Imidazoles| OAT1/SLC22A6 inhibitors| P-glycoprotein inhibitors| P-glycoprotein substrates| Photosensitizing Agents| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Tetrazoles| UGT1A1 Substrates| UGT1A3 substrates| UGT2B17 substrates| UGT2B7 substrates"
227,DB00949,Q13224|Q8TCU5|Q12879,P08684|P33261|P05181,hsa:2904|hsa:116443|hsa:2903,9|10|11|14|15|18|19|20|178|182|283|284|285|286|299|332|333|335|344|346|352|355|356|366|370|371|380|384|393|405|416|420|430|434|441|446|451|452|470|490|516|520|524|552|556|559|564|570|578|582|584|595|599|603|608|612|618|634|637|639|640|641|655|660|664|668|677|678|679|680|688|689|696|697|698|708|709|710|712,Felbamate,"Acids, Acyclic| Alcohols| Anti-epileptic Agent| Anticonvulsants| Carbamates| Carboxylic Acids| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (moderate)| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Decreased Central Nervous System Disorganized Electrical Activity| Excitatory Amino Acid Agents| Excitatory Amino Acid Antagonists| Glycols| Nervous System| Neurotransmitter Agents| NMDA Receptor Antagonists| Phenylcarbamates| Potential QTc-Prolonging Agents| Propylene Glycols| QTc Prolonging Agents"
228,DB06789,P06401,P08684|P20815|P33261,hsa:5241,9|10|11|12|18|19|20|143|144|178|179|182|185|186|192|283|284|286|332|333|334|335|337|341|344|352|374|380|405|416|420|430|432|434|440|441|443|446|452|462|490|524|535|537|553|556|579|582|599|605|614|637|640|660|671|678|679|680|684|688|689|692|696|697|698|699|704|708|709|710|711|712|776|797|818|839|840|860|861,Hydroxyprogesteronecaproate,"Adrenal Cortex Hormones| Antineoplastic Agents| Combination Contraceptives (with Estrogen and derivatives)| Contraceptive Agents, Female| Cytochrome P-450 CYP2C19 Inducers| Cytochrome P-450 CYP2C19 Inducers (strength unknown)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Estrogen Antagonists| Fused-Ring Compounds| Gonadal Hormones| Gonadal Steroid Hormones| Hormonal Contraceptives for Systemic Use| Hormone Antagonists| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Hydroxyprogesterones| Hyperglycemia-Associated Agents| Polycyclic Compounds| Pregnanes| Pregnenediones| Pregnenes| Progesterone and Derivatives| Progesterone Congeners| Progestin Contraceptives| Progestins| Steroids"
229,DB06413,Q01959,P33261|P08684|P20815|P05177|P20813|P11712,hsa:6531,9|10|11|14|18|19|33|178|182|185|189|283|284|285|286|293|299|332|333|344|349|351|352|353|355|356|368|370|371|384|393|412|414|416|420|430|434|439|441|443|446|451|457|465|470|490|507|516|520|524|552|556|564|570|578|582|584|586|595|599|603|608|618|634|640|643|658|660|664|668|677|678|679|688|696|697|708|709|710,Armodafinil,"Benzene Derivatives| Benzhydryl Compounds| Central Nervous System Agents| Central Nervous System Stimulants| Centrally Acting Sympathomimetics| Cytochrome P-450 CYP1A2 Inducers| Cytochrome P-450 CYP1A2 Inducers (strength unknown)| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (strength unknown)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (moderate)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (weak)| Cytochrome P-450 CYP3A5 Inducers| Cytochrome P-450 CYP3A5 Inducers (strength unknown)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Metabolic Side Effects of Drugs and Substances| Modafinil and isomer| Nervous System| Psychoanaleptics| Psychostimulants, Agents Used for ADHD and Nootropics| Wakefulness-Promoting Agents"
230,DB01023,Q13936|P54289|Q08289|Q01668|Q13698|O95180|Q9NY47|P0DP23|Q01064|P54750|P08235|P02585|P63316,P08684|P20815|P24462|P10632|P11712|P10635,"hsa:775|hsa:781|hsa:783|hsa:776|hsa:779|hsa:8912|hsa:9254|hsa:801,hsa:805,hsa:808|hsa:5153|hsa:5136|hsa:4306|hsa:7125|hsa:7134",9|10|11|12|14|18|19|20|37|38|178|182|183|184|185|283|284|285|286|294|299|332|333|335|340|342|344|346|351|352|355|356|362|366|370|371|374|380|384|390|392|393|405|416|420|430|434|437|440|441|443|446|449|452|470|490|501|503|516|520|524|526|529|535|550|552|553|556|564|570|573|578|579|582|584|591|594|595|598|599|603|608|614|618|619|634|637|640|643|656|660|664|666|668|671|673|677|678|679|680|684|688|689|690|692|693|694|696|697|698|700|704|708|709|710|712|738|759|773|801|822|836,Felodipine,"ACE Inhibitors and Calcium Channel Blockers| Agents causing hyperkalemia| Antiarrhythmic agents| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Beta blocking agents and calcium channel blockers| Bradycardia-Causing Agents| BSEP/ABCB11 Substrates| Calcium Channel Blockers| Calcium Channel Blockers (Dihydropyridine)| Calcium-Regulating Hormones and Agents| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strong)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dihydropyridine Derivatives| Dihydropyridines| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypotensive Agents| Membrane Transport Modulators| P-glycoprotein inhibitors| Potential QTc-Prolonging Agents| Pyridines| QTc Prolonging Agents| Selective Calcium Channel Blockers With Mainly Vascular Effects| Vasodilating Agents"
231,DB00321,P23975|P31645|P28223|P08908|P41143|P41145|P04629|Q16620|P35348|P25100|P08913|P35367|P11229|P08172|P20309|P08173|P08912|O43526|Q09470|Q9NZV8|Q9UK17|P25021|Q9H3N8|Q99720|P28335|P35368|P34969|P28221|P35372|P28222|P50406|O43525|BE0004872,P10635|P05177|P33261|P11712|P08684|P20815|P20813|P10632|P05181,hsa:6530|hsa:6532|hsa:3356|hsa:3350|hsa:4985|hsa:4986|hsa:4914|hsa:4915|hsa:148|hsa:146|hsa:150|hsa:3269|hsa:1128|hsa:1129|hsa:1131|hsa:1132|hsa:1133|hsa:3785|hsa:3736|hsa:3751|hsa:3752|hsa:3274|hsa:59340|hsa:10280|hsa:3358|hsa:147|hsa:3363|hsa:3352|hsa:4988|hsa:3351|hsa:3362|hsa:3786,9|10|11|12|14|178|182|185|189|213|214|283|284|285|332|333|344|345|351|355|356|365|370|371|374|384|390|391|416|430|434|441|446|470|490|516|520|524|540|552|556|564|570|578|582|584|595|599|603|608|613|618|634|640|660|664|668|677|678|679|688|696|697|708|709|710|712|755|818,Amitriptyline,"Adrenergic alpha-1 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Adrenergic Uptake Inhibitors| Agents producing tachycardia| Agents that produce hypertension| Agents that reduce seizure threshold| Analgesics| Analgesics, Non-Narcotic| Anticholinergic Agents| Antidepressive Agents| Antidepressive Agents Indicated for Depression| Antidepressive Agents, Tricyclic| Central Nervous System Agents| Central Nervous System Depressants| Combined Inhibitors of Serotonin/Norepinephrine Reuptake| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (moderate)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Histamine Antagonists| Histamine H1 Antagonists| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Medications that increase serum magnesium| Membrane Transport Modulators| Moderate Risk QTc-Prolonging Agents| Muscarinic Antagonists| Narrow Therapeutic Index Drugs| Neurotoxic agents| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| Non-Selective Monoamine Reuptake Inhibitors| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Psychotropic Drugs| QTc Prolonging Agents| Sensory System Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin 5-HT2C Receptor Antagonists| Serotonin Agents| Serotonin Modulators| Serotonin Receptor Antagonists| Tertiary amine tricyclic antidepressants| Tricyclics and Other Norepinephrine-reuptake Inhibitors| UGT1A1 Inhibitors| UGT1A4 substrates"
232,DB00990,P11511,P08684|P11511,hsa:1588,9|10|11|12|18|19|143|144|178|179|182|185|186|192|283|284|286|332|333|334|335|341|344|352|374|416|420|430|432|434|441|443|446|490|516|524|535|553|556|564|579|582|599|640|660|664|671|672|678|679|684|688|692|696|697|704|708|709|710|711|712|776|797|818|860,Exemestane,"Androstanes| Androstenes| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Aromatase Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Endocrine Therapy| Enzyme Inhibitors| Estrogen Antagonists| Fused-Ring Compounds| Hormone Antagonists| Hormone Antagonists and Related Agents| Hormones, Hormone Substitutes, and Hormone Antagonists| Polycyclic Compounds| Steroid Synthesis Inhibitors| Steroids"
233,DB01065,P48039|P49286|P03372|Q92753|P0DP23|P05164|P11678|P27797|P46597|P16083,P04798|P05177|Q16678|P33261|P11712|P46597|P14902|P05164|P11511,"hsa:4543|hsa:4544|hsa:2099|hsa:801,hsa:805,hsa:808|hsa:4353|hsa:8288|hsa:811|hsa:438|hsa:4835",9|10|11|14|15|18|19|143|148|149|178|182|283|284|285|286|299|332|333|340|341|344|345|351|352|355|356|357|358|365|366|370|371|372|373|374|376|377|381|382|384|385|386|387|390|392|393|396|399|400|403|405|416|418|420|430|431|434|435|437|439|441|442|443|445|446|447|449|451|453|464|470|472|476|482|490|491|495|498|502|506|516|520|521|523|524|527|528|530|538|539|540|541|542|545|546|548|549|552|555|556|564|565|570|573|574|576|577|578|582|584|585|589|592|594|595|599|600|603|604|606|607|608|613|618|619|626|628|633|634|637|640|641|643|645|646|651|655|656|657|660|664|665|666|668|677|678|679|680|682|683|688|689|691|696|697|698|699|702|708|709|710|712|721|735|758|784|798|821,Melatonin,"Amines| Antioxidants| Biogenic Amines| Biogenic Monoamines| Biological Factors| Central Nervous System Agents| Central Nervous System Depressants| Compounds used in a research, industrial, or household setting| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Hypnotics and Sedatives| Indoles| Melatonin Receptor Agonists| Melatonin, agonists| Nervous System| OAT3/SLC22A8 Inhibitors| Protective Agents| Psycholeptics| Tryptamines"
234,DB00696,P28221|P28222|P28223|P14416|P35348|P35368|P25100|P08913|P18089|P23975|BE0004889|P08908|P30939|P28335|P41595,P08684|P05177,hsa:3352|hsa:3351|hsa:3356|hsa:1813|hsa:148|hsa:147|hsa:146|hsa:150|hsa:151|hsa:6530|hsa:3350|hsa:3355|hsa:3358|hsa:3357,9|10|11|12|13|14|15|16|18|19|20|143|145|146|148|149|150|152|153|157|178|180|181|182|183|184|185|189|192|196|199|206|283|284|285|286|299|308|332|333|335|338|340|341|344|345|351|352|355|356|357|358|365|370|371|372|373|374|376|377|380|384|385|386|387|390|391|392|393|396|399|400|403|405|406|416|418|420|430|431|434|435|437|439|441|442|443|445|446|447|449|451|453|462|464|470|472|482|490|491|495|502|506|516|520|521|523|524|527|528|530|535|536|537|538|539|540|545|546|549|552|555|556|559|563|564|566|569|570|576|577|578|579|580|582|584|585|592|593|595|599|600|602|603|605|607|608|611|612|613|614|615|617|618|628|633|634|637|640|643|645|646|656|657|659|660|661|664|665|668|677|678|679|680|683|684|688|691|692|696|697|702|704|708|709|710|712|737|755|758|779|797|800|818|821,Ergotamine,"Adrenergic Agents| Adrenergic alpha-1 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Agents that produce hypertension| Alkaloids| Analgesics| Analgesics, Non-Narcotic| Antidepressive Agents| Antimigraine Preparations| Cardiovascular Agents| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors (strong)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Ergot Alkaloids and Derivatives| Ergotamine Derivative| Ergotamines| Heterocyclic Compounds| Heterocyclic Compounds with 4 or More Rings| Heterocyclic Compounds, Fused-Ring| Narrow Therapeutic Index Drugs| Nervous System| Neurotransmitter Agents| P-glycoprotein inhibitors| Peripheral Nervous System Agents| Reproductive Control Agents| Sensory System Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT1 Receptor Agonists| Serotonin 5-HT2 Receptor Agonists| Serotonin Agents| Serotonin Modulators| Serotonin Receptor Agonists| Sympatholytic (Adrenergic Blocking) Agents| Uterotonic agents| Vasoconstrictor Agents"
235,DB08882,P27487,P08684,hsa:1803,9|10|11|12|14|15|16|17|18|19|143|148|149|178|180|181|182|183|184|185|190|191|192|199|283|284|285|286|299|332|333|338|340|344|345|351|352|355|356|357|358|359|365|370|371|374|375|376|377|378|379|381|384|385|386|387|388|389|390|391|393|396|397|403|416|417|418|420|427|430|431|434|437|438|439|441|442|443|446|449|450|451|453|464|470|472|482|484|485|487|490|493|494|495|499|502|504|506|516|519|520|521|523|524|528|530|535|536|538|539|540|545|546|547|549|552|553|555|556|560|564|569|570|572|576|578|580|582|584|585|592|593|595|596|599|600|601|602|603|607|608|611|613|618|621|624|628|633|634|636|640|643|645|646|647|650|654|656|657|660|664|665|668|673|674|677|678|679|683|688|696|708|709|710|758|821,Linagliptin,"Agents causing angioedema| Alimentary Tract and Metabolism| Blood Glucose Lowering Agents| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (moderate)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| DPP-IV Inhibitors| Drugs Used in Diabetes| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Incretins| OCT1 inhibitors| OCT2 Inhibitors| OCT2 Substrates| Oral Hypoglycemics| P-glycoprotein inhibitors| P-glycoprotein substrates| Protease Inhibitors| Purines| Quinazolines"
236,DB01193,P08588|P07550,P10635,hsa:153|hsa:154,9|10|11|12|14|15|18|19|20|178|182|283|284|285|286|299|308|332|333|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|376|377|381|382|384|390|392|393|405|406|416|420|430|432|434|437|439|441|443|446|449|451|464|470|476|490|493|495|498|502|516|520|524|528|535|540|541|542|545|546|548|549|552|553|556|564|565|566|567|570|571|573|574|578|579|581|582|584|585|589|592|594|595|597|599|600|603|604|606|607|608|613|614|618|619|620|623|625|626|628|632|633|634|637|638|640|641|642|643|645|651|655|656|657|659|660|662|663|664|665|666|668|671|672|677|678|679|680|682|683|684|685|688|689|692|696|698|704|708|709|710|721|737|756|784|800|819,Acebutolol,"Adrenergic Agents| Adrenergic Antagonists| Adrenergic beta-1 Receptor Antagonists| Adrenergic beta-Antagonists| Agents causing hyperkalemia| Alcohols| Amines| Amino Alcohols| Antiarrhythmic agents| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Autonomic Agents| Beta Blocking Agents and Thiazides| Beta Blocking Agents, Selective| Beta Blocking Agents, Selective, and Thiazides| Beta-Blockers (Beta1 Selective)| Bradycardia-Causing Agents| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Hypotensive Agents| Neurotransmitter Agents| P-glycoprotein substrates| Peripheral Nervous System Agents| Phenoxypropanolamines| Propanolamines| Propanols| QTc Prolonging Agents| Sympathomimetics"
237,DB00813,P35372|P41143|P41145,P08684|P20815|P24462,hsa:4988|hsa:4985|hsa:4986,9|10|11|12|14|15|18|178|180|181|182|185|189|192|283|284|285|286|332|333|338|340|344|345|351|352|355|356|365|370|371|374|376|377|384|390|391|416|420|430|434|437|439|441|443|446|449|451|464|470|490|495|502|516|520|524|535|540|545|546|549|552|556|564|570|578|582|584|585|592|593|595|599|600|603|607|608|613|618|628|633|634|640|645|646|656|657|660|664|665|668|677|678|679|683|688|696|708|709|710,Fentanyl,"Adjuvants| Adjuvants, Anesthesia| Agents that produce hypertension| Agents that reduce seizure threshold| Analgesics| Anesthetics| Anesthetics, General| Anesthetics, Intravenous| Antidepressive Agents| Bradycardia-Causing Agents| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Fentanyl and fentanyl analogues| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| High-risk opioids| Narcotics| Nervous System| Neuraxial Anesthetics| Opiate Agonists| Opioid Agonist| Opioid Anesthetics| Opioids| Opioids, Anilidopiperidine| P-glycoprotein inhibitors| Peripheral Nervous System Agents| Phenylpiperidine opioids| Piperidines| Sensory System Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin Agents| Serotonin Modulators"
238,DB01028,P14867|P42261|P23415|P98194|Q09470|P30049|P03886|BE0004797,P05181|P05177|P11509|P20813|P11712|P10635|P08684,hsa:2554|hsa:2890|hsa:2741|hsa:27032|hsa:3736|hsa:513|hsa:4535,9|18|23|24|37|38|283|284|286|287|294|342|343|344|352|360|361|363|366|374|405|551,Methoxyflurane,"Agents that produce hypertension| Analgesics| Anesthetics| Anesthetics, General| Anesthetics, Inhalation| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Ethers| Ethyl Ethers| Methyl Ethers| Miscellaneous Analgesics and Antipyretics| Nervous System"
239,DB00704,P41143|P35372|P41145|Q5T1J1,P22309,hsa:4985|hsa:4988|hsa:4986,9|10|11|12|14|18|19|20|115|116|143|146|178|179|180|181|182|185|189|192|199|283|284|285|286|308|332|333|334|335|337|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|381|382|384|390|391|405|406|416|420|430|432|434|441|443|446|462|470|476|490|498|516|520|524|535|537|540|541|542|544|548|552|556|564|565|566|567|570|573|574|578|579|582|584|589|590|592|594|595|599|603|604|605|606|607|608|613|614|617|618|619|620|626|630|631|632|634|637|639|640|641|651|655|656|659|660|662|663|664|666|667|668|677|678|679|680|681|682|683|684|686|688|689|690|691|692|693|695|696|697|698|699|700|701|702|703|704|705|707|708|709|710|711|712|714|735|755|756|761|776|777|779|797|798|800|803|818|819|821|824|826,Naltrexone,"Agents Causing Muscle Toxicity| Alcohol Deterrents| Alimentary Tract and Metabolism| Alkaloids| Analgesics| Antiobesity Preparations, Excl. Diet Products| Central Nervous System Agents| Centrally Acting Antiobesity Products| Drugs Used in Addictive Disorders| Drugs Used in Alcohol Dependence| Heterocyclic Compounds| Heterocyclic Compounds with 4 or More Rings| Heterocyclic Compounds, Bridged-Ring| Heterocyclic Compounds, Fused-Ring| Morphinans| Natural Opium Alkaloids| Nervous System| Opiate Alkaloids| Opiate Antagonists| Opioid Antagonists| Opioids| Peripheral Nervous System Agents| Phenanthrene opioids| Phenanthrenes| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Sensory System Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| UGT1A1 Substrates"
240,DB00753,P14867|P98194|P23415|P42261|Q09470|P30049|P0DP23|BE0004797,P05181|P20813|P03886,"hsa:2554|hsa:27032|hsa:2741|hsa:2890|hsa:3736|hsa:513|hsa:801,hsa:805,hsa:808",9|18|23|24|25|37|283|284|286|287|294|342|343|344|346|352|361|363|366|405,Isoflurane,"Agents that produce hypertension| Agents that reduce seizure threshold| Anesthetics| Anesthetics, General| Anesthetics, Inhalation| Anticholinergic Agents| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (strength unknown)| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Ethers| Hydrocarbons, Halogenated| Hypotensive Agents| Methyl Ethers| Nervous System| Nicotinic Antagonists| Potential QTc-Prolonging Agents| QTc Prolonging Agents"
241,DB01418,Q9BQB6,P11712|P05177|P33261|P08684,hsa:79001,9|10|11|12|14|18|19|20|178|182|184|185|189|192|283|284|285|286|301|308|332|333|335|340|341|344|351|352|355|356|370|371|374|376|377|380|381|382|384|385|395|401|405|406|409|416|420|423|430|432|434|437|440|441|443|446|449|452|454|455|464|470|476|490|493|498|502|514|516|520|524|535|541|542|545|546|548|549|552|553|556|558|564|565|570|573|574|575|578|579|581|582|584|589|590|592|594|595|597|599|600|603|604|606|607|608|614|617|618|619|620|622|623|625|626|632|633|634|637|639|640|641|642|651|653|655|660|664|665|666|667|668|671|672|677|678|679|680|683|684|688|689|692|693|694|696|697|698|699|704|705|706|708|709|710|712|716|756|779|819,Acenocoumarol,"4-Hydroxycoumarins| Anticoagulants| Benzopyrans| Blood and Blood Forming Organs| Coumarins| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Substrates| Hematologic Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Narrow Therapeutic Index Drugs| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Pyrans| Vitamin K Antagonists| Warfarin and isomers"
242,DB00703,P00915|P00918|P22748|P43166|P07451,P33261|P11712|P10635|P05181|P08684,hsa:759|hsa:760|hsa:762|hsa:766|hsa:761,9|10|14|15|16|18|19|33|34|143|148|149|283|284|285|286|293|299|300|305|344|351|352|365|374|375|379|390|396|412|414|418|420|421|422|439|443|450|451|453|457|459|467|468|475|479|487|489|496|508|519|521|540,Methazolamide,"Antiglaucoma Preparations and Miotics| Azoles| Carbonic Anhydrase Inhibitors| Cardiovascular Agents| Diuretics| Drugs causing inadvertant photosensitivity| Enzyme Inhibitors| Genito Urinary System and Sex Hormones| Gynecological Antiinfectives and Antiseptics| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypotensive Agents| Natriuretic Agents| OAT1/SLC22A6 inhibitors| Ophthalmologicals| Photosensitizing Agents| Sensory Organs| Sulfonamides| Sulfur Compounds| Thiadiazoles| Thiazoles"
243,DB00968,P08913|P20711,P21964,hsa:150|hsa:1644,9|10|11|14|18|19|20|178|182|283|284|285|286|299|308|332|333|336|340|341|344|351|352|355|356|370|371|374|380|381|382|384|393|406|416|420|430|434|440|441|443|446|452|470|490|498|516|520|524|535|536|541|542|544|548|552|556|564|566|567|570|573|574|578|579|582|584|590|592|595|599|603|606|607|608|617|618|619|631|634|637|640|641|643|651|655|660|663|664|667|668|677|678|679|680|683|684|688|689|691|692|696|697|698|699|703|704|708|709|710|714|735|761|777|798|824,Methyldopa,"Adrenergic Agents| Adrenergic Agonists| Adrenergic alpha-2 Receptor Agonists| Adrenergic alpha-Agonists| Agents Causing Muscle Toxicity| Amines| Amino Acids| Amino Acids, Aromatic| Amino Acids, Cyclic| Amino Acids, Peptides, and Proteins| Antiadrenergic Agents, Centrally Acting| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Aromatic L-amino Acid Decarboxylase Inhibitors| Autonomic Agents| Benzene Derivatives| Bradycardia-Causing Agents| Cardiovascular Agents| Cardiovascular System| Catecholamines| Catechols| Central alpha-2 Adrenergic Agonist| Central Alpha-agonists| COMT Substrates| Dihydroxyphenylalanine| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hypotensive Agents| Neurotransmitter Agents| Peripheral Nervous System Agents| Phenols| Sympatholytics"
244,DB00847,P61278|P49146,P05164,hsa:6750|hsa:4887,9|14|33|283|284|285|293|299|344|345|349|351|353|365|368|393|413|528|643,Cysteamine,"Alimentary Tract and Metabolism| Amines| Amino Acids and Derivatives| Cystine Depleting Agents| Cystine Disulfide Reduction| EENT Drugs, Miscellaneous| Ethylamines| Mercaptoethylamines| Ophthalmics| Ophthalmologicals| Other Miscellaneous Therapeutic Agents| Sensory Organs| Sulfhydryl Compounds| Sulfur Compounds"
245,DB00841,P08588|P07550|BE0004864|P03372,P21964,hsa:153|hsa:154|hsa:2099,9|10|11|12|14|18|19|178|182|185|189|283|284|285|286|299|308|332|333|338|340|341|344|345|351|352|355|356|365|370|371|374|381|382|384|390|392|393|406|416|430|434|441|446|470|490|498|516|520|524|528|540|541|542|544|548|552|556|564|567|570|573|574|578|582|584|590|592|595|599|603|606|607|608|613|617|618|619|631|634|637|640|641|643|651|655|656|660|663|664|667|668|677|678|679|680|683|688|689|691|696|698|699|702|708|709|710|714|735|761|777|798|824,Dobutamine,"Adrenergic Agents| Adrenergic Agonists| Adrenergic alpha-1 Receptor Agonists| Adrenergic alpha-Agonists| Adrenergic and Dopaminergic Agents| Adrenergic beta-1 Receptor Agonists| Adrenergic beta-2 Receptor Agonists| Adrenergic beta-Agonists| Agents producing tachycardia| Agents that produce hypertension| Amines| Autonomic Agents| Benzene Derivatives| Cardiac Stimulants Excl. Cardiac Glycosides| Cardiac Therapy| Cardiotonic Agents| Cardiovascular Agents| Cardiovascular System| Catecholamines| Catechols| Compounds used in a research, industrial, or household setting| COMT Substrates| Drugs that are Mainly Renally Excreted| Ethylamines| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Neurotransmitter Agents| Peripheral Nervous System Agents| Phenethylamines| Phenols| Protective Agents| Selective Beta 1-adrenergic Agonists| Sympathomimetic (Adrenergic) Agents| Sympathomimetics"
246,DB00921,P35372|P41145|P41143|P41146,P08684|P20815|P11712|P10632|P24462|O60656|P10635|P33260|P33261|P05177|P11509,hsa:4988|hsa:4986|hsa:4985|hsa:4987,9|10|11|12|14|18|19|20|115|116|143|146|178|179|180|181|182|185|186|189|192|199|206|283|284|285|286|308|332|333|334|335|337|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|391|405|406|416|430|434|441|446|470|476|490|498|516|520|524|540|541|542|544|548|552|556|564|565|567|570|573|574|578|582|584|589|590|592|594|595|599|603|604|606|607|608|613|614|617|618|619|620|626|630|631|632|634|637|639|640|641|651|655|656|660|662|663|664|666|667|668|677|678|679|680|681|682|683|688|689|690|691|696|697|698|699|700|701|702|703|708|709|710|711|712|714|735|755|756|761|776|777|779|797|798|800|818|819|821|824,Buprenorphine,"Alkaloids| Analgesics| BCRP/ABCG2 Inhibitors| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2C18 Substrates| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs Used in Addictive Disorders| Drugs Used in Opioid Dependence| Heterocyclic Compounds| Heterocyclic Compounds with 4 or More Rings| Heterocyclic Compounds, Bridged-Ring| Heterocyclic Compounds, Fused-Ring| Mixed Agonist / Antagonist Opioids| Morphinans| Narcotics| Nervous System| Opiate Agonists| Opiate Alkaloids| Opiate Partial Agonists| Opioid Antagonists| Opioids| Oripavine Derivatives| P-glycoprotein inhibitors| Peripheral Nervous System Agents| Phenanthrene opioids| Phenanthrenes| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Sensory System Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| UGT1A1 Substrates| UGT1A9 Substrates"
247,DB01119,Q14654|P00915|P00918|P05023|Q12791|P55017,P15104,hsa:3767|hsa:759|hsa:760|hsa:476|hsa:3778|hsa:6559,9|10|11|14|15|18|19|33|37|178|182|183|184|185|283|284|285|293|294|299|305|332|340|342|344|351|353|355|362|370|371|374|375|376|377|383|384|390|392|393|414|416|418|434|437|438|441|442|446|449|450|457|459|464|465|470|483|490|495|501|502|503|516|519|520|524|531|532|533|539|545|546|549|550|552|556|564|570|578|582|584|585|591|592|595|596|598|599|600|603|607|608|613|618|628|633|634|640|643|656|657|660|664|665|668|677|678|679|683|729|747|767|792|810|830,Diazoxide,"Antihypertensive Agents| Arteriolar Smooth Muscle, Agents Acting On| Benzothiadiazines| Cardiovascular Agents| Cardiovascular System| Direct Vasodilators| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hyperglycemia-Associated Agents| Hypoglycemia-Treating Agents| Hypotensive Agents| Potassium Channel Opener| Sulfonamides| Sulfones| Sulfur Compounds| Thiazide Derivatives| Vasodilating Agents"
248,DB01274,P07550,P10635|P33261|P11509|P11712,hsa:154,9|10|11|12|14|15|18|19|20|178|182|185|189|283|284|285|286|299|308|332|333|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|376|377|381|382|384|390|392|393|405|406|416|420|430|434|437|441|446|448|449|451|464|470|476|490|495|498|502|516|520|524|528|540|541|542|543|545|546|548|549|552|556|564|565|566|570|571|573|574|578|582|584|585|587|589|590|592|594|595|599|600|603|604|606|607|608|613|617|618|619|626|628|633|634|637|640|641|643|645|651|655|656|657|659|660|664|665|666|667|668|677|678|679|680|682|683|688|689|690|696|698|701|708|709|710|714|737|763|777|800|826,Arformoterol,Adrenergic Agents| Adrenergic Agonists| Adrenergic beta-2 Receptor Agonists| Adrenergic beta-Agonists| Agents producing tachycardia| Agents that produce hypertension| Agents to Treat Airway Disease| Alcohols| Amines| Amino Alcohols| Autonomic Agents| Bronchodilator Agents| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Ethanolamines| Long-acting beta-adrenoceptor agonists| Peripheral Nervous System Agents| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Respiratory System Agents
249,DB00437,P47989,Q06278|P47989,hsa:7498,9|10|14|15|16|18|143|148|149|178|183|184|283|284|285|286|299|300|332|333|344|345|351|352|355|356|358|359|365|370|372|373|375|376|379|381|384|387|389|390|393|394|396|398|399|403|416|418|420|422|430|435|438|439|441|442|443|445|446|447|449|450|451|453|464|467|472|477|482|484|486|487|488|491|493|495|496|504|506|510|515|517|519|521|522|523|527|528|530|535|538|540|545|549|553|555|560|572|576|580|585|593|596|601|613|616|621|624|628|636|644|646|647|654|657|672|673|674,Allopurinol,"Antigout Preparations| Antimetabolites| Antioxidants| BCRP/ABCG2 Substrates| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Free Radical Scavengers| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Musculo-Skeletal System| OAT3/SLC22A8 Substrates| Preparations Inhibiting Uric Acid Production| Protective Agents| Purines| Uricosuric Agents| Xanthine Oxidase Inhibitors"
250,DB08912,P15056|P04049|P57059|Q8NG66|P53667,P08684|P10632,hsa:673|hsa:5894|hsa:150094|hsa:79858|hsa:3984,9|10|11|12|14|15|16|18|19|23|24|33|34|143|148|149|178|182|183|184|185|189|192|283|284|285|287|293|299|305|332|333|334|340|344|345|351|353|355|356|357|358|364|365|370|371|372|373|374|375|376|377|379|383|384|387|389|390|393|396|403|412|414|416|418|421|430|431|434|435|437|441|442|445|446|447|449|450|453|457|459|464|465|470|472|473|474|475|480|482|483|484|487|489|490|491|495|500|502|504|506|507|508|516|519|520|521|523|524|530|531|533|538|539|540|545|546|549|552|555|556|560|564|570|572|576|578|582|584|585|586|592|593|595|596|599|600|601|603|607|608|613|618|621|628|633|634|636|640|643|654|656|657|658|660|664|665|668|674|677|678|679|683|688|696|697|708|709|710|737|800,Dabrafenib,"Amines| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Azoles| B-Raf serine-threonine kinase (BRAF) inhibitors| BCRP/ABCG2 Inhibitors| BCRP/ABCG2 Substrates| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (strength unknown)| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Inducers| Cytochrome P-450 CYP2C19 Inducers (strength unknown)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C8 Inducers| Cytochrome P-450 CYP2C8 Inducers (strength unknown)| Cytochrome P-450 CYP2C8 Inducers (weak)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strong)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C9 Inducers| Cytochrome P-450 CYP2C9 Inducers (strength unknown)| Cytochrome P-450 CYP2C9 Inducers (strong)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hydroxylamines| Hyperglycemia-Associated Agents| Kinase Inhibitor| Narrow Therapeutic Index Drugs| OAT1/SLC22A6 inhibitors| OAT3/SLC22A8 Inhibitors| OATP1B1/SLCO1B1 Inhibitors| OATP1B1/SLCO1B1 Substrates| OATP1B3 inhibitors| OATP1B3 substrates| OCT2 Inhibitors| Organic Anion Transporter 1 Inhibitors| Organic Anion Transporting Polypeptide 1B1 Inhibitors| Organic Anion Transporting Polypeptide 1B3 Inhibitors| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Photosensitizing Agents| Potential QTc-Prolonging Agents| Protein Kinase Inhibitors| Proto-Oncogene Proteins B-raf, antagonists & inhibitors| QTc Prolonging Agents| UGT1A1 Inhibitors"
251,DB01283,P35354|P23219,P11712|P33261|O60656|P05177,hsa:5743|hsa:5742,9|10|11|14|18|19|23|37|178|182|185|189|283|284|285|286|287|294|299|308|332|333|340|342|344|351|352|355|356|362|364|370|371|374|376|377|380|384|390|392|393|406|416|420|430|434|437|440|441|443|446|449|452|464|470|490|495|501|502|503|516|520|524|535|545|546|549|550|552|556|564|570|577|578|579|582|584|585|591|592|595|597|598|599|600|603|607|608|609|613|617|618|628|633|634|637|640|641|643|655|656|657|660|664|665|668|677|678|679|680|682|683|684|685|688|689|692|696|697|698|699|704|708|709|710|716|734|758|771|779|797|821|834,Lumiracoxib,"Acids, Carbocyclic| Agents causing hyperkalemia| Agents that produce hypertension| Analgesics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Antiinflammatory and Antirheumatic Products| Antiinflammatory and Antirheumatic Products, Non-Steroids| Antirheumatic Agents| Carboxylic Acids| COX-2 Inhibitors| Cyclooxygenase Inhibitors| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 Substrates| Enzyme Inhibitors| Musculo-Skeletal System| Nephrotoxic agents| Peripheral Nervous System Agents| Phenylacetates| Selective Cyclooxygenase 2 Inhibitors (NSAIDs)| Sensory System Agents| UGT1A9 Substrates"
252,DB00762,P11387|Q969P6,P08684|P20815|P20813|P24462|P22309|O60656|P23141|O00748|P06276,hsa:7150|hsa:116447,9|10|11|12|13|14|15|16|18|19|20|143|145|146|178|180|181|182|183|184|185|187|188|190|191|192|198|199|206|283|284|285|286|308|332|333|337|338|340|341|344|345|346|351|352|355|356|357|358|365|366|370|371|374|376|377|380|381|382|384|385|386|387|390|391|396|397|403|405|406|416|418|420|430|431|434|437|439|440|441|442|443|446|449|451|452|453|462|464|470|472|476|482|490|493|495|498|502|506|516|520|521|523|524|530|535|537|538|539|540|541|542|545|546|548|549|552|553|555|556|564|565|567|569|570|573|574|576|577|578|579|581|582|584|585|589|592|593|594|595|597|599|600|603|604|606|607|608|611|612|613|614|617|618|619|622|623|626|628|633|634|637|638|640|641|642|645|646|651|655|656|657|660|662|663|664|665|666|667|668|671|677|678|679|680|681|682|683|684|686|688|689|691|692|693|694|695|696|697|698|699|702|703|704|707|708|709|710|712|721|735|758|784|798|821,Irinotecan,Alkaloids| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| BCRP/ABCG2 Substrates| Cholinesterase substrates| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Enzyme Inhibitors| FOLFIRI chemotherapy regimen| Heterocyclic Compounds| Immunosuppressive Agents| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| OATP1B1/SLCO1B1 Inhibitors| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Pharmaceutical Preparations| Topoisomerase 1 (TOP1) inhibitors| Topoisomerase I Inhibitors| Topoisomerase Inhibitors| UGT1A1 Substrates| UGT1A1 Substrates with a Narrow Therapeutic Index| UGT1A9 Substrates| UGT1A9 Substrates with a Narrow Therapeutic Index
253,DB00563,P00374,P00374|Q06278|P42898|P52209|Q05932|P04818|P31939|Q92820,hsa:1719,9|10|11|12|14|15|16|17|18|19|20|178|182|183|184|185|190|191|192|283|284|285|286|299|308|332|333|338|340|344|345|351|352|355|356|357|358|359|365|370|371|372|373|374|375|376|377|378|379|380|384|386|387|388|389|390|391|392|393|396|403|406|416|418|420|430|431|434|435|437|438|439|440|441|442|443|445|446|447|449|450|451|452|453|464|470|472|482|484|485|487|490|491|493|495|499|502|504|506|516|519|520|521|523|524|528|530|535|536|538|539|540|545|546|547|549|552|553|555|556|560|564|566|569|570|572|577|578|579|582|584|585|592|593|595|596|597|599|600|601|602|603|607|608|611|613|617|618|621|623|628|633|634|636|637|640|643|645|646|654|656|657|659|660|664|665|668|671|672|674|677|678|679|680|682|683|684|685|688|690|692|693|694|695|704|707|708|709|710|716|779,Methotrexate,"Abortifacient Agents| Abortifacient Agents, Nonsteroidal| Agents Causing Muscle Toxicity| Antimetabolites| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Antirheumatic Agents| BCRP/ABCG2 Substrates| Biological Factors| Cancer immunotherapy| Cardiotoxic antineoplastic agents| CMF chemotherapy regimen| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Substrates| Dermatologicals| Drugs causing inadvertant photosensitivity| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Folic Acid Analogues| Folic Acid Antagonists| Hepatotoxic Agents| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Immunologic Factors| Immunosuppressive Agents| Immunotherapy| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| Nephrotoxic agents| Noxae| Nucleic Acid Synthesis Inhibitors| OAT1/SLC22A6 inhibitors| OAT3/SLC22A8 Inhibitors| OAT3/SLC22A8 Substrates| OAT3/SLC22A8 Substrates with a Narrow Therapeutic Index| OATP1B1/SLCO1B1 Substrates| OATP1B3 substrates| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Photosensitizing Agents| Pigments, Biological| Pteridines| Pterins| Reproductive Control Agents| Toxic Actions"
254,DB00518,F1L7U3|Q71U36|P68371|P83223,P08684|P04798|P05177,hsa:7846|hsa:10383,9|10|11|14|15|18|19|33|143|148|149|178|182|283|284|285|286|293|299|332|340|344|349|351|353|355|357|358|366|368|370|371|374|375|376|377|379|380|383|384|386|387|389|390|392|393|396|399|400|403|405|412|416|418|420|431|434|437|441|442|446|449|450|451|452|453|464|470|472|482|484|485|487|488|490|495|499|500|502|504|506|507|516|519|520|523|524|527|530|531|532|538|539|545|546|547|549|552|555|556|559|560|564|569|570|572|576|578|582|584|585|586|592|595|596|599|600|603|607|608|611|613|618|628|629|633|634|636|640|643|647|654|657|658|660|664|665|668|674|677|678|679|683|725|746|770|788|809|833,Albendazole,"Acids, Acyclic| Anthelmintics| Anti-Infective Agents| Anticestodal Agents| Antihelminthic| Antimitotic Agents| Antinematodal Agents| Antiparasitic Agents| Antiparasitic Products, Insecticides and Repellents| Antiplatyhelmintic Agents| Benzimidazole Derivatives| Benzimidazoles| Carbamates| Carboxylic Acids| Cytochrome P-450 CYP1A2 Inducers| Cytochrome P-450 CYP1A2 Inducers (strong)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates (strength unknown)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Mitosis Modulators| P-glycoprotein substrates| Tubulin Modulators"
255,DB00353,P21728|P41595,P08684,hsa:1812|hsa:3357,9|10|11|12|14|15|18|19|143|148|149|178|182|183|184|185|189|192|283|284|285|286|299|308|332|333|335|338|340|344|345|346|351|352|355|356|357|358|365|366|370|371|372|373|374|376|377|384|385|386|387|390|391|392|393|396|399|400|403|406|416|418|420|430|431|434|435|437|439|441|442|443|445|446|447|449|451|453|464|470|472|482|490|491|495|502|506|516|520|521|523|524|527|528|530|535|538|539|540|545|546|549|552|555|556|564|566|570|571|576|577|578|580|582|584|585|592|593|595|599|600|603|607|608|613|617|618|628|633|634|637|640|643|645|646|656|657|659|660|664|665|668|677|678|679|683|688|696|697|708|709|710|712|737|755|758|779|797|800|818|821,Methylergometrine,"Agents that produce hypertension| Alkaloids| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dopamine Antagonists| Ergolines| Ergonovine| Ergot Alkaloids and Derivatives| Genito Urinary System and Sex Hormones| Heterocyclic Compounds| Heterocyclic Compounds with 4 or More Rings| Heterocyclic Compounds, Fused-Ring| Reproductive Control Agents| Uterotonic agents"
256,DB00257,P10613|O15554|O75469|Q14994,P10632|P08684|P20813|P05108|P05177|P10635|P15538|P11511|P11509|P33261|P11712|P05181|P24462,hsa:3783|hsa:8856|hsa:9970,9|10|11|12|14|15|37|143|148|149|178|182|185|189|192|196|283|284|285|294|332|333|336|340|342|344|345|351|355|356|358|362|365|370|371|372|373|375|376|379|384|387|389|390|391|396|397|403|416|418|430|434|435|441|442|445|446|447|449|450|453|464|470|472|482|484|485|487|490|491|495|499|501|502|503|504|506|516|519|520|521|524|539|540|546|547|549|550|552|556|560|564|569|570|572|578|582|584|591|592|595|596|598|599|603|607|608|611|613|618|628|633|634|636|640|654|656|660|664|668|674|677|678|679|683|688|696|697|708|709|710|712|759|822,Clotrimazole,"Anti-Infective Agents| Anti-Infective Agents, Local| Antifungal Agents| Antifungal Agents (Vaginal)| Antifungals for Dermatological Use| Antifungals for Topical Use| Antiinfectives and Antiseptics for Local Oral Treatment| Azole Antifungals| Azoles| BSEP/ABCB11 Inhibitors| BSEP/ABCB11 Substrates| Cytochrome P-450 CYP2A6 Inhibitors| Cytochrome P-450 CYP2A6 Inhibitors (strong)| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (strength unknown)| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strong)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (moderate)| Cytochrome P-450 CYP2C8 Inhibitors (strong)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (moderate)| Cytochrome P-450 CYP2C9 Inhibitors (strong)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (moderate)| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (moderate)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inducers (strong)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A7 Inducers| Cytochrome P-450 CYP3A7 Inducers (strong)| Cytochrome P-450 CYP3A7 Inducers (weak)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dermatologicals| Enzyme Inhibitors| Gynecological Antiinfectives and Antiseptics| Heterocyclic Compounds| Hormone Antagonists| Hormones, Hormone Substitutes, and Hormone Antagonists| Imidazole and Triazole Derivatives| Imidazole Derivatives| Imidazoles| OATP1B1/SLCO1B1 Inhibitors| OATP1B1/SLCO1B1 Substrates| OATP1B3 inducers| P-glycoprotein inducers| P-glycoprotein inhibitors| P-glycoprotein substrates| Steroid Synthesis Inhibitors| Stomatological Preparations"
257,DB04840,P23975,P10635|P04798,hsa:6530,9|10|11|14|15|178|180|181|182|185|283|284|285|299|332|333|344|345|351|355|356|365|370|371|375|384|390|391|393|416|418|430|434|441|446|450|464|470|488|490|516|519|520|524|540|549|552|556|560|564|570|578|582|584|592|595|596|599|603|607|608|613|618|628|633|634|640|654|656|660|664|668|677|678|679|683|688|696|708|709|710|712|755|818,Debrisoquin,"Adrenergic Agents| Antiadrenergic Agents, Peripherally Acting| Antihypertensive Agents| Autonomic Agents| Cardiovascular Agents| Cardiovascular System| Catecholamines| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Substrates| Guanidine Derivatives| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Isoquinolines| Neurotransmitter Agents| P-glycoprotein substrates| Peripheral Nervous System Agents| Sympatholytics"
258,DB06777,Q96RI1|O75469|Q8TDU6|P52895,Q02318|P08684|P16662,hsa:9971|hsa:8856|hsa:151306|hsa:1646,0|9|10|11|12|18|19|20|143|144|178|179|185|186|192|193|283|284|286|308|332|333|334|335|339|341|344|346|352|366|374|380|406|420|440|443|452|535|571|579|582|617|637|679|680|684|688|689|690|692|696|697|698|699|701|704|708|709|710|711|712|776|777|797|798|818|819|839|860,Chenodeoxycholicacid,Alimentary Tract and Metabolism| Bile Acid Preparations| Bile acids and derivatives| Bile Acids and Salts| Bile and Liver Therapy| Bile Therapy| Cholanes| Cholic Acids| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Fused-Ring Compounds| Gastrointestinal Agents| Polycyclic Compounds| Steroids| UGT2B7 Inhibitors
259,DB00179,P09917|P04278,P51589,hsa:240|hsa:6462,9|10|11|12|18|19|20|178|182|185|189|283|284|286|308|332|333|335|341|344|352|355|356|370|371|374|381|382|384|406|416|430|434|441|446|470|490|498|516|520|524|541|542|544|548|552|556|564|567|570|573|574|578|582|584|590|595|599|603|606|608|617|618|619|631|634|637|640|641|651|655|660|663|664|667|668|677|678|679|680|688|689|696|697|698|699|708|709|710|712|714|735|761|777|798|824,Masoprocol,"Analgesics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Antioxidants| Benzene Derivatives| Benzyl Compounds| Biological Factors| Catechols| Compounds used in a research, industrial, or household setting| Cyclooxygenase Inhibitors| Enzyme Inhibitors| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Lignans| Lipoxygenase Inhibitors| Peripheral Nervous System Agents| Phenols| Protective Agents| Sensory System Agents"
260,DB11828,P00533,P08684|P31513,hsa:1956,9|10|11|12|14|15|16|18|19|37|178|182|183|184|185|189|190|191|192|199|283|284|285|286|294|299|332|333|340|341|342|344|345|346|351|352|355|356|357|358|362|365|366|370|371|372|373|374|376|377|381|382|384|385|386|387|390|391|392|393|396|403|405|416|418|419|420|429|430|431|434|435|437|439|441|442|443|445|446|447|449|451|453|461|464|466|470|472|476|482|490|491|495|498|501|502|503|505|506|516|520|521|523|524|530|538|539|540|541|542|543|545|546|548|549|550|551|552|553|555|556|564|565|566|568|570|573|574|576|577|578|582|583|584|585|589|591|592|593|594|595|598|599|600|601|603|604|606|607|608|613|614|615|618|619|620|621|626|628|632|633|634|637|638|640|641|643|645|651|652|655|656|657|659|660|664|665|666|668|671|672|676|677|678|679|680|682|683|688|689|691|696|697|698|702|703|708|709|710|714|721|728|737|742|750|758|763|764|777|784|791|800|805|813|821|826|827,Neratinib,"Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Substrates| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors| Kinase Inhibitor| Narrow Therapeutic Index Drugs| P-glycoprotein inhibitors| Protein Kinase Inhibitors| Tyrosine Kinase Inhibitors"
261,DB01393,Q07869|Q03181|P37231|O75469|P19793|P28702|P48443,P04798|P10632|P08684,hsa:5465|hsa:5467|hsa:5468|hsa:8856|hsa:6256|hsa:6257|hsa:6258,9|10|11|12|14|18|19|20|37|178|182|185|189|283|284|285|286|294|299|308|332|333|337|341|342|344|345|351|352|355|356|362|365|370|371|374|380|381|382|384|390|392|393|405|406|416|420|430|434|439|440|441|443|446|451|452|462|464|470|476|490|493|498|501|503|516|520|524|528|535|537|540|541|542|548|549|550|552|553|556|564|565|567|570|573|574|578|579|582|584|589|591|592|594|595|597|598|599|603|604|605|606|607|608|613|614|617|618|619|620|623|626|628|632|633|634|637|640|641|643|645|646|651|655|656|660|662|663|664|666|668|671|672|677|678|679|680|683|684|688|689|692|696|704|708|709|710|714|717|777|780,Bezafibrate,"Acids, Acyclic| Acids, Carbocyclic| Agents Causing Muscle Toxicity| Amides| Benzamides and benzamide derivatives| Benzene Derivatives| Benzoates| Butyrates| Carboxylic Acids| Cardiovascular System| Chlorobenzoates| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Inhibitors (weak)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Ethers| Fibric Acid Derivatives| Fibric Acids| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hypolipidemic Agents| Hypolipidemic Agents Indicated for Hyperlipidemia| Isobutyrates| Lipid Modifying Agents| Lipid Modifying Agents, Plain| Lipid Regulating Agents| Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia| OATP1B1/SLCO1B1 Inhibitors| Phenols| Phenyl Ethers"
262,DB00997,P11388|Q14978,P08684|P20813|P10635|Q16678|P16152|O75828|P14550|P42330|P15559|P47989|P29475|P35228|P29474|O75306|O75489|O75251|P16435,hsa:7153|hsa:9221,9|10|11|12|14|18|19|20|21|178|181|182|185|189|192|196|199|203|206|283|284|285|286|299|308|332|333|337|338|339|340|341|344|345|346|347|351|352|355|356|365|366|367|370|371|374|380|381|382|384|393|405|406|416|420|430|432|434|441|443|446|462|470|476|490|493|498|516|520|524|528|535|537|541|542|548|552|553|556|563|564|565|566|567|570|571|573|574|575|578|579|581|582|584|589|590|592|594|595|597|599|603|604|606|608|610|614|617|618|619|623|625|626|634|637|638|639|640|641|642|643|651|655|660|661|662|663|664|666|667|668|671|672|677|678|679|680|681|684|686|687|688|689|690|692|693|696|697|698|699|700|701|704|705|708|709|710|712|713|719|734|735|755|756|776|777|782|797|798|803|818|819,Doxorubicin,"ABVD chemotherapy regimen| Anthracycline Topoisomerase Inhibitor| Anthracyclines| Anthracyclines and Related Substances| Antibiotics, Antineoplastic| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| BCRP/ABCG2 Substrates| BEACOPP chemotherapy regimen| BSEP/ABCB11 Substrates| BSEP/ABCB11 Substrates with a Narrow Therapeutic Index| Carbohydrates| Cardiotoxic antineoplastic agents| CHOP chemotherapy regimen| CHOP-R chemotherapy regimen| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Cytotoxic Antibiotics and Related Substances| Drugs causing inadvertant photosensitivity| Enzyme Inhibitors| Glycosides| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Immunosuppressive Agents| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| P-glycoprotein inducers| P-glycoprotein inhibitors| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Photosensitizing Agents| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Topoisomerase II Inhibitors| Topoisomerase Inhibitors"
263,DB00248,P14416|P41595|P35462|P28223|P18089|P28221|P21917|P08913|P08908|P18825|P21918|P21728|P28222|P28335|P34969|P35348|P35368|P25100|P08588|P07550|BE0004889,P08684,hsa:1813|hsa:3357|hsa:1814|hsa:3356|hsa:151|hsa:3352|hsa:1815|hsa:150|hsa:3350|hsa:152|hsa:1816|hsa:1812|hsa:3351|hsa:3358|hsa:3363|hsa:148|hsa:147|hsa:146|hsa:153|hsa:154,9|10|11|12|14|15|16|18|19|143|148|149|178|180|181|182|185|189|192|283|284|285|286|299|332|333|335|338|340|344|345|351|352|355|356|357|358|365|370|371|372|373|374|375|376|377|384|385|386|387|390|391|392|393|396|399|400|403|416|418|420|430|431|434|435|437|439|441|442|443|445|446|447|449|451|453|464|470|472|482|490|491|495|502|506|516|520|521|523|524|527|528|530|535|538|539|540|545|546|549|552|555|556|560|564|570|576|577|578|579|580|582|584|585|592|593|595|599|600|603|607|608|613|618|628|633|634|636|640|643|645|646|647|650|654|656|657|660|664|665|668|677|678|679|683|684|688|692|695|696|697|704|707|708|709|710|712|737|755|758|776|779|797|800|818|821,Cabergoline,"Agents that produce hypertension| Alkaloids| Anti-Dyskinesia Agents| Anti-Parkinson Drugs| Antidepressive Agents| Antineoplastic Agents| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dopamine Agents| Dopamine Agonists| Ergolines| Ergot Alkaloids and Derivatives| Ergot-derivative Dopamine Receptor Agonists| Genito Urinary System and Sex Hormones| Heterocyclic Compounds| Heterocyclic Compounds with 4 or More Rings| Heterocyclic Compounds, Fused-Ring| Narrow Therapeutic Index Drugs| Nervous System| Neurotransmitter Agents| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Prolactine Inhibitors| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT1 Receptor Agonists| Serotonin 5-HT2 Receptor Agonists| Serotonin Agents| Serotonin Modulators| Serotonin Receptor Agonists"
264,DB09119,Q99571,P33261|P08684,hsa:5025,9|10|11|12|14|15|18|19|178|182|185|189|213|215|216|283|284|285|286|299|332|333|339|340|341|344|346|351|352|355|356|366|370|371|374|375|376|377|380|384|390|391|393|405|416|420|430|434|437|440|441|443|446|449|451|452|464|470|490|495|502|516|520|524|545|546|548|549|552|556|560|564|570|573|574|577|578|582|584|585|592|594|595|599|600|603|604|607|608|613|614|618|619|628|633|634|637|638|640|641|645|654|655|656|657|660|664|665|666|668|674|677|678|679|680|682|683|688|689|696|697|698|708|709|710|758|821,Eslicarbazepineacetate,"Anticonvulsants| Carboxamide Derivatives| Cardiovascular Agents| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (moderate)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (weak)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Eslicarbazepine and prodrugs| Heterocyclic Compounds| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Membrane Transport Modulators| Nervous System| Sodium Channel Blockers| UGT1A1 Substrates| Voltage-Gated Sodium Channel Blockers"
265,DB01014,P37231|P35354|P23219|P09917,Q9FAW5,hsa:5468|hsa:5743|hsa:5742|hsa:240,9|10|11|12|14|15|18|19|20|178|182|185|189|283|284|285|286|299|300|308|332|333|340|341|344|345|351|352|355|356|365|370|371|376|377|380|381|382|384|390|392|393|406|416|420|422|430|434|437|439|440|441|443|446|449|451|452|464|470|490|493|498|502|516|520|524|528|535|540|541|542|545|546|548|549|552|553|556|564|570|573|574|575|578|579|580|581|582|584|590|592|595|597|599|600|603|606|607|608|613|617|618|619|623|625|628|633|634|637|638|639|640|641|642|643|645|646|651|655|656|660|664|665|667|668|671|672|677|678|679|680|682|683|684|685|688|689|692|695|698|704|707|708|709|710|716|721|737|756|779|784|800|819,Balsalazide,"Acids, Carbocyclic| Agents causing hyperkalemia| Agents that produce hypertension| Alimentary Tract and Metabolism| Aminobenzoates| Aminosalicylate| Aminosalicylic Acids| Analgesics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)| Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents| Benzene Derivatives| Benzoates| Carboxylic Acids| Colitis, Ulcerative| Gastrointestinal Agents| Hydrazines| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hydroxy Acids| Hydroxybenzoates| Inflammatory Bowel Diseases| Intestinal Antiinflammatory Agents| meta-Aminobenzoates| Nephrotoxic agents| Non COX-2 selective NSAIDS| Peripheral Nervous System Agents| Phenols| Prodrugs| Salicylates| Sensory System Agents"
266,DB00720,P12235|P05141|P12236|BMOL0000029,P35354,hsa:291|hsa:292|hsa:293,18|19|20|30|31|37|38|292|294|308|314|360|411|425|456,Clodronicacid,Bisphosphonates| Bone Density Conservation Agents| Drugs Affecting Bone Structure and Mineralization| Drugs for Treatment of Bone Diseases| Musculo-Skeletal System| Organophosphonates| Organophosphorus Compounds
267,DB00883,P16066,P08684|P05181,hsa:4881,9|10|14|15|18|19|20|21|143|146|150|153|283|284|286|301|332|339|341|344|346|352|366|401|405|423|455|567|582|614|637|639|662|679|680|681|689|690|701,Isosorbidedinitrate,Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use| Alcohols| Antianginal Agents| Carbohydrates| Cardiac Therapy| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Hypotensive Agents| Methemoglobinemia Associated Agents| Nitrate Vasodilator| Nitrates and Nitrites| Nitric Oxide Donors| Organic Nitrates| Sugar Alcohols| Vasodilating Agents| Vasodilation| Vasodilators Used in Cardiac Diseases| Vasoprotectives
268,DB01262,P26358,P27707,hsa:1786,9|10|11|14|15|16|18|19|20|143|146|178|183|184|283|284|285|286|299|308|332|339|341|344|345|346|351|352|365|366|373|375|379|389|390|391|393|396|397|403|405|406|418|420|447|450|451|453|484|487|491|504|519|521|540|560|567|571|572|582|592|596|612|613|614|617|636|637|638|639|645|646|647|654|662|663|680|682|683|690|691|702,Decitabine,"Antimetabolites| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Aza Compounds| Carbohydrates| Cytidine Deaminase Substrates| Enzyme Inhibitors| Glycosides| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Immunosuppressive Agents| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| Noxae| Nucleic Acid Synthesis Inhibitors| Nucleic Acids, Nucleotides, and Nucleosides| Nucleoside Metabolic Inhibitor| Nucleosides| Pyrimidine Analogues| Pyrimidine Nucleosides| Pyrimidines| Ribonucleosides| Toxic Actions"
269,DB00889,P46098,P08684|P04798|P10635|P20815,hsa:3359,9|10|11|12|14|15|16|18|143|148|149|178|180|181|182|185|187|188|192|283|284|285|286|299|300|332|333|338|340|344|345|351|352|355|356|357|358|365|370|371|374|376|377|384|385|386|387|390|391|392|393|396|416|418|420|422|430|431|434|437|439|441|442|443|446|449|451|453|464|467|470|477|490|493|494|495|496|502|515|516|520|521|523|524|528|530|535|536|538|539|540|545|546|549|552|553|555|556|564|569|570|576|578|579|582|584|585|592|593|595|597|599|600|601|603|607|608|611|613|616|618|621|623|628|633|634|640|643|644|645|646|656|657|660|664|665|668|671|677|678|679|683|684|685|688|692|696|704|708|709|710|758|821,Granisetron,"Alimentary Tract and Metabolism| Antidepressive Agents| Antiemetic Serotonin 5-HT3 Receptor Antagonists| Antiemetics| Antiemetics and Antinauseants| Autonomic Agents| Aza Compounds| Azabicyclo Compounds| Azoles| Bicyclo Compounds, Heterocyclic| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Gastrointestinal Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Bridged-Ring| Heterocyclic Compounds, Fused-Ring| Indazoles| Moderate Risk QTc-Prolonging Agents| Neurotransmitter Agents| Peripheral Nervous System Agents| Pyrazoles| QTc Prolonging Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 3 Receptor Antagonists| Serotonin 5-HT3 Receptor Antagonists| Serotonin Agents| Serotonin Receptor Antagonists"
270,DB00805,P21397|P41595|P28223|P28335|P22303|P31645|P21728|P14416|P11229,P10635,hsa:4128|hsa:3357|hsa:3356|hsa:3358|hsa:43|hsa:6532|hsa:1812|hsa:1813|hsa:1128,9|10|11|12|14|15|16|18|178|180|181|182|183|184|185|192|283|284|285|286|299|300|332|333|340|344|345|346|351|352|355|356|357|358|365|366|370|371|374|375|376|378|379|384|387|390|391|392|393|405|416|418|422|430|431|434|437|438|441|442|446|449|450|464|467|470|477|486|490|495|502|515|516|517|519|520|523|524|528|530|538|539|540|545|546|549|552|555|556|560|564|566|569|570|576|578|582|584|585|592|595|596|599|600|603|607|608|611|613|614|615|616|618|628|633|634|635|640|643|644|654|656|657|659|660|664|665|668|677|678|679|683|688|696|697|708|709|710,Minaprine,"Agents that produce hypertension| Agents that reduce seizure threshold| Antidepressive Agents| Central Nervous System Agents| Central Nervous System Depressants| Central Nervous System Stimulants| Cholinesterase Inhibitors| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates| Monoamine Oxidase Inhibitors| Nervous System| Psychoanaleptics| Psychotropic Drugs| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin 5-HT2C Receptor Antagonists| Serotonin Agents| Serotonin Receptor Antagonists"
271,DB08897,P11229|P08172|P20309|P08173|P08912,P06276,hsa:1128|hsa:1129|hsa:1131|hsa:1132|hsa:1133,9|10|11|12|14|18|19|20|33|34|143|149|150|156|178|180|181|182|185|187|188|192|283|284|285|286|293|308|332|333|335|337|339|341|344|345|346|349|351|352|353|355|365|366|368|370|371|380|381|382|383|384|390|391|405|406|412|416|420|421|434|440|441|443|446|452|462|470|471|476|480|490|498|500|507|513|516|520|524|531|532|535|537|540|541|542|548|552|556|564|565|566|567|570|573|574|578|579|582|584|586|589|592|594|595|597|599|603|604|606|608|613|614|615|617|618|619|620|626|632|634|637|638|640|641|651|655|656|658|659|660|662|663|664|666|667|668|677|678|679|680|682|683|684|688|689|692|696|708|709|710,Aclidinium,"Adrenergics, Inhalants| Agents producing tachycardia| Agents to Treat Airway Disease| Alkaloids| Anticholinergic Agents| Antimuscarinics Antispasmodics| Aza Compounds| Azabicyclo Compounds| Bicyclo Compounds, Heterocyclic| Cholinesterase substrates| Drugs for Obstructive Airway Diseases| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, Bridged-Ring| Muscarinic Antagonists| Respiratory System"
272,DB01181,O75469,P20813|P08684|P20815|P33261|P11712|P10632|P11509|P33260|P23219|P24462,hsa:8856,9|10|14|15|18|19|30|37|38|178|180|181|283|284|285|286|294|299|304|314|332|342|343|344|345|346|351|352|361|365|366|390|393|407|411|425|456|528|540|609|613|638|643|656,Ifosfamide,"Alkylating Activity| Alkylating Drugs| Antineoplastic Agents| Antineoplastic Agents, Alkylating| Antineoplastic and Immunomodulating Agents| Cardiotoxic antineoplastic agents| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C18 Substrates| Cytochrome P-450 CYP2C18 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C8 Inducers| Cytochrome P-450 CYP2C8 Inducers (strength unknown)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hydrocarbons| Hydrocarbons, Halogenated| Immunosuppressive Agents| Methemoglobinemia Associated Agents| Mustard Compounds| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| Nitrogen Mustard Analogues| Nitrogen Mustard Compounds| Noxae| Organophosphorus Compounds| Oxazines| Phosphoramide Mustards| Phosphoramides| Toxic Actions"
273,DB01128,P10275,P08684|P33261|P11712|P10635,hsa:367,9|10|11|12|14|15|18|19|20|23|24|25|33|178|182|185|189|283|284|285|286|287|293|299|308|332|333|337|340|341|344|349|351|352|353|355|356|363|364|368|370|371|374|376|377|383|384|390|392|393|406|412|414|416|419|420|429|430|434|437|439|441|443|446|449|451|457|459|462|464|465|466|470|490|495|500|502|507|516|520|524|531|532|535|537|545|546|549|552|556|564|566|568|570|578|582|584|585|586|592|595|599|600|603|607|608|613|618|628|633|634|640|643|645|656|657|658|659|660|664|665|668|676|677|678|679|683|688|696|708|709|710|712|716|737|755|779|800|818,Bicalutamide,"Amides| Amines| Androgen Receptor Antagonists| Androgen Receptor Inhibitors| Aniline Compounds| Antiandrogens| Antiandrogens, non-steroidal| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Benzene Derivatives| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Endocrine Therapy| Hormone Antagonists| Hormone Antagonists and Related Agents| Hormones and Related Agents| Hormones, Hormone Substitutes, and Hormone Antagonists| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Narrow Therapeutic Index Drugs| P-glycoprotein inhibitors| Sulfones| Sulfur Compounds"
274,DB00180,P04150,P08684,hsa:2908,0|9|10|11|12|18|19|20|23|143|144|146|150|178|179|182|185|186|192|283|284|286|287|308|332|333|334|335|337|339|341|344|346|352|366|374|380|405|406|416|420|430|432|434|441|443|446|462|490|516|524|535|537|553|556|563|567|571|579|581|582|599|605|610|614|617|637|639|640|642|660|661|662|671|672|678|679|680|681|684|688|689|690|692|693|696|697|698|699|700|701|704|705|708|709|710|711|712|776|777|797|798|818|819|839|840|860|861|866,Flunisolide,"Adrenal Cortex Hormones| Adrenals| Agents to Treat Airway Disease| Anti-Asthmatic Agents| Anti-Inflammatory Agents| Corticosteroid Hormone Receptor Agonists| Corticosteroids| Corticosteroids for Systemic Use| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Drugs for Obstructive Airway Diseases| Fused-Ring Compounds| Immunosuppressive Agents| Medications that reduce magnesium levels| Nasal Preparations| Polycyclic Compounds| Pregnadienes| Pregnanes| Respiratory System| Respiratory System Agents| Steroids| Steroids, Fluorinated"
275,DB01241,Q07869,P10632|P05177|P08684|P33261|P11712,hsa:5465,9|10|11|18|19|178|182|283|284|286|308|332|333|334|341|344|346|352|355|356|366|370|371|374|380|381|382|384|405|406|416|420|430|434|440|441|443|446|452|470|476|490|498|516|520|524|535|541|542|548|552|556|564|565|570|573|574|578|579|582|584|589|594|595|599|603|604|606|608|614|617|618|619|620|626|632|634|637|640|641|651|655|660|664|666|668|677|678|679|680|684|688|689|690|693|698|699|700|708|709|710|711|713|735|756|776|798|819,Gemfibrozil,"Acids, Acyclic| Agents Causing Muscle Toxicity| Benzene Derivatives| Butyrates| Carboxylic Acids| Cardiovascular System| Chemically-Induced Disorders| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (strong)| Cytochrome P-450 CYP2C8 Inducers| Cytochrome P-450 CYP2C8 Inducers (strength unknown)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strong)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strong)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drug-Related Side Effects and Adverse Reactions| Drugs causing inadvertant photosensitivity| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Ethers| Fatty Acids| Fatty Acids, Volatile| Fibric Acid Derivatives| Fibric Acids| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hypolipidemic Agents| Hypolipidemic Agents Indicated for Hyperlipidemia| Isobutyrates| Lipid Modifying Agents| Lipid Modifying Agents, Plain| Lipid Regulating Agents| Lipids| Metabolic Side Effects of Drugs and Substances| Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia| Noxae| OAT3/SLC22A8 Inhibitors| OATP1B1/SLCO1B1 Inhibitors| OATP1B3 inhibitors| Organic Anion Transporting Polypeptide 2B1 Inhibitors| Pentanoic Acids| Peroxisome Proliferator Receptor alpha Agonist| Peroxisome Proliferator-activated Receptor alpha Agonists| Phenols| Phenyl Ethers| Photosensitizing Agents| Toxic Actions| UGT1A1 Inhibitors| UGT1A1 Substrates| UGT1A3 Inhibitors| UGT1A3 substrates| UGT1A9 Substrates| UGT2B17 substrates| UGT2B7 substrates| Valerates"
276,DB00636,Q07869,P05181|P09210|P08684|P04798|P11509|P20813|Q02928,hsa:5465,9|10|11|18|19|37|178|182|283|284|286|294|332|333|337|341|342|344|346|352|355|362|366|370|371|374|380|381|382|384|405|416|420|434|440|441|443|446|452|462|470|476|490|498|501|503|516|520|524|535|537|541|542|548|550|552|556|564|565|567|570|573|574|578|582|584|589|591|594|595|598|599|603|604|605|606|608|614|618|619|620|626|632|634|637|640|641|651|655|660|662|664|666|668|677|678|679|680|689|722|785,Clofibrate,"Acids, Acyclic| Agents Causing Muscle Toxicity| Anticholesteremic Agents| Benzene Derivatives| Butyrates| Carboxylic Acids| Cardiovascular System| Clofibric Acid| Cytochrome P-450 CYP2A6 Inhibitors| Cytochrome P-450 CYP2A6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2E1 Inducers| Cytochrome P-450 CYP2E1 Inducers (strength unknown)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Ethers| Fibric Acids| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hypolipidemic Agents| Isobutyrates| Lipid Modifying Agents| Lipid Modifying Agents, Plain| Lipid Regulating Agents| Phenols| Phenyl Ethers| Thyroxine-binding globulin inducers"
277,DB03128,P22303|P11229|P08172|P20309|P08173|P36544,P10635,hsa:43|hsa:1128|hsa:1129|hsa:1131|hsa:1132|hsa:1139,9|10|14|18|19|283|284|285|286|344|345|346|351|352|365|366|374|380|390|391|405|420|440|443|452|540|566|614|615|659,Acetylcholine,Amines| Antiglaucoma Preparations and Miotics| Biogenic Amines| Cardiovascular Agents| Cholinergic Agents| Cholinergic Agonists| Cholinergic Receptor Agonist| Cholinesterase substrates| Miotics| Neurotransmitter Agents| OCT1 substrates| Ophthalmologicals| Parasympathomimetics| Sensory Organs| Vasodilating Agents
278,DB00784,P35354|P23219,P11712|P10632,hsa:5743|hsa:5742,9|10|11|14|18|19|178|182|185|189|283|284|285|286|299|308|332|333|340|344|351|352|355|356|370|371|374|376|377|380|384|390|392|393|406|416|420|430|434|437|440|441|443|446|449|452|464|470|490|493|495|502|516|520|524|535|545|546|548|549|552|553|556|564|570|573|574|577|578|579|580|582|584|585|592|595|597|599|600|603|607|608|613|617|618|619|623|624|628|633|634|637|638|640|641|643|655|656|657|660|664|665|667|668|671|672|673|677|678|679|680|683|684|688|689|692|696|698|704|708|709|710|712|737|755|758|800|818|821,Mefenamicacid,"Acids, Carbocyclic| Agents causing hyperkalemia| Agents that produce hypertension| Amines| Aminobenzoates| Analgesics| Analgesics, Non-Narcotic| Aniline Compounds| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)| Antiinflammatory and Antirheumatic Products| Antiinflammatory and Antirheumatic Products, Non-Steroids| Antirheumatic Agents| Benzene Derivatives| Benzoates| Carboxylic Acids| Central Nervous System Agents| Cyclooxygenase Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (weak)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (weak)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Enzyme Inhibitors| Fenamates| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Musculo-Skeletal System| Nephrotoxic agents| ortho-Aminobenzoates| Other Nonsteroidal Anti-inflammatory Agents| Peripheral Nervous System Agents| Photosensitizing Agents| Sensory System Agents| UGT1A9 Inhibitors| UGT2B7 Inhibitors"
279,DB01191,P31645|P28335,P10635|P05177|P11509|P33261|P11712|P05181,hsa:6532|hsa:3358,9|10|11|14|23|24|178|182|283|284|285|287|299|332|333|338|340|344|345|351|355|356|363|365|370|371|374|384|390|392|393|416|430|434|441|446|470|490|516|520|524|528|540|552|556|564|570|578|582|584|592|595|599|603|607|608|613|618|634|640|643|656|660|664|668|677|678|679|683|688|696|697|708|709|710|734|797,Dexfenfluramine,"Alimentary Tract and Metabolism| Amines| Antidepressive Agents| Antiobesity Preparations, Excl. Diet Products| Central Nervous System Depressants| Centrally Acting Antiobesity Products| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 CYP2E1 Inhibitors (weak)| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Ethylamines| Neurotransmitter Agents| Phenethylamines| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin Agents"
280,DB00289,P23975|P31645|Q01959|BE0004956,P10635|P33261|P08684,hsa:6530|hsa:6532|hsa:6531,9|10|11|12|14|18|178|182|185|189|283|284|285|286|299|332|333|339|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|392|393|405|416|430|434|441|446|470|476|490|498|516|520|524|528|540|541|542|548|552|556|564|565|570|573|574|578|582|584|589|592|594|595|599|603|604|606|608|613|614|618|619|620|626|632|634|637|638|640|641|643|651|655|660|664|666|668|677|678|679|680|683|688|689|696|698|708|709|710|756|819,Atomoxetine,"Adrenergic Agents| Agents producing tachycardia| Agents that produce hypertension| Amines| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Membrane Transport Modulators| Miscellaneous Central Nervous System Agents| Nervous System| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| Norepinephrine Reuptake Inhibitor| Norepinephrine Uptake Inhibitors| Potential QTc-Prolonging Agents| Propylamines| Psychostimulants, Agents Used for ADHD and Nootropics| QTc Prolonging Agents"
281,DB06695,P00734,P23141|O00748|O60656|P16662|P54855|P16083,hsa:2147,9|10|11|12|13|14|15|16|18|19|20|143|148|149|178|182|183|184|185|189|192|283|284|285|286|299|332|333|340|344|345|346|351|352|355|356|357|358|359|365|366|370|371|372|373|374|375|376|377|378|379|380|384|386|387|389|390|391|392|393|396|397|403|405|416|418|420|430|431|434|435|437|438|439|440|441|442|443|445|446|447|449|450|451|452|453|464|470|472|482|484|485|487|490|491|493|495|499|502|504|506|516|519|520|521|523|524|528|530|535|538|539|540|545|546|547|549|552|553|555|556|560|564|569|570|572|576|577|578|579|580|582|584|585|592|595|596|597|599|600|603|607|608|611|612|613|614|618|623|628|633|634|636|637|638|640|643|645|646|647|654|656|657|660|664|665|668|671|672|674|677|678|679|680|683|684|685|688|689|692|695|704|707|708|709|710|716|737|770|779|800|833,Dabigatranetexilate,"Anticoagulants| Antithrombins| Benzimidazoles| Blood and Blood Forming Organs| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Hematologic Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| P-glycoprotein substrates| Protease Inhibitors| Pyridines| Serine Protease Inhibitors| UGT1A9 Substrates| UGT2B7 substrates"
282,DB08815,P14416|P28223|P34969|P08908|P18825|P08913,P08684,hsa:1813|hsa:3356|hsa:3363|hsa:3350|hsa:152|hsa:150,9|10|11|12|14|15|16|18|19|33|143|144|145|146|148|149|150|151|157|164|178|179|180|181|182|185|192|283|284|285|286|293|305|332|333|335|344|345|351|352|353|355|356|358|365|370|371|375|376|378|379|383|384|385|387|390|391|416|418|420|421|430|434|438|439|441|442|443|446|449|450|451|464|470|471|483|490|495|513|516|519|520|523|524|530|531|532|535|538|540|545|549|552|555|556|560|564|569|570|576|578|579|582|584|585|592|595|596|599|600|603|607|608|611|613|618|628|629|633|634|640|645|646|650|654|656|657|660|664|665|668|677|678|679|683|684|685|687|688|692|696|697|704|708|709|710|712|757|797|818|820|839|860,Lurasidone,"Adrenergic Agents| Adrenergic alpha-2 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Agents that produce hypertension| Antidepressive Agents| Antipsychotic Agents| Antipsychotic Agents (Second Generation [Atypical])| Azoles| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Dopamine Agents| Dopamine Antagonists| Dopamine D2 Receptor Antagonists| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hyperglycemia-Associated Agents| Indole Derivatives| Isoindoles| Nervous System| Neurotoxic agents| Neurotransmitter Agents| Potential QTc-Prolonging Agents| Psycholeptics| Psychotropic Drugs| QTc Prolonging Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT1 Receptor Antagonists| Serotonin 5-HT1A Receptor Antagonists| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin Agents| Serotonin Receptor Antagonists| Sulfur Compounds| Thiazoles| Tranquilizing Agents"
283,DB00629,P08913|P18089,P05177,hsa:150|hsa:151,9|10|11|14|15|16|37|38|178|182|283|284|285|294|299|300|332|333|342|344|345|351|355|356|362|365|370|371|375|384|393|416|418|430|434|435|441|442|446|447|450|470|490|501|503|516|520|524|538|550|552|555|556|564|570|578|582|584|591|595|598|599|603|608|618|634|640|660|664|668|677|678|679|688|708|709|710|752|759|815|822,Guanabenz,Adrenergic Agents| Adrenergic Agonists| Adrenergic alpha-2 Receptor Agonists| Adrenergic alpha-Agonists| Agents producing tachycardia| Agents that produce hypertension| Amidines| Antihypertensive Agents| Cardiovascular Agents| Central alpha-2 Adrenergic Agonist| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 Substrates| Guanidines| Neurotransmitter Agents
284,DB00602,O75311|P28472,P08684,hsa:8001|hsa:2562,9|10|11|12|13|18|19|20|21|22|143|146|150|153|178|181|182|185|188|189|192|195|199|202|206|209|283|284|286|308|332|333|335|337|339|341|344|346|347|352|366|367|374|380|405|406|416|420|430|434|440|441|443|446|452|490|516|524|535|556|563|564|567|571|573|579|581|582|594|599|610|614|617|619|637|639|640|641|642|660|661|662|663|664|666|667|678|679|680|681|684|686|688|689|690|692|693|696|697|698|700|701|704|705|708|709|710|712|776|777|798|819,Ivermectin,"Agents Causing Muscle Toxicity| Agrochemicals| Anthelmintics| Anti-Infective Agents| Antinematodal Agents| Antiparasitic Agents| Antiparasitic Products, Insecticides and Repellents| Avermectines| BCRP/ABCG2 Substrates| Compounds used in a research, industrial, or household setting| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Dermatologicals| Insecticides| Lactones| OATP1B1/SLCO1B1 Inhibitors| OATP1B3 inhibitors| P-glycoprotein inducers| P-glycoprotein inhibitors| P-glycoprotein substrates| Pediculicides| Pesticides| Polyketides| Scabicides and Pediculicides| Toxic Actions"
285,DB01351,P14867|P47869|P34903|P48169|P31644|Q16445|P43681|P36544|P42262|Q13002,P11509,hsa:2554|hsa:2555|hsa:2556|hsa:2557|hsa:2558|hsa:2559|hsa:1137|hsa:1139|hsa:2891|hsa:2898,9|10|11|14|15|18|19|178|180|181|283|284|285|286|299|332|333|334|335|344|351|352|374|375|390|392|393|420|439|443|451|535|560|579|580|582|588|592|593|613|636|645|647|650|654|679|683|684|688|692|697|708|709|710|711,Amobarbital,"Anticholinergic Agents| Anticonvulsants| Barbiturates| Barbiturates, Plain| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 Enzyme Inducers| GABA Agents| GABA Modulators| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypnotics and Sedatives| Nervous System| Neurotransmitter Agents| Nicotinic Antagonists| Psycholeptics| Pyrimidines| Pyrimidinones"
286,DB11901,P10275|BE0004797,P08684|P10632|P33261|P11712,hsa:367,9|10|11|12|14|15|16|18|19|23|24|25|33|129|130|143|145|146|178|182|183|184|185|283|284|285|286|287|293|299|332|333|336|340|344|345|351|352|355|356|357|358|363|364|365|370|371|372|373|374|375|376|377|384|387|390|391|392|393|396|403|416|418|419|420|421|429|430|431|434|435|437|439|441|442|443|445|446|447|449|451|453|464|466|470|472|482|490|491|493|495|499|502|506|508|516|520|521|523|524|528|530|535|536|538|540|545|546|547|549|552|553|555|556|560|564|568|569|570|576|577|578|579|582|584|585|592|595|597|599|600|602|603|607|608|611|613|618|623|628|633|634|636|640|645|646|647|654|656|657|660|664|665|668|671|672|674|676|677|678|679|683|684|688|692|695|704|707|708|709|710|716|779,Apalutamide,"Androgen Receptor Inhibitors| Antiandrogens| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Azoles| BCRP/ABCG2 Inducers| Cytochrome P-450 CYP2C19 Inducers| Cytochrome P-450 CYP2C19 Inducers (strong)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Inducers| Cytochrome P-450 CYP2C9 Inducers (weak)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inducers (strong)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strong)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Endocrine Therapy| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hormone Antagonists and Related Agents| Imidazoles| Imidazolidines| MATE 1 Inhibitors| MATE 2 Inhibitors| MATE inhibitors| OAT3/SLC22A8 Inhibitors| OATP1B1/SLCO1B1 Inducers| OCT2 Inhibitors| P-glycoprotein inducers| Prostatic Neoplasms, drug therapy"
287,DB01161,Q9Y5Y9|Q8TCU5|Q9GZZ6|P46098|Q01959,P06276,hsa:6336|hsa:116443|hsa:57053|hsa:3359|hsa:6531,9|10|11|14|15|18|19|37|178|182|283|284|285|286|294|299|332|333|340|342|344|345|346|351|352|355|356|362|365|366|370|371|374|376|377|380|384|390|391|393|405|416|420|430|434|437|440|441|443|446|449|452|464|470|490|493|501|502|503|516|520|524|535|540|545|546|548|549|550|552|553|556|564|566|570|573|574|578|579|582|584|591|592|594|595|597|598|599|600|603|604|607|608|614|615|618|619|623|633|634|637|640|641|643|655|656|659|660|664|665|666|668|669|671|672|677|678|679|680|683|684|688|689|691|692|695|698|703|704|707|708|709|710|716|750|759|779|813|822,Chloroprocaine,"Acids, Carbocyclic| Aminobenzoates| Anesthetics| Anesthetics, Local| Benzene Derivatives| Benzoates| Carboxylic Acids| Central Nervous System Agents| Central Nervous System Depressants| Cholinesterase substrates| Esters of Aminobenzoic Acid| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Local Anesthesia| Local Anesthetics (Ester)| Nervous System| para-Aminobenzoates| Peripheral Nervous System Agents| Sensory System Agents"
288,DB01559,P14867|P47869|P34903|P31644|Q8N1C3|P18507|Q99928|P18505|P47870|P28472|O14764|P78334|O00591|P24046|P28476|A8MPY1,P20813|P33260|P33261|P08684,hsa:2554|hsa:2555|hsa:2556|hsa:2558|hsa:2565|hsa:2566|hsa:2567|hsa:2560|hsa:2561|hsa:2562|hsa:2563|hsa:2564|hsa:2568|hsa:2569|hsa:2570|hsa:200959,9|10|11|12|14|15|18|33|37|143|149|178|182|213|218|219|283|284|285|286|293|294|332|333|340|342|344|345|351|352|353|355|356|362|365|370|371|374|376|383|384|390|391|412|416|418|420|421|430|431|434|439|441|442|443|446|449|451|453|464|470|471|480|489|490|495|500|501|503|507|508|513|516|520|524|531|532|536|538|540|545|549|550|552|555|556|564|569|570|576|578|582|584|585|586|591|592|595|598|599|600|603|607|608|611|613|618|628|633|634|640|645|646|656|657|658|660|664|665|668|677|678|679|683|688|696|697|708|709|710|759|822,Clotiazepam,"Anti-Anxiety Agents| Benzodiazepines and benzodiazepine derivatives| Central Nervous System Depressants| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C18 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Nervous System| Psycholeptics"
289,DB00446,P0ADY7|P24093|P08174,P08684|P20815|P24462|P33261|P00484|P26841|Q56148|P10632|P11712,hsa:1604,9|10|11|14|15|18|19|20|37|38|178|182|283|284|285|286|294|299|301|308|332|333|338|339|340|341|342|343|344|345|346|351|352|355|356|360|361|365|366|370|371|376|377|384|390|392|393|395|401|406|416|420|423|430|434|437|439|441|443|446|449|451|454|455|464|470|490|502|514|516|520|524|528|540|545|546|548|549|552|556|558|561|564|566|570|571|573|574|578|582|584|592|595|599|600|603|607|608|609|613|617|618|619|633|634|637|639|640|641|643|645|646|655|656|659|660|664|665|667|668|677|678|679|680|683|688|689|691|696|698|703|708|709|710|716|779,Chloramphenicol,"Alcohols| Amphenicols| Anti-Acne Preparations| Anti-Acne Preparations for Topical Use| Anti-Bacterial Agents| Anti-Infective Agents| Antibacterials for Systemic Use| Antibiotics for Topical Use| Antiinfectives for Systemic Use| Antiinfectives for Treatment of Acne| Benzene Derivatives| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (strong)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A7 Inhibitors| Cytochrome P-450 CYP3A7 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Dermatologicals| Enzyme Inhibitors| Genito Urinary System and Sex Hormones| Glycols| Gynecological Antiinfectives and Antiseptics| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Immunosuppressive Agents| Myelosuppressive Agents| Nitro Compounds| Nitrobenzenes| OAT1/SLC22A6 inhibitors| Ophthalmological and Otological Preparations| Ophthalmologicals| Otologicals| Propylene Glycols| Protein Synthesis Inhibitors| Sensory Organs"
290,DB01248,Q9H4B7|P10415|P11137|P27816|P10636|O75469,P08684|P20815|P24462|Q16678,hsa:81027|hsa:596|hsa:4133|hsa:4134|hsa:4137|hsa:8856,9|10|11|12|13|14|18|19|20|21|129|132|178|179|182|185|189|192|196|199|227|228|283|284|285|286|299|308|332|333|334|335|337|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|380|384|390|392|393|405|406|416|420|430|432|434|440|441|443|446|451|452|462|464|470|490|493|516|520|524|528|535|537|540|548|549|552|553|556|559|564|566|567|570|571|573|574|578|579|580|581|582|584|592|594|595|597|599|603|604|607|608|612|613|614|617|618|619|623|628|633|634|637|638|639|640|641|642|643|645|646|655|659|660|662|663|664|666|667|668|671|672|677|678|679|680|681|683|684|686|688|689|690|692|693|696|697|698|699|700|701|704|705|708|709|710|711|712|776|777|782|797|798|803|818|819|824,Docetaxel,"Agents Causing Muscle Toxicity| Antimitotic Agents| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| BCRP/ABCG2 Substrates| Cardiotoxic antineoplastic agents| Cyclodecanes| Cycloparaffins| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Diterpenes| Hepatotoxic Agents| Hydrocarbons| Hydrocarbons, Alicyclic| Hydrocarbons, Cyclic| Immunosuppressive Agents| Microtubule Inhibition| Microtubule Inhibitors| Mitosis Modulators| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| OATP1B3 substrates| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Taxane Derivatives| Taxoids| Terpenes| Tubulin Modulators"
291,DB00327,P35372|P41143|P41145,P08684|P11712|P10635|P23219|O60656,hsa:4988|hsa:4985|hsa:4986,9|10|11|12|14|18|19|143|146|178|179|180|181|182|185|189|192|199|283|284|285|286|308|332|333|334|335|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|391|405|406|416|420|430|432|434|441|443|446|462|470|476|490|498|516|520|524|535|537|540|541|542|544|548|552|556|564|565|567|570|573|574|578|579|582|584|589|590|592|594|595|599|603|604|605|606|607|608|613|614|617|618|619|620|626|630|631|632|634|637|640|641|651|655|656|660|662|663|664|666|667|668|677|678|679|680|682|683|684|688|689|690|691|692|693|695|696|697|698|699|701|702|703|704|705|707|708|709|710|711|712|714|735|755|756|761|776|777|779|797|798|800|818|819|821|824,Hydromorphone,"Alkaloids| Analgesics| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds with 4 or More Rings| Heterocyclic Compounds, Bridged-Ring| Heterocyclic Compounds, Fused-Ring| High-risk opioids| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Morphinans| Morphine Derivatives| Narcotics| Natural Opium Alkaloids| Nervous System| Opiate Agonists| Opiate Alkaloids| Opioid Agonist| Opioids| Peripheral Nervous System Agents| Phenanthrene opioids| Phenanthrenes| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Semi-synthetic Opioids| Sensory System Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| UGT1A3 substrates| UGT2B7 substrates"
292,DB00527,Q9Y5Y9|Q14524|P0DP23,P06276,"hsa:6336|hsa:6331|hsa:801,hsa:805,hsa:808",9|10|11|12|14|15|18|19|178|182|183|184|185|283|284|285|286|299|332|333|340|344|345|346|351|352|355|356|357|358|365|366|370|371|374|376|377|381|384|385|386|387|390|391|392|393|396|403|405|416|418|420|430|431|434|437|439|441|442|443|446|449|451|453|464|470|472|476|482|490|493|495|498|502|506|516|520|523|524|528|530|535|538|539|540|541|542|545|546|548|549|552|553|555|556|564|565|569|570|573|574|576|577|578|579|582|584|585|589|592|594|595|597|599|600|603|604|606|607|608|611|612|613|614|618|619|620|623|626|628|632|633|634|637|640|641|643|645|646|651|655|656|657|660|664|665|666|668|671|672|677|678|679|680|682|683|684|685|686|688|689|691|692|696|697|698|703|704|708|709|710|712|758|821,Cinchocaine,"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use| Amides| Analgesics and Anesthetics| Anesthetics| Anesthetics for Topical Use| Anesthetics, Local| Antipruritics and Local Anesthetics| Antipruritics, Incl. Antihistamines, Anesthetics, Etc.| Cardiovascular System| Cell-mediated Immunity| Central Nervous System Agents| Central Nervous System Depressants| Cholinesterase Inhibitors| Dermatologicals| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Increased Histamine Release| Local Anesthetics (Amide)| Nervous System| Ophthalmologicals| Otologicals| Peripheral Nervous System Agents| Quinolines| Sensory Organs| Sensory System Agents| Standardized Chemical Allergen| Vasoprotectives"
293,DB01009,P23219|P35354|P25024,P11712|P10632,hsa:5742|hsa:5743|hsa:3577,9|10|11|12|18|19|178|182|185|189|283|284|286|308|332|333|335|341|344|352|355|356|370|371|374|380|384|406|416|420|430|432|434|440|441|443|446|452|470|490|493|516|520|524|535|552|553|556|564|570|578|579|582|584|595|597|599|603|608|617|618|623|634|637|640|641|655|660|664|668|671|672|677|678|679|680|684|688|689|692|696|697|698|699|704|708|709|710|712|734|797,Ketoprofen,"Acids, Carbocyclic| Agents causing hyperkalemia| Agents that produce hypertension| Amino Acids| Amino Acids, Basic| Amino Acids, Diamino| Amino Acids, Peptides, and Proteins| Analgesics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)| Antiinflammatory and Antirheumatic Products| Antiinflammatory and Antirheumatic Products, Non-Steroids| Antiinflammatory Preparations, Non-Steroids for Topical Use| Antirheumatic Agents| Arylpropionic acid NSAIDS| Carboxylic Acids| Cyclooxygenase Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (weak)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Ketoprofen and isomer| Musculo-Skeletal System| Nephrotoxic agents| Non COX-2 selective NSAIDS| OAT1/SLC22A6 inhibitors| OAT3/SLC22A8 Inhibitors| Other Nonsteroidal Anti-inflammatory Agents| Peripheral Nervous System Agents| Phenylpropionates| Photosensitizing Agents| Propionates| Sensory System Agents| Topical Products for Joint and Muscular Pain| UGT1A1 Substrates"
294,DB00700,P08235,P08684|P20815|P24462|P19099,hsa:4306,9|10|11|12|18|19|20|115|118|143|144|146|150|178|179|182|185|186|192|283|284|286|332|333|334|335|337|339|341|344|346|352|366|374|380|405|416|420|430|432|434|440|441|443|446|452|490|524|535|553|556|579|582|599|614|637|640|641|660|671|678|679|680|681|684|686|688|689|690|692|693|696|697|698|699|700|701|704|705|708|709|710|711|712|776|777|797|798|818|819|839|840|860|861,Eplerenone,"Agents causing hyperkalemia| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Substrates| Diuretics| Fused-Ring Compounds| Hormone Antagonists| Hormones, Hormone Substitutes, and Hormone Antagonists| Hypotensive Agents| Lactones| Mineralocorticoid (Aldosterone) Receptor Antagonists| Mineralocorticoid Receptor Antagonists| Natriuretic Agents| Polycyclic Compounds| Potassium-Sparing Diuretics| Pregnanes| Pregnenes| Steroids"
295,DB01135,Q15822|P08172,P06276,hsa:1135|hsa:1129,9|10|11|12|13|14|15|18|19|20|21|22|37|38|178|180|181|182|183|184|185|189|192|196|199|203|206|283|284|285|286|332|333|338|340|341|344|345|346|351|352|355|356|365|366|370|371|374|380|381|382|384|390|391|405|416|420|430|434|440|441|443|446|452|464|470|476|490|498|520|524|535|540|541|542|544|548|549|552|556|564|565|567|570|573|574|575|578|579|582|584|589|592|594|595|599|603|604|606|607|608|613|614|618|619|626|628|630|633|634|637|638|639|640|641|651|653|655|656|660|662|664|666|668|677|678|679|680|681|682|683|686|687|688|689|690|691|696|697|698|699|700|701|702|703|708|709|710|712|714|735|740|755|756|761|777|798|803|818|819|824,Doxacuriumchloride,"Anticholinergic Agents| Central Nervous System Depressants| Cholinesterase substrates| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Muscarinic Antagonists| Muscle Relaxants| Muscle Relaxants, Peripherally Acting Agents| Musculo-Skeletal System| Neuromuscular Agents| Neuromuscular Blocking Agents| Neuromuscular-Blocking Agents (Nondepolarizing)| Nicotinic Antagonists| Peripheral Nervous System Agents"
296,DB00672,Q09428,P11712|P33261|P23219,hsa:6833,9|10|11|14|15|18|19|33|37|178|182|283|284|285|286|293|294|299|305|332|342|344|345|351|353|355|362|365|370|371|374|375|383|384|390|392|393|414|416|420|434|441|446|451|457|459|465|470|483|490|501|503|516|520|524|528|531|532|540|550|552|556|560|564|570|578|582|584|591|595|598|599|603|608|613|618|634|640|643|645|646|654|660|664|668|677|678|679|726|789,Chlorpropamide,"Alimentary Tract and Metabolism| Amides| Benzene Derivatives| Benzenesulfonamides| Blood Glucose Lowering Agents| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Drugs Used in Diabetes| Genito Urinary System and Sex Hormones| Gynecological Antiinfectives and Antiseptics| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hypoglycemia-Associated Agents| Insulin Secretagogues| OAT1/SLC22A6 inhibitors| Oral Hypoglycemics| Sulfonamides| Sulfones| Sulfonylureas| Sulfur Compounds"
297,DB05246,O43497,P33261,hsa:8913,9|10|11|14|18|19|143|145|146|178|182|283|284|285|286|332|333|334|344|351|352|355|356|365|370|371|374|384|390|391|416|420|430|434|439|441|443|446|451|470|490|516|520|524|535|540|552|556|564|570|578|579|582|584|592|595|597|599|603|607|608|613|618|634|640|645|646|650|656|660|664|668|677|678|679|683|684|685|687|688|692|696|697|704|708|709|710|711|712,Methsuximide,"Agents causing hyperkalemia| Anti-epileptic Agent| Antiarrhythmic agents| Anticonvulsants| Bradycardia-Causing Agents| Calcium Channel Blockers| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Decreased Central Nervous System Disorganized Electrical Activity| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Imides| Nervous System| Potential QTc-Prolonging Agents| Pyrrolidines| Pyrrolidinones| QTc Prolonging Agents| Succinimide Derivatives"
298,DB00822,P05091|P09172,P05181|P11712|P08684|P20815|P05177|P10635,hsa:217|hsa:1621,9|10|11|14|15|33|34|35|283|284|285|293|344|345|351|365|374|390|391|421|508|540|656,Disulfiram,"Acetyl Aldehyde Dehydrogenase Inhibitors| Acids, Acyclic| Agents that reduce seizure threshold| Alcohol Deterrents| Aldehyde Dehydrogenase Inhibitor| Antiparasitic Products, Insecticides and Repellents| BSEP/ABCB11 Substrates| Carbamates| Carboxylic Acids| Central Nervous System Agents| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Disulfides| Drugs Used in Addictive Disorders| Drugs Used in Alcohol Dependence| Ectoparasiticides, Incl. Scabicides| Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents| Enzyme Inhibitors| Nervous System| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Sulfides| Sulfur Compounds| Sulfur Containing Products| Thiocarbamates"
299,DB13953,P03372|O75469|Q92731|P43681|Q15596|Q99527|P00846|Q14457|P37059|P62508,P05177|P22309|P08684|P20815|P24462|P04798|Q16678|P33261|P10632|P11712,hsa:2099|hsa:8856|hsa:2100|hsa:1137|hsa:10499|hsa:2852|hsa:4508|hsa:8678|hsa:3294|hsa:2104,0|9|10|11|12|18|19|143|144|178|179|182|185|186|189|192|199|283|284|286|308|332|333|334|335|339|341|344|346|352|355|356|366|370|371|374|380|381|382|384|405|406|416|420|430|434|440|441|443|446|452|470|476|490|493|498|516|520|524|535|541|542|548|552|553|556|564|565|570|571|573|574|578|579|582|584|589|594|595|597|599|603|604|606|608|614|617|618|619|620|622|623|626|632|634|637|640|641|651|655|660|664|666|668|671|672|677|678|679|680|684|688|689|692|696|697|698|699|704|708|709|710|711|712|714|735|755|776|777|797|798|818|840|860|861,Estradiolbenzoate,"Adrenal Cortex Hormones| BCRP/ABCG2 Inhibitors| Contraceptive Agents, Hormonal| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP1A2 Inhibitors (weak)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Estradiol Congeners| Estranes| Estrenes| Estrogens| Fused-Ring Compounds| Gonadal Hormones| Gonadal Steroid Hormones| Hormonal Contraceptives for Systemic Use| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| OATP1B1/SLCO1B1 Inhibitors| OCT1 inhibitors| OCT2 Inhibitors| Organic Anion Transporting Polypeptide 2B1 Inhibitors| P-glycoprotein substrates| Polycyclic Compounds| Reproductive Control Agents| Steroids| UGT1A1 Substrates"
300,DB01114,P35367|P31645|P23975|Q01959,P24462|P08684|P10635|P20815,hsa:3269|hsa:6532|hsa:6530|hsa:6531,9|10|11|12|14|15|37|178|182|183|184|185|283|284|285|294|332|333|335|340|342|344|345|351|355|356|357|358|362|365|370|371|372|373|374|376|384|387|390|391|396|403|416|418|430|431|434|435|437|441|442|445|446|447|449|453|464|470|472|482|490|491|495|501|502|503|506|516|520|521|523|524|530|538|539|540|545|546|549|550|552|555|556|564|570|576|577|578|582|584|585|591|592|595|598|599|600|603|607|608|613|618|628|633|634|640|656|657|660|664|665|668|677|678|679|683|688|696|697|708|709|710|712|717|780,Chlorphenamine,"Anti-Allergic Agents| Antidepressive Agents| Antihistamines for Systemic Use| Antipruritics| Central Nervous System Depressants| Combined Inhibitors of Serotonin/Norepinephrine Reuptake| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dermatologicals| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Moderate Risk QTc-Prolonging Agents| Neurotransmitter Agents| OCT1 inhibitors| OCT2 Inhibitors| Propylamine Derivatives| Pyridines| QTc Prolonging Agents| Respiratory System| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin Agents| Serotonin Modulators| Substituted Alkylamines"
301,DB09123,P06401|P10275,P08684,hsa:5241|hsa:367,9|10|11|12|14|18|19|143|144|178|179|182|185|189|192|283|284|285|286|308|332|333|334|335|337|341|344|351|352|374|406|416|419|420|429|430|432|434|441|443|446|490|524|535|553|556|564|568|579|582|599|617|637|640|660|664|671|676|678|679|680|684|688|689|692|696|697|698|699|704|708|709|710|711|712|797|818|839|840|860|861,Dienogest,"Adrenal Cortex Hormones| Antineoplastic Agents| Antineoplastic Agents, Hormonal| Combination Contraceptives (with Estrogen and derivatives)| Contraceptive Agents, Female| Contraceptive Agents, Hormonal| Contraceptive Agents, Male| Contraceptives, Oral| Contraceptives, Oral, Hormonal| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Estranes| Estrenes| Fused-Ring Compounds| Genito Urinary System and Sex Hormones| Gonadal Hormones| Gonadal Steroid Hormones| Hormonal Contraceptives for Systemic Use| Hormone Antagonists| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Hyperglycemia-Associated Agents| Polycyclic Compounds| Pregnadien Derivatives| Progestin Contraceptives| Progestins| Progestogens and Estrogens, Sequential Preparations| Reproductive Control Agents| Sex Hormones and Modulators of the Genital System| Steroids| Testosterone Congeners"
302,DB01408,P07550,P06276,hsa:154,9|10|11|12|14|15|18|19|20|178|182|283|284|285|286|299|308|332|333|336|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|380|381|382|384|390|391|392|393|405|406|416|420|430|434|441|446|451|452|470|476|490|498|520|524|528|540|541|542|548|552|556|564|565|566|570|571|573|574|575|578|582|584|589|592|594|595|599|603|604|606|607|608|612|613|617|618|619|622|626|634|637|639|640|641|643|646|651|653|655|656|659|660|664|666|667|668|677|678|679|680|681|683|688|689|690|691|696|698|699|700|701|702|708|709|710|735|740|798|803,Bambuterol,Adrenergic Agonists| Adrenergic beta-2 Receptor Agonists| Adrenergic beta-Agonists| Adrenergics for Systemic Use| Agents producing tachycardia| Agents that produce hypertension| Agents to Treat Airway Disease| Alcohols| Amines| Amino Alcohols| Anti-Asthmatic Agents| Autonomic Agents| Bronchodilator Agents| Cholinesterase Inhibitors| Cholinesterase substrates| Delayed-Action Preparations| Drugs for Obstructive Airway Diseases| Ethanolamines| Long-acting beta-adrenoceptor agonists| Peripheral Nervous System Agents| Prodrugs| Respiratory System| Respiratory System Agents| Selective Beta 2-adrenergic Agonists
303,DB00677,P22303|P06276|P02787,P06276,hsa:43|hsa:590|hsa:7018,9|10|18|19|23|30|283|284|286|314|316|332|339|341|344|346|352|366|374|407|411|425|456,Isoflurophate,Cholinergic Agents| Cholinesterase Inhibitors| Enzyme Inhibitors| Neurotransmitter Agents| Ophthalmics| Organofluorophosphonates| Organophosphonates| Organophosphorus Compounds| Protease Inhibitors
304,DB01235,P21728|P21918|P14416|P35462|P21917,P20711|P10635,hsa:1812|hsa:1816|hsa:1813|hsa:1814|hsa:1815,9|10|11|14|18|19|20|178|182|283|284|285|286|299|308|332|333|338|340|341|344|345|351|352|355|356|365|370|371|380|381|382|384|393|406|416|420|430|434|440|441|443|446|452|470|490|498|516|520|524|528|535|536|541|542|544|548|552|556|564|566|567|570|573|574|578|579|582|584|590|592|595|599|603|606|607|608|617|618|619|631|634|637|640|641|643|651|655|660|663|664|667|668|677|678|679|680|683|684|688|689|691|692|696|698|699|703|704|708|709|710|714|735|761|777|798|824,Levodopa,"Amines| Amino Acids| Amino Acids, Aromatic| Amino Acids, Cyclic| Amino Acids, Peptides, and Proteins| Anti-Dyskinesia Agents| Anti-Parkinson Agents (Dopamine Agonist)| Anti-Parkinson Drugs| Benzene Derivatives| Biogenic Amines| Biogenic Monoamines| Catecholamines| Catechols| Central Nervous System Agents| Central Nervous System Depressants| Dihydroxyphenylalanine| Dopa and Dopa Derivatives| Dopamine Agents| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hypotensive Agents| Levodopa, antagonists & inhibitors| Nervous System| Neurotransmitter Agents| Phenols| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
305,DB00589,P14416|P35462|P21917|P21728|P21918|P08908|P28221|P41595|P28223|P28335|P28222|P08913|P18089|P18825|P34969,P10635|P08684,hsa:1813|hsa:1814|hsa:1815|hsa:1812|hsa:1816|hsa:3350|hsa:3352|hsa:3357|hsa:3356|hsa:3358|hsa:3351|hsa:150|hsa:151|hsa:152|hsa:3363,9|10|11|12|14|15|16|18|143|148|149|178|182|183|184|185|189|192|283|284|285|286|299|332|333|338|340|344|345|351|355|356|357|358|365|370|371|372|373|374|375|376|377|384|385|386|387|390|391|392|393|396|399|400|403|416|418|420|430|431|434|435|437|441|442|445|446|447|449|451|453|464|470|472|482|490|491|495|502|506|516|520|521|523|524|527|528|530|538|539|540|545|546|549|552|555|556|560|564|569|570|576|577|578|582|584|585|592|595|599|600|603|607|608|611|613|618|628|633|634|636|640|643|645|646|654|656|657|660|664|665|668|677|678|679|683|688|696|697|708|709|710|712|737|755|758|779|797|800|818|821,Lisuride,"Agents that produce hypertension| Alkaloids| Analgesics| Anti-Dyskinesia Agents| Anti-Parkinson Drugs| Antidepressive Agents| Antimigraine Preparations| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Dopamine Agents| Dopamine Agonists| Dopamine Antagonists| Ergolines| Ergot Alkaloids and Derivatives| Ergot-derivative Dopamine Receptor Agonists| Genito Urinary System and Sex Hormones| Heterocyclic Compounds| Heterocyclic Compounds with 4 or More Rings| Heterocyclic Compounds, Fused-Ring| Nervous System| Neurotransmitter Agents| Prolactine Inhibitors| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT1 Receptor Agonists| Serotonin 5-HT2 Receptor Antagonists| Serotonin Agents| Serotonin Receptor Agonists| Serotonin Receptor Antagonists"
306,DB09231,BE0008715|Q00975|BE0008716,P08684|P20815,hsa:774,9|10|11|12|14|15|18|19|20|178|180|181|182|183|184|185|189|192|199|283|284|285|286|299|301|332|333|335|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|376|377|380|384|390|391|392|393|395|401|405|416|420|423|430|434|437|440|441|443|446|449|452|454|455|464|470|490|502|514|516|520|524|535|540|545|546|549|552|553|556|558|564|566|570|573|578|579|582|584|592|594|595|599|600|603|607|608|613|614|615|618|619|628|633|634|637|640|643|656|659|660|664|665|666|668|671|673|677|678|679|680|682|683|684|688|689|690|692|693|694|696|697|698|700|704|708|709|710|712|737|800,Benidipine,"Agents causing hyperkalemia| Antiarrhythmic agents| Bradycardia-Causing Agents| Calcium Channel Blockers| Calcium-Regulating Hormones and Agents| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (moderate)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dihydropyridine Derivatives| Dihydropyridines| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Membrane Transport Modulators| Moderate Risk QTc-Prolonging Agents| Pyridines| QTc Prolonging Agents| Selective Calcium Channel Blockers With Mainly Vascular Effects| Vasodilating Agents"
307,DB01011,P15538|P00183,P19099|P11509|P08684|P15538|P05181,hsa:1584,9|10|11|14|15|18|178|183|184|185|190|191|283|284|285|286|332|333|334|341|344|345|351|352|355|356|358|365|370|371|372|373|374|376|384|387|390|396|403|416|418|420|430|432|434|435|441|442|443|445|446|447|449|453|464|470|472|482|490|491|493|495|502|506|516|520|521|523|524|530|535|538|539|540|545|546|549|552|553|555|556|564|570|576|577|578|579|580|582|584|585|592|595|597|599|600|603|607|608|613|618|623|624|628|633|634|640|656|657|660|664|665|668|671|672|673|677|678|679|683|684|685|688|692|695|696|697|708|709|710|711|712,Metyrapone,"Cytochrome P-450 CYP2A6 Inhibitors| Cytochrome P-450 CYP2A6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Diagnostic Agents| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Noxae| Pyridines| Steroid Synthesis Inhibitors| Tests for Pituitary Function| Toxic Actions"
308,DB09262,P11229|P08172|P20309,P08684|P22310,hsa:1128|hsa:1129|hsa:1131,9|10|11|12|14|15|18|143|148|149|178|182|185|189|283|284|285|286|299|332|333|334|344|345|351|352|355|356|358|359|365|370|371|372|373|374|375|376|379|384|387|389|390|391|393|396|397|403|416|418|420|430|434|435|438|439|441|442|443|445|446|447|449|450|451|453|470|472|482|484|485|487|490|491|495|499|502|504|506|516|519|520|521|524|535|539|540|546|547|552|556|560|564|569|570|572|578|579|582|584|592|595|596|597|599|603|607|608|611|613|618|634|636|640|654|656|660|664|668|674|677|678|679|683|684|685|688|692|696|697|704|708|709|710|711|712,Imidafenacin,"Agents producing tachycardia| Anticholinergic Agents| Azoles| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs for Urinary Frequency and Incontinence| Drugs that are Mainly Renally Excreted| Genito Urinary System and Sex Hormones| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Muscarinic Antagonists| UGT1A4 substrates| Urologicals"
309,DB00737,P35367|Q14994,P05177,hsa:3269|hsa:9970,9|10|11|12|14|15|37|178|180|181|182|185|189|192|196|199|283|284|285|294|332|333|338|340|342|344|345|351|355|356|362|365|370|371|374|384|390|391|416|430|434|441|446|464|470|490|501|503|516|520|524|540|549|550|552|556|564|569|570|578|582|584|591|592|595|598|599|603|607|608|611|613|618|628|633|634|640|656|660|664|668|677|678|679|683|688|696|697|708|709|710|717|734|780|797,Meclizine,"Anti-Allergic Agents| Anticholinergic Agents| Antiemetics| Antihistamines for Systemic Use| Antivertigo Preparations| Autonomic Agents| Benzene Derivatives| Benzhydryl Compounds| Central Nervous System Agents| Central Nervous System Depressants| Cholinergic Agents| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Substrates| Emesis Suppression| Gastrointestinal Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Neurotransmitter Agents| Peripheral Nervous System Agents| Piperazine Derivatives| Piperazines| Respiratory System"
310,DB00443,P04150,P08684|P11511,hsa:2908,9|10|11|12|18|19|20|23|143|144|178|179|182|185|186|192|283|284|286|287|308|332|333|334|335|337|339|341|344|346|352|366|374|406|416|420|430|432|434|441|443|446|462|490|516|524|535|537|553|556|571|579|582|599|617|637|639|640|660|671|672|678|679|680|681|684|688|689|692|693|696|697|698|699|704|705|708|709|710|711|712|776|777|797|798|818|819|839|840|860|861,Betamethasone,"Adrenal Cortex Hormones| Adrenals| Agents Causing Muscle Toxicity| Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use| Alimentary Tract and Metabolism| Anti-Inflammatory Agents| Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents| Cardiovascular System| Corticosteroid Hormone Receptor Agonists| Corticosteroids| Corticosteroids Acting Locally| Corticosteroids for Systemic Use| Corticosteroids for Systemic Use, Plain| Corticosteroids, Dermatological Preparations| Corticosteroids, Potent (Group III)| Cytochrome P-450 CYP2A6 Inducers| Cytochrome P-450 CYP2A6 Inducers (strength unknown)| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (strength unknown)| Cytochrome P-450 CYP2C19 Inducers| Cytochrome P-450 CYP2C19 Inducers (strength unknown)| Cytochrome P-450 CYP2C8 Inducers| Cytochrome P-450 CYP2C8 Inducers (strength unknown)| Cytochrome P-450 CYP2C9 Inducers| Cytochrome P-450 CYP2C9 Inducers (strength unknown)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inducers| Cytochrome P-450 CYP3A5 Inducers (weak)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Dermatologicals| Drugs for Obstructive Airway Diseases| Fused-Ring Compounds| Glucocorticoids| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Hyperglycemia-Associated Agents| Immunosuppressive Agents| Intestinal Antiinflammatory Agents| Medications that reduce magnesium levels| Nasal Preparations| Ophthalmological and Otological Preparations| Ophthalmologicals| Otologicals| P-glycoprotein substrates| Polycyclic Compounds| Pregnadienes| Pregnadienetriols| Pregnanes| Respiratory System| Respiratory System Agents| Steroids| Steroids, Fluorinated| Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins| Thyroxine-binding globulin inhibitors| Vasoprotectives"
311,DB00455,P35367|Q12809,P10632|P08684|P33261|P10635|P11712,hsa:3269|hsa:3757,9|10|11|12|14|15|18|19|37|178|180|181|182|183|184|185|192|213|217|283|284|285|286|294|332|333|340|342|344|345|346|351|352|355|356|357|358|362|365|366|370|371|372|373|374|376|380|384|387|390|391|396|403|405|416|418|420|430|431|434|435|437|441|442|445|446|447|449|451|452|453|464|470|472|482|490|491|495|501|502|503|506|516|520|521|523|524|530|538|539|540|545|546|549|550|552|555|556|564|570|576|577|578|582|584|585|591|592|595|598|599|600|603|607|608|612|613|618|628|633|634|640|645|646|656|657|660|664|665|668|677|678|679|683|688|696|697|708|709|710|712|717|738|755|780|801|818,Loratadine,"Anti-Allergic Agents| Antihistamines for Systemic Use| Antipruritics| Benzocycloheptenes| BSEP/ABCB11 Substrates| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (weak)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (moderate)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dermatologicals| Dibenzocycloheptenes| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Histamine Antagonists| Histamine H1 Antagonists| Histamine H1 Antagonists, Non-Sedating| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Loratadine and derivatives| Neurotransmitter Agents| P-glycoprotein inhibitors| P-glycoprotein substrates| Piperidines| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Respiratory System"
312,DB00866,P08588|P07550|P08908|P13945,P10635,hsa:153|hsa:154|hsa:3350|hsa:155,9|10|11|14|18|19|178|182|283|284|285|286|299|308|332|333|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|392|393|405|406|416|430|434|441|446|470|476|490|498|516|520|524|528|540|541|542|548|552|556|564|565|566|567|570|571|573|574|578|582|584|589|594|595|599|603|604|606|608|613|614|618|619|620|626|632|634|637|638|640|641|643|651|655|656|659|660|662|663|664|666|668|677|678|679|680|688|689|696|698|708|709|710|756|819,Alprenolol,"Adrenergic Agents| Adrenergic Antagonists| Adrenergic beta-Antagonists| Agents causing hyperkalemia| Alcohols| Amines| Amino Alcohols| Antiarrhythmic agents| Antidepressive Agents| Antihypertensive Agents| Autonomic Agents| Beta Blocking Agents, Non-Selective| Bradycardia-Causing Agents| Cardiovascular Agents| Cardiovascular System| Central Nervous System Depressants| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Substrates| Neurotransmitter Agents| Peripheral Nervous System Agents| Phenoxypropanolamines| Propanolamines| Propanols| Serotonin 5-HT1 Receptor Antagonists| Serotonin 5-HT1A Receptor Antagonists| Serotonin Agents| Serotonin Receptor Antagonists| Sympatholytics"
313,DB00568,P35367|Q13936|Q01668|O60840|Q13698|O43497|O95180|Q9P0X4|P14416|BE0004889|BE0004890,P10635|P11712|P05177|P20813|P11509|P04798,hsa:3269|hsa:775|hsa:776|hsa:778|hsa:779|hsa:8913|hsa:8912|hsa:8911|hsa:1813,9|10|11|12|14|15|178|180|181|182|185|189|192|196|199|283|284|285|332|333|338|340|344|345|351|355|356|365|370|371|384|390|391|416|430|434|441|446|464|470|490|516|520|524|540|549|552|556|564|569|570|578|582|584|592|595|599|603|607|608|611|613|618|628|633|634|640|656|660|664|668|677|678|679|683|688|696|697|708|709|710,Cinnarizine,"Agents causing hyperkalemia| Antiarrhythmic agents| Antivertigo Preparations| Bradycardia-Causing Agents| Calcium Channel Blockers| Calcium-Regulating Hormones and Agents| Cardiovascular Agents| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Membrane Transport Modulators| Moderate Risk QTc-Prolonging Agents| Nervous System| Neurotransmitter Agents| Piperazines| QTc Prolonging Agents| Vasodilating Agents"
314,DB00869,P00918|P22748|P00915|P07451,P11712|P08684,hsa:760|hsa:762|hsa:759|hsa:761,9|10|11|14|15|18|19|20|33|34|143|149|178|184|283|284|285|293|299|305|332|333|338|340|344|345|349|351|353|355|356|365|368|370|371|374|383|384|390|392|393|412|414|416|421|430|434|441|446|457|459|464|465|470|471|479|480|483|490|500|507|513|520|524|528|531|532|540|549|552|556|564|570|582|586|592|595|599|607|608|613|628|633|634|640|643|656|658|660|668|678|679|688|708|709|710,Dorzolamide,"Amides| Antiglaucoma Preparations and Miotics| Antihypertensive Agents| Carbonic Anhydrase Inhibitors| Cardiovascular Agents| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 Substrates| Diuretics| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Genito Urinary System and Sex Hormones| Gynecological Antiinfectives and Antiseptics| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Intraocular Pressure, drug effects| Ophthalmologicals| Sensory Organs| Sulfonamides| Sulfones| Sulfur Compounds"
315,DB06738,P35372|P41145|P41143|BE0004956,P23219|P11712|P08684|O60656|P20813|P33261|P10632,hsa:4988|hsa:4986|hsa:4985,9|10|11|14|18|19|178|180|181|182|185|283|284|285|286|308|332|333|334|341|344|345|351|352|355|356|365|370|371|374|381|382|384|390|391|406|416|420|430|432|434|441|443|446|470|490|498|516|520|524|535|540|541|542|548|552|556|564|570|573|574|578|579|582|584|590|592|595|597|599|603|606|608|613|617|618|619|634|637|640|641|651|655|656|660|664|667|668|677|678|679|680|683|684|685|688|689|692|693|696|697|698|699|704|705|708|709|710|711|712|735|798,Ketobemidone,"Acids, Heterocyclic| Analgesics| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Excitatory Amino Acid Agents| Excitatory Amino Acid Antagonists| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Isonipecotic Acids| Narcotics| Nervous System| Neurotransmitter Agents| Opioids| Peripheral Nervous System Agents| Phenylpiperidine opioids| Piperidines| Sensory System Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| UGT1A9 Substrates"
316,DB00471,Q9Y271|P09917,P10632|P08684|P11712|P23219|P11509,hsa:10800|hsa:240,9|10|11|12|13|14|18|19|33|37|115|116|178|182|183|184|185|189|192|196|199|283|284|285|286|293|294|308|332|333|334|337|340|341|342|344|349|351|352|353|355|356|357|358|362|368|370|371|374|376|377|380|384|385|386|387|390|396|403|406|412|416|418|420|430|431|434|437|440|441|442|443|446|449|452|453|464|470|472|482|490|495|501|502|503|506|507|516|520|523|524|530|535|538|539|545|546|548|549|550|552|555|556|564|570|573|574|576|577|578|579|582|584|585|586|591|592|595|598|599|600|603|607|608|613|617|618|619|628|633|634|637|640|641|655|656|657|658|660|664|665|667|668|677|678|679|680|683|684|688|689|696|697|698|708|709|710|711|712|717|734|750|755|758|780|797|813|818|821,Montelukast,"Acids, Acyclic| Agents Causing Muscle Toxicity| Agents to Treat Airway Disease| Anions| Anti-Asthmatic Agents| Carboxylic Acids| Cycloparaffins| Cytochrome P-450 CYP1A2 Inducers| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs for Obstructive Airway Diseases| Electrolytes| Fatty Acids| Fatty Acids, Volatile| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hormone Antagonists| Hormones, Hormone Substitutes, and Hormone Antagonists| Hydrocarbons| Hydrocarbons, Alicyclic| Hydrocarbons, Cyclic| Hydrogen Sulfide| Ions| Leukotriene Antagonists| Leukotriene Modifiers| Lipids| OATP2B1/SLCO2B1 substrates| Respiratory System| Respiratory System Agents| Sulfur Compounds"
317,DB01156,Q01959|P23975|P32297,P20813|P10635|P05177|P11509|P10632|P11712|P05181|P08684,hsa:6531|hsa:6530|hsa:1136,9|10|11|14|18|37|178|182|283|284|285|286|294|299|332|333|336|338|340|341|342|344|345|351|352|355|356|362|365|370|371|374|384|390|392|393|416|420|430|432|434|441|443|446|470|490|493|501|503|516|520|524|528|535|536|540|550|552|553|556|564|570|578|579|582|584|591|592|595|597|598|599|602|603|607|608|613|618|623|634|640|643|656|660|664|668|671|672|677|678|679|683|684|688|692|696|704|708|709|710|738|801,Bupropion,"Agents that reduce seizure threshold| Aminoketone Antidepressants| Antidepressive Agents| Antidepressive Agents Indicated for Depression| Antiobesity Preparations, Excl. Diet Products| Central Nervous System Agents| Central Nervous System Depressants| Centrally Acting Antiobesity Products| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strong)| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dopamine Agents| Dopamine And Norepinephrine Reuptake Inhibitors| Dopamine Uptake Inhibitors| Drugs causing inadvertant photosensitivity| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Increased Dopamine Activity| Increased Norepinephrine Activity| Ketones| Metabolic Side Effects of Drugs and Substances| Miscellaneous Antidepressants| Nervous System| Neurotransmitter Uptake Inhibitors| Norepinephrine Uptake Inhibitors| OCT2 Inhibitors| Photosensitizing Agents| Psychoanaleptics| Psychotropic Drugs| Smoking Cessation Agents"
318,DB09167,P08908|P28223|P35367|P11229|P08172|P20309|P08173|P08912|BE0004864|BE0004863|P23975|P31645,P10635|P05177|P33261|P11712,hsa:3350|hsa:3356|hsa:3269|hsa:1128|hsa:1129|hsa:1131|hsa:1132|hsa:1133|hsa:6530|hsa:6532,9|10|11|12|14|33|178|182|185|189|213|216|283|284|285|293|332|333|344|345|349|351|353|355|356|365|368|370|371|374|383|384|390|391|412|416|430|434|441|446|470|490|500|507|516|520|524|531|532|540|552|556|564|570|578|582|584|586|595|599|603|608|613|618|634|640|658|660|664|668|677|678|679|688|696|697|708|709|710|712|755|757|818|820,Dosulepin,"Adrenergic Agents| Adrenergic Uptake Inhibitors| Agents producing tachycardia| Agents that produce hypertension| Agents that reduce seizure threshold| Anticholinergic Agents| Antidepressive Agents| Antidepressive Agents, Tricyclic| Central Nervous System Agents| Central Nervous System Depressants| Combined Inhibitors of Serotonin/Norepinephrine Reuptake| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (moderate)| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (moderate)| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dibenzothiepins| Heterocyclic Compounds| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Histamine Antagonists| Histamine H1 Antagonists| Membrane Transport Modulators| Muscarinic Antagonists| Narrow Therapeutic Index Drugs| Nervous System| Neurotoxic agents| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| Non-Selective Monoamine Reuptake Inhibitors| Potential QTc-Prolonging Agents| Psychoanaleptics| Psychotropic Drugs| QTc Prolonging Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT1 Receptor Antagonists| Serotonin 5-HT1A Receptor Antagonists| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin Agents| Serotonin Modulators| Serotonin Receptor Antagonists| Sulfur Compounds| Tertiary amine tricyclic antidepressants| Thiepins"
319,DB00973,P35610|Q9UHC9|P15144,P22309|P35503|P54855|P16662|P08684,hsa:6646|hsa:29881|hsa:290,9|10|11|12|14|18|19|23|24|129|131|132|178|182|185|189|192|196|283|284|285|286|287|308|332|333|335|338|339|340|341|344|345|346|351|352|355|356|364|365|366|370|371|376|377|381|382|384|390|391|406|416|420|430|434|437|439|441|443|446|449|451|464|470|490|495|498|502|516|520|524|535|540|541|542|545|546|548|549|552|556|564|570|571|573|574|578|579|580|582|584|585|590|592|595|599|600|603|606|607|608|613|617|618|619|628|633|634|637|640|641|645|646|651|655|656|657|660|664|665|667|668|677|678|679|680|683|684|688|689|691|692|693|696|697|698|702|703|704|705|708|709|710|714|777,Ezetimibe,"Anticholesteremic Agents| Azetines| BCRP/ABCG2 Substrates| BSEP/ABCB11 Substrates| Cardiovascular System| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Decreased Cholesterol Absorption| Dietary Cholesterol Absorption Inhibitor| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypolipidemic Agents| Hypolipidemic Agents Indicated for Hyperlipidemia| Lipid Modifying Agents| Lipid Modifying Agents, Plain| Lipid Regulating Agents| Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia| OATP1B1/SLCO1B1 Substrates| P-glycoprotein substrates| UGT1A1 Substrates| UGT1A3 substrates| UGT2B7 substrates"
320,DB01431,P06401|P03372,P08684,hsa:5241|hsa:2099,0|9|10|11|12|18|143|144|178|179|182|185|186|192|283|284|286|308|332|333|334|335|337|341|344|352|374|406|416|430|434|441|446|490|516|524|556|582|599|617|637|640|641|660|678|679|680|688|689|696|697|698|699|708|709|710|711|712|776|797|818|839|840|860|861,Allylestrenol,"Adrenal Cortex Hormones| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates (strength unknown)| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Estranes| Estren Derivatives| Estrenes| Fused-Ring Compounds| Genito Urinary System and Sex Hormones| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Polycyclic Compounds| Progestins| Sex Hormones and Modulators of the Genital System| Steroids"
321,DB00655,P03372|Q92731|P10275|P11511|P04278,P04798|P05177|P08684|Q16678|P20813|P11712|P05181|P20815|Q02928,hsa:2099|hsa:2100|hsa:367|hsa:1588|hsa:6462,9|10|11|12|18|19|143|144|178|179|182|185|189|192|283|284|286|308|332|333|334|335|341|344|352|355|356|370|371|374|381|382|384|406|416|420|430|432|434|441|443|446|470|490|498|516|520|524|535|541|542|548|552|556|564|570|573|574|578|579|582|584|590|595|599|603|606|608|617|618|619|634|637|640|641|651|655|660|664|667|668|677|678|679|680|684|688|689|692|696|697|698|699|704|708|709|710|711|712|714|735|755|776|777|797|798|818|860,Estrone,"17-Ketosteroids| Adrenal Cortex Hormones| BCRP/ABCG2 Inhibitors| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Substrates| Estradiol Congeners| Estranes| Estrenes| Estrogens| Fused-Ring Compounds| Genito Urinary System and Sex Hormones| Gonadal Hormones| Gonadal Steroid Hormones| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Ketosteroids| Natural and Semisynthetic Estrogens, Plain| OAT3/SLC22A8 Substrates| OATP1B1/SLCO1B1 Inhibitors| Organic Anion Transporting Polypeptide 2B1 Inhibitors| P-glycoprotein inducers| P-glycoprotein substrates| Polycyclic Compounds| Sex Hormones and Modulators of the Genital System| Steroids| Thyroxine-binding globulin inducers"
322,DB12483,P42336|O00329,P08684|P20815|P24462|Q9HB55,hsa:5290|hsa:5293,9|10|11|12|14|15|16|17|18|19|20|143|148|149|178|180|181|182|183|184|185|190|191|192|199|283|284|285|286|299|332|333|340|341|344|345|346|351|352|355|356|358|365|366|370|371|372|373|374|375|376|377|379|381|382|384|387|389|390|391|392|393|396|403|405|416|418|420|430|434|435|437|438|439|441|442|443|445|446|447|449|450|451|453|464|470|472|476|482|484|487|490|491|493|495|498|504|506|516|519|520|521|523|524|530|535|538|540|541|542|543|544|545|548|549|552|553|555|556|560|564|565|566|567|569|570|572|573|574|576|578|580|582|584|585|589|592|593|594|595|596|599|600|601|603|604|606|607|608|611|613|614|615|618|619|620|621|624|626|628|630|632|633|634|636|637|638|640|641|647|651|652|654|655|656|657|659|660|662|664|665|666|668|672|673|674|677|678|679|680|682|683|688|689|691|699|702|703|708|709|710|714|735|742|758|761|763|777|798|805|821|824|826,Copanlisib,"Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| BCRP/ABCG2 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Kinase Inhibitor| MATE 2 Inhibitors| MATE inhibitors| Narrow Therapeutic Index Drugs| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Phosphatidylinositol-3-kinase (Pi3K) inhibitors| Protein Kinase Inhibitors"
323,DB00757,P46098,P08684|P10635|P11712,hsa:3359,0|9|10|11|12|14|15|18|19|143|148|149|178|180|181|182|185|187|188|192|194|195|199|283|284|285|286|299|332|333|335|338|339|340|341|344|345|346|351|352|355|356|357|358|365|366|370|371|372|373|376|377|380|384|385|386|387|390|391|392|393|396|399|400|403|405|416|418|420|430|431|432|434|435|437|440|441|442|443|445|446|447|449|452|453|464|470|472|482|490|491|493|495|502|506|516|520|521|523|524|527|528|530|535|536|538|539|540|545|546|548|549|552|553|555|556|564|570|573|574|576|577|578|579|580|582|584|585|592|594|595|597|599|600|602|603|604|607|608|613|614|618|619|623|624|628|633|634|637|638|640|641|643|655|656|657|660|664|665|666|668|671|672|673|677|678|679|680|682|683|684|685|688|689|692|696|697|698|699|704|708|709|710|712|758|821,Dolasetron,"Alimentary Tract and Metabolism| Antidepressive Agents| Antiemetic Serotonin 5-HT3 Receptor Antagonists| Antiemetics| Antiemetics and Antinauseants| Autonomic Agents| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Gastrointestinal Agents| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Moderate Risk QTc-Prolonging Agents| Neurotransmitter Agents| Peripheral Nervous System Agents| QTc Prolonging Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 3 Receptor Antagonists| Serotonin 5-HT3 Receptor Antagonists| Serotonin Agents| Serotonin Receptor Antagonists"
324,DB05219,P27815|Q07343|Q08493|Q08499,P05177|P20813|P10632|P11712,hsa:5141|hsa:5142|hsa:5143|hsa:5144,6|9|10|11|14|18|19|143|149|178|182|185|189|274|276|283|284|285|286|308|332|333|341|344|346|351|352|355|356|366|370|371|381|382|384|405|416|419|429|430|434|441|446|466|470|476|490|498|516|520|524|541|542|548|552|556|564|565|568|570|573|574|578|582|584|589|594|595|599|603|604|606|608|614|618|619|620|626|632|634|637|640|641|651|655|660|664|666|668|676|677|678|679|680|681|688|689|698|699|708|709|710|714|735|777|798,Crisaborole,"Agents for Dermatitis, Excluding Corticosteroids| Anti-Inflammatory Agents| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (weak)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (moderate)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (moderate)| Cytochrome P-450 Enzyme Inhibitors| Dermatologicals| Heterocyclic Compounds| Heterocyclic Compounds, Bridged-Ring| Phosphodiesterase 4 Inhibitors| Phosphodiesterase Inhibitors"
325,DB00496,P20309|P11229|P08172|P08173|P08912,P08684|P10635,hsa:1131|hsa:1128|hsa:1129|hsa:1132|hsa:1133,9|10|11|12|14|15|18|19|143|145|146|149|150|178|182|185|189|192|196|283|284|285|286|299|332|333|334|335|341|344|345|346|351|352|355|356|365|366|370|371|381|382|384|390|391|393|405|416|420|430|434|439|441|443|446|451|470|476|490|498|516|520|524|535|540|541|542|548|552|556|564|565|570|573|574|578|579|582|584|589|592|594|595|597|599|603|604|606|607|608|613|614|618|619|620|626|632|634|637|640|641|651|655|656|660|664|666|668|677|678|679|680|683|684|685|688|689|692|695|696|697|698|699|704|708|709|710|711|712|714|734|756|777|797|819,Darifenacin,"Agents producing tachycardia| Anticholinergic Agents| Cholinergic Agents| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (moderate)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs for Urinary Frequency and Incontinence| Genito Urinary System and Sex Hormones| Genitourinary Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Muscarinic Antagonists| Neurotransmitter Agents| Urological Agents| Urologicals"
326,DB01050,P35354|P23219|P10415|P07204|P00750|P12104|P37231|P13569|P46059|Q07869,P11712|P10632|P33261|P22309|P35503|O60656|P06133|P16662|P23219|P35354,hsa:5743|hsa:5742|hsa:596|hsa:7056|hsa:5327|hsa:2169|hsa:5468|hsa:1080|hsa:6564|hsa:5465,9|10|11|18|19|178|182|283|284|286|308|332|333|335|344|352|355|356|370|371|374|380|384|406|416|420|430|434|440|441|443|446|452|470|490|516|520|524|535|552|556|564|570|578|579|582|584|595|597|599|603|608|617|618|634|637|640|641|655|660|664|668|677|678|679|680|684|688|689|692|696|697|698|704|708|709|710|712|713|776,Ibuprofen,"Acids, Carbocyclic| Agents causing angioedema| Agents causing hyperkalemia| Agents that produce hypertension| Analgesics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Antiinflammatory and Antirheumatic Products| Antiinflammatory and Antirheumatic Products, Non-Steroids| Antiinflammatory Preparations, Non-Steroids for Topical Use| Antiinflammatory Products for Vaginal Administration| Antirheumatic Agents| Arylpropionic acid NSAIDS| Carboxylic Acids| Central Nervous System Agents| COX-1 Inhibitors| COX-2 Inhibitors| Cyclooxygenase Inhibitors| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Experimental Unapproved Treatments for COVID-19| Ibuprofen and isomer| Nephrotoxic agents| Nervous System| Non COX-2 selective NSAIDS| OAT1/SLC22A6 inhibitors| OAT3/SLC22A8 Inhibitors| OATP2B1/SLCO2B1 substrates| Other Nonsteroidal Anti-inflammatory Agents| P-glycoprotein inhibitors| P-glycoprotein substrates| Peripheral Nervous System Agents| Pharmaceutical Preparations| Phenylpropionates| Propionates| Sensory System Agents| Throat Preparations| Topical Products for Joint and Muscular Pain| UDP Glucuronosyltransferases Inhibitors| UGT1A1 Substrates| UGT1A3 substrates| UGT1A9 Substrates| UGT2B17 Inhibitors| UGT2B7 substrates"
327,DB01012,P41180,P08684|P10635|P05177,hsa:846,9|10|11|12|14|23|24|178|182|185|189|192|196|283|284|285|287|299|332|333|338|340|344|345|351|355|356|363|365|370|371|374|384|385|390|392|393|416|430|434|441|446|464|470|490|516|520|524|528|540|549|552|556|564|570|578|582|584|592|595|599|603|607|608|613|618|628|633|634|640|643|656|660|664|668|677|678|679|683|688|696|697|708|709|710|712|734|755|797|818,Cinacalcet,"Anti-Parathyroid Agents| Calcimimetic Agents| Calcium Homeostasis| Calcium-Regulating Hormones and Agents| Calcium-sensing Receptor Agonist| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strong)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Hormone Antagonists| Hormones, Hormone Substitutes, and Hormone Antagonists| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Increased Calcium-sensing Receptor Sensitivity| Naphthalenes| Other Miscellaneous Therapeutic Agents| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins"
328,DB00255,P03372|P62508|Q92731|P11474|O95718|Q15596|O75469|P10275|P04278,P21964|P11511|P11509|P08684|P10632|P11712|P05181,hsa:2099|hsa:2104|hsa:2100|hsa:2101|hsa:2103|hsa:10499|hsa:8856|hsa:367|hsa:6462,9|10|11|12|18|19|178|182|185|189|283|284|286|308|332|333|341|344|352|355|356|370|371|374|381|382|384|406|416|430|434|441|446|470|490|498|516|520|524|541|542|548|552|556|564|570|573|574|578|582|584|590|595|599|603|606|608|617|618|619|634|637|640|641|651|655|660|664|667|668|677|678|679|680|688|689|696|698|708|709|710|714|777,Diethylstilbestrol,"Adrenal Cortex Hormones| Antineoplastic Agents, Hormonal| Antineoplastic and Immunomodulating Agents| BCRP/ABCG2 Inhibitors| Benzene Derivatives| Benzylidene Compounds| BSEP/ABCB11 Substrates| Carcinogens| COMT Substrates| Contraceptive Agents, Female| Contraceptive Agents, Male| Contraceptives, Postcoital| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strong)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Endocrine Therapy| Estrogen Contraceptives| Estrogens| Estrogens, Non-Steroidal| Genito Urinary System and Sex Hormones| Hormonal Contraceptives for Systemic Use| Hormones| Hormones and Related Agents| Hormones, Hormone Substitutes, and Hormone Antagonists| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Medications that reduce magnesium levels| Noxae| OATP1B1/SLCO1B1 Inhibitors| OATP2B1/SLCO2B1 substrates| P-glycoprotein substrates| Sex Hormones and Modulators of the Genital System| Stilbenes| Stilbestrols| Synthetic Estrogens, Plain| Thyroxine-binding globulin inducers| Toxic Actions"
329,DB00745,Q01959|P35368,P33261|P08684|P05177|P20813|P11712|P20815,hsa:6531|hsa:147,9|10|11|14|18|19|33|178|182|185|189|283|284|285|286|293|299|332|333|344|349|351|352|353|355|356|368|370|371|384|393|412|414|416|420|430|434|439|441|443|446|451|457|465|470|490|507|516|520|524|552|556|564|570|578|582|584|586|595|599|603|608|618|634|640|643|658|660|664|668|677|678|679|688|696|697|708|709|710,Modafinil,"Benzene Derivatives| Benzhydryl Compounds| Central Nervous System Agents| Central Nervous System Stimulants| Central Nervous System Stimulation| Centrally Acting Sympathomimetics| Cytochrome P-450 CYP1A2 Inducers| Cytochrome P-450 CYP1A2 Inducers (strength unknown)| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (strength unknown)| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Inducers| Cytochrome P-450 CYP2C9 Inducers (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (moderate)| Cytochrome P-450 CYP3A4 Inducers (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inducers| Cytochrome P-450 CYP3A5 Inducers (moderate)| Cytochrome P-450 CYP3A5 Inducers (weak)| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Increased Sympathetic Activity| Metabolic Side Effects of Drugs and Substances| Modafinil and isomer| Nervous System| Psychoanaleptics| Psychostimulants, Agents Used for ADHD and Nootropics| Stimulants| Sympathomimetic-like Agent| Wakefulness-Promoting Agents"
330,DB00322,P04818,P19971|P11712,hsa:7298,9|10|11|14|15|18|19|20|23|143|146|178|183|184|283|284|285|286|287|299|308|332|339|341|344|345|346|351|352|355|358|364|365|366|370|372|373|375|376|379|381|384|387|389|390|391|392|393|396|397|399|400|403|405|406|416|418|420|435|439|441|442|443|445|446|447|449|450|451|453|464|472|482|484|487|488|491|493|495|504|506|519|521|523|527|530|535|538|540|545|549|553|555|560|567|571|572|576|580|582|585|592|593|596|601|612|613|614|617|621|624|628|636|637|638|639|645|646|647|650|654|656|657|662|663|672|673|674|680|682|683|690|691|702,Floxuridine,"Antimetabolites| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strong)| Cytochrome P-450 Enzyme Inhibitors| Deoxyribonucleosides| Deoxyuridine| Drugs that are Mainly Renally Excreted| Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Immunosuppressive Agents| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| Noxae| Nucleic Acids, Nucleotides, and Nucleosides| Nucleosides| Pyrimidine Analogues| Pyrimidine Nucleosides| Pyrimidines| Thyroxine-binding globulin inducers| Toxic Actions"
331,DB06616,P11274|P00519|P07948|P08631|P12931|P24941|Q02750|P36507|Q9Y2U5|Q13555,P08684,hsa:613|hsa:25|hsa:4067|hsa:3055|hsa:6714|hsa:1017|hsa:5604|hsa:5605|hsa:10746|hsa:818,9|10|11|12|14|15|16|18|19|37|38|178|180|181|182|183|184|185|189|192|199|283|284|285|286|294|299|332|333|340|341|342|344|345|346|351|352|355|356|357|358|362|365|366|370|371|372|373|374|376|377|381|382|384|385|386|387|390|391|392|393|396|403|405|416|418|419|429|430|431|434|435|437|441|442|445|446|447|449|453|464|466|470|472|476|482|490|491|495|498|501|502|503|505|506|520|521|523|524|530|538|539|540|541|542|544|545|546|548|549|550|551|552|555|556|564|565|567|568|569|570|573|574|576|577|578|582|583|584|585|589|591|592|593|594|595|598|600|601|603|604|606|607|608|609|611|613|614|618|619|620|621|626|628|630|632|633|634|637|638|640|641|643|651|652|655|656|657|660|662|664|665|666|668|676|677|678|679|680|682|683|688|689|691|696|697|698|699|702|703|708|709|710|714|721|722|729|735|742|752|758|761|764|771|777|784|785|792|798|805|815|821|824|827|834,Bosutinib,"Amines| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Bcr-Abl Tyrosine Kinase Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Inhibitors (weak)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Immunosuppressive Agents| Kinase Inhibitor| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| P-glycoprotein inhibitors| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Protein Kinase Inhibitors| Tyrosine Kinase Inhibitors"
332,DB13874,P48735,P05177|P20813|P10632|P11712|P33261|P10635|P08684|P22309|P35503|P22310|O60656|P16662|P54855,hsa:3418,9|10|11|12|14|15|16|18|23|24|25|178|183|184|185|190|191|192|197|198|283|284|285|286|287|299|308|332|333|337|340|341|344|345|351|352|355|357|358|359|363|365|370|371|372|373|374|375|376|377|379|384|387|389|390|392|393|396|403|406|416|418|431|434|435|437|438|441|442|445|446|447|449|450|453|464|470|472|482|484|487|490|491|495|502|504|506|516|519|520|521|523|524|528|530|538|539|540|545|546|549|552|555|556|560|564|566|569|570|572|576|577|578|582|584|585|592|593|595|596|599|600|601|603|607|608|611|613|618|621|628|633|634|636|640|643|654|656|657|659|660|664|665|668|674|677|678|679|683|688,Enasidenib,"Amines| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| BCRP/ABCG2 Inhibitors| BCRP/ABCG2 Substrates| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (strength unknown)| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Isocitrate Dehydrogenase 2 Inhibitor| Isocitrate dehydrogenase-2 (IDH2) Inhibitors| Narrow Therapeutic Index Drugs| OAT1/SLC22A6 inhibitors| OAT3/SLC22A8 Inhibitors| OATP1B1/SLCO1B1 Inhibitors| OATP1B3 inhibitors| OCT2 Inhibitors| P-glycoprotein inhibitors| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Pyridines| UGT1A1 Inhibitors| UGT1A1 Substrates| UGT1A1 Substrates with a Narrow Therapeutic Index| UGT1A3 substrates| UGT1A3 Substrates with a Narrow Therapeutic Index| UGT1A4 substrates| UGT1A9 Substrates| UGT1A9 Substrates with a Narrow Therapeutic Index| UGT2B7 substrates| UGT2B7 Substrates with a Narrow Therapeutic Index"
333,DB08932,P25101|P24530,P08684|P33261,hsa:1909|hsa:1910,6|7|9|10|11|12|14|15|16|18|19|20|33|178|182|183|184|185|190|191|192|272|274|283|284|285|286|299|305|332|333|344|345|346|351|352|355|356|358|365|366|370|371|372|373|374|375|376|378|379|381|384|387|389|390|393|396|403|405|416|418|430|434|435|438|441|442|445|446|447|449|450|453|459|464|470|472|476|482|484|487|490|491|495|498|504|506|516|519|520|521|523|524|528|530|538|540|541|545|548|549|552|555|556|560|564|565|567|570|572|573|576|578|582|584|585|589|592|593|594|595|596|599|601|603|604|606|607|608|612|613|614|618|620|621|626|628|632|634|636|637|638|640|641|643|652|654|655|657|660|662|664|665|666|668|674|677|678|679|680|683|688|689|696|697|698|708|709|710|712,Macitentan,"Amides| Antihypertensive Agents| Antihypertensives for Pulmonary Arterial Hypertension| Cardiovascular System| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Endothelin A Receptor Antagonists| Endothelin B Receptor Antagonists| Endothelin Receptor Antagonists| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Sulfones| Sulfur Compounds| Vasodilating Agents"
334,DB09212,P35354|P23219,P23219|P35354,hsa:5743|hsa:5742,9|10|11|18|19|143|144|178|182|283|284|286|308|332|333|335|341|344|352|355|356|370|371|374|380|384|406|416|420|430|432|434|440|441|443|446|452|470|490|516|520|524|535|552|556|564|570|578|579|582|584|595|597|599|603|608|617|618|634|637|640|641|655|660|664|668|677|678|679|680|684|688|689|692|696|697|698|704|708|709|710|712|713|776,Loxoprofen,"Acids, Carbocyclic| Agents causing hyperkalemia| Agents that produce hypertension| Analgesics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Antiinflammatory Preparations, Non-Steroids for Topical Use| Antirheumatic Agents| Carboxylic Acids| Musculo-Skeletal System| Nephrotoxic agents| Non COX-2 selective NSAIDS| Peripheral Nervous System Agents| Sensory System Agents| Topical Products for Joint and Muscular Pain| UGT2B7 substrates"
335,DB06774,Q8NER1|Q99623,P08684|P35354|P05164|P05177|P05181|P21397|P09172|P15104|P06276,hsa:7442|hsa:11331,9|10|11|12|14|18|19|178|182|283|284|285|286|299|308|332|333|335|341|344|345|351|352|355|356|365|366|370|371|374|381|382|384|390|392|393|405|406|416|420|430|434|439|441|443|446|451|464|470|476|490|498|516|520|524|528|535|540|541|542|544|548|549|552|556|564|565|567|570|573|574|578|579|582|584|589|590|592|594|595|599|603|604|606|607|608|613|617|618|619|626|628|630|631|633|634|637|640|641|643|645|646|651|655|656|660|662|663|664|666|667|668|677|678|679|680|682|683|684|688|689|691|692|699|702|708|709|710|714|735|761|777|798|824,Capsaicin,"Alkaloids| Alkenes| Amides| Analgesics| Anesthetics| Anesthetics, Local| Antipruritics| Basic Lotions and Liniments| Benzene Derivatives| Capsaicin and Similar Agents| Cholinesterase Inhibitors| Cytochrome P-450 CYP1A2 Inducers| Cytochrome P-450 CYP1A2 Inducers (strength unknown)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dermatologicals| Heterocyclic Compounds| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Lipids| Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates| Peripheral Nervous System Agents| Phenols| Polyunsaturated Alkamides| Sensory System Agents| Solanaceous Alkaloids| Topical Products for Joint and Muscular Pain| TRPV1 Channel Agonists"
336,DB01213,P07327|P00325|P00326|P04040,P05181|P11509,hsa:124|hsa:125|hsa:126|hsa:847,9|10|14|15|143|148|149|283|284|285|299|300|332|333|344|345|351|355|356|358|365|370|372|373|374|376|384|387|393|394|398|399|416|418|422|430|435|441|442|445|446|447|449|464|467|477|496|515|522|523|527|528|530|538|545|549|555|576|593|599|601|616|621|644,Fomepizole,"Antidotes| Azoles| Compounds used in a research, industrial, or household setting| Cytochrome P-450 CYP2A6 Inhibitors| Cytochrome P-450 CYP2A6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2E1 Inducers| Cytochrome P-450 CYP2E1 Inducers (strength unknown)| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Protective Agents| Pyrazoles"
337,DB00381,Q13936|P54289|Q08289|Q01668|Q13698|Q00975|Q8IZS8|Q6TME4|P00915|P17405,P08684|P20815|P24462|P05177|P04798|P20813|P11509|P10632|P11712|P10635,hsa:775|hsa:781|hsa:783|hsa:776|hsa:779|hsa:774|hsa:55799|hsa:759|hsa:6609,9|10|11|12|14|15|18|19|20|37|178|182|183|184|185|283|284|285|286|294|299|332|333|335|340|342|344|345|346|351|352|355|356|362|365|366|370|371|374|380|384|390|392|393|405|416|420|430|434|437|440|441|443|446|449|452|470|490|501|503|516|520|524|528|535|550|552|553|556|564|566|570|573|578|579|582|584|591|594|595|598|599|603|608|614|615|618|619|634|637|640|643|656|659|660|664|666|668|671|673|677|678|679|680|684|688|689|690|692|693|694|696|697|698|700|704|708|709|710|712|759|822,Amlodipine,"ACE Inhibitors and Calcium Channel Blockers| Agents causing hyperkalemia| Angiotensin II Antagonists and Calcium Channel Blockers| Angiotensin II receptor blockers (ARBs) and calcium channel blockers| Antianginal Agents| Antiarrhythmic agents| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Bradycardia-Causing Agents| Calcium Channel Blockers| Calcium Channel Blockers (Dihydropyridine)| Calcium Channel Blockers and Diuretics| Calcium-Regulating Hormones and Agents| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (moderate)| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (weak)| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dihydropyridine Derivatives| Dihydropyridines| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypotensive Agents| Membrane Transport Modulators| P-glycoprotein inhibitors| P-glycoprotein substrates| Pyridines| Selective Calcium Channel Blockers With Mainly Vascular Effects| Vasodilating Agents"
338,DB00640,P29274|P29275|P0DMS8|P30542,P00813|P55263,hsa:135|hsa:136|hsa:140|hsa:134,9|10|11|14|15|16|18|19|20|143|146|148|149|150|178|183|184|283|284|285|286|299|308|332|339|340|341|344|345|346|351|352|355|357|358|359|365|366|373|375|376|377|378|379|384|386|387|388|389|390|391|393|396|397|403|405|406|416|418|431|437|438|441|442|447|449|450|453|464|472|482|484|485|487|491|495|499|504|506|519|521|523|530|538|540|545|547|549|555|560|566|567|569|571|572|582|585|592|593|596|601|611|612|613|614|617|621|628|636|637|638|639|654|656|657|659|662|663|674|680|681|682|683|690|691|702,Adenosine,"Adenosine, antagonists & inhibitors| Agents producing tachycardia| Alkenes| Analgesics| Antiarrhythmic agents| Antiarrhythmics, Class V| Biological Factors| Carbohydrates| Cardiac Therapy| Cardiovascular Agents| Cardiovascular System| Central Nervous System Agents| Cyclohexanes| Cyclohexenes| Cycloparaffins| Glycosides| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hydrocarbons| Hydrocarbons, Acyclic| Hydrocarbons, Alicyclic| Hydrocarbons, Cyclic| Macrocyclic Compounds| Miscellaneous Cardiac Drugs| Miscellaneous Therapeutic Agents| Moderate Risk QTc-Prolonging Agents| Neurotransmitter Agents| Nucleic Acids, Nucleotides, and Nucleosides| Nucleosides| Peripheral Nervous System Agents| Polycyclic Compounds| Polyenes| Purine Nucleosides| Purinergic Agents| Purinergic Agonists| Purinergic P1 Receptor Agonists| Purines| QTc Prolonging Agents| Ribonucleosides| Sensory System Agents| Terpenes| Vasodilating Agents"
339,DB01107,P14867|BE0004797,P10635,hsa:2554,9|10|11|14|18|19|178|180|181|283|284|285|286|299|332|333|334|335|341|344|345|351|352|365|374|390|392|393|420|432|439|443|451|528|535|540|579|580|582|588|592|613|643|645|646|656|679|683|684|695|708|709|710|711,Methyprylon,"Central Nervous System Depressants| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypnotics and Sedatives| Nervous System| Piperidinedione Derivatives| Piperidines| Psycholeptics"
340,DB00796,P30556,P11712|P10632|P35503|P23219,hsa:185,9|10|11|12|13|14|15|16|18|19|20|143|148|149|150|155|156|178|179|182|185|189|192|196|199|283|284|285|286|299|300|332|333|339|340|341|344|345|346|347|351|352|355|356|357|358|359|365|366|367|370|371|374|375|376|377|379|380|384|386|387|389|390|391|393|394|396|397|398|399|403|405|416|418|420|422|430|431|434|437|438|440|441|442|443|446|449|450|452|453|464|470|472|482|484|485|486|487|488|490|493|495|499|502|504|506|515|516|517|519|520|521|523|524|530|535|538|539|540|545|546|547|548|549|552|553|555|556|560|563|564|569|570|572|573|574|576|578|579|580|582|584|585|592|594|595|596|597|599|600|603|604|607|608|610|611|612|613|614|618|619|623|624|628|633|634|635|636|637|638|640|641|654|655|656|657|660|661|664|665|666|668|671|672|673|674|677|678|679|680|682|683|684|685|688|689|692|696|697|698|704|708|709|710|712|713|737|755|758|770|776|800|818|821|833,Candesartancilexetil,"Agents Acting on the Renin-Angiotensin System| Agents causing hyperkalemia| Angiotensin 2 Receptor Blocker| Angiotensin II Antagonists and Diuretics| Angiotensin II receptor antagonists| Angiotensin Receptor Antagonists| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Azoles| Benzene Derivatives| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strong)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hypotensive Agents| P-glycoprotein inhibitors| UGT1A3 substrates"
341,DB01071,P35367,P10635|P08684,hsa:3269,9|10|11|12|14|15|33|178|180|181|182|185|187|188|189|192|194|195|199|206|283|284|285|293|332|333|335|340|344|345|351|353|355|365|370|371|376|377|383|384|390|391|412|416|434|437|441|446|449|464|470|490|495|500|502|507|516|520|524|531|532|533|540|545|546|549|552|556|564|570|577|578|582|584|585|586|592|593|595|599|600|603|607|608|613|618|628|633|634|640|656|657|658|660|664|665|668|677|678|679|683|708|709|710|712|767|830,Mequitazine,"Anti-Allergic Agents| Antihistamines for Systemic Use| Bronchodilator Agents| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Neurotransmitter Agents| Phenothiazine Derivatives| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Respiratory System| Sulfur Compounds"
342,DB01144,P00915|P00918|P22748|P43166|P07451,P11712,hsa:759|hsa:760|hsa:762|hsa:766|hsa:761,9|10|14|15|18|19|20|33|34|37|38|178|182|283|284|293|294|299|305|332|342|344|353|355|362|370|371|383|384|414|416|434|441|446|457|459|465|470|483|490|501|503|520|524|526|529|531|532|550|552|556|564|570|578|582|584|591|595|598|599|603|608|618|634|640|660|664|668|677|678|679|726|745|747|768|773|789|808|810|831|836,Diclofenamide,Amides| Antiglaucoma Preparations and Miotics| Carbonic Anhydrase Inhibitors| Diuretics| Enzyme Inhibitors| Genito Urinary System and Sex Hormones| Gynecological Antiinfectives and Antiseptics| Hypotensive Agents| Ophthalmics| Ophthalmologicals| Sensory Organs| Sulfonamides| Sulfones| Sulfur Compounds
343,DB01435,P35354|P23219,P10632|P11712|P05177|P33261|P08684|P11509|P20813|P33260|P10635|P05181,hsa:5743|hsa:5742,9|10|11|14|15|18|143|148|149|178|182|283|284|285|286|300|332|340|344|351|352|355|357|358|365|370|371|374|376|377|381|384|387|390|396|416|418|420|422|431|434|437|439|441|442|443|446|449|451|453|464|467|470|477|482|490|493|495|496|502|515|516|518|520|521|523|524|530|535|538|539|540|545|546|549|552|553|555|556|564|570|577|578|579|580|582|584|585|592|593|595|599|600|601|603|607|608|613|616|618|621|623|624|628|633|634|640|644|645|656|657|660|664|665|668|671|673|677|678|679|683,Antipyrine,"Agents causing hyperkalemia| Agents that produce hypertension| Analgesics| Analgesics and Anesthetics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)| Azoles| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C18 Substrates| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Methemoglobinemia Associated Agents| Nephrotoxic agents| Nervous System| Non COX-2 selective NSAIDS| OAT1/SLC22A6 inhibitors| Otologicals| Peripheral Nervous System Agents| Pyrazoles| Pyrazolones| Sensory Organs| Sensory System Agents"
344,DB01216,P31213|P18405|P51857,P20815|P24462|P08684,hsa:6716|hsa:6715|hsa:6718,0|9|10|11|12|14|15|18|19|143|144|178|179|183|184|185|186|192|283|284|285|286|299|332|333|334|335|336|338|340|344|345|351|352|365|374|390|392|393|416|420|434|439|441|443|446|451|464|490|516|524|528|535|540|553|556|579|582|592|613|640|643|645|646|656|660|671|672|678|679|683|684|688|692|696|697|704|708|709|710|711|712|776|779|797|800|818|821|839|860,Finasteride,"5-alpha Reductase Inhibitors| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Agents that produce hypertension| Androstanes| Androstenes| Azasteroids| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Substrates| Dermatologicals| Drugs Used in Benign Prostatic Hypertrophy| Enzyme Inhibitors| Fused-Ring Compounds| Genito Urinary System and Sex Hormones| Genitourinary Agents| Hormone Antagonists| Hormones, Hormone Substitutes, and Hormone Antagonists| Misc. Skin and Mucous Membrane Agents| Polycyclic Compounds| Steroid Synthesis Inhibitors| Steroids| Steroids, Heterocyclic| Urological Agents| Urologicals"
345,DB01064,P08588|P07550|P13945|P28482|P27986|O00459|Q92569|Q4ZHU6|P00441,P04798,hsa:153|hsa:154|hsa:155|hsa:5594|hsa:5295|hsa:5296|hsa:8503|hsa:6647,9|10|11|14|18|19|178|182|283|284|285|286|299|308|332|333|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|392|393|406|416|430|434|441|446|470|490|498|516|520|524|528|540|541|542|544|548|552|556|564|566|567|570|571|573|574|578|582|584|590|592|595|599|603|606|607|608|613|617|618|619|631|634|637|640|641|643|651|655|656|659|660|663|664|667|668|677|678|679|680|681|683|688|689|690|691|696|698|699|701|702|708|709|710|714|735|761|777|798|824,Isoprenaline,"Adrenergic Agents| Adrenergic Agonists| Adrenergic and Dopaminergic Agents| Adrenergic beta-2 Receptor Agonists| Adrenergic beta-Agonists| Adrenergics for Systemic Use| Adrenergics, Inhalants| Agents producing tachycardia| Agents that produce hypertension| Alcohols| Amines| Amino Alcohols| Anti-Asthmatic Agents| Autonomic Agents| Benzene Derivatives| Bronchodilator Agents| Cardiac Stimulants Excl. Cardiac Glycosides| Cardiac Therapy| Cardiotonic Agents| Cardiovascular Agents| Cardiovascular System| Catecholamines| Catechols| Cholinesterase Inhibitors| Compounds used in a research, industrial, or household setting| COMT Substrates| Drugs for Obstructive Airway Diseases| Ethanolamines| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Neurotransmitter Agents| Non-selective Beta-adrenergic Agonists| Peripheral Nervous System Agents| Phenols| Protective Agents| Respiratory System| Respiratory System Agents| Sympathomimetics"
346,DB00402,P14867|P47869|P34903|P31644|P30536|BE0004797,P08684|P10632|P11712|P23219,hsa:2554|hsa:2555|hsa:2556|hsa:2558|hsa:706,9|10|11|12|14|15|16|18|19|37|143|145|146|178|180|181|183|184|185|190|191|192|283|284|285|286|294|332|340|342|344|345|346|351|352|355|357|358|362|365|366|370|371|372|373|374|375|376|378|379|380|384|387|390|391|396|403|405|416|418|420|431|434|435|437|438|439|441|442|443|445|446|447|449|450|451|452|453|461|464|470|472|482|484|485|487|490|491|493|494|495|499|501|502|503|506|516|519|520|521|523|524|530|535|536|538|539|540|545|546|547|548|549|550|552|553|555|556|560|564|566|569|570|573|574|576|577|578|579|580|582|584|585|591|592|593|594|595|596|598|599|600|602|603|604|607|608|609|611|612|613|615|618|619|623|624|628|633|634|636|637|638|640|645|646|647|654|656|657|659|660|664|665|666|668|671|673|674|677|678|682|683|685|686,Eszopiclone,"Benzodiazepine hypnotics and sedatives| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypnotics (Nonbenzodiazepine)| Hypnotics and Sedatives| Miscellaneous Anxiolytics Sedatives and Hypnotics| Muscle Relaxants| Muscle Relaxants, Centrally Acting Agents| Nervous System| Photosensitizing Agents| Piperazines| Psycholeptics| Pyrazines| Pyridines| Zopiclone and prodrugs"
347,DB01039,Q07869|O43923|P37231|Q03181|O75469,P10632|P11712|P08684,hsa:5465|hsa:5468|hsa:5467|hsa:8856,9|10|11|12|18|19|20|37|178|182|185|189|283|284|286|294|332|333|337|339|341|342|344|346|352|355|356|362|366|370|371|374|380|381|382|384|405|416|420|430|432|434|440|441|443|446|452|462|470|476|490|493|498|501|503|516|520|524|535|537|541|542|548|550|552|553|556|564|565|567|570|573|574|578|579|582|584|589|591|594|595|597|598|599|603|604|605|606|608|614|618|619|620|623|626|632|634|637|640|641|651|655|660|662|664|666|668|671|672|677|678|679|680|684|688|689|692|693|696|697|698|704|705|708|709|710|714|717|777|780,Fenofibrate,"Acids, Acyclic| Agents Causing Muscle Toxicity| Benzene Derivatives| Benzophenones| BSEP/ABCB11 Substrates| Butyrates| Carboxylic Acids| Cardiovascular System| Cytochrome P-450 CYP2A6 Inhibitors| Cytochrome P-450 CYP2A6 Inhibitors (weak)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (weak)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (weak)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Ethers| Fatty Acids| Fatty Acids, Volatile| Fibric Acid Derivatives| Fibric Acids| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hypolipidemic Agents| Hypolipidemic Agents Indicated for Hyperlipidemia| Isobutyrates| Ketones| Lipid Modifying Agents| Lipid Modifying Agents, Plain| Lipid Regulating Agents| Lipids| Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia| Noxae| P-glycoprotein inhibitors| Peroxisome Proliferator Receptor alpha Agonist| Peroxisome Proliferator-activated Receptor alpha Agonists| Phenols| Phenyl Ethers| Toxic Actions| UGT1A9 Substrates"
348,DB00477,P14416|P21728|P28223|P08908|P35348|P35368|P35367|Q12809|BE0004889|P35462|P21917|P21918|P28335|BE0004881|BE0004863|BE0004864|P11229|P20309|P17405|P0DP23|BE0004879|P50406|P34969|Q9H3N8,P10635|P05177|P08684|P05181|P06276,"hsa:1813|hsa:1812|hsa:3356|hsa:3350|hsa:148|hsa:147|hsa:3269|hsa:3757|hsa:1814|hsa:1815|hsa:1816|hsa:3358|hsa:1128|hsa:1131|hsa:6609|hsa:801,hsa:805,hsa:808|hsa:3362|hsa:3363|hsa:59340",9|10|11|12|14|15|33|37|178|182|183|184|185|189|192|283|284|285|293|294|332|340|342|344|345|351|353|355|362|365|370|371|374|376|377|383|384|390|391|412|416|434|437|441|446|449|464|470|490|495|500|501|502|503|507|516|520|524|531|532|533|540|545|546|549|550|552|556|564|570|577|578|582|584|585|586|591|592|593|595|598|599|600|603|607|608|613|618|628|633|634|640|656|657|658|660|664|665|668|677|678|679|683|726|750|767|789|813|830,Chlorpromazine,"Adrenergic alpha-1 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Agents producing tachycardia| Agents that produce hypertension| Agents that reduce seizure threshold| Anticholinergic Agents| Antidepressive Agents| Antiemetics| Antipsychotic Agents| Antipsychotic Agents (First Generation [Typical])| Autonomic Agents| BSEP/ABCB11 Inhibitors| Central Nervous System Agents| Central Nervous System Depressants| Cholinesterase Inhibitors| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (moderate)| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates (strength unknown)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dopamine Agents| Dopamine Antagonists| Dopamine D2 Receptor Antagonists| Drugs causing inadvertant photosensitivity| Drugs that are Mainly Renally Excreted| Gastrointestinal Agents| Heterocyclic Compounds| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Histamine Antagonists| Histamine H1 Antagonists| Hyperglycemia-Associated Agents| Hypotensive Agents| Moderate Risk QTc-Prolonging Agents| Muscarinic Antagonists| Nervous System| Neurotoxic agents| Neurotransmitter Agents| P-glycoprotein inhibitors| P-glycoprotein substrates| Peripheral Nervous System Agents| Phenothiazines| Phenothiazines With Aliphatic Side-Chain| Photosensitizing Agents| Psycholeptics| Psychotropic Drugs| QTc Prolonging Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT1 Receptor Antagonists| Serotonin 5-HT1A Receptor Antagonists| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin Agents| Serotonin Receptor Antagonists| Sulfur Compounds| Tranquilizing Agents"
349,DB00802,P35372,P08684|P24462|P20815,hsa:4988,9|10|11|12|14|15|16|18|19|143|148|149|178|180|181|182|185|283|284|285|286|300|332|333|336|340|344|345|346|351|352|355|365|366|370|371|374|375|376|377|379|384|389|390|391|396|405|416|418|420|422|434|437|439|441|443|446|449|450|451|453|464|470|486|487|490|495|496|502|504|515|516|517|518|519|520|521|524|535|540|545|546|549|552|556|560|564|566|569|570|578|582|584|585|592|593|595|596|599|600|603|607|608|611|613|615|618|628|633|634|636|637|640|645|646|654|656|657|659|660|664|665|668|677|678|679|682|683|708|710,Alfentanil,"Agents that produce hypertension| Analgesics| Anesthetics| Anesthetics, General| Anesthetics, Intravenous| Bradycardia-Causing Agents| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Substrates| Fentanyl and fentanyl analogues| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| High-risk opioids| Narcotics| Nervous System| Opiate Agonists| Opioid Agonist| Opioid Anesthetics| Opioids| Opioids, Anilidopiperidine| P-glycoprotein inhibitors| Peripheral Nervous System Agents| Phenylpiperidine opioids| Piperidines| Sensory System Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
350,DB00434,P35367|P28223|P28335|P11229|P08172|P20309|P34969,P35503,hsa:3269|hsa:3356|hsa:3358|hsa:1128|hsa:1129|hsa:1131|hsa:3363,9|10|11|12|14|178|180|181|182|185|189|192|213|217|283|284|285|332|333|344|345|351|355|356|365|370|371|374|384|390|391|416|430|434|441|446|470|490|516|520|524|540|552|556|564|570|578|582|584|592|595|599|603|608|613|618|634|640|656|660|664|668|677|678|679|683|688|696|697|708|709|710|712|755|818,Cyproheptadine,"Agents producing tachycardia| Agents that reduce seizure threshold| Anti-Allergic Agents| Anticholinergic Agents| Antidepressive Agents| Antihistamines for Systemic Use| Antipruritics| Benzocycloheptenes| Central Nervous System Depressants| Dermatologicals| Dibenzocycloheptenes| Drugs causing inadvertant photosensitivity| Gastrointestinal Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Miscellaneous Derivatives| Muscarinic Antagonists| Neurotransmitter Agents| OCT1 inhibitors| Photosensitizing Agents| Piperidines| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Respiratory System| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin 5-HT2C Receptor Antagonists| Serotonin Agents| Serotonin Receptor Antagonists| UGT1A3 substrates| UGT1A4 substrates"
351,DB01118,Q12809|P08588|O95180|Q9NY47|P10827|P10828|P37231,P08684|P10632|P10635|P11712|P05177|P33261|P04798|P20815|P24462|P11509,hsa:3757|hsa:153|hsa:8912|hsa:9254|hsa:7067|hsa:7068|hsa:5468,9|10|11|12|14|18|19|46|47|143|149|178|182|185|189|283|284|285|286|298|332|333|341|344|345|346|350|351|352|355|356|365|366|370|371|374|381|382|384|385|390|391|405|409|416|420|430|432|434|441|443|446|470|476|490|493|498|516|520|524|535|540|541|542|548|552|553|556|564|565|566|570|573|574|578|579|581|582|584|588|589|594|595|597|599|603|604|606|608|614|615|618|619|620|623|625|626|632|634|637|640|641|642|651|655|656|659|660|664|666|668|671|672|677|678|679|680|684|686|687|688|689|692|693|696|697|698|699|704|705|708|709|710|712|714|756|777|819,Amiodarone,"Agents causing hyperkalemia| Agents Causing Muscle Toxicity| alpha-Galactosidase, antagonists & inhibitors| Antiarrhythmic agents| Antiarrhythmics, Class III| Benzofurans| Bradycardia-Causing Agents| BSEP/ABCB11 Inhibitors| BSEP/ABCB11 Substrates| BSEP/ABCB11 Substrates with a Narrow Therapeutic Index| Calcium Channel Blockers| Cardiac Therapy| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP1A2 Inhibitors (strong)| Cytochrome P-450 CYP2A6 Inhibitors| Cytochrome P-450 CYP2A6 Inhibitors (moderate)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Inhibitors (weak)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (moderate)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors (strong)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates (strength unknown)| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Highest Risk QTc-Prolonging Agents| Hypotensive Agents| Medications that reduce magnesium levels| Membrane Transport Modulators| Metabolic Side Effects of Drugs and Substances| Narrow Therapeutic Index Drugs| OCT2 Inhibitors| P-glycoprotein inducers| P-glycoprotein inhibitors| Photosensitizing Agents| Potassium Channel Blockers| QTc Prolonging Agents| Sodium Channel Blockers| Vasodilating Agents"
352,DB00622,Q13936|Q08289|Q01668|P54289|P54750|Q01064|P35348|P35368|P25100|P11229|P08172|P20309|P08173|P08912|P0DP23,P08684|P10635|P11712|P33261|P10632|P20813|P05181|P20815,"hsa:775|hsa:783|hsa:776|hsa:781|hsa:5136|hsa:5153|hsa:148|hsa:147|hsa:146|hsa:1128|hsa:1129|hsa:1131|hsa:1132|hsa:1133|hsa:801,hsa:805,hsa:808",9|10|11|12|14|15|18|19|20|178|182|183|184|185|189|192|283|284|285|286|299|301|332|333|335|340|344|345|346|351|352|355|356|365|366|370|371|374|376|377|380|384|390|391|392|393|395|401|405|416|420|423|430|434|437|440|441|443|446|449|452|454|455|464|470|490|502|514|516|520|524|535|540|545|546|549|552|553|556|558|564|566|570|573|578|579|582|584|592|594|595|599|600|603|607|608|613|614|615|618|619|628|633|634|637|640|643|656|659|660|664|665|666|668|671|673|677|678|679|680|683|684|688|689|690|692|693|694|696|697|698|700|704|708|709|710|712|737|800,Nicardipine,"Adrenergic alpha-1 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Agents causing hyperkalemia| Agents producing tachycardia| Antiarrhythmic agents| Anticholinergic Agents| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Bradycardia-Causing Agents| BSEP/ABCB11 Substrates| Calcium Channel Blockers| Calcium Channel Blockers (Dihydropyridine)| Calcium-Regulating Hormones and Agents| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (strength unknown)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (moderate)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors (strong)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (moderate)| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (moderate)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dihydropyridine Derivatives| Dihydropyridines| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypotensive Agents| Membrane Transport Modulators| Muscarinic Antagonists| OATP1B1/SLCO1B1 Inhibitors| P-glycoprotein inhibitors| P-glycoprotein substrates| Potential QTc-Prolonging Agents| Pyridines| QTc Prolonging Agents| Selective Calcium Channel Blockers With Mainly Vascular Effects| Vasodilating Agents"
353,DB00829,P14867|P47869|P34903|P31644|P18505|P47870|P28472|Q8N1C3|P18507|Q99928|O14764|P78334|O00591|P24046|P28476|A8MPY1|Q9UN88|P30536|BE0004797,P08684|P20815|P24462|P33261|P11712|P20813|P05177|P33260|P10632|P23219|P05181,hsa:2554|hsa:2555|hsa:2556|hsa:2558|hsa:2560|hsa:2561|hsa:2562|hsa:2565|hsa:2566|hsa:2567|hsa:2563|hsa:2564|hsa:2568|hsa:2569|hsa:2570|hsa:200959|hsa:55879|hsa:706,9|10|11|12|14|15|18|37|178|182|185|189|213|218|219|283|284|285|286|294|332|333|340|342|344|345|351|352|355|356|362|365|370|371|374|376|377|384|390|391|416|418|420|430|431|434|437|439|441|442|443|446|449|451|453|464|470|490|495|501|502|503|516|520|524|536|538|540|545|546|549|550|552|555|556|564|569|570|576|578|582|584|585|591|592|595|598|599|600|603|607|608|611|613|618|628|633|634|640|645|646|656|657|660|664|665|668|677|678|679|683|688|696|697|708|709|710|729|738|758|792|801|821,Diazepam,"Adjuvants, Anesthesia| Agents that modify thyroid function| Anesthetics| Anesthetics, General| Anesthetics, Intravenous| Anti-Anxiety Agents| Anticonvulsants| Autonomic Agents| Benzazepines| Benzodiazepine hypnotics and sedatives| Benzodiazepines and benzodiazepine derivatives| Benzodiazepinones| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C18 Substrates| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| GABA Agents| GABA Modulators| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hypnotics and Sedatives| Muscle Relaxants| Muscle Relaxants, Centrally Acting Agents| Nervous System| P-glycoprotein substrates| Peripheral Nervous System Agents| Psycholeptics| Psychotropic Drugs| Tranquilizing Agents"
354,DB00927,P25021,P33261,hsa:3274,9|10|11|14|15|16|18|19|33|34|143|148|149|283|284|285|293|299|305|332|340|344|349|351|353|355|357|358|368|370|375|376|379|383|387|390|393|396|403|412|416|418|421|431|437|438|441|442|446|449|450|453|459|472|473|474|475|480|482|484|487|489|495|500|502|506|507|508|531|533|538|539|546|560|586|599|643|654|658|674,Famotidine,"Acid Reducers| Alimentary Tract and Metabolism| Anti-Ulcer Agents| Azoles| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (weak)| Cytochrome P-450 Enzyme Inhibitors| Drugs for Acid Related Disorders| Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)| Gastric Acid Lowering Agents| Gastrointestinal Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Histamine Agents| Histamine Antagonists| Histamine H2 Antagonists| MATE 1 Inhibitors| MATE inhibitors| Neurotransmitter Agents| OAT3/SLC22A8 Inhibitors| OAT3/SLC22A8 Substrates| OCT2 Inhibitors| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Sulfur Compounds| Thiazoles"
355,DB00843,P22303|P28223,P10635|P08684|P11712,hsa:43|hsa:3356,9|10|11|12|14|18|19|143|144|178|180|181|182|185|189|192|283|284|285|286|332|333|335|341|344|345|351|352|355|356|365|366|370|371|374|381|382|384|390|391|405|416|420|430|432|434|441|443|446|464|470|476|490|493|498|516|520|524|535|540|541|542|544|548|549|552|553|556|564|565|567|570|573|574|578|579|582|584|589|592|594|595|597|599|603|604|606|607|608|613|618|619|623|626|628|630|633|634|637|640|641|651|655|656|660|662|664|666|668|671|672|677|678|679|680|683|684|686|688|689|692|693|696|697|698|699|704|705|708|709|710|712|714|735|755|761|777|798|818|824|839|860,Donepezil,"Anti-Dementia Drugs| BCRP/ABCG2 Substrates| Bradycardia-Causing Agents| Central Nervous System Agents| Central Nervous System Depressants| Cholinergic Agents| Cholinesterase Inhibitors| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Indans| Indenes| Muscle Relaxants| Muscle Relaxants, Centrally Acting Agents| Nervous System| Neurotransmitter Agents| Nootropic Agents| Parasympathomemetic (Cholinergic) Agents| Piperidines| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Psychoanaleptics"
356,DB01426,Q14524,P10635,hsa:6331,9|10|11|12|14|15|18|19|143|144|145|146|150|178|180|181|182|185|187|188|192|194|195|199|283|284|285|286|308|332|333|334|335|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|376|377|384|390|391|406|416|430|434|437|441|446|449|464|470|490|495|502|516|520|524|540|545|546|549|552|556|564|569|570|571|578|582|584|585|592|595|599|600|603|607|608|611|613|617|618|628|633|634|637|638|640|641|655|656|657|660|664|665|668|677|678|679|680|682|683|688|689|690|691|696|697|698|699|701|702|703|708|709|710|711|712|758|821|839|842|847|861|863,Ajmaline,"Ajmaline and derivatives| Alkaloids| Antiarrhythmic agents| Antiarrhythmics, Class I| Antiarrhythmics, Class Ia| Antiarrhythmics, Class Ic| Cardiac Therapy| Cardiovascular Agents| Cardiovascular System| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Indole Alkaloids| Indoles| Indolizidines| Indolizines| Membrane Transport Modulators| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Secologanin Tryptamine Alkaloids| Sodium Channel Blockers| Voltage-Gated Sodium Channel Blockers"
357,DB00441,P23921|P04818|P30085,P32320|P27707,hsa:6240|hsa:7298|hsa:51727,9|10|11|14|15|18|19|20|23|24|143|146|178|183|184|283|284|285|286|287|299|308|332|339|341|344|345|346|351|352|355|358|363|365|366|370|371|372|373|375|376|378|379|384|387|389|390|391|393|396|397|403|405|406|416|418|420|434|435|438|441|442|445|446|447|449|450|451|453|464|472|482|484|487|491|495|502|504|506|516|519|521|523|530|538|539|540|545|546|549|555|560|567|571|572|576|582|585|592|593|596|601|612|613|614|617|621|628|636|637|638|639|643|645|646|647|654|656|657|662|663|674|680|682|683|690|691|702,Gemcitabine,"Antimetabolites| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Carbohydrates| Cytidine Deaminase Substrates| Deoxycytidine| Deoxyribonucleosides| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Glycosides| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Immunosuppressive Agents| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| Noxae| Nucleic Acid Synthesis Inhibitors| Nucleic Acids, Nucleotides, and Nucleosides| Nucleoside Metabolic Inhibitor| Nucleosides| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Pyrimidine Analogues| Pyrimidine Nucleosides| Pyrimidines| Ribonucleosides| Ribonucleotide Reductases, antagonists & inhibitors| Toxic Actions"
358,DB08893,P13945,P08684|P10635|P06276,hsa:155,9|10|11|12|14|15|16|18|19|33|143|148|149|178|182|185|189|283|284|285|286|293|299|308|332|333|339|340|341|344|345|346|349|351|352|353|355|356|357|358|365|366|368|370|371|375|376|377|379|383|384|387|390|392|393|396|403|406|412|416|418|420|421|430|431|434|437|439|441|442|443|446|449|450|451|453|464|470|472|473|474|475|480|482|484|487|489|490|495|500|502|506|507|508|511|516|520|524|528|531|533|535|538|539|540|545|546|548|549|552|556|560|564|566|570|571|573|574|578|579|580|582|584|585|586|592|593|595|597|599|600|603|607|608|613|617|618|619|628|633|634|637|640|641|643|645|654|655|656|657|659|660|664|665|667|668|674|677|678|679|680|683|688|689|696|698|708|709|710|716|779,Mirabegron,"Adrenergic Agents| Adrenergic Agonists| Adrenergic beta-3 Receptor Agonists| Adrenergic beta-Agonists| Agents producing tachycardia| Agents that produce hypertension| Amides| Amines| Anilides| Aniline Compounds| Azoles| Cholinesterase substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (moderate)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs for Urinary Frequency and Incontinence| Drugs that are Mainly Renally Excreted| Genito Urinary System and Sex Hormones| Genitourinary Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| OCT1 substrates| OCT2 Substrates| P-glycoprotein inhibitors| P-glycoprotein substrates| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Selective Beta 3-adrenergic Agonists| Sulfur Compounds| UGT1A3 substrates| UGT2B7 substrates| Urological Agents| Urologicals"
359,DB00836,P35372|P41143|P41145|O00555|P01189|P0DP23|Q14994,P08684|P10632|P20813|P10635,"hsa:4988|hsa:4985|hsa:4986|hsa:773|hsa:5443|hsa:801,hsa:805,hsa:808|hsa:9970",9|10|11|12|14|15|18|19|37|178|180|181|182|185|189|192|196|199|283|284|285|286|294|308|332|333|334|337|341|342|344|345|351|352|355|356|362|365|370|371|374|384|390|391|406|416|420|430|434|439|441|443|446|451|470|490|501|503|516|520|524|535|540|548|550|552|556|564|570|573|574|578|579|582|584|591|592|595|597|598|599|603|607|608|613|617|618|619|634|637|638|640|641|646|655|656|660|664|667|668|677|678|679|680|683|684|685|688|689|692|696|697|698|704|708|709|710|711|712|717|780,Loperamide,"Agents causing hyperkalemia| Alimentary Tract and Metabolism| Antiarrhythmic agents| Antidiarrheals| Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents| Antipropulsives| Bradycardia-Causing Agents| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors (strong)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Gastrointestinal Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Moderate Risk QTc-Prolonging Agents| Opioid Agonist| P-glycoprotein substrates| Piperidines| QTc Prolonging Agents"
360,DB01228,Q14524,P10635,hsa:6331,9|10|11|12|14|15|18|19|178|180|181|182|185|189|192|283|284|285|286|299|332|333|338|340|341|344|345|351|352|355|356|365|366|370|371|374|376|377|381|382|384|390|391|392|393|405|416|420|430|434|437|439|441|443|446|449|451|464|470|476|490|493|495|498|502|516|520|524|535|540|541|542|545|546|548|549|552|553|556|564|565|570|573|574|578|579|582|584|585|589|592|594|595|597|599|600|603|604|606|607|608|613|618|619|623|626|628|633|634|637|640|641|643|645|651|655|656|657|660|664|665|666|668|671|672|677|678|679|680|683|684|688|689|691|692|693|696|697|702|704|705|708|709|710|714|758|777|821,Encainide,"Amides| Amines| Anilides| Aniline Compounds| Antiarrhythmic agents| Antiarrhythmics, Class I| Antiarrhythmics, Class Ic| Cardiac Therapy| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Substrates| Membrane Transport Modulators| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Sodium Channel Blockers| Voltage-Gated Sodium Channel Blockers"
361,DB00346,P35348|P35368|P25100|Q12809,P08684,hsa:148|hsa:147|hsa:146|hsa:3757,9|10|11|12|14|15|16|18|19|20|143|146|178|182|183|184|185|283|284|285|286|299|332|333|339|340|341|344|345|346|351|352|355|356|357|358|365|366|370|371|374|375|376|377|378|379|381|382|384|385|386|387|389|390|391|392|393|396|403|405|416|418|420|430|431|434|437|438|439|441|442|443|446|449|450|451|453|462|464|470|472|476|482|484|487|490|495|498|502|504|506|519|520|523|524|528|530|535|537|538|539|540|541|542|544|545|546|548|549|552|555|556|560|564|565|566|567|570|572|573|574|576|578|579|582|584|585|589|592|593|594|595|596|600|601|603|604|605|606|607|608|613|614|615|618|619|621|626|628|630|633|634|636|637|638|640|641|643|645|646|651|652|654|655|656|657|659|660|662|664|665|666|668|674|677|678|679|680|682|683|684|688|689|691|693|699|702|703|708|709|710|714|721|735|742|758|761|777|784|798|805|821|824,Alfuzosin,"Adrenergic Agents| Adrenergic alpha-1 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs Used in Benign Prostatic Hypertrophy| Genito Urinary System and Sex Hormones| Genitourinary Agents| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Neurotransmitter Agents| P-glycoprotein substrates| Peripheral alpha-1 blockers| Potential QTc-Prolonging Agents| Prostatic Hyperplasia| QTc Prolonging Agents| Selective Alfa-1-adrenergic Blocking Agents| Urological Agents| Urologicals"
362,DB13783,P23219|P35354,P16662,hsa:5742|hsa:5743,9|10|11|12|14|18|19|20|37|143|148|149|178|182|185|189|283|284|285|286|294|308|332|333|340|341|342|344|346|351|352|355|356|357|358|362|366|370|371|374|376|377|380|381|382|384|385|386|387|390|391|396|397|403|405|406|416|418|420|430|431|434|437|439|440|441|442|443|446|449|451|452|453|462|464|470|472|476|482|490|493|495|498|501|502|503|506|516|520|523|524|530|535|537|538|539|541|542|545|546|548|549|550|552|553|555|556|564|565|567|570|573|574|576|577|578|579|582|584|585|589|591|592|594|595|597|598|599|600|603|604|605|606|607|608|613|614|618|619|623|626|628|633|634|637|640|641|645|651|655|656|657|660|662|663|664|665|666|668|671|672|677|678|679|680|682|683|684|685|688|689|691|692|695|696|697|698|699|702|703|704|707|708|709|710|712|717|721|735|758|780|784|798|821,Acemetacin,"Acetic Acid Derivatives and Related Substances| Agents causing hyperkalemia| Agents that produce hypertension| Analgesics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Antigout Preparations| Antiinflammatory and Antirheumatic Products| Antiinflammatory and Antirheumatic Products, Non-Steroids| Antirheumatic Agents| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Indoles| Musculo-Skeletal System| Nephrotoxic agents| Non COX-2 selective NSAIDS| Peripheral Nervous System Agents| Sensory System Agents| UGT2B7 substrates"
363,DB04835,P51681,P08684,hsa:1234,0|9|10|11|12|14|15|16|18|23|24|143|145|146|148|149|150|178|179|180|181|182|185|192|283|284|285|286|287|300|308|332|333|335|338|340|344|345|351|352|355|356|358|359|363|365|370|371|374|375|379|384|389|390|391|396|397|403|406|416|418|422|430|434|438|441|442|446|450|453|464|467|470|472|484|486|487|490|504|506|515|516|517|519|520|521|524|538|539|540|549|552|556|560|564|570|572|578|582|584|592|593|595|596|599|603|607|608|613|617|618|633|634|637|640|644|654|656|660|664|668|677|678|679|680|683|688|689|696|698|708|709|710,Maraviroc,"Anti-HIV Agents| Anti-Infective Agents| Anti-Retroviral Agents| Antiinfectives for Systemic Use| Antiviral Agents| Antivirals for Systemic Use| Azoles| CCR5 Co-receptor Antagonist| CCR5 Receptor Antagonists| Cyclohexanes| Cycloparaffins| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Direct Acting Antivirals| Hepatotoxic Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| HIV Fusion Inhibitors| Hydrocarbons| Hydrocarbons, Alicyclic| Hydrocarbons, Cyclic| Triazoles| Viral Fusion Protein Inhibitors"
364,DB00136,P11473|P31260|P02774,Q07973|P08684,hsa:7421|hsa:3206|hsa:2638,9|10|11|12|18|19|143|144|178|179|185|186|283|284|286|308|332|333|334|335|337|339|341|344|346|352|366|374|406|416|430|434|441|446|490|524|556|564|571|573|582|599|617|637|639|640|641|660|664|667|678|679|680|688|689|690|696|697|698|699|701|708|709|710|711|712|803|818|839|860,Calcitriol,"Alimentary Tract and Metabolism| Antipsoriatics| Antipsoriatics for Topical Use| Bone Density Conservation Agents| Calcium-Regulating Hormones and Agents| Cholestanes| Cholestenes| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Diet, Food, and Nutrition| Food| Fused-Ring Compounds| Growth Substances| Lipids| Membrane Lipids| Membrane Transport Modulators| Micronutrients| Misc. Skin and Mucous Membrane Agents| Physiological Phenomena| Polycyclic Compounds| Secosteroids| Steroids| Sterols| Vitamin D and Analogues| Vitamins| Vitamins (Fat Soluble)"
365,DB00356,Q12791,P05181|P04798|P05177|P11509|P08684|P10635,hsa:3778,9|10|14|18|19|37|143|148|149|178|182|283|284|285|286|294|299|332|340|341|342|344|351|352|355|357|358|362|370|371|376|377|380|381|382|384|386|387|390|392|393|396|399|400|403|405|409|416|418|420|431|432|434|437|441|442|443|446|449|451|452|453|461|464|470|472|476|482|490|492|493|494|495|497|498|501|502|503|506|516|520|523|524|527|530|535|536|538|539|541|542|543|545|546|548|549|550|552|553|555|556|559|564|565|566|570|573|574|576|578|579|582|584|585|589|591|592|594|595|597|598|599|600|602|603|604|606|607|608|612|613|615|618|619|622|623|626|628|633|634|637|640|641|643|645|651|655|657|659|660|664|665|666|668|671|672|677|678|679|680|683|684|689|692|722|750|763|785|813|826,Chlorzoxazone,"Benzoxazoles and derivatives| Central Nervous System Agents| Central Nervous System Depressants| Centrally-mediated Muscle Relaxation| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Muscle Relaxants| Muscle Relaxants, Centrally Acting Agents| Musculo-Skeletal System| Oxazol, Thiazine, and Triazine Derivatives| Peripheral Nervous System Agents"
366,DB01429,Q14524|P0DP23,P10635,"hsa:6331|hsa:801,hsa:805,hsa:808",9|10|11|12|14|15|143|144|178|182|185|189|283|284|285|332|333|338|340|344|345|351|355|356|365|370|371|374|376|377|384|390|391|416|430|434|437|441|446|449|464|470|490|495|502|516|520|524|540|545|546|549|552|556|564|570|578|582|584|585|592|593|595|599|600|603|607|608|613|618|628|633|634|640|656|657|660|664|665|668|677|678|679|683|688|696|708|709|710|712|755|818|842|860,Aprindine,"Antiarrhythmic agents| Antiarrhythmics, Class I| Antiarrhythmics, Class Ib| Cardiac Therapy| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Substrates| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Indans| Indenes| Membrane Transport Modulators| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Sodium Channel Blockers| Voltage-Gated Sodium Channel Blockers"
367,DB00363,P14416|P28223|P21728|P35462|P21917|P08908|P28222|P28221|P28566|P28335|P46098|P50406|P34969|P35367|Q9H3N8|P35348|P35368|P08913|P18089|P18825|P11229|P08172|P20309|P08173|P08912|Q9NYX4|P09211,P05177|P10635|P11712|P08684|P33261|P11509|P10632|P31513|P22310|P05181|P04798|Q16678,hsa:1813|hsa:3356|hsa:1812|hsa:1814|hsa:1815|hsa:3350|hsa:3351|hsa:3352|hsa:3354|hsa:3358|hsa:3359|hsa:3362|hsa:3363|hsa:3269|hsa:59340|hsa:148|hsa:147|hsa:150|hsa:151|hsa:152|hsa:1128|hsa:1129|hsa:1131|hsa:1132|hsa:1133|hsa:50632|hsa:2950,9|10|11|12|14|15|16|37|178|180|181|182|185|189|192|213|218|219|283|284|285|294|299|332|333|340|342|344|345|351|355|356|362|365|370|371|374|375|376|377|384|390|391|392|393|416|418|430|434|437|438|441|442|446|449|450|453|464|470|487|490|495|501|502|503|516|519|520|524|538|540|545|546|547|549|550|552|555|556|564|569|570|576|577|578|582|584|585|591|592|593|595|596|598|599|600|603|607|608|611|613|618|628|633|634|640|643|656|657|660|664|665|668|677|678|679|683|688|708|709|710|729|750|758|770|792|813|821|833,Clozapine,"Adrenergic alpha-1 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Agents producing tachycardia| Agents that produce hypertension| Agents that reduce seizure threshold| Anticholinergic Agents| Antidepressive Agents| Antipsychotic Agents| Antipsychotic Agents (Second Generation [Atypical])| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Inhibitors (weak)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (moderate)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (moderate)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Diazepines, Oxazepines, Thiazepines and Oxepines| Dibenzazepines| Dopamine Antagonists| Dopamine D2 Receptor Antagonists| Drugs causing inadvertant photosensitivity| Drugs that are Mainly Renally Excreted| GABA Agents| GABA Antagonists| Heterocyclic Compounds| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Histamine Antagonists| Histamine H1 Antagonists| Hyperglycemia-Associated Agents| Hypotensive Agents| Moderate Risk QTc-Prolonging Agents| Muscarinic Antagonists| Nervous System| Neurotoxic agents| Neurotransmitter Agents| OCT1 substrates| P-glycoprotein substrates| Photosensitizing Agents| Psycholeptics| Psychotropic Drugs| QTc Prolonging Agents| Serotonin 5-HT1 Receptor Antagonists| Serotonin 5-HT1A Receptor Antagonists| Serotonin 5-HT1D Receptor Antagonists| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin 5-HT2C Receptor Antagonists| Serotonin Agents| Serotonin Receptor Antagonists| Tranquilizing Agents| UGT1A4 substrates"
368,DB04794,P10613|P20813,P11511|P33261|P05181|P08684,hsa:1555,9|10|11|12|14|15|143|148|149|178|182|185|189|192|196|283|284|285|332|333|338|340|344|345|351|355|356|358|365|370|371|372|373|375|376|379|384|387|389|390|391|396|397|403|416|418|430|434|435|441|442|445|446|447|449|450|453|464|470|472|482|484|485|487|490|491|495|499|502|504|506|516|519|520|521|524|539|540|546|547|549|552|556|560|564|569|570|572|578|582|584|592|595|596|599|603|607|608|611|613|618|628|633|634|636|640|654|656|660|664|668|674|677|678|679|683|688|696|697|708|709|710|712|713|776,Bifonazole,"Anti-Infective Agents| Antifungal Agents| Antifungals for Dermatological Use| Antifungals for Topical Use| Azole Antifungals| Azoles| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 Enzyme Inhibitors| Dermatologicals| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Imidazole and Triazole Derivatives"
369,DB00328,P23219|P35354|P14555|Q8N8N7|P37231|Q04760|Q9Y5Y4|Q07869|P42330,P33261|P11712|P23141|O60656|P22309|P16662,hsa:5742|hsa:5743|hsa:5320|hsa:145482|hsa:5468|hsa:2739|hsa:11251|hsa:5465|hsa:8644,9|10|11|12|14|18|19|20|37|143|148|149|178|182|185|189|283|284|285|286|294|308|332|333|340|341|342|344|351|352|355|356|357|358|362|366|370|371|374|376|377|380|381|382|384|385|386|387|390|391|396|397|403|405|406|416|418|420|430|431|434|437|439|440|441|442|443|446|449|451|452|453|464|470|472|476|482|490|493|495|498|501|502|503|506|516|520|523|524|530|535|538|539|541|542|545|546|548|549|550|552|553|555|556|564|565|570|573|574|576|577|578|579|582|584|585|589|591|592|594|595|597|598|599|600|603|604|606|607|608|613|617|618|619|623|626|628|633|634|637|640|641|645|651|655|656|657|660|664|665|666|668|671|672|677|678|679|680|682|683|684|685|688|689|691|692|695|696|697|698|699|702|703|704|707|708|709|710|712|717|721|735|758|780|784|798|821,Indomethacin,"Acetic Acid Derivatives and Related Substances| Agents causing hyperkalemia| Agents that produce hypertension| Analgesics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)| Antigout Preparations| Antiinflammatory and Antirheumatic Products| Antiinflammatory and Antirheumatic Products, Non-Steroids| Antiinflammatory Preparations, Non-Steroids for Topical Use| Antirheumatic Agents| BSEP/ABCB11 Substrates| Cardiac Therapy| Cardiovascular Agents| Cardiovascular System| Central Nervous System Agents| Cyclooxygenase Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hypoglycemia-Associated Agents| Immunosuppressive Agents| Indoles| Musculo-Skeletal System| Myelosuppressive Agents| Nephrotoxic agents| Non COX-2 selective NSAIDS| OAT1/SLC22A6 inhibitors| OAT1/SLC22A6 Substrates| OAT3/SLC22A8 Inhibitors| OAT3/SLC22A8 Substrates| OATP1B1/SLCO1B1 Inhibitors| Ophthalmologicals| Other Nonsteroidal Anti-inflammatory Agents| P-glycoprotein inhibitors| P-glycoprotein substrates| Peripheral Nervous System Agents| Sensory Organs| Sensory System Agents| Tocolytic Agents| Topical Products for Joint and Muscular Pain| UGT1A1 Inhibitors| UGT1A1 Substrates| UGT1A9 Substrates| UGT2B7 Inhibitors| UGT2B7 substrates"
370,DB06410,P11473,Q02318,hsa:7421,0|1|9|10|11|12|18|19|143|144|178|179|185|186|283|284|286|308|332|333|334|335|339|341|344|346|352|366|374|406|416|430|434|441|446|490|516|524|556|564|571|573|582|599|617|637|639|640|641|660|664|667|678|679|680|688|689|690|696|697|701|708|709|710|711|712|803|818|839|860,Doxercalciferol,"Anti-Parathyroid Agents| Bone Density Conservation Agents| Calcium Homeostasis| Cholestanes| Cholestenes| Diet, Food, and Nutrition| Food| Fused-Ring Compounds| Lipids| Medications that increase serum magnesium| Membrane Lipids| Micronutrients| Physiological Phenomena| Polycyclic Compounds| Secosteroids| Steroids| Sterols| Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins| Vitamin D and Analogues| Vitamins| Vitamins (Fat Soluble)"
371,DB00674,P22303|P02708|P11230|Q07001|P07510|Q04844|Q15822|P32297|P43681|P30532|Q15825|P36544|Q9UGM1|Q9GZZ6|P17787|Q05901|P30926|P06276,P08684|P10635,hsa:43|hsa:1134|hsa:1140|hsa:1144|hsa:1146|hsa:1145|hsa:1135|hsa:1136|hsa:1137|hsa:1138|hsa:8973|hsa:1139|hsa:55584|hsa:57053|hsa:1141|hsa:1142|hsa:1143|hsa:590,9|10|11|12|14|18|19|143|146|178|182|185|189|213|218|219|283|284|285|286|308|332|333|334|339|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|391|405|406|416|430|434|441|446|464|470|476|490|498|516|520|524|540|541|542|544|548|549|552|556|564|565|567|570|571|573|574|578|582|584|589|592|594|595|599|603|604|606|607|608|613|614|617|618|619|620|626|628|630|632|633|634|637|639|640|641|651|655|656|660|662|664|666|667|668|677|678|679|680|682|683|688|689|690|691|696|697|698|699|700|701|702|708|709|710|711|712|714|735|755|756|761|777|798|818|819|824,Galantamine,"Alkaloids| Amaryllidaceae Alkaloids| Anti-Dementia Drugs| Autonomic Agents| Benzazepines| Bradycardia-Causing Agents| Central Nervous System Agents| Cholinergic Agents| Cholinesterase Inhibitors| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Nervous System| Neurotransmitter Agents| Nootropic Agents| P-glycoprotein inhibitors| Parasympathomemetic (Cholinergic) Agents| Parasympathomimetics| Peripheral Nervous System Agents| Potential QTc-Prolonging Agents| Psychoanaleptics| QTc Prolonging Agents"
372,DB04946,P28223|P14416|P21728|P35462|P21917|P08908|P50406|P34969|P35348|P35367|P18825,P10635|P20815|P08684|P24462|P05181|P05177,hsa:3356|hsa:1813|hsa:1812|hsa:1814|hsa:1815|hsa:3350|hsa:3362|hsa:3363|hsa:148|hsa:3269|hsa:152,9|10|11|12|14|15|18|19|20|23|143|148|149|178|180|181|182|185|189|192|283|284|285|286|287|301|332|333|335|340|341|344|345|346|351|352|355|356|357|358|364|365|366|370|371|374|376|381|382|384|385|387|390|391|395|405|416|418|420|423|430|431|432|434|437|441|442|443|446|449|454|464|470|476|490|493|498|514|516|520|523|524|530|535|538|539|540|541|542|544|545|548|549|552|553|555|556|558|564|565|567|570|573|574|576|578|579|580|582|584|589|592|594|595|597|599|600|603|604|606|607|608|613|614|618|619|620|623|624|626|630|632|633|634|637|638|640|641|651|652|655|656|660|662|664|665|666|668|671|672|673|677|678|679|680|683|684|686|688|689|692|693|696|697|698|699|704|705|708|709|710|714|735|756|761|777|798|819|824,Iloperidone,"Adrenergic alpha-1 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Agents that produce hypertension| Antidepressive Agents| Antipsychotic Agents| Antipsychotic Agents (Second Generation [Atypical])| Azoles| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Substrates| Dopamine Antagonists| Dopamine D2 Receptor Antagonists| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Highest Risk QTc-Prolonging Agents| Histamine Antagonists| Histamine H1 Antagonists| Hyperglycemia-Associated Agents| Nervous System| Neurotoxic agents| Psycholeptics| Psychotropic Drugs| QTc Prolonging Agents| Schizophrenia| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT1 Receptor Antagonists| Serotonin 5-HT1A Receptor Antagonists| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin Agents| Serotonin Receptor Antagonists| Tranquilizing Agents"
373,DB01177,P11388,P11712|P10635,hsa:7153,9|10|11|12|14|18|19|20|21|178|179|181|182|185|189|192|196|199|206|283|284|285|286|299|308|332|333|337|338|339|340|341|344|345|346|347|351|352|355|356|365|366|367|370|371|374|380|381|382|384|393|405|406|416|420|430|432|434|441|443|446|462|470|490|493|498|516|520|524|528|535|537|541|548|552|553|556|563|564|566|567|570|571|573|574|575|578|579|581|582|584|590|592|594|595|597|599|603|604|606|608|610|614|617|618|619|623|625|634|637|638|639|640|641|642|643|651|655|660|661|662|663|664|666|667|668|671|672|677|678|679|680|681|684|686|687|688|689|690|692|693|696|697|698|699|700|701|704|705|708|709|710|712|713|719|734|735|755|756|776|777|782|797|798|803|818|819,Idarubicin,"Anthracycline Topoisomerase Inhibitor| Anthracyclines| Anthracyclines and Related Substances| Antibiotics, Antineoplastic| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Carbohydrates| Cardiotoxic antineoplastic agents| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Substrates| Cytotoxic Antibiotics and Related Substances| Enzyme Inhibitors| Glycosides| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Immunosuppressive Agents| Myelosuppressive Agents| Naphthacenes| Narrow Therapeutic Index Drugs| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Topoisomerase II Inhibitors| Topoisomerase Inhibitors"
374,DB06203,P27487,P08684|P10635,hsa:1803,9|10|11|12|14|15|16|18|19|178|180|181|182|183|184|185|192|283|284|285|286|299|332|333|338|340|344|345|351|352|355|356|358|365|370|371|374|375|376|378|379|381|384|387|389|390|391|393|396|397|403|416|418|419|420|429|430|434|438|439|441|442|443|446|449|450|451|453|464|466|470|472|482|484|487|490|493|495|502|504|506|516|519|520|521|523|524|528|530|535|538|539|540|545|546|549|552|553|555|556|560|564|568|569|570|572|578|580|582|584|585|592|593|595|596|599|601|603|607|608|611|613|618|621|624|628|633|634|636|640|643|645|646|647|650|654|656|657|660|664|668|673|674|676|677|678|679|683|688|696|708|709|710|712|755|818,Alogliptin,"Agents causing angioedema| Alimentary Tract and Metabolism| Blood Glucose Lowering Agents| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| DPP-IV Inhibitors| Drugs that are Mainly Renally Excreted| Drugs Used in Diabetes| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Incretins| Oral Hypoglycemics| Protease Inhibitors| Pyrimidines| Pyrimidinones"
375,DB00211,P35348|P35368|P25100,P10635,hsa:148|hsa:147|hsa:146,9|10|11|14|15|18|19|20|178|182|283|284|285|286|299|308|332|333|339|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|392|393|405|406|416|420|430|434|439|441|443|446|451|470|476|490|498|516|520|524|528|536|540|541|542|548|552|556|564|565|566|569|570|571|573|574|575|578|582|584|589|592|594|595|599|603|604|606|607|608|611|613|617|618|619|626|634|637|639|640|641|643|645|646|651|655|656|659|660|664|666|667|668|677|678|679|680|681|682|683|688|689|691|696|698|699|702|708|709|710|719|735|756|782|798|819,Midodrine,Adrenergic Agents| Adrenergic Agonists| Adrenergic alpha-1 Receptor Agonists| Adrenergic alpha-Agonists| Adrenergic and Dopaminergic Agents| Agents producing tachycardia| Agents that produce hypertension| Alcohols| Amines| Amino Alcohols| Autonomic Agents| Bradycardia-Causing Agents| Cardiac Stimulants Excl. Cardiac Glycosides| Cardiac Therapy| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Substrates| Ethanolamines| Neurotransmitter Agents| Peripheral Nervous System Agents| Sympathomimetics| Vasoconstrictor Agents
376,DB00130,P17812|Q06203|P15104,P00488|O94925|Q9UI32|P21980|O43548|O95932|P22735|P49221|Q08188|Q96PF1|P49915|P08243|Q16773|O15067|O75879|O94808|P27708|P47897|Q6IA69,hsa:1503|hsa:5471|hsa:2752,9|10|14|15|18|19|283|284|285|286|299|308|332|338|340|344|345|351|352|365|380|393|406|420|439|440|443|451|452|528|535|536|566|579|582|592|617|637|643|680|683|684|685|691|693|694|695,    Lglutamine,"Alimentary Tract and Metabolism| Amino Acids| Amino Acids and Derivatives| Amino Acids, Basic| Amino Acids, Diamino| Amino Acids, Neutral| Amino Acids, Peptides, and Proteins| Dietary Supplements| Glutamine| Proteinogenic Amino Acids| Supplements"
377,DB05676,Q08499|P27815|Q07343|P01375|P60568|P01579|P29474,P08684,hsa:5144|hsa:5141|hsa:5142|hsa:7124|hsa:3558|hsa:3458|hsa:4846,9|10|11|12|14|15|18|19|20|33|143|148|149|178|182|185|189|283|284|285|286|293|308|332|333|338|340|341|344|345|346|349|351|352|353|355|356|365|366|368|370|371|374|376|377|381|382|384|390|391|405|406|412|414|416|418|420|430|434|437|439|441|442|443|446|449|451|453|457|459|464|465|470|476|490|493|498|502|507|516|520|524|535|539|540|541|542|544|545|546|548|549|552|553|556|564|565|567|570|573|574|578|579|580|582|584|586|589|592|593|594|595|597|599|600|603|604|606|607|608|613|614|618|619|620|623|624|626|628|630|632|633|634|637|640|641|645|646|650|651|655|656|660|662|664|665|666|668|671|672|673|677|678|679|680|682|683|684|685|687|688|689|691|692|696|698|699|702|703|704|708|709|710|712|714|735|737|755|758|761|777|798|800|818|821|824,Apremilast,"Agents reducing cytokine levels| Anti-Inflammatory Agents| Antineoplastic and Immunomodulating Agents| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Disease-modifying Antirheumatic Agents| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, Fused-Ring| Immunosuppressive Agents| Immunotherapy| Isoindoles| P-glycoprotein substrates| Phosphodiesterase 4 Inhibitors| Phosphodiesterase Inhibitors| Phthalimides| Selective Immunosuppressants"
378,DB11560,Q96S37|Q9NSA0,P11712,hsa:116085|hsa:55867,6|9|10|11|12|14|15|18|19|33|115|116|143|148|149|178|182|185|189|272|274|283|284|285|286|293|300|308|332|333|335|340|344|349|351|352|353|355|356|368|370|371|375|376|377|379|380|384|385|389|390|391|396|397|403|406|412|416|418|420|422|430|434|437|440|441|443|446|449|450|452|453|464|467|470|473|475|482|484|486|487|489|490|495|502|504|507|516|517|519|520|524|545|546|549|552|556|560|564|570|572|578|582|584|585|592|595|596|599|600|603|607|608|613|618|628|633|634|640|654|657|660|664|665|668|674|677|678|679|683|688|696|697|708|709|710|712|716|734|737|755|758|779|797|800|818|821,Lesinurad,"Acetates| Acids, Acyclic| Antigout Preparations| Antirheumatic Agents| Azoles| Carboxylic Acids| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (weak)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Musculo-Skeletal System| Preparations Increasing Uric Acid Excretion| Sulfhydryl Compounds| Sulfur Compounds| Urate Transporter 1 Inhibitor| Urate Transporter 1 Inhibitors| Uricosuric Agents"
379,DB00956,P35372|P41143,P10635|P08684,hsa:4988|hsa:4985,9|10|11|12|14|18|19|143|146|178|179|180|181|182|185|189|192|199|283|284|285|286|332|333|334|335|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|391|405|416|420|430|432|434|441|443|446|462|470|476|490|498|516|520|524|535|537|540|541|542|544|548|552|556|564|565|567|570|573|574|578|579|582|584|589|592|594|595|599|603|604|605|606|607|608|613|614|618|619|620|626|630|632|634|637|640|641|651|655|656|660|662|664|666|668|677|678|679|680|682|683|684|688|689|690|691|692|693|695|696|697|698|699|700|701|702|703|704|705|707|708|709|710|711|712|714|735|755|756|761|776|777|779|797|798|800|818|819|821|824,Hydrocodone,"Alkaloids| Analgesics| Antitussive Agents| Central Nervous System Agents| Central Nervous System Depressants| Cough and Cold Preparations| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds with 4 or More Rings| Heterocyclic Compounds, Bridged-Ring| Heterocyclic Compounds, Fused-Ring| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Morphinans| Morphine Derivatives| Narcotics| Opiate Alkaloids| Opioid Agonist| Opioids| Opium Alkaloids and Derivatives| Peripheral Nervous System Agents| Phenanthrene opioids| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Respiratory System| Respiratory System Agents| Semi-synthetic Opioids| Sensory System Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
380,DB00316,P23219|P35354|O00519|Q8NER1|P09211,P05181|P05177|P10635|P04798|P11509|P10632|P11712|P08684|P22309|P19224|O60656|P54855|Q9HAW8|P50225|P0DMM9|P49888|Q06520|P11245,hsa:5742|hsa:5743|hsa:2166|hsa:7442|hsa:2950,9|10|11|14|18|19|178|182|283|284|285|286|299|308|332|340|341|344|351|352|355|370|371|374|376|377|381|382|384|390|392|393|406|416|420|434|437|439|441|443|446|449|451|464|470|490|495|498|502|516|520|524|541|542|545|546|548|549|552|556|564|570|573|574|578|582|584|585|590|592|595|599|600|603|606|607|608|613|617|618|619|628|633|634|637|640|641|643|645|651|655|656|657|660|664|665|667|668|677|678|679|680|682|683|689|721|784,Acetaminophen,"Acetaminophen and Prodrugs| Amides| Amines| Analgesics| Analgesics, Non-Narcotic| Anilides| Aniline Compounds| Antipyretics| Central Nervous System Agents| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Methemoglobinemia Associated Agents| Miscellaneous Analgesics and Antipyretics| Nervous System| P-glycoprotein inhibitors| P-glycoprotein substrates| Sensory System Agents| UGT1A1 Substrates| UGT1A6 substrate| UGT1A9 Substrates"
381,DB00758,Q9H244,P08684|P20813|P20815|P33261|P11712|P05177|P10632|P23141,hsa:64805,9|10|11|12|14|18|19|33|37|143|149|178|182|183|184|185|283|284|285|286|293|294|332|333|338|340|342|344|345|349|351|352|353|355|356|362|365|366|368|370|371|374|380|383|384|390|391|405|412|416|420|421|430|434|440|441|443|446|452|464|470|471|480|490|500|501|503|507|513|516|520|524|531|532|535|536|540|549|550|552|556|564|566|570|578|579|582|584|586|591|592|595|597|598|599|602|603|607|608|613|615|618|628|633|634|637|640|641|655|656|658|659|660|664|668|677|678|679|680|683|684|688|689|692|696|698|704|708|709|710|759|822,Clopidogrel,"Antiplatelet agents| Blood and Blood Forming Organs| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (moderate)| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strong)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Decreased Platelet Aggregation| Hematologic Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Neurotransmitter Agents| OCT1 inhibitors| OCT2 Inhibitors| P-glycoprotein substrates| P2Y12 Platelet Inhibitor| Platelet Aggregation Inhibitors Excl. Heparin| Purinergic Agents| Purinergic Antagonists| Purinergic P2 Receptor Antagonists| Purinergic P2Y Receptor Antagonists| Pyridines| Sulfur Compounds| Thienopyridines| Thiophenes"
382,DB01117,Q02768|Q08210|Q02127,P11712,hsa:1723,9|10|11|12|18|19|37|178|179|182|185|189|192|196|199|283|284|286|294|308|332|333|335|341|342|344|352|355|356|362|370|371|384|406|416|420|430|432|434|441|443|446|462|470|490|493|498|501|503|516|520|524|535|537|550|552|553|556|564|570|578|579|582|584|591|595|597|598|599|603|608|617|618|623|634|637|640|641|655|660|664|668|671|672|677|678|679|680|684|687|688|689|692|693|696|697|698|704|708|709|710|712|717|755|776|780|797|818,Atovaquone,"Anti-Infective Agents| Antibiotics for Pneumocystis Pneumonia| Antimalarials| Antiparasitic Agents| Antiparasitic Products, Insecticides and Repellents| Antiprotozoals| Biguanides| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Enzyme Inhibitors| Miscellaneous Antiprotozoals| Naphthalenes| Naphthoquinones| P-glycoprotein inhibitors| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Quinones"
383,DB00546,P14867|P47869|P34903|P31644|Q8N1C3|P18507|Q99928|P18505|P47870|P28472|O14764|P78334|O00591|P24046|P28476|A8MPY1,P33261|P08684,hsa:2554|hsa:2555|hsa:2556|hsa:2558|hsa:2565|hsa:2566|hsa:2567|hsa:2560|hsa:2561|hsa:2562|hsa:2563|hsa:2564|hsa:2568|hsa:2569|hsa:2570|hsa:200959,9|10|11|12|14|15|16|37|143|148|149|178|182|185|189|213|218|219|283|284|285|294|300|332|333|340|342|344|345|351|355|356|358|359|362|365|370|371|374|375|376|377|379|384|389|390|391|396|397|403|416|418|422|430|431|434|437|438|441|442|446|449|450|453|464|467|470|472|482|484|486|487|490|495|501|502|503|504|506|515|516|517|519|520|524|538|539|540|545|546|549|550|552|555|556|560|564|569|570|572|576|578|582|584|585|591|592|595|596|598|599|600|603|607|608|611|613|618|628|633|634|640|644|654|656|657|660|664|665|668|674|677|678|679|683|688|696|697|708|709|710|729|738|758|792|801|821,Adinazolam,"Anti-Anxiety Agents| Antidepressive Agents| Benzazepines| Benzodiazepines and benzodiazepine derivatives| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Nervous System| Psycholeptics| Psychotropic Drugs| Triazolobenzodiazepines"
384,DB09224,P14416,P10635,hsa:1813,9|10|11|12|14|18|23|178|180|181|182|185|283|284|285|286|287|332|333|335|341|344|345|351|352|355|356|364|365|370|371|374|384|390|391|416|420|430|432|434|441|443|446|470|490|493|516|520|524|535|540|552|553|556|564|570|578|579|582|584|592|595|597|599|603|608|613|618|623|634|640|656|660|664|668|671|672|677|678|679|683|684|685|688|692|696|704|708|709|710,Melperone,Antiarrhythmic agents| Antipsychotic Agents| Antipsychotic Agents (Second Generation [Atypical])| Butyrophenone Derivatives| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Dopamine Antagonists| Dopamine D2 Receptor Antagonists| Drugs that are Mainly Renally Excreted| Ketones| Moderate Risk QTc-Prolonging Agents| Nervous System| Neurotoxic agents| Psycholeptics| Psychotropic Drugs| QTc Prolonging Agents| Tranquilizing Agents
385,DB00814,P35354|P23219,P11712|P08684|P52209|P10632,hsa:5743|hsa:5742,9|10|11|14|15|18|19|20|33|34|143|148|149|178|182|183|184|185|283|284|285|286|293|299|305|308|332|333|340|341|344|345|351|352|353|355|356|358|365|370|371|372|373|374|375|376|379|383|384|387|390|392|393|396|403|406|412|414|416|418|420|421|430|434|435|437|439|441|442|443|445|446|447|449|450|451|453|457|459|464|465|470|472|473|474|475|480|482|483|484|487|489|490|491|495|498|500|506|507|508|511|513|516|519|520|521|523|524|531|532|533|536|538|540|545|548|552|553|556|560|564|569|570|573|574|578|582|584|585|595|596|599|602|603|608|611|613|617|618|619|634|636|637|640|641|647|654|655|657|660|664|667|668|671|674|677|678|679|680|688|689|698|708|709|710|757|820,Meloxicam,"Agents causing hyperkalemia| Agents that produce hypertension| Amides| Analgesics| Analgesics, Non-Narcotic| Anesthetics| Anesthetics, Local| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)| Antiinflammatory and Antirheumatic Products| Antiinflammatory and Antirheumatic Products, Non-Steroids| Antirheumatic Agents| Azoles| COX-2 Inhibitors| Cyclooxygenase Inhibitors| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Musculo-Skeletal System| Nephrotoxic agents| Nervous System| Other Nonsteroidal Anti-inflammatory Agents| Oxicams| Peripheral Nervous System Agents| Selective Cyclooxygenase 2 Inhibitors (NSAIDs)| Sensory System Agents| Sulfur Compounds| Thiazines| Thiazoles"
386,DB00543,P23975|P31645|P14416|P21728|P08913|P35348|P11229|P14867|P28223|P28335|P50406|P34969|P35462|P21917|P35367|BE0004863|BE0004890|P41595|P46098|P08908|P28222|BE0004864|Q9H3N8|BE0004797|Q01959,P10635,hsa:6530|hsa:6532|hsa:1813|hsa:1812|hsa:150|hsa:148|hsa:1128|hsa:2554|hsa:3356|hsa:3358|hsa:3362|hsa:3363|hsa:1814|hsa:1815|hsa:3269|hsa:3357|hsa:3359|hsa:3350|hsa:3351|hsa:59340|hsa:6531,9|10|11|12|14|15|18|37|178|180|181|182|185|189|192|213|218|219|283|284|285|286|294|299|332|333|340|341|342|344|345|351|352|355|356|362|365|370|371|375|376|377|381|382|384|390|391|392|393|405|416|418|430|434|437|438|441|442|446|449|450|453|464|470|476|487|490|498|501|502|503|516|519|520|524|528|538|540|541|542|543|545|546|548|549|550|552|555|556|564|565|566|569|570|573|574|576|578|582|584|589|591|592|594|595|596|598|599|600|603|604|606|607|608|611|613|614|615|618|619|620|626|628|632|633|634|637|638|640|641|643|651|655|656|660|664|665|666|668|677|678|679|680|683|688|689|698|708|709|710|722|738|756|763|785|801|819|826,Amoxapine,"Adrenergic Agents| Adrenergic alpha-1 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Adrenergic Uptake Inhibitors| Agents producing tachycardia| Agents that produce hypertension| Agents that reduce seizure threshold| Anticholinergic Agents| Antidepressive Agents| Antidepressive Agents Indicated for Depression| Antidepressive Agents, Tetracyclic| Antidepressive Agents, Tricyclic| Antipsychotic Agents| Central Nervous System Agents| Central Nervous System Depressants| Combined Inhibitors of Serotonin/Norepinephrine Reuptake| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dibenzoxazepines| Dopamine Agents| Dopamine Antagonists| Dopamine D2 Receptor Antagonists| Heterocyclic Compounds| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Histamine Antagonists| Histamine H1 Antagonists| Membrane Transport Modulators| Muscarinic Antagonists| Narrow Therapeutic Index Drugs| Nervous System| Neurotoxic agents| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| Non-Selective Monoamine Reuptake Inhibitors| P-glycoprotein inhibitors| Potential QTc-Prolonging Agents| Psychoanaleptics| Psychotropic Drugs| QTc Prolonging Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT1 Receptor Antagonists| Serotonin 5-HT1A Receptor Antagonists| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin 5-HT2C Receptor Antagonists| Serotonin Agents| Serotonin Modulators| Serotonin Receptor Antagonists"
387,DB00467,P43700|P43702|P11388,P05177,hsa:7153,9|10|11|14|15|16|18|19|23|178|180|181|183|184|185|190|191|192|283|284|285|286|287|299|308|332|333|341|344|345|351|352|355|356|358|359|364|365|370|371|372|373|374|375|376|378|379|380|381|382|384|385|387|388|389|390|391|392|393|396|397|403|406|416|418|420|430|432|434|435|438|440|441|442|443|445|446|447|449|450|452|453|464|470|472|482|484|487|490|491|493|495|504|506|519|520|521|523|524|528|530|535|538|540|545|548|549|552|553|555|556|560|564|569|570|572|573|574|576|577|578|579|580|581|582|584|585|588|592|595|596|597|600|603|607|608|611|613|617|618|619|623|624|628|633|634|636|637|638|640|641|642|643|654|655|656|657|660|664|665|667|668|671|672|673|674|677|678|679|680|683|684|688|689|691|692|695|697|698|702|704|708|709|710,Enoxacin,"Anti-Bacterial Agents| Anti-Infective Agents| Antibacterials for Systemic Use| Antiinfectives for Systemic Use| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strong)| Cytochrome P-450 Enzyme Inhibitors| Enzyme Inhibitors| Fluoroquinolones| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Metabolic Side Effects of Drugs and Substances| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Quinolines| Quinolones| Topoisomerase II Inhibitors| Topoisomerase Inhibitors"
388,DB01394,Q9H4B7|P07437,P08684|P20813|P10632|P11712|P05181,hsa:81027|hsa:203068,9|10|11|12|14|18|19|20|178|182|213|217|220|224|283|284|285|286|299|332|333|338|340|341|344|345|351|352|355|356|365|366|370|371|374|381|382|384|390|392|393|405|416|420|430|432|434|439|441|443|446|451|462|464|470|476|490|493|498|516|520|524|528|535|537|540|541|542|544|548|549|552|553|556|564|565|567|570|573|574|575|578|579|582|584|589|592|594|595|597|599|603|604|605|606|607|608|613|618|619|623|626|628|630|633|634|637|639|640|641|643|645|646|651|653|655|656|660|662|664|666|668|671|672|677|678|679|680|683|684|685|688|689|690|691|692|696|697|698|699|700|701|702|703|704|708|709|710|712|714|735|740|755|756|761|777|798|803|818|819|824,Colchicine,Agents Causing Muscle Toxicity| Alkaloids| Antigout Preparations| Antimitotic Agents| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2E1 Inducers| Cytochrome P-450 CYP2E1 Inducers (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Experimental Unapproved Treatments for COVID-19| Heterocyclic Compounds| Mitosis Modulators| Musculo-Skeletal System| P-glycoprotein inducers| P-glycoprotein substrates| Preparations With No Effect on Uric Acid Metabolism| Tubulin Modulators
389,DB09229,Q13936|Q01668|O60840|Q13698|BE0004888,BE0004866,hsa:775|hsa:776|hsa:778|hsa:779,9|10|11|12|14|15|18|19|20|178|182|183|184|185|283|284|285|286|299|301|332|333|335|340|341|344|346|351|352|355|356|366|370|371|374|376|377|380|384|390|392|393|395|401|405|416|420|423|430|432|434|437|440|441|443|446|449|452|454|455|462|464|470|490|502|514|516|520|524|535|537|545|546|549|552|553|556|558|564|570|573|578|579|582|584|592|594|595|599|600|603|605|607|608|614|618|619|633|634|637|640|643|656|660|664|665|666|668|671|673|677|678|679|680|683|684|688|689|690|691|692|693|694|695|696|697|698|700|703|704|707|708|709|710|712|758|821,Aranidipine,"Agents causing hyperkalemia| Antiarrhythmic agents| Bradycardia-Causing Agents| Calcium Channel Blockers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Potential QTc-Prolonging Agents| Pyridines| QTc Prolonging Agents| Vasodilating Agents"
390,DB00627,P49019|Q8TDS4|Q15274|P40261,P10635,hsa:8843|hsa:338442|hsa:23475|hsa:4837,9|10|14|18|19|178|183|184|283|284|285|286|308|332|333|344|345|351|352|355|356|358|365|370|371|372|373|376|380|384|387|390|396|403|406|416|418|420|430|434|435|440|441|442|443|445|446|447|449|452|453|464|470|472|482|490|491|493|495|502|506|516|520|521|523|524|530|535|538|539|540|545|546|548|549|552|553|555|556|564|570|573|574|576|577|578|579|580|582|584|585|592|595|597|599|600|603|607|608|613|617|618|619|623|624|628|633|634|637|638|640|641|655|656|657|660|664|665|667|668|671|672|673|677|678|680|683|684|691|695|702|708|709,Niacin,"Acids, Heterocyclic| Agents Causing Muscle Toxicity| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Diet, Food, and Nutrition| Food| Growth Substances| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hyperglycemia-Associated Agents| Hypolipidemic Agents| Hypolipidemic Agents Indicated for Hyperlipidemia| Lipid Modifying Agents| Lipid Modifying Agents, Plain| Lipid Regulating Agents| Micronutrients| Miscellaneous Antilipemic Agents| Nicotinic Acid and Derivatives| Nicotinic Acids| Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia| Noxae| Organic Anion Transporting Polypeptide 2B1 Inhibitors| Peripheral Vasodilators| Physiological Phenomena| Pyridines| Thyroxine-binding globulin inhibitors| Toxic Actions| Vasodilating Agents| Vitamin B Complex| Vitamins"
391,DB06210,P40238,P10632|P05177|P22309|P35503,hsa:4352,9|10|11|12|14|15|16|18|19|20|143|148|149|178|182|185|189|192|196|283|284|285|286|299|300|308|332|333|340|341|344|351|352|355|356|370|371|374|376|377|380|381|382|384|390|393|394|398|406|416|418|420|430|431|434|437|439|440|441|442|443|446|449|451|452|464|467|470|477|490|493|495|498|502|515|516|518|520|524|535|538|539|541|543|545|546|548|549|552|553|556|564|566|570|573|574|578|579|582|584|585|587|590|592|595|597|599|600|603|606|607|608|613|617|618|619|623|628|633|634|637|640|641|643|644|645|651|655|656|657|660|664|665|667|668|671|672|677|678|679|680|683|684|688|689|692|696|697|698|699|704|708|709|710|712|716|734|737|755|756|763|779|797|800|818|819|826,Eltrombopag,"Acids, Carbocyclic| Azoles| BCRP/ABCG2 Inhibitors| Benzene Derivatives| Blood and Blood Forming Organs| Carboxylic Acids| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (moderate)| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Hematinics| Hemostatics| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Increased Megakaryocyte Maturation| Increased Platelet Production| OATP1B1/SLCO1B1 Inhibitors| Organic Anion Transporting Polypeptide 1B1 Inhibitors| Thrombopoietin Receptor Agonist| Thrombopoietin Receptor Agonists| UGT1A1 Inhibitors| UGT1A1 Substrates| UGT1A3 Inhibitors| UGT1A3 substrates| UGT1A4 Inhibitors| UGT1A6 Inhibitors| UGT1A9 Inhibitors| UGT2B15 Inhibitors| UGT2B7 Inhibitors"
392,DB00996,P54289|Q9NY47|Q00975|P30542|BE0004956|Q9UBS5|O75899,P54687,hsa:781|hsa:9254|hsa:774|hsa:134|hsa:2550|hsa:9568,9|10|11|14|18|19|178|179|283|284|285|286|299|308|332|333|334|344|345|351|352|365|380|393|406|420|440|443|452|528|535|579|582|592|617|637|679|680|682|683|684|685|688|689|692|696|697|698|704|708|709|710|711,Gabapentin,"Acids, Acyclic| Acids, Carbocyclic| Amines| Amino Acids| Amino Acids, Peptides, and Proteins| Aminobutyrates| Analgesics| Anti-epileptic Agent| Anticonvulsants| Butyrates| Carboxylic Acids| Central Nervous System Agents| Central Nervous System Depressants| Cyclohexanecarboxylic Acids| Cyclohexanes| Cycloparaffins| Decreased Central Nervous System Disorganized Electrical Activity| Drugs causing inadvertant photosensitivity| Gabapentin and Prodrugs| Gabapentinoids| Miscellaneous Anticonvulsants| Nervous System| Neurotransmitter Agents| Peripheral Nervous System Agents| Photosensitizing Agents| Psychotropic Drugs| Sensory System Agents| Tranquilizing Agents"
393,DB00389,P07202,P11511|P05177,hsa:7173,9|10|14|15|18|19|33|143|148|149|283|284|285|286|293|344|345|346|351|352|358|365|366|370|372|373|374|375|376|379|380|387|389|390|391|396|397|403|405|416|418|420|421|435|442|445|446|447|449|450|451|452|453|472|482|484|485|487|491|495|499|502|504|506|508|516|519|521|539|540|546|547|560|569|572|596|611|612|636|645|646|647|654|674,Carbimazole,"Agents Causing Muscle Toxicity| Antithyroid agents| Azoles| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hormone Antagonists| Hormones, Hormone Substitutes, and Hormone Antagonists| Imidazoles| Sulfur-Containing Imidazole Derivatives| Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins| Thyroid Products"
394,DB00575,P08913|P18089|P18825|P35348|P35368|P25100,P10635|P05177|P08684|P04798|P20815,hsa:150|hsa:151|hsa:152|hsa:148|hsa:147|hsa:146,9|10|11|14|15|37|38|143|148|149|178|182|283|284|285|294|299|332|340|342|344|345|351|355|362|365|370|371|375|376|377|384|390|392|393|416|418|434|437|441|446|449|450|453|464|470|487|490|495|501|503|516|519|520|524|528|540|545|549|550|552|556|560|564|569|570|578|582|584|585|591|592|595|596|598|599|600|603|607|608|609|611|613|618|628|633|634|636|640|643|654|657|660|664|665|668|674|677|678|679|683|752|771|815|834,Clonidine,"Adrenergic Agents| Adrenergic Agonists| Adrenergic alpha-1 Receptor Agonists| Adrenergic alpha-2 Receptor Agonists| Adrenergic alpha-Agonists| Agents producing tachycardia| Agents that produce hypertension| Analgesics| Anesthetics| Anesthetics, General| Antiadrenergic Agents, Centrally Acting| Antiglaucoma Preparations and Miotics| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Antimigraine Preparations| Autonomic Agents| Azoles| Bradycardia-Causing Agents| Cardiovascular Agents| Cardiovascular System| Central alpha-2 Adrenergic Agonist| Central Alpha-agonists| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypotensive Agents| Imidazoles| Imidazoline Receptor Agonists| Imidazolines| Narrow Therapeutic Index Drugs| Nervous System| Neurotransmitter Agents| Ophthalmologicals| Peripheral Nervous System Agents| Sensory Organs| Sensory System Agents| Sympatholytics| Sympathomimetics in Glaucoma Therapy"
395,DB00993,P00492|P63000,P47989|P51580|P08263|P09210|P09488,hsa:3251|hsa:5879,9|10|11|14|15|16|18|19|33|143|148|149|150|155|156|178|183|184|283|284|285|293|299|301|332|340|351|353|355|357|358|359|365|373|374|375|376|377|378|379|383|384|386|387|388|389|390|391|392|393|395|396|397|399|400|401|403|412|416|418|423|431|437|438|441|442|447|449|450|453|454|455|464|472|473|475|482|484|485|487|488|489|491|495|499|500|504|506|507|514|519|521|523|527|528|530|531|533|538|540|545|547|549|555|558|560|569|572|585|586|593|596|601|611|613|621|628|629|636|648|654|657|658|674,Azathioprine,"Antimetabolites| Antineoplastic and Immunomodulating Agents| Antirheumatic Agents| Carbohydrates| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Glycosides| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Immunologic Factors| Immunosuppressive Agents| Immunotherapy| Noxae| Nucleic Acid Synthesis Inhibitors| Nucleic Acids, Nucleotides, and Nucleosides| Nucleosides| P-glycoprotein substrates| Purine Antimetabolite| Purines| Sulfhydryl Compounds| Sulfur Compounds| Thionucleosides| Thiopurine Analogs| Toxic Actions"
396,DB00445,O14646|P11388,P16662|P47712,hsa:1105|hsa:7153,9|10|11|12|14|18|19|20|21|178|181|182|185|189|192|196|199|203|206|283|284|285|286|299|308|332|333|337|338|339|340|341|344|345|346|347|351|352|355|356|365|366|367|370|371|374|380|381|382|384|393|405|406|416|420|430|432|434|441|443|446|462|470|476|490|493|498|516|520|524|528|535|537|541|542|548|552|553|556|563|564|565|566|567|570|571|573|574|575|578|579|581|582|584|589|590|592|594|595|597|599|603|604|606|608|610|614|617|618|619|623|625|626|634|637|638|639|640|641|642|643|651|655|660|661|662|663|664|666|667|668|671|672|677|678|679|680|681|684|686|687|688|689|690|692|693|696|697|698|699|700|701|704|705|708|709|710|712|713|719|734|735|755|756|776|777|782|797|798|803|818|819,Epirubicin,"Anthracycline Topoisomerase Inhibitor| Anthracyclines| Anthracyclines and Related Substances| Antibiotics, Antineoplastic| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Carbohydrates| Cardiotoxic antineoplastic agents| Cytotoxic Antibiotics and Related Substances| Enzyme Inhibitors| Glycosides| Hepatotoxic Agents| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Immunosuppressive Agents| Myelosuppressive Agents| Naphthacenes| Narrow Therapeutic Index Drugs| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Topoisomerase II Inhibitors| Topoisomerase Inhibitors| UGT2B7 substrates| UGT2B7 Substrates with a Narrow Therapeutic Index"
397,DB05541,Q7L0J3|BE0004901,P08684|P33261|P20813|P11712,hsa:9900,9|10|11|14|15|18|19|143|145|146|283|284|285|286|299|332|333|335|338|340|344|345|351|352|365|374|390|391|393|420|439|443|451|535|536|540|569|579|582|592|602|611|613|643|645|646|656|679|683|684|685|692|708|709|710,Brivaracetam,"Anticonvulsants| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Epoxide Hydrolase Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Miscellaneous Anticonvulsants| Nervous System| Pyrrolidines"
398,DB00411,P11229|P08172|Q15822|P22303|P20309|P08173,P47712,hsa:1128|hsa:1129|hsa:1135|hsa:43|hsa:1131|hsa:1132,9|10|14|15|18|19|37|283|284|285|286|299|344|345|346|351|352|365|366|374|380|390|391|393|405|420|451|452|540|559|566|612|615|659,Carbachol,"Alcohols| Amines| Amino Alcohols| Ammonium Compounds| Analgesics| Analgesics, Non-Narcotic| Antiglaucoma Preparations and Miotics| Autonomic Agents| Cardiotonic Agents| Cardiovascular Agents| Central Nervous System Agents| Choline Esters| Cholinergic Agents| Cholinergic Agonists| Cholinergic Receptor Agonist| Compounds used in a research, industrial, or household setting| Ethanolamines| Miotics| Nervous System| Neurotransmitter Agents| Nitrogen Compounds| Onium Compounds| Ophthalmologicals| Parasympathomemetic (Cholinergic) Agents| Parasympathomimetics| Peripheral Nervous System Agents| Protective Agents| Quaternary Ammonium Compounds| Sensory Organs| Sensory System Agents| Trimethyl Ammonium Compounds"
399,DB09195,P28223|P28335|BE0004863|BE0004864|P35367|P31645,P10635|P08684,hsa:3356|hsa:3358|hsa:3269|hsa:6532,9|10|11|12|14|15|16|23|24|143|144|145|146|148|149|150|157|178|180|181|182|185|283|284|285|287|300|332|333|335|340|344|345|351|355|356|358|359|363|365|370|371|375|376|377|379|384|389|390|391|396|397|403|416|418|422|430|434|437|438|441|442|446|449|450|453|464|467|470|472|484|486|487|490|495|502|504|506|515|516|517|519|520|521|524|538|539|540|545|546|549|552|556|560|564|569|570|572|578|582|584|585|592|593|595|596|599|600|603|607|608|611|613|618|628|633|634|640|644|654|656|657|660|664|665|668|677|678|679|683|688|708|709|710|712|737|800|860,Lorpiprazole,Antidepressive Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin 5-HT2C Receptor Antagonists| Serotonin Agents| Serotonin Modulators| Serotonin Receptor Antagonists
400,DB00731,Q09428|P37231,P11712|P08684|P20815|P24462|P23219|O60656|P10635,hsa:6833|hsa:5468,9|10|11|12|14|18|19|178|179|182|185|283|284|285|286|308|332|333|335|338|340|344|345|351|352|355|356|365|370|371|374|380|384|390|406|416|418|420|430|434|440|441|442|443|446|452|453|470|490|516|520|524|535|536|538|539|552|556|564|566|570|578|579|582|584|592|595|599|603|607|608|617|618|634|637|640|660|664|668|677|678|679|680|683|684|688|689|692|696|697|698|699|704|708|709|710|712|776,Nateglinide,"Alimentary Tract and Metabolism| Amino Acids| Amino Acids, Aromatic| Amino Acids, Cyclic| Amino Acids, Peptides, and Proteins| Blood Glucose Lowering Agents| Cyclohexanes| Cycloparaffins| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Drugs Used in Diabetes| Glinide| Hydrocarbons| Hydrocarbons, Alicyclic| Hydrocarbons, Cyclic| Hypoglycemia-Associated Agents| Insulin Secretagogues| OAT1/SLC22A6 inhibitors| Oral Hypoglycemics| Potassium Channel Blockers| UGT1A9 Substrates"
401,DB01211,P0A7J6|Q12809|Q9Y6L6|Q9NPD5,P08684|P20815|P33261|P24462|P05177,hsa:3757|hsa:10599|hsa:28234,9|10|11|12|13|14|18|19|20|21|178|181|185|188|283|284|285|286|308|332|333|335|337|338|339|340|341|344|345|346|347|351|352|365|366|367|374|380|390|391|405|406|420|432|440|443|452|535|540|563|566|567|571|579|581|582|592|610|613|614|617|637|638|639|642|659|661|662|663|679|680|681|684|686|688|689|690|692|693|696|697|698|699|700|701|704|705|708|709|710,Clarithromycin,"Alimentary Tract and Metabolism| Anti-Bacterial Agents| Anti-Infective Agents| Antibacterials for Systemic Use| Antiinfectives for Systemic Use| BSEP/ABCB11 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strong)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (strong)| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs for Acid Related Disorders| Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)| Enzyme Inhibitors| Erythromycin and similars| Lactones| Macrolide Antimicrobial| Macrolides| Macrolides, Lincosamides and Streptogramins| Metabolic Side Effects of Drugs and Substances| Moderate Risk QTc-Prolonging Agents| OATP1B1/SLCO1B1 Inhibitors| OATP1B3 inhibitors| Other Macrolides| P-glycoprotein inhibitors| P-glycoprotein substrates| Polyketides| Protein Synthesis Inhibitors| QTc Prolonging Agents"
402,DB09048,P25103,Q9HB55|P11712|P10635|P08684,hsa:6869,9|10|11|12|14|15|16|18|23|24|25|178|180|181|182|183|184|185|189|192|199|283|284|285|286|287|332|333|334|340|344|345|351|352|355|356|358|363|365|370|371|372|373|374|375|376|377|378|379|384|387|390|391|396|403|416|418|420|430|434|435|437|438|439|441|442|443|445|446|447|449|450|451|453|464|470|472|482|484|487|490|491|495|499|502|506|516|519|520|521|523|524|530|535|538|539|540|545|546|547|549|552|555|556|560|564|569|570|577|578|579|582|584|585|592|595|596|597|599|600|603|607|608|611|613|618|628|633|634|636|640|645|646|654|656|657|660|664|665|668|674|677|678|679|683|684|688|692|696|697|704|708|709|710|711|712|734|755|797|818,Netupitant,"Acetamides| Amides| BCRP/ABCG2 Inhibitors| Benzene Derivatives| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (moderate)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Netupitant and prodrug| Neurokinin 1 Antagonists| P-glycoprotein inhibitors| Substance P/Neurokinin-1 Receptor Antagonist"
403,DB04861,P08588|P07550,P10635,hsa:153|hsa:154,9|10|11|12|14|18|19|20|23|24|178|182|184|185|189|191|192|199|283|284|285|286|287|299|308|332|333|339|341|344|345|346|351|352|355|356|364|365|366|370|371|381|382|384|390|392|393|405|406|416|430|434|441|446|470|476|490|498|516|520|524|528|540|541|542|548|552|556|564|565|566|567|570|571|573|574|578|582|584|589|592|594|595|599|603|604|606|608|613|614|617|618|619|620|626|632|634|637|638|640|641|643|651|655|656|659|660|662|663|664|666|668|677|678|679|680|683|688|689|696|697|698|699|708|709|710|756|819,Nebivolol,"Adrenergic Agents| Adrenergic Agonists| Adrenergic Antagonists| Adrenergic beta-1 Receptor Agonists| Adrenergic beta-Agonists| Adrenergic beta-Antagonists| Agents causing hyperkalemia| Alcohols| Amines| Amino Alcohols| Antiarrhythmic agents| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Benzopyrans| Beta blocking agents and calcium channel blockers| Beta Blocking Agents and Thiazides| Beta Blocking Agents, Selective| Beta Blocking Agents, Selective, and Thiazides| Beta-Blockers (Beta1 Selective)| Bradycardia-Causing Agents| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Ethanolamines| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hypotensive Agents| Neurotransmitter Agents| Pyrans| Vasodilating Agents"
404,DB01395,P06401|P08235|P10275,P35354|P06276|P08684,hsa:5241|hsa:4306|hsa:367,0|9|10|11|12|18|19|115|116|122|123|143|144|146|150|178|179|182|185|186|192|283|284|286|332|333|334|335|337|341|344|352|374|380|405|416|420|430|432|434|440|441|443|446|452|490|524|535|553|556|579|582|599|614|637|640|660|671|678|679|680|684|686|688|689|692|696|697|698|699|704|708|709|710|711|712|776|797|798|818|819|839|840|860|861,Drospirenone,"Adrenal Cortex Hormones| Agents causing hyperkalemia| Androstanes| Combination Contraceptives (with Estrogen and derivatives)| Contraceptive Agents, Female| Contraceptives, Oral| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates (strength unknown)| Cytochrome P-450 Substrates| Diuretics| Fused-Ring Compounds| Genito Urinary System and Sex Hormones| Hormonal Contraceptives for Systemic Use| Hormone Antagonists| Hormones, Hormone Substitutes, and Hormone Antagonists| Hyperglycemia-Associated Agents| Mineralocorticoid Receptor Antagonists| Natriuretic Agents| Polycyclic Compounds| Progesterone Congeners| Progestin Contraceptives| Progestins| Sex Hormones and Modulators of the Genital System| Steroids"
405,DB04574,P03372|Q92731,P08684|P05177|P11712,hsa:2099|hsa:2100,9|10|11|12|18|19|20|33|143|144|178|179|182|185|189|192|283|284|286|308|332|333|334|335|341|344|352|355|356|370|371|374|381|382|384|408|416|420|430|432|434|441|443|446|458|459|470|490|498|516|520|524|535|541|542|548|552|556|564|570|573|574|578|579|582|584|595|599|603|606|608|618|619|634|637|640|641|651|655|660|664|668|677|678|679|680|684|688|689|692|696|697|698|699|704|708|709|710|711|712|714|735|755|776|777|797|798|818|860,Estronesulfate,"17-Ketosteroids| Adrenal Cortex Hormones| Contraceptive Agents, Hormonal| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Estradiol Congeners| Estranes| Estrenes| Estrogens| Estrogens, Conjugated (USP)| Fused-Ring Compounds| Gonadal Hormones| Gonadal Steroid Hormones| Hormonal Contraceptives for Systemic Use| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Hyperglycemia-Associated Agents| Ketosteroids| MATE 1 Substrates| MATE 2 Substrates| MATE substrates| NTCP Inhibitors| Polycyclic Compounds| Reproductive Control Agents| Steroids| Thyroxine-binding globulin inducers"
406,DB12010,P43405|P0DMS8|Q99870|O00519|Q99808|P22309|O76074|P09917|P25774|P07711|P00519|P62344|P9WI81|Q9UK32|P29597|Q8NI60|P23458|P08581|Q8IY84|Q9P289|P17612|Q9Y6E0|Q13188|P42680|Q9BYT3|Q8TDR2|Q9NRP7|Q15208|Q9Y2H1|Q9UEW8|Q7L7X3|Q9UL54|Q9H2K8|Q9UHD2|Q02763|Q15569|P36897|P37173|P35590|Q9UKI8|Q86UE8|Q9UKE5|Q13470|Q07912|Q59H18|Q9BXA7|P33981|P42681|Q06418|O75385|Q8IYT8|Q6PHR2|P30291|P07947|Q56UN5|Q9NYL2|P43403|Q2M2I8|P42684|Q04771|P36896|Q96D53|Q9UM73|Q8NFD2|O14965|Q96GD4|Q9UQB9|P30530|P51451|Q9NSY1|O00238|Q13873|P51813|P15056|Q06187|Q14012|Q8IU85|Q96NX5|Q9UQM7|Q13554|Q13557|Q13555|Q8N5S9|Q96RR4|O14936|P07498|P06493|Q6DT37|P11802|Q00532|Q92772|O14757|O96017|O14578|P49759|P49760|P49761|Q9HAZ1|P07333|P41240|P48729|P68400|P19784|P53355|Q9UIK4|O43293|O15075|Q8N568|Q9C098|Q08345|Q16832|Q13627|Q9Y463|P00533|Q9BQI3|P19525|Q9P2K8|P21709|P29317|P29320|P54764|P54756|Q9UF33|Q15375|P29322|P54762|P29323|P54760|O15197|P04626|Q15303|O75460|P16591|P07332|P11362|P21802|P22607|P09769|P17948|P36888|P35916|P42345|P42685|P06241|O14976|P49840|P49841|P08631|Q9H2X6|Q9H422|Q9UPZ9|O14920|Q14164|P06213|P14616|P51617|Q9Y616|Q9NWZ3|Q08881|O60674|P52333|P35968|Q9Y2K2|P10721|O95835|P06239|P53667|P53671|Q5S007|P29376|P07948|P36507|P46734|Q13163|P52564|Q13233|Q02779|Q16584|Q12852|O43283|Q6ZN16|Q9Y2U5|Q99759|Q9Y6R4|O95382|P80192|Q92918|Q12851|Q8IVH8|O95819|Q9Y4K4|P53779|O15264|Q16539|Q8TD08|P31152|Q13164|P45984|Q8IW41|Q9P0L2|Q7KZI7|P27448|Q96L34|Q7Z460|Q9Y2H9|P42679|Q14680|Q12866|Q8N4C8|Q9BUB5|Q9HBH9|Q04912|O15146|Q15746|Q9H1R3|Q32MK0|Q86YV6|Q8NEV4|Q96PY6|Q8NG66|P51955|P51956|P51957|Q6P3R8|Q8TD19|P04629|Q16620|Q16288|O60285|Q9H093|O95747|Q13153|Q13177|O75914|O96013|Q9NQU5|Q9P286|Q00536|Q00537|P16234|P09619|O15530|Q96Q40|Q16816|Q9UBF8|O00750|O75747|O00329|P48736|P11309|Q86V86|P78356|Q8TBX8|Q99640|Q16512|Q16513|P53350|Q9NYY3|Q9H4B4|O00444|Q13131|Q13131|P22694|Q05655|Q02156|P05129|P41743|Q04759|Q15139|Q13237|Q13523|Q05397|Q14289|Q13882|P04049|P07949|Q9BRS2|Q9BVS4|O14730|Q13546|O43353|P57078|O75116|P08922|Q15418|P51812|Q52WX2|P0C264|Q96BR1|P57059|Q9H0K1|Q9H2G2|Q9NRH2|P12931|Q9H3Y6|O94804|O75716|Q9UEE5|O94768|Q8WU08,P08684|O60656,"hsa:6850|hsa:140|hsa:2166|hsa:2030|hsa:54658|hsa:8654|hsa:240|hsa:1520|hsa:1514|hsa:25|hsa:27330|hsa:7297|hsa:56997|hsa:3716|hsa:4233|hsa:167359|hsa:51765|hsa:5566|hsa:8428|hsa:6788|hsa:7006|hsa:65975|hsa:140901|hsa:27148|hsa:11329|hsa:23012|hsa:27347|hsa:57551|hsa:9344|hsa:51347|hsa:29110|hsa:7010|hsa:7016|hsa:7046|hsa:7048|hsa:7075|hsa:9874|hsa:11011|hsa:23043|hsa:8711|hsa:10188|hsa:100526835,hsa:51086|hsa:83942|hsa:7272|hsa:7294|hsa:7301|hsa:8408|hsa:9706|hsa:25989|hsa:7465|hsa:7525|hsa:80122|hsa:51776|hsa:7535|hsa:22848|hsa:27|hsa:90|hsa:91|hsa:79934|hsa:238|hsa:255239|hsa:6790|hsa:9212|hsa:6795|hsa:558|hsa:640|hsa:55589|hsa:658|hsa:659|hsa:660|hsa:673|hsa:695|hsa:8536|hsa:57118|hsa:57172|hsa:815|hsa:816|hsa:817|hsa:818|hsa:84254|hsa:10645|hsa:8573|hsa:1448|hsa:983|hsa:55561|hsa:1019|hsa:8814|hsa:8999|hsa:1111|hsa:11200|hsa:11113|hsa:1195|hsa:1196|hsa:1198|hsa:57396|hsa:1436|hsa:1445|hsa:1452|hsa:1457|hsa:1459|hsa:1612|hsa:23604|hsa:1613|hsa:9201|hsa:166614|hsa:85443|hsa:780|hsa:4921|hsa:1859|hsa:9149|hsa:1956|hsa:27102|hsa:5610|hsa:440275|hsa:2041|hsa:1969|hsa:2042|hsa:2043|hsa:2044|hsa:285220|hsa:2045|hsa:2046|hsa:2047|hsa:2048|hsa:2050|hsa:2051|hsa:2064|hsa:2066|hsa:2081|hsa:2241|hsa:2242|hsa:2260|hsa:2263|hsa:2261|hsa:2268|hsa:2321|hsa:2322|hsa:2324|hsa:2475|hsa:2444|hsa:2534|hsa:2580|hsa:2931|hsa:2932|hsa:3055|hsa:28996|hsa:10114|hsa:22858|hsa:3551|hsa:9641|hsa:3643|hsa:3645|hsa:3654|hsa:11213|hsa:51135|hsa:3702|hsa:3717|hsa:3718|hsa:3791|hsa:23387|hsa:3815|hsa:9113|hsa:3932|hsa:3984|hsa:3985|hsa:120892|hsa:4058|hsa:4067|hsa:5605|hsa:5606|hsa:5607|hsa:5608|hsa:4214|hsa:4294|hsa:4296|hsa:7786|hsa:9175|hsa:389840|hsa:10746|hsa:4215|hsa:4216|hsa:9064|hsa:4293|hsa:11184|hsa:5871|hsa:8491|hsa:9448|hsa:11183|hsa:5602|hsa:5603|hsa:1432|hsa:225689|hsa:5596|hsa:5598|hsa:5601|hsa:8550|hsa:4139|hsa:2011|hsa:4140|hsa:57787|hsa:23332|hsa:22983|hsa:4145|hsa:9833|hsa:10461|hsa:50488|hsa:8569|hsa:2872|hsa:4486|hsa:4593|hsa:4638|hsa:85366|hsa:91807|hsa:340156|hsa:53904|hsa:4750|hsa:79858|hsa:4751|hsa:4752|hsa:6787|hsa:341676|hsa:91754|hsa:4914|hsa:4915|hsa:4916|hsa:9891|hsa:81788|hsa:9943|hsa:5058|hsa:5062|hsa:5063|hsa:10298|hsa:56924|hsa:57144|hsa:5127|hsa:5128|hsa:5156|hsa:5159|hsa:5170|hsa:65061|hsa:5260|hsa:5298|hsa:5287|hsa:5288|hsa:5293|hsa:5294|hsa:5292|hsa:415116|hsa:8396|hsa:79837|hsa:9088|hsa:5585|hsa:5586|hsa:5347|hsa:10769|hsa:1263|hsa:10733|hsa:5562|hsa:5562|hsa:5567|hsa:5580|hsa:5581|hsa:5582|hsa:5584|hsa:5588|hsa:5587|hsa:5593|hsa:8899|hsa:5747|hsa:2185|hsa:5753|hsa:5894|hsa:5979|hsa:83732|hsa:55781|hsa:8780|hsa:8737|hsa:8767|hsa:9475|hsa:6098|hsa:6195|hsa:6197|hsa:388228|hsa:100130827|hsa:100533105,hsa:23678|hsa:150094|hsa:23235|hsa:9748|hsa:54861|hsa:6714|hsa:6725|hsa:6793|hsa:8576|hsa:9263|hsa:9262|hsa:202374",9|10|11|12|14|15|16|18|19|20|21|23|30|178|182|183|184|185|190|191|192|197|198|199|283|284|285|286|287|299|308|314|332|333|337|340|341|344|345|351|352|355|358|364|365|366|370|371|372|373|374|375|376|377|378|379|381|382|384|387|389|390|391|392|393|396|403|405|407|411|416|418|420|425|434|435|437|438|439|441|442|443|445|446|447|449|450|451|453|456|461|462|464|470|472|476|482|484|487|490|491|495|497|498|502|504|506|516|519|520|521|523|524|530|535|537|538|539|540|541|542|543|544|545|546|548|549|552|555|556|560|564|565|566|567|570|572|573|574|575|576|577|578|582|584|585|589|592|593|594|595|596|599|600|601|603|604|605|606|607|608|613|614|615|618|619|620|621|626|628|630|632|633|634|636|637|638|639|640|641|643|645|646|647|651|652|653|654|655|656|657|659|660|662|664|665|666|668|674|677|678|679|680|682|683|689|690|691|700|701|702|703|721|740|742|761|784|803|805|824,Fostamatinib,"Amines| BCRP/ABCG2 Inhibitors| Blood and Blood Forming Organs| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Experimental Unapproved Treatments for COVID-19| Hemostatics| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Kinase Inhibitor| Oxazines| Phosphodiesterase 5 Inhibitors| Pyridines| Tyrosine Kinase Inhibitors| UGT1A1 Inhibitors| UGT1A9 Substrates| Vasodilating Agents"
407,DB00436,P55017|Q12791|P00915|P00918|P22748,P51580,hsa:6559|hsa:3778|hsa:759|hsa:760|hsa:762,9|10|11|14|15|18|19|20|23|24|33|34|178|182|183|184|185|189|192|283|284|285|287|293|299|305|332|333|340|344|345|351|353|355|356|363|365|370|371|375|376|377|383|384|390|392|393|414|416|430|434|437|441|446|449|457|459|464|465|470|483|490|495|502|516|520|524|528|531|532|533|540|545|546|549|552|556|560|564|570|578|582|584|585|592|595|599|600|603|607|608|613|618|628|633|634|640|643|654|656|657|660|664|665|668|674|677|678|679|683|688|696|708|709|710|715|725|737|745|757|767|778|788|800|808|820|830,Bendroflumethiazide,"Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Benzothiadiazines| Bradycardia-Causing Agents| Cardiovascular Agents| Cardiovascular System| Diuretics| Genito Urinary System and Sex Hormones| Gynecological Antiinfectives and Antiseptics| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hyperglycemia-Associated Agents| Hypotensive Agents| Increased Diuresis| Low-Ceiling Diuretics and Potassium-Sparing Agents| Membrane Transport Modulators| Natriuretic Agents| Sodium Chloride Symporter Inhibitors| Sulfonamides| Sulfones| Sulfur Compounds| Thiazides"
408,DB01075,P35367|P08172,P10635|P05177|P11712|P33261|P33260|P20813|P23219,hsa:3269|hsa:1129,9|10|11|12|14|18|178|182|185|189|283|284|285|286|332|333|339|341|344|345|346|351|352|355|356|365|366|370|371|374|384|390|391|405|416|430|434|441|446|470|490|516|520|524|540|548|552|556|564|566|570|573|574|578|582|584|594|595|599|603|604|608|614|615|618|619|634|637|640|641|655|659|660|664|666|668|677|678|679|680|688|689|696|697|698|708|709|710,Diphenhydramine,"Agents producing tachycardia| Amines| Aminoalkyl Ethers| Anesthetics| Anesthetics, Local| Anti-Allergic Agents| Anticholinergic Agents| Antiemetics| Antihistamines for Systemic Use| Antihistamines for Topical Use| Antipruritics, Incl. Antihistamines, Anesthetics, Etc.| Benzene Derivatives| Benzhydryl Compounds| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dermatologicals| Drugs causing inadvertant photosensitivity| Ethanolamine Derivatives| Ethylamines| First Generation Antihistamines| Gastrointestinal Agents| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Hypnotics and Sedatives| Muscarinic Antagonists| OCT2 Inhibitors| Photosensitizing Agents| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Sleep Aids, Pharmaceutical"
409,DB00741,P04150|P04083|P80365|P14060,P08684|P20815|P24462|P15538|P19099|P10632,hsa:2908|hsa:301|hsa:3291|hsa:3283,9|10|11|12|18|19|20|143|144|178|179|182|185|186|192|283|284|286|308|332|333|334|335|337|339|341|344|346|352|366|374|406|416|420|430|432|434|441|443|446|462|490|524|535|537|553|556|571|579|582|599|617|637|639|640|660|671|678|679|680|681|684|688|689|692|693|696|697|698|699|704|705|708|709|710|711|712|776|777|797|798|818|819|839|840|860|861,Hydrocortisone,"11-Hydroxycorticosteroids| 17-Hydroxycorticosteroids| Adrenal Cortex Hormones| Adrenals| Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use| Alimentary Tract and Metabolism| Anti-Inflammatory Agents| Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents| Cardiovascular System| Corticosteroid Hormone Receptor Agonists| Corticosteroids| Corticosteroids Acting Locally| Corticosteroids for Local Oral Treatment| Corticosteroids for Systemic Use| Corticosteroids for Systemic Use, Plain| Corticosteroids, Dermatological Preparations| Corticosteroids, Weak (Group I)| Cytochrome P-450 CYP2A6 Inducers| Cytochrome P-450 CYP2A6 Inducers (strength unknown)| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (strength unknown)| Cytochrome P-450 CYP2C19 Inducers| Cytochrome P-450 CYP2C19 Inducers (strength unknown)| Cytochrome P-450 CYP2C8 Inducers| Cytochrome P-450 CYP2C8 Inducers (strength unknown)| Cytochrome P-450 CYP2C9 Inducers| Cytochrome P-450 CYP2C9 Inducers (strength unknown)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Dermatologicals| Fused-Ring Compounds| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Hydrocortisone and derivatives| Hydroxycorticosteroids| Hyperglycemia-Associated Agents| Immunosuppressive Agents| Intestinal Antiinflammatory Agents| Medications that reduce magnesium levels| Nasal Preparations| OAT3/SLC22A8 Substrates| Ophthalmological and Otological Preparations| Ophthalmologicals| Otologicals| P-glycoprotein inducers| P-glycoprotein substrates| Polycyclic Compounds| Pregnanes| Pregnenediones| Pregnenes| Respiratory System| Sensory Organs| Steroids| Stomatological Preparations| Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins| Vasoprotectives"
410,DB00983,P07550|P08588|P13945,P10635|P33261|P11712|P11509,hsa:154|hsa:153|hsa:155,9|10|11|12|14|15|18|19|20|178|182|185|189|283|284|285|286|299|308|332|333|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|376|377|381|382|384|390|392|393|405|406|416|420|430|434|437|441|446|448|449|451|464|470|476|490|495|498|502|516|520|524|528|540|541|542|543|545|546|548|549|552|556|564|565|566|570|571|573|574|578|582|584|585|587|589|590|592|594|595|599|600|603|604|606|607|608|613|617|618|619|626|628|633|634|637|640|641|643|645|651|655|656|657|659|660|664|665|666|667|668|677|678|679|680|682|683|688|689|690|696|698|701|708|709|710|714|737|763|777|800|826,Formoterol,"Adrenergic Agents| Adrenergic Agonists| Adrenergic beta-2 Receptor Agonists| Adrenergic beta-Agonists| Adrenergics for Systemic Use| Adrenergics, Inhalants| Agents producing tachycardia| Agents that produce hypertension| Agents to Treat Airway Disease| Alcohols| Amines| Amino Alcohols| Anti-Asthmatic Agents| Autonomic Agents| Bronchodilator Agents| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Substrates| Drugs for Obstructive Airway Diseases| Ethanolamines| Long-acting beta-adrenoceptor agonists| OCT1 inhibitors| OCT1 substrates| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Respiratory System| Respiratory System Agents| Selective Beta 2-adrenergic Agonists| UGT1A9 Substrates| UGT2B7 substrates"
411,DB09198,P37231,P05177|P11712|P33261,hsa:5468,9|10|11|12|14|15|16|18|19|20|33|143|145|146|178|182|183|184|185|189|192|283|284|285|286|293|299|332|333|341|344|345|346|349|351|352|353|355|356|358|365|366|368|370|371|373|374|375|376|378|379|381|382|384|387|389|390|391|392|393|396|403|405|412|416|418|420|430|434|438|439|441|442|443|446|447|449|450|451|453|464|470|472|476|482|484|487|489|490|491|495|498|502|504|506|507|516|519|520|521|523|524|530|535|538|539|540|541|542|545|546|548|549|552|555|556|560|564|565|566|570|572|573|574|578|579|582|584|585|586|589|592|593|594|595|596|599|601|603|604|606|608|612|613|614|615|618|619|620|621|626|628|632|634|636|637|638|640|641|643|645|650|651|652|654|655|656|657|659|660|664|666|668|674|677|678|679|680|681|683|684|688|689|692|696|698|704|708|709|710|714|719|777|782,Lobeglitazone,"Alimentary Tract and Metabolism| Azoles| Blood Glucose Lowering Agents| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (moderate)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs Used in Diabetes| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| OATP1B1/SLCO1B1 Inhibitors| PPAR alpha, agonists| PPAR gamma, agonists| Sulfur Compounds| Thiazoles| Thiazolidinediones"
412,DB01006,P11511,P11511|P08684|P11509,hsa:1588,9|10|11|12|14|15|16|143|148|149|178|182|185|189|283|284|285|300|332|333|338|340|344|345|351|355|356|365|370|371|373|375|379|384|389|390|396|403|416|418|419|422|429|430|434|441|446|447|450|453|464|466|467|470|484|486|487|490|491|496|504|515|516|517|519|520|521|524|540|549|552|556|560|564|568|570|572|578|582|584|592|595|596|599|603|607|608|613|618|628|633|634|636|640|654|660|664|668|676|677|678|679|683|688|696|697|708|709|710|713|776,Letrozole,"Agents Causing Muscle Toxicity| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Aromatase Inhibitors| Azoles| Cytochrome P-450 CYP2A6 Inhibitors| Cytochrome P-450 CYP2A6 Inhibitors (strong)| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Endocrine Therapy| Enzyme Inhibitors| Estrogen Antagonists| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hormone Antagonists| Hormone Antagonists and Related Agents| Hormones, Hormone Substitutes, and Hormone Antagonists| Nitriles| P-glycoprotein substrates| Steroid Synthesis Inhibitors| Triazoles| UGT2B7 substrates"
413,DB00637,P35367|Q12809|O95259|P10636,P08684|P20815|P24462|P10635|P51589,hsa:3269|hsa:3757|hsa:3756|hsa:4137,9|10|11|12|14|15|16|18|23|143|148|149|178|180|181|182|185|189|192|196|199|283|284|285|286|287|299|332|333|338|340|341|344|345|351|352|355|356|357|358|364|365|366|370|371|374|375|376|377|379|381|382|384|386|387|389|390|391|392|393|396|397|403|405|416|418|430|431|434|437|441|442|446|449|450|453|464|470|472|476|482|484|485|487|490|495|498|499|502|504|506|516|519|520|521|523|524|528|530|538|539|540|541|542|545|546|547|548|549|552|555|556|560|564|565|569|570|572|573|574|576|578|582|584|585|589|592|593|594|595|596|599|600|603|604|606|607|608|611|613|618|619|626|628|633|634|636|637|640|641|643|651|654|655|656|657|660|664|665|666|668|674|677|678|679|680|683|688|689|696|708|709|710|714|770|777|833,Astemizole,"Anti-Allergic Agents| Antihistamines for Systemic Use| Benzimidazoles| BSEP/ABCB11 Substrates| BSEP/ABCB11 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates (strength unknown)| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Highest Risk QTc-Prolonging Agents| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Histamine H1 Antagonists, Non-Sedating| Medications that reduce magnesium levels| Narrow Therapeutic Index Drugs| Neurotransmitter Agents| P-glycoprotein inhibitors| QTc Prolonging Agents| Respiratory System"
414,DB00861,P35354|P23219,Q9HAW9,hsa:5743|hsa:5742,9|10|11|18|19|23|24|178|182|185|189|283|284|286|287|308|332|333|341|344|352|355|356|364|370|371|380|381|382|384|406|416|420|430|434|440|441|443|446|452|470|490|493|498|516|520|524|535|541|542|548|552|553|556|564|570|573|574|575|578|579|581|582|584|590|595|597|599|603|606|608|617|618|619|623|625|634|637|639|640|641|642|651|655|660|664|667|668|671|672|677|678|679|680|684|688|689|692|696|697|698|699|704|708|709|710|712|714|734|756|777|797|819,Diflunisal,"Agents causing hyperkalemia| Agents that produce hypertension| Analgesics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)| Antirheumatic Agents| Benzene Derivatives| Cyclooxygenase Inhibitors| Drugs causing inadvertant photosensitivity| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hydroxybenzoates| Nephrotoxic agents| Nervous System| Non COX-2 selective NSAIDS| OAT1/SLC22A6 inhibitors| Other Nonsteroidal Anti-inflammatory Agents| Peripheral Nervous System Agents| Phenols| Photosensitizing Agents| Salicylates| Salicylic Acid and Derivatives| Sensory System Agents| UGT1A9 Inhibitors"
415,DB06595,P17252|P35968|P10721|P16234|P09619|P36888,P05177|P20813|P10632|P11712|P33261|P10635|P05181|P08684|P20815|P24462|Q9HB55,hsa:5578|hsa:3791|hsa:3815|hsa:5156|hsa:5159|hsa:2322,9|10|11|12|13|14|15|16|18|19|20|143|148|149|150|155|156|157|162|163|178|181|182|185|189|192|196|199|203|206|213|215|216|283|284|285|286|299|332|333|338|339|340|341|344|345|346|351|352|355|356|357|358|365|366|370|371|374|376|377|384|385|386|387|390|391|392|393|396|397|403|405|416|418|420|430|431|434|437|439|441|442|443|446|449|451|453|464|470|472|482|485|490|493|495|499|502|506|516|520|521|523|524|528|530|535|538|539|540|545|546|547|549|552|553|555|556|564|566|567|569|570|576|577|578|579|582|584|585|592|593|595|597|599|600|603|607|608|611|612|613|614|615|618|623|628|633|634|637|638|640|645|646|656|657|659|660|662|664|665|668|671|672|677|678|679|680|681|682|683|684|685|688|689|691|692|695|696|697|702|703|704|707|708|709|710|712|713|716|734|737|755|758|770|776|779|797|800|818|821|833,Midostaurin,"Alkaloids| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Carbazoles| Cytochrome P-450 CYP1A2 Inducers| Cytochrome P-450 CYP1A2 Inducers (strength unknown)| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strong)| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (strength unknown)| Cytochrome P-450 CYP2C19 Inducers| Cytochrome P-450 CYP2C19 Inducers (strength unknown)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (weak)| Cytochrome P-450 CYP2C8 Inducers| Cytochrome P-450 CYP2C8 Inducers (strength unknown)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Inducers| Cytochrome P-450 CYP2C9 Inducers (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strong)| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strong)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inducers (strong)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Inducers (strong)| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strong)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A5 Inducers| Cytochrome P-450 CYP3A5 Inducers (strength unknown)| Cytochrome P-450 CYP3A7 Inducers| Cytochrome P-450 CYP3A7 Inducers (strength unknown)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Indole Alkaloids| Indoles| Indolizidines| Indolizines| Kinase Inhibitor| Narrow Therapeutic Index Drugs| Protein Kinase C, antagonists & inhibitors| Protein Kinase Inhibitors| Receptor Tyrosine Kinase Inhibitors| Tyrosine Kinase Inhibitors"
416,DB14006,Q9Y5K3|P22303|P49585|O14939|P06276|Q13393|Q8TCT1|P36544,Q9Y6K0|Q9Y259|P28329|P35790|Q8NE62,hsa:9468|hsa:43|hsa:5130|hsa:5338|hsa:590|hsa:5337|hsa:162466|hsa:1139,9|10|11|14|18|19|20|178|182|283|284|285|286|308|332|333|341|344|345|346|351|352|355|356|365|366|370|371|374|380|381|382|384|390|391|406|416|420|430|434|440|441|443|446|452|470|490|493|498|516|520|524|535|540|541|542|548|552|553|556|564|566|570|571|573|574|575|578|579|581|582|584|590|595|597|599|603|606|608|617|618|619|623|625|634|637|639|640|641|642|651|655|659|660|664|667|668|671|672|677|678|679|680|684|688|689|692|698|704|708|709|710|756|819,Cholinesalicylate,"Acids, Carbocyclic| Alcohols| Amines| Amino Alcohols| Analgesics| Benzene Derivatives| Benzoates| Carboxylic Acids| Drugs that are Mainly Renally Excreted| Ethanolamines| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hydroxy Acids| Hydroxybenzoates| Nervous System| OCT1 inhibitors| OCT1 substrates| OCT2 Inhibitors| OCT2 Substrates| Onium Compounds| Pharmaceutical Preparations| Phenols| Quaternary Ammonium Compounds| Salicylates| Salicylic Acid and Derivatives| Trimethyl Ammonium Compounds"
417,DB06772,P68366|Q9H4B7,P08684|P20815|P10632,hsa:7277|hsa:81027,0|9|10|11|12|13|14|18|19|20|21|129|132|178|179|182|185|189|192|196|199|227|228|283|284|285|286|299|308|332|333|334|335|337|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|380|384|390|392|393|405|406|416|420|430|432|434|440|441|443|446|451|452|462|464|470|490|493|516|520|524|528|535|537|540|548|549|552|553|556|559|564|566|567|570|571|573|574|578|579|580|581|582|584|592|594|595|597|599|603|604|605|607|608|612|613|614|617|618|619|623|628|633|634|637|638|639|640|641|642|643|645|646|655|659|660|662|663|664|666|668|671|672|677|678|679|680|681|683|684|686|688|689|690|692|693|696|697|698|699|700|701|704|705|708|709|710|711|712|776|777|782|797|798|803|818|819|824,Cabazitaxel,"Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| BCRP/ABCG2 Inhibitors| Cardiotoxic antineoplastic agents| Cyclodecanes| Cycloparaffins| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Substrates| Diterpenes| Hydrocarbons| Hydrocarbons, Alicyclic| Hydrocarbons, Cyclic| Immunosuppressive Agents| Microtubule Inhibition| Microtubule Inhibitors| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| OATP1B1/SLCO1B1 Inhibitors| OATP1B3 inhibitors| P-glycoprotein inhibitors| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Taxane Derivatives| Taxoids| Terpenes"
418,DB04855,P35348|P35368|P25100|P08913|P18089|P18825|P08588|Q12809|Q13936|Q01668|O60840|Q13698|Q02641|Q08289|P54284|O00305|P35498|O95069,P08684|P10635,hsa:148|hsa:147|hsa:146|hsa:150|hsa:151|hsa:152|hsa:153|hsa:3757|hsa:775|hsa:776|hsa:778|hsa:779|hsa:782|hsa:783|hsa:784|hsa:785|hsa:6323|hsa:3776,9|10|11|12|14|15|18|19|20|33|143|149|178|182|185|189|283|284|285|286|293|299|305|332|333|340|341|344|345|346|351|352|355|356|365|366|368|370|371|374|376|377|381|382|384|385|390|391|393|405|409|414|416|420|430|432|434|437|441|443|446|449|457|459|464|470|476|490|493|498|502|516|520|524|535|540|541|542|545|546|548|549|552|553|556|564|565|570|573|574|578|579|581|582|584|588|589|592|594|595|597|599|600|603|604|606|607|608|613|614|618|619|620|623|625|626|632|633|634|637|638|640|641|642|643|651|655|656|660|664|665|666|668|671|672|677|678|679|680|682|683|684|685|686|687|688|689|691|692|693|695|696|697|698|699|703|704|705|707|708|709|710|712|714|721|737|756|777|784|800|819,Dronedarone,"Adrenergic alpha-1 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Agents that produce hypertension| Antiarrhythmic agents| Antiarrhythmics, Class III| Benzofurans| Bradycardia-Causing Agents| Cardiac Therapy| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (moderate)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (moderate)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Highest Risk QTc-Prolonging Agents| Narrow Therapeutic Index Drugs| OAT3/SLC22A8 Inhibitors| OATP1B1/SLCO1B1 Inhibitors| OATP1B3 inhibitors| OCT1 inhibitors| OCT2 Inhibitors| P-glycoprotein inhibitors| Photosensitizing Agents| QTc Prolonging Agents"
419,DB00849,P14867|P47869|P34903|P48169|P31644|Q16445|P43681|P36544|P42262|Q13002|O75469,P33261|P20813,hsa:2554|hsa:2555|hsa:2556|hsa:2557|hsa:2558|hsa:2559|hsa:1137|hsa:1139|hsa:2891|hsa:2898|hsa:8856,9|10|11|14|15|18|19|178|180|181|182|185|283|284|285|286|299|332|333|334|344|351|352|355|356|365|370|371|374|375|384|390|391|392|393|416|420|430|434|439|441|443|446|451|470|490|516|520|524|535|540|552|556|560|564|570|578|579|580|582|584|588|592|593|595|597|599|603|607|608|613|618|634|636|640|645|646|647|650|654|660|664|668|677|678|679|683|684|688|692|696|697|704|708|709|710|711|712,Methylphenobarbital,"Anticholinergic Agents| Anticonvulsants| Barbiturates| Barbiturates and Derivatives| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| GABA Agents| GABA Modulators| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypnotics and Sedatives| Nervous System| Neurotransmitter Agents| Nicotinic Antagonists| Phenobarbital and similars| Psycholeptics| Pyrimidines| Pyrimidinones"
420,DB00394,P04150,P20815,hsa:2908,9|10|11|12|18|19|20|37|143|144|178|179|182|185|186|192|283|284|286|294|308|332|333|334|335|337|339|341|342|344|346|352|366|374|380|405|406|416|420|430|432|434|440|441|443|446|452|462|490|516|524|535|537|550|551|553|556|571|579|582|591|599|605|614|617|637|639|640|660|671|672|678|679|680|681|684|688|689|692|693|696|697|698|699|704|705|708|709|710|711|712|776|777|780|797|798|801|818|819|822|827|839|840|860|861,Beclomethasonedipropionate,"Adrenal Cortex Hormones| Adrenals| Agents to Treat Airway Disease| Alimentary Tract and Metabolism| Anti-Asthmatic Agents| Anti-Inflammatory Agents| Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents| BCRP/ABCG2 Inhibitors| Corticosteroid Hormone Receptor Agonists| Corticosteroids| Corticosteroids Acting Locally| Corticosteroids for inhalation use| Corticosteroids, Dermatological Preparations| Corticosteroids, Potent (Group III)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inducers| Cytochrome P-450 CYP3A5 Inducers (strength unknown)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Dermatologicals| Drugs for Obstructive Airway Diseases| Fused-Ring Compounds| Glucocorticoids| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Hyperglycemia-Associated Agents| Immunosuppressive Agents| Intestinal Antiinflammatory Agents| Nasal Preparations| OATP1B1/SLCO1B1 Inhibitors| OATP1B3 inhibitors| P-glycoprotein inducers| P-glycoprotein substrates| Polycyclic Compounds| Pregnadienes| Pregnadienetriols| Pregnanes| Respiratory System| Respiratory System Agents| Steroids| Steroids, Chlorinated| Thyroxine-binding globulin inhibitors"
421,DB01221,Q8TCU5|P25103|P14416|P41143|P23975|P41145|P35372|BE0004890|BE0004957|BE0004958|P46098|Q693P7|P06276|P29475,P11712|P08684|P20813|P23219|P10632,hsa:116443|hsa:6869|hsa:1813|hsa:4985|hsa:6530|hsa:4986|hsa:4988|hsa:3359|hsa:590|hsa:4842,9|10|11|14|18|37|178|179|182|185|283|284|285|286|294|299|332|333|336|340|341|342|344|351|352|355|356|362|365|370|371|374|384|390|392|393|416|420|430|432|434|441|443|446|464|470|490|501|503|516|520|524|528|535|536|540|549|550|552|556|564|570|578|579|582|584|591|592|595|597|598|599|602|603|607|608|613|618|628|633|634|640|643|660|664|668|677|678|679|683|684|688|692|696|697|704|708|709|710|712|759|822,Ketamine,"Agents producing tachycardia| Amino Acids| Amino Acids, Acidic| Amino Acids, Dicarboxylic| Amino Acids, Peptides, and Proteins| Analgesics| Anesthetics| Anesthetics, Dissociative| Anesthetics, General| Anesthetics, Intravenous| Central Nervous System Agents| Central Nervous System Depressants| Cholinesterase Inhibitors| Cyclohexanes| Cycloparaffins| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Excitatory Amino Acid Agents| Excitatory Amino Acid Agonists| Excitatory Amino Acid Antagonists| Hydrocarbons| Hydrocarbons, Alicyclic| Hydrocarbons, Cyclic| Miscellaneous General Anesthetics| N-Methylaspartate, agonists| Nervous System| Neurotransmitter Agents| NMDA Receptor Antagonists| Peripheral Nervous System Agents| Sensory System Agents| Vasodilating Agents"
422,DB00472,P31645|Q12809|P28335|P61024,P33261|P10635|P11712|Q14097|P05177|P08684|P20813|P20815,hsa:6532|hsa:3757|hsa:3358|hsa:1163,9|10|11|12|14|18|23|24|178|182|185|189|283|284|285|286|287|299|332|333|339|341|344|345|346|351|352|355|356|363|365|366|370|371|374|381|382|384|390|392|393|405|416|430|434|441|446|470|476|490|498|516|520|524|528|540|541|542|548|552|556|564|565|570|573|574|578|582|584|589|592|594|595|599|603|604|606|608|613|614|618|619|620|626|632|634|637|638|640|641|643|651|655|660|664|666|668|677|678|679|680|683|688|689|696|698|708|709|710|714|777,Fluoxetine,"Agents that reduce seizure threshold| Amines| Anticholinergic Agents| Antidepressive Agents| Antidepressive Agents Indicated for Depression| Antidepressive Agents, Second-Generation| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (strong)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (moderate)| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strong)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Enzyme Inhibitors| Highest Risk QTc-Prolonging Agents| Hypoglycemia-Associated Agents| Membrane Transport Modulators| Metabolic Side Effects of Drugs and Substances| Nervous System| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| Nicotinic Antagonists| P-glycoprotein inhibitors| Propylamines| Psychoanaleptics| Psychotropic Drugs| QTc Prolonging Agents| Selective Serotonin Reuptake Inhibitors| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2C Receptor Antagonists| Serotonin Agents| Serotonin Modulators| Serotonin Receptor Antagonists| Vasodilating Agents"
423,DB00845,Q5L2G3|O95342,P08684,hsa:8647,9|10|11|12|14|15|16|37|38|178|182|183|184|185|189|192|196|199|203|206|283|284|285|294|299|332|338|340|342|344|345|351|355|357|358|362|365|370|371|374|376|377|384|386|387|390|391|392|393|396|397|403|416|418|431|434|437|441|442|446|449|453|464|470|472|482|485|490|495|499|501|502|503|506|516|520|523|524|530|538|539|545|546|547|549|550|552|555|556|564|569|570|576|577|578|582|584|585|591|592|593|595|598|599|600|601|603|607|608|611|613|618|621|628|633|634|640|643|656|657|660|664|665|668|677|678|679|683|728|729|749|770|791|792|812|833,Clofazimine,"Anti-Bacterial Agents| Anti-Infective Agents| Anti-Inflammatory Agents| Antiinfectives for Systemic Use| Antimycobacterials| BCRP/ABCG2 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Drugs causing inadvertant photosensitivity| Drugs for Treatment of Lepra| Heterocyclic Compounds| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Leprostatic Agents| P-glycoprotein inhibitors| P-glycoprotein substrates| Phenazines| Photosensitizing Agents| Potential QTc-Prolonging Agents| QTc Prolonging Agents"
424,DB00195,P08588|P07550,P05177|P10635,hsa:153|hsa:154,9|10|11|12|14|18|19|115|116|178|182|283|284|285|286|299|308|332|333|335|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|392|393|405|406|416|430|434|441|446|470|476|490|498|516|520|524|528|540|541|542|548|552|556|564|565|566|567|570|571|573|574|578|582|584|589|594|595|599|603|604|606|608|613|614|618|619|620|626|632|634|637|638|640|641|643|651|655|656|659|660|662|663|664|666|668|677|678|679|680|688|689|696|698|708|709|710|714|777,Betaxolol,"Adrenergic Agents| Adrenergic Antagonists| Adrenergic beta-1 Receptor Antagonists| Adrenergic beta-Antagonists| Agents causing hyperkalemia| Alcohols| Amines| Amino Alcohols| Antiarrhythmic agents| Antiglaucoma Preparations and Miotics| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Autonomic Agents| Beta Blocking Agents, Selective| Beta-adrenergic Agents| Beta-Blockers (Beta1 Selective)| Bradycardia-Causing Agents| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Substrates| Hypotensive Agents| Neurotransmitter Agents| Ophthalmologicals| Peripheral Nervous System Agents| Phenoxypropanolamines| Propanolamines| Propanols| QTc Prolonging Agents| Sensory Organs| Sympatholytics"
425,DB01612,P16066,P05091,hsa:4881,9|10|14|18|19|283|284|286|301|332|344|346|352|366|374|401|423|455|582|637|680,Amylnitrite,Antianginal Agents| Antidotes| Cardiovascular Agents| Hypotensive Agents| Methemoglobinemia Associated Agents| Nitrites| Organic Nitrates| Vasodilating Agents
426,DB01222,P04150,P08684,hsa:2908,9|10|11|12|18|19|20|143|144|146|150|178|179|182|185|186|192|283|284|286|308|332|333|334|335|337|339|341|344|346|347|352|366|367|374|380|405|406|416|420|430|432|434|441|443|446|462|490|516|524|535|537|553|556|563|567|571|579|581|582|599|605|610|614|617|637|639|640|642|660|661|662|671|672|678|679|680|681|684|688|689|690|692|693|696|697|698|699|700|701|704|705|708|709|710|711|712|776|777|797|798|818|819|839|840|860|861|866,Budesonide,"Adrenal Cortex Hormones| Adrenals| Agents to Treat Airway Disease| Alimentary Tract and Metabolism| Anti-Asthmatic Agents| Anti-Inflammatory Agents| Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents| Autonomic Agents| Bronchodilator Agents| BSEP/ABCB11 Substrates| Corticosteroid Hormone Receptor Agonists| Corticosteroids| Corticosteroids Acting Locally| Corticosteroids for inhalation use| Corticosteroids for Systemic Use| Corticosteroids, Dermatological Preparations| Corticosteroids, Potent (Group III)| Cytochrome P-450 CYP2A6 Inducers| Cytochrome P-450 CYP2A6 Inducers (strength unknown)| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (strength unknown)| Cytochrome P-450 CYP2C19 Inducers| Cytochrome P-450 CYP2C19 Inducers (strength unknown)| Cytochrome P-450 CYP2C8 Inducers| Cytochrome P-450 CYP2C8 Inducers (strength unknown)| Cytochrome P-450 CYP2C9 Inducers| Cytochrome P-450 CYP2C9 Inducers (strength unknown)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inducers| Cytochrome P-450 CYP3A5 Inducers (moderate)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Dermatologicals| Drugs for Obstructive Airway Diseases| Drugs that are Mainly Renally Excreted| Fused-Ring Compounds| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Immunosuppressive Agents| Intestinal Antiinflammatory Agents| Nasal Preparations| OAT3/SLC22A8 Substrates| P-glycoprotein substrates| Peripheral Nervous System Agents| Polycyclic Compounds| Pregnanes| Pregnenediones| Pregnenes| Respiratory System| Respiratory System Agents| Steroids"
427,DB00772,P06276,P05177|P20813,hsa:590,9|10|11|18|19|20|30|33|34|283|284|286|293|314|332|344|346|349|352|353|366|368|374|380|405|407|411|420|440|443|452|535|579|614|637|681|686|687,Malathion,"Agrochemicals| Antiparasitic Products, Insecticides and Repellents| Cholinergic Agents| Cholinesterase Inhibitors| Compounds used in a research, industrial, or household setting| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 Substrates| Ectoparasiticides, Incl. Scabicides| Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents| Enzyme Inhibitors| Insecticides| Neurotransmitter Agents| Organophosphates| Organophosphorus Compounds| Organothiophosphates| Organothiophosphorus Compounds| Pesticides| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Sulfur Compounds| Toxic Actions"
428,DB00514,Q99720|Q5T1J1|Q8TCU5|Q15822|P31645|O00264|P32297|P43681|P30926|P17787|P36544|P35372|P41143|P41145|P04839|P23975,P08684|P10635|P20815|P24462|P20813|P33261|P11712|P10632|P05181,hsa:10280|hsa:116443|hsa:1135|hsa:6532|hsa:10857|hsa:1136|hsa:1137|hsa:1143|hsa:1141|hsa:1139|hsa:4988|hsa:4985|hsa:4986|hsa:1536|hsa:6530,9|10|11|12|14|18|178|179|180|181|182|185|189|192|199|283|284|285|286|332|333|334|335|338|340|341|344|345|351|352|355|356|365|366|370|371|374|381|382|384|390|391|405|416|430|434|441|446|470|476|490|498|516|520|524|540|541|542|548|552|556|564|565|570|573|574|578|582|584|589|592|594|595|599|603|604|606|607|608|613|618|619|626|634|637|640|641|651|655|656|660|664|666|668|677|678|679|680|683|688|689|696|697|698|699|708|709|710|711|712|714|735|755|776|777|779|797|798|800|818|821,Dextromethorphan,"Alkaloids| Anticholinergic Agents| Antidepressive Agents| Antitussive Agents| Central Nervous System Agents| Central Nervous System Depressants| Combined Inhibitors of Serotonin/Norepinephrine Reuptake| Cough and Cold Preparations| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Substrates| Excitatory Amino Acid Agents| Excitatory Amino Acid Antagonists| Heterocyclic Compounds| Heterocyclic Compounds with 4 or More Rings| Heterocyclic Compounds, Bridged-Ring| Heterocyclic Compounds, Fused-Ring| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Morphinans| Nervous System| Neurotransmitter Agents| Nicotinic Antagonists| NMDA Receptor Antagonists| Opiate Alkaloids| Opioids| Opium Alkaloids and Derivatives| Phenanthrene opioids| Phenanthrenes| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Respiratory System| Respiratory System Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin Agents| Serotonin Modulators| Sigma-1 Agonist| Sigma-1 Receptor Agonists| UGT2B17 substrates| UGT2B7 substrates| Uncompetitive N-methyl-D-aspartate Receptor Antagonist| Uncompetitive NMDA Receptor Antagonists"
429,DB00484,P08913|P18089|P18825,Q06278,hsa:150|hsa:151|hsa:152,6|9|10|11|14|15|16|143|148|149|178|182|183|184|185|272|274|283|284|285|299|332|340|344|345|351|355|357|358|365|370|371|372|373|375|376|377|384|386|387|390|392|393|396|403|416|418|431|434|435|437|441|442|445|446|447|449|450|453|464|470|472|482|485|487|490|491|495|499|502|506|516|519|520|521|523|524|528|530|538|539|540|545|546|547|549|552|555|556|560|564|569|570|576|577|578|582|584|585|592|593|595|596|600|601|603|607|608|611|613|618|621|628|633|634|636|640|643|654|656|657|660|664|665|668|674|677|678|679|683|728|749|770|791|812|833,Brimonidine,"Adrenergic Agents| Adrenergic Agonists| Adrenergic alpha-2 Receptor Agonists| Adrenergic alpha-Agonists| Antiglaucoma Preparations and Miotics| Cardiovascular Agents| Central Nervous System Depressants| Decongestants and Antiallergics| Dermatologicals| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hypotensive Agents| Misc. Skin and Mucous Membrane Agents| Ophthalmologicals| Quinoxalines| Sensory Organs| Sympathomimetics in Glaucoma Therapy| Sympathomimetics Used as Decongestants"
430,DB00810,P11229|Q15822,P10635,hsa:1128|hsa:1135,9|10|11|12|14|18|143|144|147|150|178|180|181|182|185|283|284|285|286|308|332|333|335|337|341|344|345|351|352|355|356|365|370|371|384|390|391|406|416|430|434|441|446|470|490|516|520|524|540|548|552|556|564|570|573|574|578|582|584|592|595|599|603|608|613|617|618|619|634|637|638|640|641|655|656|660|664|667|668|677|678|679|680|683|688|689|696|697|698|699|708|709|710|712|839|860,Biperiden,"Agents producing tachycardia| Anti-Dyskinesia Agents| Anti-Parkinson Drugs| Anticholinergic Agents| Autonomic Agents| Aza Compounds| Azabicyclo Compounds| Bicyclo Compounds| Bicyclo Compounds, Heterocyclic| Bridged Compounds| Bridged-Ring Compounds| Central Nervous System Agents| Cholinergic Agents| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, Bridged-Ring| Hydrocarbons| Hydrocarbons, Cyclic| Muscarinic Antagonists| Nervous System| Neurotransmitter Agents| Nicotinic Antagonists| Parasympatholytics| Peripheral Nervous System Agents| Piperidines| Tertiary Amines"
431,DB00872,P37288|P30518,P08684,hsa:552|hsa:554,9|10|11|12|13|14|15|16|18|19|143|148|149|178|182|185|189|192|196|199|203|213|218|219|283|284|285|286|299|332|333|340|344|345|351|352|355|356|357|358|359|365|370|371|374|375|376|377|379|384|387|389|390|391|392|393|396|399|400|403|416|418|420|430|431|434|437|438|439|441|442|443|446|449|450|451|453|464|470|472|482|484|485|487|488|490|493|495|499|502|504|506|516|519|520|523|524|527|530|535|538|539|540|545|546|547|549|552|553|555|556|560|564|569|570|572|576|578|579|582|584|585|592|593|595|596|597|599|600|603|607|608|611|613|618|623|628|633|634|636|640|643|645|646|654|656|657|660|664|665|668|671|672|674|677|678|679|683|684|688|692|695|696|697|704|707|708|709|710|712|716|755|758|779|818|821,Conivaptan,"Antidiuretic Hormone Receptor Antagonists| Cardiovascular System| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strong)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Diuretics| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hypotensive Agents| Narrow Therapeutic Index Drugs| Natriuretic Agents| P-glycoprotein inhibitors"
432,DB04817,P23219,P20813|P08684,hsa:5742,9|10|11|14|15|18|19|20|26|33|143|148|149|178|182|283|284|285|286|293|300|332|340|344|351|352|355|357|358|365|368|370|371|374|376|377|381|384|387|390|391|396|414|416|418|420|422|431|434|437|439|441|442|443|446|449|451|453|457|458|459|464|467|468|470|477|482|490|493|495|496|499|502|515|516|518|520|521|523|524|530|535|536|538|539|540|545|546|547|549|552|553|555|556|564|569|570|577|578|579|580|582|584|585|592|593|595|599|600|601|602|603|607|608|611|613|616|618|621|623|624|628|633|634|640|644|645|656|657|660|664|665|668|671|673|677|678|679|683,Metamizole,"Agents causing hyperkalemia| Agents that produce hypertension| Aminopyrine| Analgesics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Antipyretics| Azoles| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (strength unknown)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 Enzyme Inducers| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Nephrotoxic agents| Nervous System| Peripheral Nervous System Agents| Pyrazoles| Pyrazolones| Sensory System Agents"
433,DB00207,P60725|P61177|Q9UM07,P11509|P05177|P08684,hsa:23569,9|10|11|12|13|14|15|18|19|20|21|178|181|185|188|283|284|285|286|308|332|333|335|337|338|339|340|341|344|345|346|347|351|352|365|366|367|374|380|390|391|405|406|420|440|443|452|535|540|563|566|567|571|579|581|582|592|610|613|614|617|637|638|639|642|656|659|661|662|663|679|680|681|682|683|684|688|689|690|691|692|693|696|697|698|699|700|701|702|704|705|708|709|710,Azithromycin,"Anti-Bacterial Agents| Anti-Infective Agents| Antibacterials for Systemic Use| Antiinfectives for Systemic Use| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Experimental Unapproved Treatments for COVID-19| Lactones| Macrocyclic Compounds| Macrolide Antimicrobial| Macrolides| Macrolides, Lincosamides and Streptogramins| Medications that reduce magnesium levels| Moderate Risk QTc-Prolonging Agents| Ophthalmologicals| P-glycoprotein inhibitors| P-glycoprotein substrates| Photosensitizing Agents| Polycyclic Compounds| Polyketides| QTc Prolonging Agents"
434,DB01217,P11511,P11511|P05177|P11712|P08684,hsa:1588,9|10|11|12|14|15|16|143|148|149|178|182|283|284|285|300|332|333|334|344|345|351|355|356|365|370|371|373|374|375|379|384|389|390|396|403|416|418|419|422|429|430|434|441|446|447|450|453|464|467|470|484|486|487|490|491|496|504|515|517|519|520|521|524|540|549|552|556|560|564|568|570|572|578|582|584|592|595|596|599|603|607|608|613|618|628|633|634|636|640|654|660|664|668|676|677|678|679|683|688|696|697|708|709|710|711|712|734|797,Anastrozole,"Antineoplastic Agents| Antineoplastic Agents, Hormonal| Antineoplastic and Immunomodulating Agents| Aromatase Inhibitors| Azoles| Cardiotoxic antineoplastic agents| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Endocrine Therapy| Enzyme Inhibitors| Estrogen Antagonists| Heterocyclic Compounds| Hormone Antagonists| Hormone Antagonists and Related Agents| Hormones, Hormone Substitutes, and Hormone Antagonists| Medications that reduce magnesium levels| Nitriles| P-glycoprotein substrates| Steroid Synthesis Inhibitors| Triazoles| UGT1A3 substrates| UGT1A4 substrates| UGT2B7 substrates"
435,DB00297,Q9Y5Y9|P34995,P08684|P05177|P33261|P10635,hsa:6336|hsa:5731,9|10|11|12|14|15|18|178|180|181|182|185|283|284|285|286|299|332|333|338|340|344|345|351|352|355|356|365|370|371|374|376|377|384|390|391|392|393|416|420|430|434|437|439|441|443|446|449|451|464|470|490|495|516|520|524|535|536|540|545|549|552|556|564|569|570|578|579|582|584|585|592|595|599|600|602|603|607|608|611|613|618|628|633|634|640|643|645|656|657|660|664|665|668|677|678|679|683|684|688|692|697|708|709|710|734|758|797|821,Bupivacaine,"Agents that reduce seizure threshold| Amides| Amines| Anesthetics| Anesthetics, Local| Anilides| Aniline Compounds| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Hypotensive Agents| Local Anesthesia| Local Anesthetics (Amide)| Methemoglobinemia Associated Agents| Nervous System| Neuraxial Anesthetics| Peripheral Nervous System Agents| Sensory System Agents"
436,DB09061,P21554|P34972|P47775|P23415|BE0004857|O75311|Q14330|Q9Y2T6|P08908|P28223|P36544|P41143|P35372|P37231|Q8NER1|O43497|O95180|Q9P0X4|O75762|Q7Z2W7|Q9Y5S1|Q8NET8|Q9HBA0|P21796,P11712|P33261|P10635|P08684|P20815|P24752|F1T0I5|P04040|P23219|P35354|P24462|P04798|P05177|Q16678|F5GY58|O00519|P00390|P07203|P04035|P14902|P09917|P16050|Q02083|Q08257|Q6IQ20|P04054|P05093|P00441|P17405,hsa:1268|hsa:1269|hsa:2835|hsa:2741|hsa:8001|hsa:2841|hsa:9290|hsa:3350|hsa:3356|hsa:1139|hsa:4985|hsa:4988|hsa:5468|hsa:7442|hsa:8913|hsa:8912|hsa:8911|hsa:8989|hsa:79054|hsa:51393|hsa:162514|hsa:59341|hsa:7416,9|10|11|12|18|19|178|182|185|189|283|284|286|308|332|333|335|341|344|352|355|356|370|371|374|381|382|384|406|416|430|434|441|446|470|490|498|520|524|541|542|548|552|556|564|570|573|574|575|578|582|584|590|595|599|603|606|608|617|618|619|634|637|639|640|641|651|653|655|660|664|667|668|677|678|679|680|688|689|690|696|697|698|699|701|708|709|710|712|713|735|740|756|776|798|803|819,Cannabidiol,Agents producing tachycardia| Agents that produce hypertension| Anticonvulsants| Antidepressive Agents| BCRP/ABCG2 Inhibitors| Cannabinoids and similars| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Inducers| Cytochrome P-450 CYP1A2 Inducers (strength unknown)| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2A6 Inhibitors| Cytochrome P-450 CYP2A6 Inhibitors (weak)| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Inhibitors| Cytochrome P-450 CYP3A7 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Hydrocarbons| Nervous System| P-glycoprotein inhibitors| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT1 Receptor Agonists| Serotonin 5-HT2 Receptor Agonists| Serotonin Agents| Serotonin Receptor Agonists| Terpenes| UGT1A9 Inhibitors| UGT1A9 Substrates| UGT2B17 substrates| UGT2B7 Inhibitors| UGT2B7 substrates
437,DB00379,Q14524|P35869,P05177|P10635|P20813|P05181|P08684,hsa:6331|hsa:196,9|10|11|14|18|178|182|283|284|285|286|299|332|333|338|340|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|393|405|416|430|434|441|446|470|476|490|498|516|520|524|528|541|548|552|556|564|565|566|570|573|574|578|582|584|589|594|595|599|603|604|606|608|614|615|618|619|620|626|632|634|637|640|641|643|651|655|660|664|666|668|677|678|679|680|688|689|697|698|708|709|710|734|756|797|819,Mexiletine,"Amines| Antiarrhythmic agents| Antiarrhythmics, Class I| Antiarrhythmics, Class Ib| Benzene Derivatives| Cardiac Therapy| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (moderate)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Membrane Transport Modulators| Phenols| Phenyl Ethers| Propylamines| Sodium Channel Blockers| Voltage-Gated Sodium Channel Blockers"
438,DB00515,P29372|P01023|P02787|O00244,P05164|P47989|Q02928|P35354|P9WJI5|P11712|P20813|P06276|P30711|P04731|P02795|P00441|P09211|P15559|P09488,hsa:4350|hsa:7018|hsa:475,14|15|37|38|93|299,Cisplatin,"Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| BCRP/ABCG2 Substrates| Cardiotoxic antineoplastic agents| Chlorine Compounds| Cholinesterase Inhibitors| Compounds used in a research, industrial, or household setting| Cross-Linking Reagents| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Drugs that are Mainly Renally Excreted| Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index| Immunosuppressive Agents| Indicators and Reagents| Laboratory Chemicals| Medications that reduce magnesium levels| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| Nephrotoxic agents| Nitrogen Compounds| OCT2 Inhibitors| OCT2 Substrates| OCT2 Substrates with a Narrow Therapeutic Index| Platinum Compounds| Radiation-Sensitizing Agents"
439,DB00169,P11473,Q6VVX0|Q02318|P51589|P08684|P05108|P04798|P20813|P33261|P10632|P11712|P10635,hsa:7421,9|10|11|12|18|143|144|178|179|185|186|283|284|286|308|332|333|334|335|339|341|344|346|352|366|374|406|416|430|434|441|446|490|524|556|564|571|582|599|617|637|640|641|660|664|678|679|680|688|689|696|697|708|709|710|711|712|818|839|860,Cholecalciferol,"Alimentary Tract and Metabolism| Bone Density Conservation Agents| Calcium-Regulating Hormones and Agents| Cholecalciferol, antagonists & inhibitors| Cholestanes| Cholestenes| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (moderate)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Diet, Food, and Nutrition| Drugs Affecting Bone Structure and Mineralization| Drugs for Treatment of Bone Diseases| Food| Fused-Ring Compounds| Growth Substances| Lipids| Membrane Lipids| Micronutrients| Musculo-Skeletal System| Physiological Phenomena| Polycyclic Compounds| Secosteroids| Steroids| Sterols| Vitamin D and Analogues| Vitamins| Vitamins (Fat Soluble)"
440,DB00748,P35367,P20813|P33261|P10632|P11712|P10635|P05181|P08684,hsa:3269,9|10|11|12|14|15|18|37|178|182|183|184|185|283|284|285|286|294|332|333|339|340|341|342|344|345|346|351|352|355|356|357|358|362|365|366|370|371|372|373|374|376|384|387|390|391|396|403|405|416|418|430|431|434|435|437|441|442|445|446|447|449|453|461|464|470|472|482|490|491|495|501|502|503|506|516|520|521|523|524|530|538|539|540|545|546|548|549|550|552|555|556|564|566|570|573|574|576|577|578|582|584|585|591|592|594|595|598|599|600|603|604|607|608|613|614|615|618|619|628|633|634|637|640|641|655|656|657|659|660|664|665|666|668|677|678|679|680|683|688|689|696|697|698|708|709|710|717|780,Carbinoxamine,"Aminoalkyl Ethers| Antihistamines for Systemic Use| Central Nervous System Depressants| Drugs causing inadvertant photosensitivity| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Moderate Risk QTc-Prolonging Agents| Neurotransmitter Agents| Photosensitizing Agents| QTc Prolonging Agents| Respiratory System"
441,DB00343,Q06432,P08684|P20815|P24462|P33261|P10635|P10632|P11712,hsa:786,9|10|11|12|14|15|18|19|20|33|178|182|185|189|213|215|216|283|284|285|286|293|332|333|339|340|341|344|345|346|349|351|352|353|355|356|365|366|368|370|371|374|376|377|380|381|382|383|384|390|391|405|412|416|420|430|434|437|439|440|441|443|446|449|451|452|462|464|470|476|490|495|498|500|502|507|516|520|524|531|532|533|535|537|540|541|542|545|546|548|549|552|556|564|565|566|569|570|573|574|578|579|582|584|585|586|589|592|594|595|599|600|603|604|605|606|607|608|611|613|614|615|618|619|626|628|633|634|637|640|641|645|646|651|655|656|657|658|659|660|664|665|666|668|677|678|679|680|683|684|688|689|692|696|698|704|708|709|710|714|767|777|830,Diltiazem,"Agents causing hyperkalemia| Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use| Antiarrhythmic agents| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Benzazepines| Benzothiazepine Derivatives| Bradycardia-Causing Agents| Calcium Channel Blockers| Calcium Channel Blockers (Nondihydropyridine)| Calcium-Regulating Hormones and Agents| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (moderate)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (moderate)| Cytochrome P-450 CYP3A4 Inhibitors (strong)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (moderate)| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Inhibitors| Cytochrome P-450 CYP3A7 Inhibitors (moderate)| Cytochrome P-450 CYP3A7 Inhibitors (strong)| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hypotensive Agents| Membrane Transport Modulators| Miscellaneous Calcium-channel Blocking Agents| Moderate Risk QTc-Prolonging Agents| Negative Inotrope| P-glycoprotein inhibitors| P-glycoprotein substrates| Photosensitizing Agents| QTc Prolonging Agents| Selective Calcium Channel Blockers With Direct Cardiac Effects| Vasodilating Agents| Vasoprotectives"
442,DB00952,P28221|P28222|P30939|P08908,P21397,hsa:3352|hsa:3351|hsa:3355|hsa:3350,9|10|11|12|14|15|18|19|33|143|148|149|178|180|181|182|185|283|284|285|293|299|305|332|333|335|340|344|345|349|351|353|355|356|357|358|365|368|370|371|372|373|374|376|377|384|385|386|387|390|391|392|393|396|399|400|403|414|416|418|430|431|434|435|437|441|442|445|446|447|449|453|457|459|464|465|470|472|482|490|491|495|502|506|516|520|521|523|524|527|528|530|538|539|540|545|546|549|552|555|556|564|570|576|577|578|582|584|585|592|595|599|600|603|607|608|613|618|628|633|634|640|643|656|657|660|664|665|668|677|678|679|683|688|696|697|708|709|710|712|716|734|758|779|797|821,Naratriptan,"Agents that produce hypertension| Amines| Analgesics| Antidepressive Agents| Antimigraine Preparations| Biogenic Amines| Biogenic Monoamines| Cardiovascular Agents| Central Nervous System Depressants| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Indoles| Monoamine Oxidase A Substrates| Nervous System| Neurotransmitter Agents| Selective Serotonin 5-HT1 Receptor Agonists| Selective Serotonin Agonists| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 1b Receptor Agonists| Serotonin 1d Receptor Agonists| Serotonin 5-HT1 Receptor Agonists| Serotonin Agents| Serotonin Modulators| Serotonin Receptor Agonists| Serotonin-1b and Serotonin-1d Receptor Agonist| Triptans| Vasoconstrictor Agents"
443,DB01127,P10613|O75469,P11511|P05181|P08684,hsa:8856,9|10|11|12|14|15|18|37|38|143|148|149|178|182|185|189|283|284|285|286|294|332|333|339|341|342|344|345|346|351|352|355|356|358|362|365|366|370|371|372|373|375|376|379|384|387|389|390|391|396|397|403|405|416|418|430|434|435|441|442|445|446|447|449|450|453|470|472|482|484|485|487|490|491|495|499|501|502|503|504|506|516|519|520|521|524|539|540|546|547|548|550|552|556|560|564|566|569|570|572|573|574|578|582|584|591|592|594|595|596|598|599|603|604|607|608|611|613|614|615|618|619|634|636|637|640|641|654|655|656|659|660|664|666|668|674|677|678|679|680|683|688|689|696|698|708|709|710|717|752|759|780|815|822,Econazole,"14-alpha Demethylase Inhibitors| Anti-Infective Agents| Antifungal Agents| Antifungal Agents (Vaginal)| Antifungals for Dermatological Use| Antifungals for Topical Use| Azole Antifungals| Azoles| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strong)| Cytochrome P-450 Enzyme Inhibitors| Dermatologicals| Enzyme Inhibitors| Genito Urinary System and Sex Hormones| Gynecological Antiinfectives and Antiseptics| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hormone Antagonists| Hormones, Hormone Substitutes, and Hormone Antagonists| Imidazole and Triazole Derivatives| Imidazole Derivatives| Imidazoles| Metabolic Side Effects of Drugs and Substances| P-glycoprotein inhibitors| Steroid Synthesis Inhibitors"
444,DB00834,P06401|P04150|P07288|O75469,P08684|P20815|P24462|P10635|P05177,hsa:5241|hsa:2908|hsa:354|hsa:8856,9|10|11|12|14|18|19|143|144|178|179|182|185|189|192|196|199|283|284|285|286|308|332|333|334|335|337|340|341|344|351|352|355|356|365|370|371|374|376|377|384|390|391|406|416|417|420|427|430|432|434|437|441|443|446|449|460|464|470|490|495|502|516|520|524|535|540|545|546|549|552|553|556|564|570|578|579|582|584|585|592|595|599|600|603|607|608|613|617|618|628|633|634|637|640|657|660|664|665|668|671|677|678|679|680|683|684|688|689|692|696|697|698|699|704|708|709|710|711|712|716|776|779|797|818|839|840|860|861,Mifepristone,"Abortifacient Agents| Abortifacient Agents, Steroidal| Adrenal Cortex Hormones| Blood Glucose Lowering Agents| BSEP/ABCB11 Substrates| Contraceptive Agents, Female| Contraceptive Agents, Hormonal| Contraceptives, Oral| Contraceptives, Oral, Synthetic| Contraceptives, Postcoital| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (moderate)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Inhibitors| Cytochrome P-450 CYP3A7 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Estranes| Estrenes| Fused-Ring Compounds| Genito Urinary System and Sex Hormones| Highest Risk QTc-Prolonging Agents| Hormonal Contraceptives for Systemic Use| Hormone Antagonists| Hormones, Hormone Substitutes, and Hormone Antagonists| Hypoglycemia-Associated Agents| Luteolytic Agents| Menstruation-Inducing Agents| OATP1B1/SLCO1B1 Inhibitors| OATP1B3 inhibitors| P-glycoprotein inducers| P-glycoprotein inhibitors| Polycyclic Compounds| Progestational Hormone Receptor Antagonists| Progesterone Receptor Modulators| Progestin Antagonist| QTc Prolonging Agents| Reproductive Control Agents| Sex Hormones and Modulators of the Genital System| Steroids"
445,DB11827,P31639,O60656|P16662|P22309|P22310,hsa:6524,9|10|11|12|18|19|20|37|143|146|178|181|182|185|189|192|283|284|286|294|308|332|333|337|339|341|342|344|346|352|355|356|362|366|370|371|374|380|381|382|384|405|406|416|430|434|441|446|470|476|490|498|501|503|516|520|524|541|542|548|550|552|556|563|564|565|567|570|571|573|574|578|582|584|589|591|594|595|598|599|603|604|606|608|610|614|617|618|619|620|626|632|634|637|639|640|641|651|655|660|661|662|663|664|666|668|677|678|679|680|681|688|689|690|696|697|698|699|700|701|708|709|710|714|717|734|759|777|780|797|822,Ertugliflozin,"Alimentary Tract and Metabolism| BCRP/ABCG2 Substrates| Blood Glucose Lowering Agents| Diuretics| Drugs Used in Diabetes| Heterocyclic Compounds| Heterocyclic Compounds, Bridged-Ring| P-glycoprotein substrates| Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors| Sodium-Glucose Transporter 2 Inhibitors| UGT1A1 Inhibitors| UGT1A4 Inhibitors| UGT1A9 Substrates| UGT2B7 substrates"
446,DB01400,P22303,P06276,hsa:43,9|10|11|14|15|18|19|178|182|283|284|285|286|332|340|341|344|351|352|355|365|370|371|374|376|377|380|381|382|384|390|391|405|416|420|434|437|441|446|449|451|452|464|470|476|490|495|498|502|516|520|524|540|541|542|545|546|548|549|552|556|564|565|570|573|574|578|582|584|585|589|592|594|595|599|600|603|604|606|607|608|612|613|618|619|622|626|628|633|634|637|638|640|641|646|651|652|655|657|660|664|665|666|668|677|678|679|680|683|689|691|702|703|742|805,Neostigmine,Amines| Antiglaucoma Preparations and Miotics| Autonomic Agents| Cholinergic Agents| Cholinesterase Inhibitors| Enzyme Inhibitors| Nervous System| Neurotransmitter Agents| Onium Compounds| Ophthalmologicals| Parasympathomemetic (Cholinergic) Agents| Parasympathomimetics| Peripheral Nervous System Agents| Phenylammonium Compounds| Quaternary Ammonium Compounds| Sensory Organs
447,DB00134,Q9UBK8|Q99707|P50579|Q93088|Q9H2M3,P15104|P42898|P31153|Q9Y3D2|Q00266|Q9NZV6|Q9UJ68|P56192|Q96GW9|Q9NZL9,hsa:4552|hsa:4548|hsa:10988|hsa:635|hsa:23743,9|10|14|18|19|33|283|284|285|286|293|299|308|332|338|340|344|345|349|351|352|353|365|368|374|380|393|406|412|420|440|443|452|507|528|535|536|566|579|586|617|637|643,Methionine,"Amino Acids| Amino Acids, Essential| Amino Acids, Neutral| Amino Acids, Peptides, and Proteins| Amino Acids, Sulfur| Antidotes| Dietary Supplements| Proteinogenic Amino Acids| Sulfur Compounds| Supplements"
448,DB00501,P25021,P05177|P33261|P08684|P20815|P24462|P10635|P15538|P10632|P11712|P05181|P31513|Q01740,hsa:3274,9|10|11|14|15|16|33|143|148|149|283|284|285|293|299|332|340|344|345|349|351|353|355|357|358|365|368|373|374|375|376|379|387|389|390|392|393|396|399|400|403|412|416|418|419|431|437|441|442|447|449|450|453|472|482|484|485|487|488|491|495|499|504|506|507|519|521|523|524|527|528|538|539|540|545|547|560|569|572|585|586|596|611|613|636|643|654|657|658|674,Cimetidine,"Acid Reducers| Adjuvants| Agents Causing Muscle Toxicity| Alimentary Tract and Metabolism| Amidines| Anti-Ulcer Agents| Azoles| BSEP/ABCB11 Inhibitors| Chemically-Induced Disorders| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (weak)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (weak)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (moderate)| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (moderate)| Cytochrome P-450 CYP3A5 Inhibitors (weak)| Cytochrome P-450 CYP3A7 Inhibitors| Cytochrome P-450 CYP3A7 Inhibitors (moderate)| Cytochrome P-450 Enzyme Inhibitors| Drugs for Acid Related Disorders| Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Gastric Acid Lowering Agents| Gastrointestinal Agents| Guanidines| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Histamine Agents| Histamine Antagonists| Histamine H2 Antagonists| Imidazoles| MATE 1 Inhibitors| MATE 1 Substrates| MATE 2 Inhibitors| MATE 2 Substrates| MATE inhibitors| MATE substrates| Medications that reduce magnesium levels| Metabolic Side Effects of Drugs and Substances| Neurotransmitter Agents| OAT1/SLC22A6 inhibitors| OAT1/SLC22A6 Substrates| OAT3/SLC22A8 Inhibitors| OAT3/SLC22A8 Substrates| OCT1 inhibitors| OCT1 substrates| OCT2 Inhibitors| OCT2 Substrates| P-glycoprotein inducers| P-glycoprotein substrates"
449,DB00150,Q9UGM6|P00953|P23381,P48775|P20711|P00953|Q9UGM6|P17752|Q8IWU9|P23381|P14902,hsa:10352|hsa:7453,9|10|11|14|15|18|19|143|148|149|178|182|283|284|285|286|299|308|332|333|338|340|344|345|351|352|355|356|357|358|365|370|371|372|373|376|377|380|384|385|386|387|390|392|393|396|399|400|403|406|416|418|420|430|431|434|435|437|440|441|442|443|445|446|447|449|452|453|464|470|472|482|490|491|495|502|506|516|520|521|523|524|527|528|530|535|536|538|539|540|545|546|549|552|555|556|564|566|570|576|577|578|579|582|584|585|592|595|599|600|603|607|608|613|617|618|628|633|634|637|640|643|656|657|660|664|665|668|677|678|679|680|683|684|688|689|691|692|695|696|697|698|699|702|704|708|709|710|712|758|821,Ltryptophan,"Amino Acids| Amino Acids, Aromatic| Amino Acids, Cyclic| Amino Acids, Essential| Amino Acids, Peptides, and Proteins| Antidepressive Agents| Antidepressive Agents, Second-Generation| Central Nervous System Agents| Central Nervous System Depressants| Dietary Supplements| Miscellaneous Antidepressants| Nervous System| Proteinogenic Amino Acids| Psychoanaleptics| Psychotropic Drugs| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Supplements"
450,DB00542,P12821,P42898,hsa:1636,9|10|11|12|14|15|18|19|20|178|182|185|189|213|215|216|283|284|285|286|299|308|332|333|338|340|344|345|346|351|352|355|356|365|366|370|371|374|376|377|380|384|390|391|392|393|405|406|416|420|430|434|437|439|440|441|443|446|449|451|452|464|470|490|495|502|516|520|524|528|535|536|540|545|546|549|552|556|564|566|569|570|578|579|582|584|585|592|595|599|600|602|603|607|608|611|613|614|615|618|628|633|634|637|640|643|645|646|656|657|659|660|664|665|668|677|678|679|680|683|684|688|689|692|696|698|699|704|708|709|710|758|821,Benazepril,"ACE Inhibitors and Calcium Channel Blockers| ACE Inhibitors and Diuretics| Agents Acting on the Renin-Angiotensin System| Agents causing angioedema| Agents causing hyperkalemia| Angiotensin-Converting Enzyme Inhibitors| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Cardiovascular Agents| Cardiovascular System| Decreased Blood Pressure| Drugs causing inadvertant photosensitivity| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hypotensive Agents| Photosensitizing Agents| Protease Inhibitors"
451,DB06626,P17948|P35968|P35916,P08684|P20815|P05177|P33261|P22309,hsa:2321|hsa:3791|hsa:2324,9|10|11|12|14|15|16|18|33|143|148|149|178|182|183|184|185|189|192|283|284|285|286|293|299|300|308|332|333|340|344|345|351|352|353|355|356|357|358|365|370|371|372|373|374|376|377|383|384|385|386|387|390|393|394|396|398|399|403|406|412|416|418|422|430|431|434|435|437|441|442|445|446|447|449|453|464|467|470|472|477|482|490|491|495|500|502|506|507|515|516|520|521|522|523|524|527|530|531|532|538|539|540|545|546|548|549|552|555|556|564|570|573|574|576|577|578|582|584|585|586|592|593|595|599|600|601|603|607|608|613|616|617|618|619|621|628|629|633|634|637|640|641|643|644|655|656|657|658|660|664|665|667|668|677|678|679|680|683|688|689|696|698|708|709|710|715|746|757|758|778|809|820|821,Axitinib,"Acids, Carbocyclic| Amides| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Azoles| Benzamides and benzamide derivatives| Benzene Derivatives| Benzoates| Carboxylic Acids| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Substrates| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Indazoles| Kinase Inhibitor| Narrow Therapeutic Index Drugs| OATP1B1/SLCO1B1 Inhibitors| OATP1B1/SLCO1B1 Substrates| P-glycoprotein inhibitors| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Protein Kinase Inhibitors| Pyrazoles| Receptor Tyrosine Kinase Inhibitors| Tyrosine Kinase Inhibitors| UGT1A1 Substrates| UGT1A1 Substrates with a Narrow Therapeutic Index| Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors"
452,DB00146,P11473,O15528|Q07973,hsa:7421,9|10|11|12|18|19|143|144|178|179|185|186|283|284|286|308|332|333|334|335|337|339|341|344|346|352|366|374|406|416|430|434|441|446|490|524|556|564|571|582|599|617|637|640|641|660|664|678|679|680|688|689|696|697|698|699|708|709|710|711|712|818|839|860,Calcidiol,"Alimentary Tract and Metabolism| Anti-Parathyroid Agents| Bone Density Conservation Agents| Calcium Homeostasis| Cholestanes| Cholestenes| Diet, Food, and Nutrition| Food| Fused-Ring Compounds| Lipids| Membrane Lipids| Micronutrients| Physiological Phenomena| Polycyclic Compounds| Secosteroids| Steroids| Sterols| Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins| Vitamin D and Analogues| Vitamins| Vitamins (Fat Soluble)"
453,DB00233,P35354|O15111|P09917|Q9NZK7|P9WNC7,P05164,hsa:5743|hsa:1147|hsa:240|hsa:30814,9|10|14|18|19|178|182|283|284|285|286|299|308|332|333|340|341|344|351|352|355|356|370|371|376|377|380|381|382|384|393|406|416|420|430|434|437|440|441|443|446|449|452|464|470|490|493|498|502|516|520|524|535|541|542|545|546|548|549|552|553|556|564|570|573|574|575|578|579|581|582|584|590|592|595|597|599|600|603|606|607|608|617|618|619|623|625|633|634|637|638|639|640|641|642|643|651|652|655|660|664|665|667|668|671|672|677|678|679|680|683|684|688|689|691|692|695|698|703|704|707|708|709|710|716|742|756|779|805|819,Aminosalicylicacid,"Acids, Carbocyclic| Agents that modify thyroid function| Aminobenzoates| Aminosalicylic Acid and Derivatives| Aminosalicylic Acids| Anti-Bacterial Agents| Anti-Infective Agents| Antiinfectives for Systemic Use| Antimycobacterials| Benzene Derivatives| Benzoates| Carboxylic Acids| Drugs for Treatment of Tuberculosis| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hydroxy Acids| Hydroxybenzoates| Methemoglobinemia Associated Agents| para-Aminobenzoates| Phenols| Salicylates"
454,DB01136,P08588|P35348|O95298|P07550|P15692|P16860|P17302|Q12809|P19320|P25100|P35368|P18825|P18089|P08913|P16581|Q16665|P48050,P47989|P11712|P10635|P05177|P08684|P04798|P05181|P23219,hsa:153|hsa:148|hsa:4718|hsa:154|hsa:7422|hsa:4879|hsa:2697|hsa:3757|hsa:7412|hsa:146|hsa:147|hsa:152|hsa:151|hsa:150|hsa:6401|hsa:3091|hsa:3761,9|10|11|12|14|15|18|19|20|143|148|149|178|182|185|189|192|196|283|284|285|286|299|308|332|333|339|340|341|344|345|346|351|352|355|356|357|358|365|366|370|371|374|376|377|381|382|384|385|386|387|390|392|393|396|399|400|403|405|406|416|418|430|431|434|437|441|442|446|449|453|464|470|472|476|482|490|495|498|502|506|516|520|523|524|527|528|530|538|539|540|541|542|544|545|546|548|549|552|555|556|564|565|566|567|570|571|573|574|576|577|578|582|584|585|589|592|594|595|599|600|603|604|606|607|608|613|614|615|618|619|620|626|628|630|632|633|634|637|638|640|641|643|651|652|655|656|657|659|660|662|663|664|665|666|668|677|678|679|680|682|683|688|689|691|696|697|698|702|703|708|709|710|712|742|756|758|761|805|819|821|824,Carvedilol,"Adrenergic Agents| Adrenergic alpha-1 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Adrenergic beta-1 Receptor Antagonists| Adrenergic beta-Antagonists| Adrenergic beta2-Antagonists| Agents causing hyperkalemia| Alcohols| Alpha and Beta Blocking Agents| Amines| Amino Alcohols| Antiarrhythmic agents| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Antioxidants| Biological Factors| Bradycardia-Causing Agents| Calcium Channel Blockers| Calcium-Regulating Hormones and Agents| Carbazoles| Cardiovascular Agents| Cardiovascular System| Compounds used in a research, industrial, or household setting| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Hypotensive Agents| Indoles| Membrane Transport Modulators| Negative Inotrope| Neurotransmitter Agents| P-glycoprotein inhibitors| Propanolamines| Propanols| Protective Agents| UGT1A1 Substrates| UGT2B7 substrates| Vasodilating Agents"
455,DB01046,P51788,P16152,hsa:1181,9|10|11|12|18|19|20|23|24|143|144|178|181|283|284|286|287|308|332|333|335|339|341|344|346|352|363|366|374|380|405|406|420|432|440|443|452|535|563|579|581|582|614|617|637|642|661|679|680|684|686|688|689|690|692|696|697|698|699|701|704|708|709|710|712|840|860|861,Lubiprostone,"Alimentary Tract and Metabolism| Chloride Channel Agonists| Drugs for Constipation| Drugs that are Mainly Renally Excreted| Fatty Acids| Fatty Acids, Monounsaturated| Fatty Acids, Unsaturated| Laxatives| Lipids| Membrane Transport Modulators| Miscellaneous GI Drugs| Prostaglandins E"
456,DB00294,P06401|P03372,P08684,hsa:5241|hsa:2099,0|9|10|11|12|18|19|143|144|178|179|182|185|186|192|283|284|286|308|332|333|334|335|337|341|344|352|374|406|416|417|420|427|428|430|432|434|441|443|446|460|490|524|535|553|556|579|582|599|617|637|640|660|671|678|679|680|684|688|689|692|696|697|698|699|704|708|709|710|711|712|776|797|818|839|840|860|861,Etonogestrel,"Adrenal Cortex Hormones| Combination Contraceptives (with Estrogen and derivatives)| Contraceptive Agents, Female| Contraceptive Agents, Hormonal| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Fused-Ring Compounds| Genito Urinary System and Sex Hormones| Hormonal Contraceptives for Systemic Use| Hyperglycemia-Associated Agents| Intravaginal Contraceptives| Norpregnanes| Norpregnenes| Norsteroids| Polycyclic Compounds| Progesterone Congeners| Progestins| Reproductive Control Agents| Sex Hormones and Modulators of the Genital System| Steroids"
457,DB00978,P43702|P43700|P11388,P05177,hsa:7153,9|10|11|12|14|15|18|19|23|24|178|180|181|182|183|184|185|192|283|284|285|286|287|299|308|332|333|338|340|341|344|345|351|352|355|356|357|358|364|365|370|371|372|373|374|376|377|380|381|382|384|385|386|387|390|391|392|393|396|397|403|406|416|418|420|430|431|432|434|435|437|440|441|442|443|445|446|447|449|452|453|464|470|472|482|490|491|493|495|506|520|521|523|524|528|530|535|538|540|545|548|549|552|553|555|556|564|569|570|573|574|576|577|578|579|580|581|582|584|585|588|592|593|595|597|600|601|603|607|608|611|613|617|618|619|621|623|624|628|633|634|637|638|640|641|642|643|655|656|657|660|664|665|667|668|671|672|673|677|678|679|680|683|684|688|689|691|692|695|696|697|698|702|703|704|707|708|709|710|716|749|758|779|812|821,Lomefloxacin,"Anti-Bacterial Agents| Anti-Infective Agents| Anti-Infective Agents, Urinary| Antibacterials for Systemic Use| Antiinfectives for Systemic Use| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Enzyme Inhibitors| Fluoroquinolone Antibacterial| Fluoroquinolones| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Moderate Risk QTc-Prolonging Agents| Ophthalmologicals| Photosensitizing Agents| QTc Prolonging Agents| Quinolines| Quinolones| Sensory Organs| Topoisomerase II Inhibitors| Topoisomerase Inhibitors"
458,DB04839,P10275|P07288,P11511|P10635,hsa:367|hsa:354,0|9|10|11|12|18|19|20|37|115|116|143|144|178|179|182|185|189|192|283|284|286|294|332|333|334|335|337|341|342|344|352|374|380|405|416|420|430|432|434|440|441|443|446|452|462|490|524|535|537|550|553|556|564|579|582|591|605|614|637|640|660|664|671|678|679|680|684|688|689|692|696|697|698|699|704|708|709|710|711|712|776|797|818|839|840|860|861,Cyproteroneacetate,"Adrenal Cortex Hormones| Antiandrogens| Antiandrogens and Estrogens| Antineoplastic Agents| Combination Contraceptives (with Estrogen and derivatives)| Contraceptive Agents, Female| Contraceptive Agents, Male| Contraceptives, Oral| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Fused-Ring Compounds| Genito Urinary System and Sex Hormones| Hormonal Contraceptives for Systemic Use| Hormone Antagonists| Hormones, Hormone Substitutes, and Hormone Antagonists| Hyperglycemia-Associated Agents| Other Miscellaneous Therapeutic Agents| Polycyclic Compounds| Pregnadienes| Pregnanes| Progestin Contraceptives| Progestins| Reproductive Control Agents| Sex Hormones and Modulators of the Genital System| Steroids| Steroids, Chlorinated"
459,DB00979,P11229,P06276,hsa:1128,9|10|11|12|14|18|19|143|144|178|182|283|284|285|286|308|332|333|335|337|341|344|345|346|351|352|355|356|365|366|370|371|374|380|384|390|391|405|406|416|420|430|434|440|441|443|446|452|470|490|516|520|524|535|540|552|556|564|566|570|578|579|581|582|584|595|597|599|603|608|614|615|617|618|634|637|639|640|641|642|655|659|660|664|668|677|678|679|680|684|688|689|692|696|697|698|704|708|709|710|712,Cyclopentolate,"Acids, Carbocyclic| Anticholinergic Agents| Autonomic Agents| Carboxylic Acids| Cholinergic Agents| Cholinesterase substrates| Muscarinic Antagonists| Mydriatics| Mydriatics and Cycloplegics| Neurotransmitter Agents| Ophthalmologicals| Parasympatholytics| Peripheral Nervous System Agents| Phenylacetates| Sensory Organs"
460,DB06710,P10275|P03372,P11511|P20813|P08684,hsa:367|hsa:2099,9|10|11|12|18|19|143|144|178|179|182|185|186|192|283|284|286|308|332|333|334|335|337|341|344|352|374|406|416|420|430|432|434|441|443|446|490|524|535|553|556|579|582|599|617|637|640|660|671|678|679|680|684|688|689|692|696|697|698|699|704|708|709|710|711|712|776|797|818|839|840|860|861,Methyltestosterone,"3-Oxoandrosten (4) Derivatives| Anabolic Agents| Androgens| Androgens and Estrogens| Androstanes| Androstenes| Androstenols| Antineoplastic Agents| Antineoplastic Agents, Hormonal| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Fused-Ring Compounds| Genito Urinary System and Sex Hormones| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| OAT3/SLC22A8 Inducers| Polycyclic Compounds| Sex Hormones and Modulators of the Genital System| Steroids| Testosterone Congeners| Thyroxine-binding globulin inhibitors"
461,DB01466,P35372,P10635|P16435|P20813|P08684|P24462,hsa:4988,9|10|11|12|14|18|19|143|146|178|180|181|182|185|189|192|196|199|283|284|285|286|308|332|333|334|335|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|391|405|406|416|430|434|441|446|470|476|490|498|516|520|524|540|541|542|544|548|552|556|564|565|567|570|571|573|574|578|582|584|589|592|594|595|599|603|604|606|607|608|613|614|617|618|619|620|626|630|632|634|637|640|641|651|655|656|660|662|663|664|666|667|668|677|678|679|680|682|683|688|689|690|691|696|697|698|699|700|701|702|703|708|709|710|711|712|714|735|755|756|761|776|777|779|797|798|800|818|819|821|824,Ethylmorphine,"Alkaloids| Analgesics| Antitussive Agents| Central Nervous System Agents| Central Nervous System Depressants| Cough and Cold Preparations| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds with 4 or More Rings| Heterocyclic Compounds, Bridged-Ring| Heterocyclic Compounds, Fused-Ring| Morphinans| Morphine Derivatives| Narcotics| Ophthalmologicals| Opiate Alkaloids| Opioids| Opium Alkaloids and Derivatives| Peripheral Nervous System Agents| Phenanthrenes| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Respiratory System| Respiratory System Agents| Sensory Organs| Sensory System Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
462,DB00459,P19793|P10276|P10826|P13631|P28702|P48443|P09455,O43174,hsa:6256|hsa:5914|hsa:5915|hsa:5916|hsa:6257|hsa:6258|hsa:5947,9|10|11|12|18|19|178|182|283|284|286|308|332|333|341|344|352|355|356|366|370|371|374|380|381|382|384|405|406|416|420|430|434|440|441|443|446|452|470|476|490|498|516|520|524|541|542|548|552|553|556|564|565|570|573|574|578|582|584|589|594|595|599|603|604|606|608|618|619|626|634|637|640|641|651|655|660|664|666|667|668|671|677|678|679|680|688|689|696|697|698|699|708|709|710|712|713|714|734|735|755|756|776|777|797|798|818|819,Acitretin,"Alkenes| Antipsoriatics| Antipsoriatics for Systemic Use| Biological Factors| Carotenoids| Cyclohexanes| Cyclohexenes| Cycloparaffins| Dermatologicals| Drugs causing inadvertant photosensitivity| Hepatotoxic Agents| Hydrocarbons| Hydrocarbons, Acyclic| Keratolytic Agents| Misc. Skin and Mucous Membrane Agents| Photosensitizing Agents| Pigments, Biological| Polyenes| Retinoids| Retinoids for Treatment of Psoriasis| Terpenes"
463,DB00216,P28221|P28222|P30939|P08908|P28566|P41595|P34969,P08684|P10635|P11712|P33261|P23219|P11509,hsa:3352|hsa:3351|hsa:3355|hsa:3350|hsa:3354|hsa:3357|hsa:3363,9|10|11|12|14|15|18|19|33|143|145|146|148|149|150|178|182|185|189|283|284|285|293|299|332|333|338|340|344|345|349|351|353|355|356|357|358|365|368|370|371|372|373|374|376|377|383|384|385|386|387|390|391|392|393|396|399|400|403|412|414|416|418|430|431|434|435|437|441|442|445|446|447|449|453|457|459|464|465|470|472|482|490|491|495|500|502|506|507|516|520|521|523|524|527|528|530|531|532|538|539|540|545|546|549|552|555|556|564|570|576|577|578|582|584|585|586|592|595|599|600|603|607|608|613|618|628|633|634|640|643|656|657|658|660|664|665|668|677|678|679|683|688|696|697|708|709|710|712|716|734|758|779|797|821,Eletriptan,"Agents that produce hypertension| Amines| Analgesics| Antidepressive Agents| Antimigraine Preparations| Biogenic Amines| Biogenic Monoamines| Central Nervous System Depressants| Cytochrome P-450 CYP2A6 Inducers| Cytochrome P-450 CYP2A6 Inducers (strength unknown)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Indoles| Nervous System| Neurotransmitter Agents| P-glycoprotein substrates| Selective Serotonin 5-HT1 Receptor Agonists| Selective Serotonin Agonists| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 1b Receptor Agonists| Serotonin 1d Receptor Agonists| Serotonin 5-HT1 Receptor Agonists| Serotonin Agents| Serotonin Modulators| Serotonin Receptor Agonists| Serotonin-1b and Serotonin-1d Receptor Agonist| Triptans"
464,DB01244,O00555|O95180|Q9NY47|P05023|P51787|P63316|P0DP23|Q01064|P54750|Q12809,P10635,"hsa:773|hsa:8912|hsa:9254|hsa:476|hsa:3784|hsa:7134|hsa:801,hsa:805,hsa:808|hsa:5153|hsa:5136|hsa:3757",9|10|11|12|14|15|18|143|145|146|178|182|185|189|283|284|285|286|332|333|335|338|340|344|345|346|351|352|355|356|365|366|370|371|374|376|377|384|390|391|405|416|430|434|437|441|446|449|464|470|490|495|502|516|520|524|540|545|546|549|552|556|564|566|569|570|578|582|584|585|592|595|599|600|603|607|608|611|613|614|615|618|628|633|634|638|640|656|657|659|660|664|665|668|677|678|679|683|688|708|709|710,Bepridil,"Agents causing hyperkalemia| Antiarrhythmic agents| Antihypertensive Agents| Bradycardia-Causing Agents| Calcium Channel Blockers| Calcium-Regulating Hormones and Agents| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Highest Risk QTc-Prolonging Agents| Hypotensive Agents| Membrane Transport Modulators| Non-Selective Calcium Channel Blockers| P-glycoprotein inhibitors| Phenylalkylamine Derivatives| Pyrrolidines| QTc Prolonging Agents| Vasodilating Agents"
465,DB01234,P04150|P51843|P04083|P35228|O75469,P08684|P20815|P24462|P11712|P05108|P05093|P11511|P04798|Q16678|P11509|P20813|P33261|P10632|P10635|P05181|Q9HB55|Q02928,hsa:2908|hsa:190|hsa:301|hsa:4843|hsa:8856,9|10|11|12|18|19|20|23|143|144|178|179|182|185|186|192|283|284|286|287|308|332|333|334|335|337|339|341|344|346|352|366|374|406|416|420|430|432|434|441|443|446|462|490|516|524|535|537|553|556|571|579|582|599|617|637|639|640|660|671|672|678|679|680|681|684|688|689|692|693|696|697|698|699|704|705|708|709|710|711|712|776|777|797|798|818|819|839|840|860|861,Dexamethasone,"Adrenal Cortex Hormones| Adrenals| Agents Causing Muscle Toxicity| Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use| Alimentary Tract and Metabolism| Anti-Acne Preparations| Anti-Acne Preparations for Topical Use| Anti-Inflammatory Agents| Antiemetics| Antineoplastic Agents| Antineoplastic Agents, Hormonal| Autonomic Agents| BCRP/ABCG2 Inhibitors| BSEP/ABCB11 inducers| Cardiovascular System| Central Nervous System Agents| Corticosteroid Hormone Receptor Agonists| Corticosteroids| Corticosteroids for Local Oral Treatment| Corticosteroids for Systemic Use| Corticosteroids for Systemic Use, Plain| Corticosteroids, Dermatological Preparations| Corticosteroids, Moderately Potent (Group II)| Cytochrome P-450 CYP2A6 Inducers| Cytochrome P-450 CYP2A6 Inducers (strength unknown)| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (strength unknown)| Cytochrome P-450 CYP2C19 Inducers| Cytochrome P-450 CYP2C19 Inducers (strength unknown)| Cytochrome P-450 CYP2C8 Inducers| Cytochrome P-450 CYP2C8 Inducers (strength unknown)| Cytochrome P-450 CYP2E1 Inducers| Cytochrome P-450 CYP2E1 Inducers (strength unknown)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inducers (strong)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (moderate)| Cytochrome P-450 CYP3A4 Inducers (strong)| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inducers| Cytochrome P-450 CYP3A5 Inducers (moderate)| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Inducers| Cytochrome P-450 CYP3A7 Inducers (strength unknown)| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dermatologicals| Experimental Unapproved Treatments for COVID-19| Fused-Ring Compounds| Gastrointestinal Agents| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Hyperglycemia-Associated Agents| Immunosuppressive Agents| Inducers of Drug Clearance| Medications that reduce magnesium levels| Nasal Preparations| OAT3/SLC22A8 Substrates| Ophthalmological and Otological Preparations| Ophthalmologicals| Otologicals| P-glycoprotein inducers| P-glycoprotein inhibitors| P-glycoprotein substrates| Peripheral Nervous System Agents| Polycyclic Compounds| Pregnadienes| Pregnadienetriols| Pregnanes| Respiratory System| Sensory Organs| Steroids| Steroids, Fluorinated| Stomatological Preparations| Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins| Vasoprotectives"
466,DB13954,P03372|O75469|Q92731|P43681|Q15596|Q99527|P00846|Q14457|P37059|P62508,P05177|P22309|P08684|P20815|P24462|P04798|Q16678|P33261|P10632|P11712,hsa:2099|hsa:8856|hsa:2100|hsa:1137|hsa:10499|hsa:2852|hsa:4508|hsa:8678|hsa:3294|hsa:2104,0|9|10|11|12|18|19|143|144|150|151|178|179|182|185|186|192|283|284|286|308|332|333|334|335|339|341|344|346|352|355|356|366|370|371|374|380|381|382|384|405|406|416|420|430|434|440|441|443|446|452|470|490|498|516|520|524|535|541|542|548|552|556|564|570|573|574|578|579|582|584|590|595|599|603|606|608|614|617|618|619|634|637|640|641|651|655|660|664|667|668|677|678|679|680|684|688|689|692|696|697|698|699|704|708|709|710|711|712|714|735|755|776|777|797|798|818|840|860|861,Estradiolcypionate,"Adrenal Cortex Hormones| BCRP/ABCG2 Inhibitors| Contraceptive Agents, Female| Contraceptive Agents, Hormonal| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Estradiol Congeners| Estranes| Estrenes| Estrogen Contraceptives| Estrogens| Fused-Ring Compounds| Gonadal Hormones| Gonadal Steroid Hormones| Hormonal Contraceptives for Systemic Use| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| OATP1B1/SLCO1B1 Inhibitors| OCT1 inhibitors| OCT2 Inhibitors| Organic Anion Transporting Polypeptide 2B1 Inhibitors| P-glycoprotein substrates| Polycyclic Compounds| Reproductive Control Agents| Steroids| Thyroxine-binding globulin inducers| UGT1A1 Substrates"
467,DB01254,P00519|P12931|P29317|P06239|P07947|P10721|P09619|P51692|P42684|P06241|Q06187|Q92570|P11274|P41240|P54756|P54760|P09769|P42685|P11142|P07948|Q9NYL2|Q16539|Q06203,P08684|P04798|P05177|Q16678|P20815|P31513,hsa:25|hsa:6714|hsa:1969|hsa:3932|hsa:7525|hsa:3815|hsa:5159|hsa:6777|hsa:27|hsa:2534|hsa:695|hsa:8013|hsa:613|hsa:1445|hsa:2044|hsa:2050|hsa:2268|hsa:2444|hsa:3312|hsa:4067|hsa:51776|hsa:1432|hsa:5471,9|10|11|12|14|15|16|18|19|33|37|143|148|149|178|180|181|182|183|184|185|192|283|284|285|286|293|294|299|308|332|333|340|342|344|345|346|351|352|353|355|356|358|359|362|365|366|370|371|372|373|374|375|376|377|378|379|383|384|387|389|390|391|392|393|396|403|406|412|416|418|420|421|430|434|435|437|438|439|441|442|443|445|446|447|449|450|451|453|464|470|472|473|474|475|480|482|484|487|489|490|491|493|495|500|501|502|503|504|506|507|508|511|513|516|519|520|521|523|524|530|532|533|535|538|539|540|545|546|549|550|552|553|555|556|560|564|566|569|570|571|572|578|580|582|584|585|591|592|593|595|596|598|599|600|601|603|607|608|609|611|613|618|621|624|628|633|634|636|640|643|645|654|656|657|659|660|664|665|668|672|673|674|677|678|679|683|688|708|709|710|738|758|771|801|821|834,Dasatinib,"Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Azoles| Bcr-Abl Tyrosine Kinase Inhibitors| BCRP/ABCG2 Inhibitors| BCRP/ABCG2 Substrates| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Immunosuppressive Agents| Kinase Inhibitor| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| P-glycoprotein inhibitors| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Photosensitizing Agents| Potential QTc-Prolonging Agents| Protein Kinase Inhibitors| Pyrimidines| QTc Prolonging Agents| Sulfur Compounds| Thiazoles| Tyrosine Kinase Inhibitors"
468,DB00751,P35367|P25021|P35348|P08913|P28223|P34969,P20813|P10635|P08684,hsa:3269|hsa:3274|hsa:148|hsa:150|hsa:3356|hsa:3363,9|10|11|12|14|15|143|148|149|178|182|185|189|213|215|216|283|284|285|299|332|333|338|340|344|345|351|355|356|365|370|371|375|376|377|384|390|391|393|416|418|430|434|437|441|446|449|450|453|464|470|487|490|495|502|516|519|520|524|540|545|546|549|552|556|560|564|569|570|578|582|584|585|592|595|596|599|600|603|607|608|611|613|618|628|633|634|640|654|656|657|660|664|665|668|674|677|678|679|683|688|696|697|708|709|710|712|755|758|818|821,Epinastine,"Acid Reducers| Antidepressive Agents| Azoles| Central Nervous System Depressants| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Decongestants and Antiallergics| Decreased Histamine Release| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Histamine H1 Inhibitors| Histamine H2 Antagonists| Neurotransmitter Agents| Ophthalmics| Ophthalmologicals| P-glycoprotein substrates| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Respiratory System| Sensory Organs| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin Agents| Serotonin Receptor Antagonists"
469,DB00122,Q9Y5K3|P22303|P49585|O14939|P06276|Q13393|Q8TCT1|P36544,Q9Y6K0|Q9Y259|P28329|P35790|Q8NE62,hsa:9468|hsa:43|hsa:5130|hsa:5338|hsa:590|hsa:5337|hsa:162466|hsa:1139,9|10|14|18|283|284|285|286|308|344|345|346|351|352|365|366|374|390|391|406|540|566|571|659,Choline,Alcohols| Amines| Amino Alcohols| Analgesics| Antimetabolites| Central Nervous System Agents| Dietary Supplements| Ethanolamines| Gastrointestinal Agents| Hypolipidemic Agents| Lipid Regulating Agents| Lipotropic Agents| Nervous System| Nootropic Agents| OCT1 inhibitors| OCT1 substrates| OCT2 Inhibitors| OCT2 Substrates| Onium Compounds| Other Nutritional Agents| Quaternary Ammonium Compounds| Salicylic Acid and Derivatives| Supplements| Trimethyl Ammonium Compounds| Vitamin B Complex| Vitamins
470,DB06637,Q09470|P16389|P22001|P22459|P22460|P17658|Q96RP8|Q16322|Q14721|Q92953|P48547|Q96PR1|Q14003|Q9NSA2|Q9NZV8|Q9UK17,P05181,hsa:3736|hsa:3737|hsa:3738|hsa:3739|hsa:3741|hsa:3742|hsa:3743|hsa:3744|hsa:3745|hsa:9312|hsa:3746|hsa:3747|hsa:3748|hsa:3750|hsa:3751|hsa:3752,9|10|14|15|178|183|184|283|284|285|299|332|340|344|345|351|355|358|365|370|371|372|373|376|377|384|387|390|392|393|396|399|400|403|416|418|431|434|435|441|442|445|446|447|449|453|464|470|472|482|490|491|495|502|506|516|520|521|523|524|527|528|530|538|539|540|545|546|549|552|555|556|564|570|576|577|578|582|584|585|592|595|599|600|603|607|608|613|618|628|633|634|640|643|656|657|660|664|665|668|677|678|683,Dalfampridine,"Amines| Aminopyridines| Cardiovascular Agents| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Membrane Transport Modulators| Narrow Therapeutic Index Drugs| Nervous System| OCT2 Substrates| OCT2 Substrates with a Narrow Therapeutic Index| Other Miscellaneous Therapeutic Agents| Potassium Channel Blockers| Pyridines"
471,DB01194,P00918|P00915|P22748|P35218|P07451,P08684,hsa:760|hsa:759|hsa:762|hsa:763|hsa:761,9|10|11|14|15|18|19|20|33|34|143|149|178|183|184|283|284|285|286|293|299|305|332|333|338|340|344|345|346|351|352|353|355|356|365|366|370|371|374|383|384|390|392|393|405|412|414|416|421|430|434|441|446|457|459|464|465|470|471|479|480|483|490|500|507|513|520|524|528|531|532|540|549|552|556|564|569|570|582|586|592|595|599|607|608|611|613|628|633|634|638|640|643|656|658|660|668|678|683|708|710,Brinzolamide,"Amides| Antiglaucoma Preparations and Miotics| Carbonic Anhydrase Inhibitors| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Diuretics| Enzyme Inhibitors| Genito Urinary System and Sex Hormones| Gynecological Antiinfectives and Antiseptics| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Ophthalmics| Ophthalmologicals| Sensory Organs| Sulfonamides| Sulfones| Sulfur Compounds"
472,DB00318,P35372|P41145|P41143,P10635|P08684|P20815|P24462|P16662|P06133,hsa:4988|hsa:4986|hsa:4985,9|10|11|12|14|18|19|143|146|178|180|181|182|185|189|192|196|199|283|284|285|286|308|332|333|334|335|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|391|405|406|416|430|434|441|446|470|476|490|498|516|520|524|540|541|542|544|548|552|556|564|565|567|570|571|573|574|578|582|584|589|592|594|595|599|603|604|606|607|608|613|614|617|618|619|620|626|630|632|634|637|640|641|651|655|656|660|662|663|664|666|667|668|677|678|679|680|682|683|688|689|690|691|696|697|698|699|700|701|702|703|708|709|710|711|712|714|735|755|756|761|776|777|779|797|798|800|818|819|821|824,Codeine,"Alkaloids| Analgesics| Antitussive Agents| Central Nervous System Agents| Central Nervous System Depressants| Cough and Cold Preparations| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds with 4 or More Rings| Heterocyclic Compounds, Bridged-Ring| Heterocyclic Compounds, Fused-Ring| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Morphinans| Morphine Derivatives| Narcotics| Natural Opium Alkaloids| Nervous System| OAT1/SLC22A6 inhibitors| OCT1 inhibitors| OCT1 substrates| Opiate Agonists| Opiate Alkaloids| Opioid Agonist| Opioids| Opium Alkaloids and Derivatives| Phenanthrene opioids| Phenanthrenes| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Respiratory System| Respiratory System Agents| Sensory System Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| UGT2B7 substrates"
473,DB01252,Q09428|P37231,P35503|P16662,hsa:6833|hsa:5468,9|10|11|12|14|18|19|143|145|146|178|179|182|185|283|284|285|286|308|332|333|335|344|345|351|352|355|356|365|370|371|380|384|390|391|406|416|420|430|434|439|440|441|443|446|451|452|470|490|516|520|524|535|540|552|556|564|570|578|579|582|584|592|595|599|603|608|613|617|618|634|637|640|645|646|656|660|664|668|677|678|679|680|682|683|684|685|686|687|688|689|692|696|697|698|704|708|709|710|712|818,Mitiglinide,"Alimentary Tract and Metabolism| Blood Glucose Lowering Agents| Drugs Used in Diabetes| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Oral Hypoglycemics| UGT1A3 substrates| UGT2B7 substrates"
474,DB00414,P48048,P16152,hsa:3758,9|10|11|14|15|18|19|20|33|178|179|182|185|283|284|285|286|293|299|305|332|333|338|340|341|344|345|351|352|353|355|356|365|370|371|374|375|383|384|390|392|393|414|416|420|430|432|434|441|443|446|451|457|459|465|470|483|490|493|516|520|524|528|531|532|535|540|552|553|556|560|564|570|578|579|582|584|592|595|597|599|603|608|613|618|623|634|640|643|645|646|654|660|664|668|671|672|677|678|679|683|684|688|692|696|704|708|709|710|715|778,Acetohexamide,"Alimentary Tract and Metabolism| Amides| Benzene Derivatives| Benzenesulfonamides| Blood Glucose Lowering Agents| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 Substrates| Drugs Used in Diabetes| Genito Urinary System and Sex Hormones| Gynecological Antiinfectives and Antiseptics| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Insulin Secretagogues| Oral Hypoglycemics| Sulfonamides| Sulfones| Sulfonylureas| Sulfur Compounds"
475,DB00769,P04150,P08684,hsa:2908,9|10|11|12|14|18|19|20|143|144|178|179|182|185|186|192|283|284|285|286|308|332|333|334|335|337|339|341|344|345|346|351|352|365|366|374|380|390|391|405|406|416|420|430|432|434|440|441|443|446|452|462|490|524|535|536|537|540|553|556|566|571|579|582|599|602|605|614|615|617|637|639|640|656|659|660|671|678|679|680|681|684|688|689|692|693|696|697|698|699|704|705|708|709|710|711|712|776|777|797|798|818|819|839|840|860|861,Hydrocortamate,Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 Enzyme Inducers
476,DB00887,Q13621|P55011|Q9UP95|Q9H2X9|P13569,P35354,hsa:6557|hsa:6558|hsa:6560|hsa:57468|hsa:1080,9|10|11|12|14|15|18|19|20|33|178|182|185|189|283|284|285|286|293|299|305|308|332|333|340|341|344|345|351|352|353|355|356|365|370|371|374|376|377|380|381|382|383|384|390|392|393|405|406|414|416|420|430|434|437|440|441|443|446|449|452|457|459|464|465|470|476|483|490|493|495|498|502|516|520|524|528|531|532|534|535|540|541|542|543|545|546|548|549|552|553|556|564|565|566|570|573|574|578|579|582|584|585|589|592|594|595|597|599|600|603|604|606|607|608|613|614|615|617|618|619|620|623|626|628|629|632|633|634|637|640|641|643|651|655|656|657|659|660|664|665|666|667|668|671|672|677|678|679|680|682|683|684|685|688|689|690|692|693|698|700|701|704|705|708|709|710|714|736|737|746|762|763|777|799|800|809|825|826,Bumetanide,"Acids, Carbocyclic| Agents Causing Muscle Toxicity| Amides| Aminobenzoates| Benzene Derivatives| Benzoates| Carboxylic Acids| Cardiovascular Agents| Cardiovascular System| Diuretics| Drugs causing inadvertant photosensitivity| Drugs that are Mainly Renally Excreted| Genito Urinary System and Sex Hormones| Gynecological Antiinfectives and Antiseptics| High-Ceiling Diuretics| High-Ceiling Diuretics and Potassium-Sparing Agents| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hyperglycemia-Associated Agents| Hypotensive Agents| Increased Diuresis at Loop of Henle| Membrane Transport Modulators| meta-Aminobenzoates| Natriuretic Agents| Nephrotoxic agents| Non Potassium Sparing Diuretics| OAT1/SLC22A6 inhibitors| OAT3/SLC22A8 Inhibitors| OAT3/SLC22A8 Substrates| Photosensitizing Agents| Sodium Potassium Chloride Symporter Inhibitors| Sulfonamides| Sulfones| Sulfur Compounds"
477,DB04846,P08588|P07550,P08684,hsa:153|hsa:154,9|10|11|12|14|15|18|19|20|178|182|283|284|285|286|299|308|332|333|336|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|375|376|377|381|382|384|390|391|392|393|405|406|416|420|430|432|434|437|441|443|446|449|451|464|470|476|490|493|495|498|502|516|520|524|528|535|540|541|542|545|546|548|549|552|553|556|560|564|565|566|567|570|571|573|574|578|579|581|582|584|585|589|592|594|595|597|599|600|603|604|606|607|608|613|614|618|619|620|623|625|626|628|632|633|634|636|637|638|640|641|642|643|645|646|651|654|655|656|657|659|660|662|663|664|665|666|668|671|672|674|677|678|679|680|682|683|684|685|688|689|692|696|698|704|708|709|710|721|737|756|784|800|819,Celiprolol,"Adrenergic Agents| Adrenergic Agonists| Adrenergic Antagonists| Adrenergic beta-1 Receptor Antagonists| Adrenergic beta-2 Receptor Agonists| Adrenergic beta-3 Receptor Agonists| Adrenergic beta-Agonists| Adrenergic beta-Antagonists| Agents causing hyperkalemia| Alcohols| Amides| Amines| Amino Alcohols| Antiarrhythmic agents| Antihypertensive Agents| Autonomic Agents| Benzene Derivatives| Beta Blocking Agents, Selective| Beta-Blockers (Beta1 Selective)| Bradycardia-Causing Agents| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Substrates| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Neurotransmitter Agents| Peripheral Nervous System Agents| Phenoxypropanolamines| Phenylurea Compounds| Potential QTc-Prolonging Agents| Propanolamines| Propanols| QTc Prolonging Agents| Sympathomimetics| Vasodilating Agents"
478,DB01005,P23921,P10635,hsa:6240,14|15|18|19|285|286|299|301|308|375|393|395|420|451,Hydroxyurea,Amides| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Antisickling Agents| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Enzyme Inhibitors| Hematologic Agents| Immunosuppressive Agents| Methemoglobinemia Associated Agents| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| Nucleic Acid Synthesis Inhibitors| OATP1B1/SLCO1B1 Substrates
479,DB09223,P14416|P35462|P28223,P08684,hsa:1813|hsa:1814|hsa:3356,9|10|11|12|14|15|23|178|180|181|182|183|184|185|192|227|231|283|284|285|287|332|333|340|344|345|351|355|356|357|358|364|365|370|371|374|375|376|378|379|384|387|390|391|396|403|416|418|430|431|434|437|438|441|442|446|449|450|453|464|470|472|482|484|487|490|495|502|506|516|519|520|523|524|530|538|539|540|545|546|549|552|555|556|560|564|569|570|577|578|582|584|585|592|595|596|599|600|603|607|608|611|613|618|628|633|634|636|640|654|656|657|660|664|665|668|674|677|678|679|683|688|696|697|708|709|710|712,Blonanserin,"Antidepressive Agents| Antipsychotic Agents| Antipsychotic Agents (Second Generation [Atypical])| Central Nervous System Depressants| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Dopamine Antagonists| Dopamine D2 Receptor Antagonists| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Neurotoxic agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin Agents| Serotonin Receptor Antagonists"
480,DB01143,P10696|P22413,P05186,hsa:251|hsa:5167,9|10|14|15|18|19|30|33|283|284|285|293|299|308|314|332|344|345|349|351|353|365|368|390|392|393|411|425|456|528|540|593|613|643|656,Amifostine,"Compounds used in a research, industrial, or household setting| Cytoprotective Agent| Detoxifying Agents for Antineoplastic Treatment| Free Radical Scavenging Activity| Hypotensive Agents| Organophosphates| Organophosphorus Compounds| Organothiophosphates| Organothiophosphorus Compounds| Protective Agents| Radiation-Protective Agents| Sulfur Compounds"
481,DB00591,P04150,P47712,hsa:2908,0|9|10|11|12|18|19|20|23|24|143|144|146|150|178|179|182|185|186|192|283|284|286|287|308|332|333|334|335|337|339|341|344|346|352|366|374|380|405|406|416|420|430|432|434|441|443|446|462|490|516|524|535|537|553|556|563|567|571|579|581|582|599|605|610|614|617|637|639|640|642|660|661|662|671|672|678|679|680|681|684|688|689|690|692|693|696|697|698|699|700|701|704|705|708|709|710|711|712|776|777|797|798|818|819|839|840|860|861|866,Fluocinoloneacetonide,"Adrenal Cortex Hormones| Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use| Anti-Inflammatory Agents| Corticosteroid Hormone Receptor Agonists| Corticosteroids| Corticosteroids, Dermatological Preparations| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Dermatologicals| Drugs that are Mainly Renally Excreted| Fused-Ring Compounds| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Immunosuppressive Agents| Ophthalmologicals| Otologicals| Polycyclic Compounds| Pregnadienes| Pregnanes| Steroids| Steroids, Fluorinated| Vasoprotectives"
482,DB04920,O60840|Q13698|Q01668|Q13936,P11712|P10635|P05181|P33261|P05177|P08684|P06276,hsa:778|hsa:779|hsa:776|hsa:775,9|10|11|12|14|18|19|20|37|38|178|182|183|184|185|283|284|285|286|294|299|332|333|335|340|342|344|351|352|355|356|362|366|367|370|371|374|380|384|390|392|393|405|416|420|430|434|437|440|441|443|446|449|452|470|490|501|503|516|520|524|526|529|535|550|552|553|556|563|564|570|573|578|579|582|584|591|594|595|598|599|603|608|610|618|619|634|637|640|643|656|660|661|664|666|668|671|673|677|678|679|680|684|688|689|690|692|693|694|696|697|698|700|704|708|709|710|712|738|759|773|801|822|836,Clevidipine,"Agents causing hyperkalemia| Antiarrhythmic agents| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Bradycardia-Causing Agents| Calcium Channel Blockers| Calcium Channel Blockers (Dihydropyridine)| Calcium-Regulating Hormones and Agents| Cardiovascular Agents| Cardiovascular System| Cholinesterase substrates| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dihydropyridine Derivatives| Dihydropyridines| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypotensive Agents| Membrane Transport Modulators| Selective Calcium Channel Blockers With Mainly Vascular Effects| Vasodilating Agents"
483,DB11633,P50859|Q12809|Q13936|P48051|Q92806|Q14654|P22460|Q9UK17|P51787|Q14524,P08684|P20815|P10632|P11712|P33261|P10635|P20813|O60656|Q9HAW9,hsa:3757|hsa:775|hsa:3763|hsa:3765|hsa:3767|hsa:3741|hsa:3752|hsa:3784|hsa:6331,9|10|11|12|14|15|16|18|23|24|33|143|148|149|150|155|156|178|182|185|189|283|284|285|286|287|293|300|308|332|333|335|337|340|341|344|345|349|351|352|353|355|356|357|358|364|365|368|370|371|373|374|375|376|379|383|384|387|389|390|396|403|406|412|416|418|419|421|422|429|430|431|434|437|441|442|446|447|449|450|453|464|466|467|470|472|473|474|475|480|482|484|486|487|489|490|491|495|496|500|502|504|506|507|508|515|516|517|519|520|521|524|530|531|533|538|539|540|546|548|549|552|555|556|560|564|566|568|570|572|573|574|576|578|582|584|586|592|595|596|599|603|607|608|613|617|618|619|628|633|634|636|637|638|640|641|654|655|656|658|659|660|664|667|668|676|677|678|679|680|683|688|689|696|697|698|708|709|710|712|713|776,Isavuconazole,"Anti-Infective Agents| Antifungal Agents| Antiinfectives for Systemic Use| Antimycotics for Systemic Use| Azole Antifungals| Azoles| BCRP/ABCG2 Inhibitors| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (weak)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Inducers| Cytochrome P-450 CYP2C8 Inducers (weak)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Inducers| Cytochrome P-450 CYP2C9 Inducers (weak)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (weak)| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (moderate)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates (strength unknown)| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (moderate)| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Isavuconazole and Prodrugs| OCT2 Inhibitors| P-glycoprotein inhibitors| Triazole and tetrazole derivatives| Triazole Derivatives| UGT1A9 Inhibitors"
484,DB00400,P10875|P87066|Q99456,P05177|P08684,hsa:3859,9|10|11|12|18|19|20|37|143|149|178|182|185|189|283|284|286|294|332|333|335|337|341|342|344|352|355|356|362|366|370|371|374|381|382|384|405|416|420|430|432|434|441|443|446|462|470|476|490|493|498|501|505|520|524|535|537|541|542|548|550|551|552|553|556|564|565|567|570|573|574|575|578|579|581|582|583|584|589|591|594|595|597|598|603|604|605|606|608|614|618|619|620|623|625|626|632|634|637|639|640|641|642|651|653|655|660|662|664|666|668|671|677|678|679|680|681|684|686|688|689|690|692|693|694|696|697|698|699|700|701|704|705|706|708|709|710|712|714|722|738|740|756|764|777|785|801|803|819|824|827,Griseofulvin,"Anti-Infective Agents| Antifungal Agents| Antifungals for Dermatological Use| Antifungals for Systemic Use| Antifungals for Topical Use| Benzofurans| Cytochrome P-450 CYP1A2 Inducers| Cytochrome P-450 CYP1A2 Inducers (strength unknown)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 Enzyme Inducers| Decreased Mitosis| Dermatologicals| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Macrocyclic Compounds| Microtubule Inhibition| Tubulin Inhibiting Agent"
485,DB08906,P04150,P08684,hsa:2908,9|10|11|12|18|19|20|23|24|33|143|144|149|150|178|179|182|185|186|192|283|284|286|287|293|308|332|333|334|335|337|339|341|344|346|352|353|355|366|368|370|371|374|380|381|384|405|406|409|412|416|420|430|432|434|436|440|441|443|446|448|452|462|470|476|490|493|498|507|516|520|524|535|537|541|542|548|552|553|556|564|565|567|570|571|573|574|578|579|582|584|586|589|594|595|597|599|603|604|605|606|608|614|617|619|620|623|626|632|634|637|640|641|651|655|660|662|664|666|668|671|672|677|678|679|680|681|684|688|689|690|692|693|694|696|697|698|699|700|704|705|708|709|710|711|712|776|777|797|798|818|819|839|840|860|861,Fluticasonefuroate,Adrenal Cortex Hormones| Agents to Treat Airway Disease| Androstanes| Androstenes| Corticosteroids| Corticosteroids for inhalation use| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strong)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inducers| Cytochrome P-450 CYP3A5 Inducers (strength unknown)| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs for Obstructive Airway Diseases| Fused-Ring Compounds| Glucocorticoids| Hyperglycemia-Associated Agents| Immunosuppressive Agents| Nasal Preparations| OATP1B1/SLCO1B1 Inhibitors| P-glycoprotein inducers| P-glycoprotein substrates| Polycyclic Compounds| Respiratory System| Steroids| Thyroxine-binding globulin inhibitors
486,DB09280,P13569,P08684|P20813|P10632|P11712|P33261,hsa:1080,9|10|11|12|14|15|18|19|20|23|24|115|116|143|146|178|182|183|184|185|189|192|283|284|285|286|287|299|308|332|333|334|340|341|344|351|352|355|356|357|358|363|370|371|374|375|376|378|379|380|381|382|384|387|390|392|393|396|403|405|406|416|418|420|430|431|434|437|438|439|440|441|442|443|446|449|450|451|452|453|464|470|472|476|482|484|487|490|493|495|498|502|506|516|519|520|523|524|530|535|538|539|541|542|544|545|546|548|549|552|553|555|556|560|563|564|565|567|570|573|574|576|577|578|579|582|584|585|589|592|594|595|596|597|599|600|603|604|606|607|608|610|613|617|618|619|623|626|628|630|633|634|636|637|640|641|643|645|647|651|654|655|656|657|660|661|662|664|665|666|667|668|671|672|674|677|678|679|680|683|684|688|689|691|692|693|695|696|697|698|699|702|703|704|705|707|708|709|710|711|712|714|734|735|761|777|797|798|824,Lumacaftor,"Amines| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (strength unknown)| Cytochrome P-450 CYP2C19 Inducers| Cytochrome P-450 CYP2C19 Inducers (strength unknown)| Cytochrome P-450 CYP2C8 Inducers| Cytochrome P-450 CYP2C8 Inducers (strength unknown)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Inducers| Cytochrome P-450 CYP2C9 Inducers (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inducers (strong)| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strong)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Dioxoles| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| P-glycoprotein inducers| P-glycoprotein inhibitors| Pyridines| Respiratory System"
487,DB00240,P04150,P08684,hsa:2908,9|10|11|12|18|19|20|37|143|144|178|179|182|185|186|192|283|284|286|294|308|332|333|334|335|337|339|341|342|343|344|346|352|361|366|374|406|416|420|430|432|434|441|443|446|462|490|516|524|535|537|550|553|556|571|579|582|591|599|617|637|639|640|660|671|672|678|679|680|681|684|688|689|692|693|696|697|698|699|704|705|708|709|710|711|712|776|777|780|797|798|801|818|819|822|839|840|860|861,Alclometasone,"Adrenal Cortex Hormones| Anti-Inflammatory Agents| Corticosteroid Hormone Receptor Agonists| Corticosteroids| Corticosteroids, Dermatological Preparations| Corticosteroids, Moderately Potent (Group II)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Dermatologicals| Fused-Ring Compounds| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Immunosuppressive Agents| Ophthalmologicals| Polycyclic Compounds| Pregnadienes| Pregnadienetriols| Pregnanes| Sensory Organs| Steroids"
488,DB00222,Q14654|P48048|Q09428,P11712,hsa:3767|hsa:3758|hsa:6833,9|10|11|12|14|15|16|18|19|20|33|143|148|149|178|179|182|185|283|284|285|286|293|299|305|308|332|333|335|338|340|344|345|351|352|353|355|356|365|370|371|374|375|383|384|390|391|393|406|414|416|418|420|430|434|439|441|443|446|450|451|453|457|459|464|465|470|483|487|490|516|519|520|524|531|532|535|540|552|553|556|559|564|570|578|579|582|584|592|595|596|599|603|607|608|613|618|634|640|645|646|656|660|664|668|671|677|678|679|683|688|696|708|709|710|715|778|779,Glimepiride,Alimentary Tract and Metabolism| Amides| Blood Glucose Lowering Agents| BSEP/ABCB11 Substrates| Cardiovascular Agents| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 Substrates| Drugs Used in Diabetes| Hypoglycemia-Associated Agents| Immunosuppressive Agents| Insulin Secretagogues| Oral Hypoglycemics| Sulfones| Sulfonylureas| Sulfur Compounds
489,DB00967,P35367,P11712|P33261|P05177|P10635,hsa:3269,9|10|11|12|14|15|37|178|180|181|182|183|184|185|192|213|217|283|284|285|294|299|332|333|340|342|344|345|351|355|356|357|358|362|365|370|371|372|373|376|384|387|390|392|393|396|403|416|418|430|431|434|435|437|441|442|445|446|447|449|453|464|470|472|482|490|491|495|501|502|503|506|516|520|521|523|524|528|530|538|539|540|545|546|549|550|552|555|556|564|570|576|577|578|582|584|585|591|592|595|598|599|600|603|607|608|613|618|628|633|634|640|643|656|657|660|664|665|668|677|678|679|683|688|696|697|708|709|710|712|717|738|755|780|801|818,Desloratadine,"Anticholinergic Agents| Antihistamines for Systemic Use| Benzocycloheptenes| Central Nervous System Depressants| Cholinergic Agents| Dibenzocycloheptenes| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Histamine H1 Antagonists, Non-Sedating| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Loratadine and derivatives| Moderate Risk QTc-Prolonging Agents| Neurotransmitter Agents| P-glycoprotein inhibitors| Piperidines| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| QTc Prolonging Agents| Respiratory System"
490,DB06691,P35367,P10635,hsa:3269,9|10|11|12|14|15|18|178|182|183|184|185|283|284|285|286|332|333|341|344|345|351|352|355|356|358|365|366|370|371|372|373|374|375|376|378|379|381|382|384|387|390|391|396|403|405|416|418|430|434|435|438|441|442|445|446|447|449|450|453|464|470|472|476|482|484|487|490|491|495|498|502|506|516|519|520|521|523|524|530|538|539|540|541|542|545|546|548|549|552|555|556|560|564|565|569|570|573|574|576|577|578|582|584|585|589|592|594|595|596|599|600|603|604|606|607|608|611|613|618|619|626|628|633|634|636|637|640|641|651|654|655|656|657|660|664|665|666|668|674|677|678|679|680|683|688|689|691|702|708|709|710|714|777,Mepyramine,"Amines| Aminopyridines| Anti-Allergic Agents| Antihistamines for Systemic Use| Antihistamines for Topical Use| Antipruritics, Incl. Antihistamines, Anesthetics, Etc.| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Dermatologicals| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Hypnotics and Sedatives| Neurotransmitter Agents| Potential QTc-Prolonging Agents| Pyridines| QTc Prolonging Agents| Respiratory System| Sleep Aids, Pharmaceutical| Substituted Ethylene Diamines"
491,DB06736,P35354|P23219,P11712,hsa:5743|hsa:5742,9|10|11|12|14|18|19|20|37|38|178|182|185|189|283|284|285|286|294|299|308|332|333|340|342|344|346|351|352|355|356|362|366|370|371|376|377|380|384|390|392|393|405|406|416|420|430|434|437|440|441|443|446|449|452|462|464|470|490|495|501|502|503|516|520|524|535|537|545|546|549|550|552|556|564|567|570|577|578|579|582|584|585|591|592|595|597|598|599|600|603|605|607|608|609|613|614|618|628|633|634|637|640|641|643|655|656|657|660|662|663|664|665|668|677|678|679|680|682|683|684|685|688|689|692|696|698|704|708|709|710|752|758|771|815|821|834,Aceclofenac,"Acetic Acid Derivatives and Related Substances| Acids, Carbocyclic| Agents causing hyperkalemia| Agents that produce hypertension| Analgesics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)| Antiinflammatory and Antirheumatic Products| Antiinflammatory and Antirheumatic Products, Non-Steroids| Antiinflammatory Preparations, Non-Steroids for Topical Use| Antirheumatic Agents| Carboxylic Acids| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Musculo-Skeletal System| Nephrotoxic agents| Peripheral Nervous System Agents| Phenylacetates| Selective Cyclooxygenase 2 Inhibitors (NSAIDs)| Sensory System Agents| Topical Products for Joint and Muscular Pain"
492,DB09128,P08908|P14416|P28223|P18825|P35368,P10635|P08684,hsa:3350|hsa:1813|hsa:3356|hsa:152|hsa:147,9|10|11|12|14|15|18|19|33|143|149|178|180|181|182|183|184|185|189|192|199|283|284|285|286|293|299|332|333|340|341|344|345|346|349|351|352|353|355|356|357|358|365|366|368|370|371|376|377|381|382|383|384|385|386|387|390|391|392|393|396|399|400|403|405|412|416|418|420|421|430|431|434|437|439|441|442|443|446|449|451|453|464|470|471|472|476|480|482|490|493|495|498|500|502|506|507|513|516|520|523|524|527|530|531|532|535|538|539|540|541|542|545|546|548|549|552|553|555|556|564|565|569|570|573|574|576|577|578|579|582|584|585|586|589|592|594|595|597|599|600|603|604|606|607|608|611|613|614|618|619|620|623|626|628|629|632|633|634|637|638|640|641|643|645|651|652|655|656|657|658|660|664|665|666|668|671|672|677|678|679|680|682|683|684|688|689|691|692|695|696|698|702|703|704|707|708|709|710|714|742|746|757|758|777|805|809|820|821,Brexpiprazole,"Adrenergic alpha-1 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Agents that produce hypertension| Antidepressive Agents| Antidepressive Agents Indicated for Depression| Antipsychotic Agents| Antipsychotic Agents (Second Generation [Atypical])| Central Nervous System Depressants| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Dopamine Agents| Dopamine Agonists| Dopamine D2 Receptor Agonists| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hyperglycemia-Associated Agents| MATE 2 Inhibitors| MATE inhibitors| Nervous System| Neurotoxic agents| Neurotransmitter Agents| Psycholeptics| Quinolines| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT1 Receptor Agonists| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin Agents| Serotonin Receptor Agonists| Serotonin Receptor Antagonists| Sulfur Compounds"
493,DB00482,P35354|O15530|P00918|P07451,P11712|P08684|P10635|P10632,hsa:5743|hsa:5170|hsa:760|hsa:761,9|10|11|12|14|15|18|19|23|24|33|143|148|149|178|182|185|189|283|284|285|287|293|299|300|305|332|333|340|344|351|353|355|356|357|358|363|370|371|374|376|377|383|384|387|390|396|414|416|418|422|430|431|434|437|441|442|446|449|453|457|459|464|465|467|470|477|482|483|490|495|502|515|516|520|523|524|530|531|532|538|539|545|546|549|552|555|556|564|570|576|577|578|582|584|585|592|593|595|599|600|601|603|607|608|613|616|618|621|628|633|634|640|644|656|657|660|664|665|668|677|678|679|683|688|696|697|708|709|710|713|725|776|788,Celecoxib,"Agents causing hyperkalemia| Agents that produce hypertension| Amides| Analgesics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Antiinflammatory and Antirheumatic Products| Antiinflammatory and Antirheumatic Products, Non-Steroids| Antineoplastic and Immunomodulating Agents| Antirheumatic Agents| BCRP/ABCG2 Substrates| Benzene Derivatives| Benzenesulfonamides| BSEP/ABCB11 Inhibitors| Cardiovascular System| Central Nervous System Agents| COX-2 Inhibitors| Cyclooxygenase Inhibitors| Cyclooxygenase-2 (COX-2) Inhibitors| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (moderate)| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Enzyme Inhibitors| Genito Urinary System and Sex Hormones| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Methemoglobinemia Associated Agents| Musculo-Skeletal System| Nephrotoxic agents| P-glycoprotein substrates| Peripheral Nervous System Agents| Photosensitizing Agents| Pyrazoles| Selective Cyclooxygenase 2 Inhibitors (NSAIDs)| Sensory System Agents| Sulfonamides| Sulfones| Sulfur Compounds"
494,DB01184,P14416|P35462,P20815|P24462|P08684|P05177|P20813|P10632|P10635,hsa:1813|hsa:1814,9|10|11|12|14|15|16|18|19|37|143|145|146|148|149|150|178|180|181|182|185|189|192|283|284|285|286|294|299|332|338|340|342|344|345|351|355|357|358|362|365|370|371|375|376|377|379|384|386|387|389|390|391|392|393|396|397|399|400|403|416|418|420|431|434|437|441|442|446|449|450|451|453|464|470|472|482|484|485|487|488|490|495|499|501|502|503|504|506|516|519|520|521|523|524|527|530|538|539|540|545|546|547|549|550|552|555|556|560|564|569|570|572|576|578|582|584|585|591|592|593|595|596|598|599|600|603|607|608|611|613|618|628|633|634|636|640|643|645|646|654|656|657|660|664|665|668|674|677|678|679|683|729|750|770|792|813|833,Domperidone,"Alimentary Tract and Metabolism| Antiemetics| Autonomic Agents| Benzimidazoles| Central Nervous System Agents| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Substrates| Dopamine Agents| Dopamine Antagonists| Dopamine D2 Receptor Antagonists| Drugs for Functional Gastrointestinal Disorders| Gastrointestinal Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Highest Risk QTc-Prolonging Agents| Neurotransmitter Agents| P-glycoprotein substrates| Peripheral Nervous System Agents| Piperidines| Prokinetic Agents| Propulsives| QTc Prolonging Agents"
495,DB00613,P50135,P10632|P04798|Q16678|P10635|P11712,hsa:3176,9|10|11|12|14|15|18|37|178|182|183|184|185|189|192|283|284|285|286|294|299|308|332|333|340|341|342|344|345|351|352|355|356|357|358|362|365|370|371|372|373|374|376|377|381|382|384|385|386|387|390|391|392|393|396|403|406|416|418|430|431|434|435|437|441|442|445|446|447|449|453|464|470|472|482|490|491|495|498|501|502|503|506|516|520|521|523|524|530|538|539|540|541|542|545|546|548|549|550|552|555|556|564|570|573|574|576|577|578|582|584|585|590|591|592|593|595|598|599|600|601|603|606|607|608|613|617|618|619|621|628|633|634|637|638|640|641|643|651|655|656|657|660|664|665|667|668|677|678|679|680|682|683|688|689|696|698|708|709|710|717|721|737|750|756|758|780|784|800|813|819|821,Amodiaquine,"Aminoquinolines| Anti-Infective Agents| Antimalarials| Antiparasitic Agents| Antiparasitic Products, Insecticides and Repellents| Antiprotozoals| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| P-glycoprotein inhibitors| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Quinolines"
496,DB06403,P25101|P24530,P08684|P33261|O60656|P16662|P35503|P20815,hsa:1909|hsa:1910,9|10|11|12|14|15|18|19|20|178|182|183|184|185|189|192|283|284|285|286|308|332|333|337|339|340|341|344|346|351|352|355|356|357|358|366|370|371|374|375|376|379|380|384|387|389|390|396|403|405|406|416|418|420|430|431|434|437|440|441|442|443|446|449|450|452|453|462|464|470|472|482|484|487|490|495|502|504|506|516|519|520|523|524|530|535|537|538|539|545|546|548|549|552|555|556|560|564|567|570|572|573|574|578|579|581|582|584|585|592|593|594|595|596|599|600|601|603|604|605|608|612|613|617|618|619|621|628|633|634|636|637|639|640|641|642|654|655|657|660|662|663|664|665|666|668|674|677|678|679|680|684|688|689|692|696|697|698|704|708|709|710|712,Ambrisentan,"Acids, Carbocyclic| Antihypertensive Agents| Antihypertensives for Pulmonary Arterial Hypertension| Carboxylic Acids| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Substrates| Endothelin Receptor Antagonists| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypertension, Pulmonary| OATP1B1/SLCO1B1 Substrates| OATP1B3 substrates| P-glycoprotein substrates| UGT1A3 substrates| UGT1A9 Substrates| UGT2B7 substrates| Vasodilating Agents"
497,DB00963,P35354|P23219,P35354,hsa:5743|hsa:5742,6|9|10|11|14|18|19|178|182|185|189|272|274|283|284|285|286|299|308|332|333|340|341|344|351|352|355|356|370|371|376|377|380|384|393|406|416|420|430|432|434|437|440|441|443|446|449|452|464|470|490|493|516|520|524|535|545|549|552|553|556|564|570|578|579|580|582|584|592|595|597|599|600|603|607|608|617|618|623|624|633|634|637|640|641|655|660|664|665|668|671|672|673|677|678|679|680|682|683|684|685|688|689|692|696|697|698|699|704|708|709|710|734|758|797|821,Bromfenac,"Agents causing hyperkalemia| Analgesics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)| Antirheumatic Agents| Benzene Derivatives| Central Nervous System Agents| Cyclooxygenase Inhibitors| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Brominated| Hydrocarbons, Cyclic| Hydrocarbons, Halogenated| Ketones| Nephrotoxic agents| Ophthalmologicals| Peripheral Nervous System Agents| Selective Cyclooxygenase 2 Inhibitors (NSAIDs)| Sensory Organs| Sensory System Agents"
498,DB00357,P11511|P05108,P08684|P05177|P33261,hsa:1588|hsa:1583,9|10|11|14|15|18|19|178|180|181|182|185|283|284|285|286|299|332|333|334|340|344|351|352|355|356|370|371|374|376|377|384|390|392|393|416|420|430|434|437|439|441|443|446|449|451|464|470|490|502|516|520|524|535|545|546|549|552|556|564|570|578|579|582|584|592|595|597|599|600|603|607|608|613|618|633|634|640|643|645|650|656|660|664|665|668|677|678|679|683|684|688|692|694|695|696|697|704|708|709|710|711|712|716|779,Aminoglutethimide,"Antineoplastic Agents| Antineoplastic Agents, Hormonal| Antineoplastic and Immunomodulating Agents| Aromatase Inhibitors| Cytochrome P-450 CYP2C19 Inducers| Cytochrome P-450 CYP2C19 Inducers (strength unknown)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 Enzyme Inducers| Endocrine Therapy| Enzyme Inhibitors| Estrogen Antagonists| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hormone Antagonists| Hormone Antagonists and Related Agents| Hormones, Hormone Substitutes, and Hormone Antagonists| Narrow Therapeutic Index Drugs| Piperidines| Piperidones| Steroid Synthesis Inhibitors"
499,DB09214,P23219|P35354,P23219|P35354,hsa:5742|hsa:5743,9|10|11|12|18|19|178|182|185|189|283|284|286|308|332|333|335|341|344|352|355|356|370|371|374|380|384|406|416|420|430|432|434|440|441|443|446|452|470|490|493|516|520|524|535|552|553|556|564|570|578|579|582|584|595|597|599|603|608|617|618|623|634|637|640|641|655|660|664|668|671|672|677|678|679|680|684|688|689|692|696|697|698|699|704|708|709|710|712|734|797,Dexketoprofen,"Acids, Carbocyclic| Agents causing hyperkalemia| Agents that produce hypertension| Alcohols| Analgesics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)| Antiinflammatory and Antirheumatic Products| Antiinflammatory and Antirheumatic Products, Non-Steroids| Antiinflammatory Preparations, Non-Steroids for Topical Use| Antirheumatic Agents| Carboxylic Acids| Central Nervous System Agents| Drugs that are Mainly Renally Excreted| Glycols| Ketoprofen and isomer| Musculo-Skeletal System| Nephrotoxic agents| Nervous System| Non COX-2 selective NSAIDS| Peripheral Nervous System Agents| Phenylpropionates| Propionates| Propylene Glycols| Sensory System Agents| Topical Products for Joint and Muscular Pain"
500,DB00898,P14867|Q8TCU5|P23415|P23416|Q02641|P46098|P47869|Q9GZZ6|Q13936|P31644|P48169|P34903|P42261|Q06432|Q15822|Q16445|P42262|P48058|P42263|P43681|P17787|P48549|P48051|P19320|Q99808|P48544|P36544|Q9UGM1|P18505|P28472|P47870|Q13698|Q01668|P30926|P32297|P30532|Q15825|Q05901|Q8N1C3|Q99928|P78334|O00591|Q9UN88|O14764|Q14542|A5X5Y0|O95264|Q70Z44|Q8WXA8|Q9Y698|Q92806|P32004,P05181|P04798|P05177|P20813|P33261|P11712|P08684|Q02928|P07327|P00325|P00326|P11766|P08319|P40394|P28332|P14550,hsa:2554|hsa:116443|hsa:2741|hsa:2742|hsa:782|hsa:3359|hsa:2555|hsa:57053|hsa:775|hsa:2558|hsa:2557|hsa:2556|hsa:2890|hsa:786|hsa:1135|hsa:2559|hsa:2891|hsa:2893|hsa:2892|hsa:1137|hsa:1141|hsa:3760|hsa:3763|hsa:7412|hsa:2030|hsa:3762|hsa:1139|hsa:55584|hsa:2560|hsa:2562|hsa:2561|hsa:779|hsa:776|hsa:1143|hsa:1136|hsa:1138|hsa:8973|hsa:1142|hsa:2565|hsa:2567|hsa:2564|hsa:2568|hsa:55879|hsa:2563|hsa:3177|hsa:285242|hsa:9177|hsa:200909|hsa:170572|hsa:10369|hsa:3765|hsa:3897,9|18|283|284|286|308|344|346|352|366|374|406|571,Ethanol,"Agents Causing Muscle Toxicity| Alcohols| Anti-Infective Agents| Anti-Infective Agents, Local| Antidotes| Antiseptics and Disinfectants| Central Nervous System Agents| Central Nervous System Depressants| Compounds used in a research, industrial, or household setting| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (weak)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2E1 Inducers| Cytochrome P-450 CYP2E1 Inducers (moderate)| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dermatologicals| Miscellaneous Local Anti-infectives| Miscellaneous Therapeutic Agents| Nerve Depressants| Neurotoxic agents| NMDA Receptor Antagonists| Solvents"
501,DB00633,P08913,P05181|P05177|P04798|P10635,hsa:150,9|10|11|14|15|143|148|149|178|182|283|284|285|299|332|333|335|340|344|345|351|355|356|357|358|365|370|371|372|373|374|375|376|379|384|387|389|390|392|393|396|399|400|403|416|418|430|431|434|435|437|441|442|445|446|447|449|450|453|470|472|482|484|485|487|488|490|491|495|499|502|504|506|516|519|520|521|523|524|527|528|538|539|540|545|546|547|552|556|560|564|569|570|572|578|582|584|585|592|595|596|599|603|607|608|611|613|618|634|636|640|654|657|660|664|665|668|674|677|678|679|683|688|696|697|708|709|710|712|734|755|797|818,Dexmedetomidine,"Adrenergic Agents| Adrenergic Agonists| Adrenergic alpha-2 Receptor Agonists| Adrenergic alpha-Agonists| Agents producing tachycardia| Agents that produce hypertension| Analgesics| Analgesics, Non-Narcotic| Anesthetics| Anesthetics, General| Azoles| Bradycardia-Causing Agents| Central alpha-2 Adrenergic Agonist| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypnotics and Sedatives| Hypotensive Agents| Imidazoles| Miscellaneous Anxiolytics Sedatives and Hypnotics| Nervous System| Neurotransmitter Agents| Peripheral Nervous System Agents| Psycholeptics| Sensory System Agents"
502,DB00153,P11473,Q07973|O15528|Q02318|P08684|Q6VVX0,hsa:7421,9|10|11|12|18|143|144|178|179|185|186|283|284|286|308|332|333|334|335|339|341|344|346|352|366|374|406|416|430|434|441|446|490|516|524|556|564|571|582|599|617|637|640|641|660|664|678|679|680|688|689|696|697|708|709|710|711|712|818|839|860,Ergocalciferol,"Alimentary Tract and Metabolism| Bone Density Conservation Agents| Calcium-Regulating Hormones and Agents| Diet, Food, and Nutrition| Food| Fused-Ring Compounds| Growth Substances| Lipids| Micronutrients| Physiological Phenomena| Polycyclic Compounds| Secosteroids| Vitamin D and Analogues| Vitamins| Vitamins (Fat Soluble)"
503,DB01018,P08913|P18089,P08684|P11712|P33261,hsa:150|hsa:151,9|10|11|14|15|18|37|38|178|182|283|284|285|286|294|299|332|333|342|344|351|352|355|356|362|370|371|375|384|390|392|393|416|418|420|430|434|439|441|443|446|450|451|470|488|490|501|503|516|519|520|524|535|550|552|556|560|564|570|578|579|582|584|591|592|595|596|597|598|599|603|607|608|613|618|634|640|643|647|654|660|664|668|677|678|679|683|684|688|692|696|704|708|709|710|752|759|815|822,Guanfacine,"Adrenergic Agents| Adrenergic Agonists| Adrenergic alpha-2 Receptor Agonists| Adrenergic alpha-Agonists| Agents producing tachycardia| Agents that produce hypertension| Amidines| Antiadrenergic Agents, Centrally Acting| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Bradycardia-Causing Agents| Carboxylic Acids| Cardiovascular Agents| Cardiovascular System| Central alpha-2 Adrenergic Agonist| Central Alpha-agonists| Central Nervous System Depressants| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Guanidines| Hypotensive Agents| Imidazoline Receptor Agonists| MATE 1 Inhibitors| MATE inhibitors| Neurotransmitter Agents| OCT1 inhibitors| OCT1 substrates| OCT2 Substrates"
504,DB00006,P00734,P05164,hsa:2147,9|10|11|12|13|14|15|16|17|18|19|20|21|22|143|145|146|150|152|153|157|159|160|178|182|185|189|192|196|283|284|285|286|299|308|332|333|335|338|340|341|344|345|351|352|355|356|365|370|371|374|375|380|381|382|384|390|391|392|393|406|416|418|420|430|434|439|440|441|443|446|450|451|452|470|488|490|498|516|519|520|524|528|535|536|540|541|542|548|552|556|560|564|566|569|570|573|574|578|579|580|582|584|590|592|593|595|596|599|602|603|606|607|608|611|613|617|618|619|634|637|638|640|641|643|645|646|651|654|655|656|659|660|664|667|668|677|678|679|680|682|683|684|685|686|687|688|689|691|692|693|694|695|696|698|702|704|708|709|710|714|777,Bivalirudin,"Amino Acids, Peptides, and Proteins| Anticoagulants| Antithrombins| Blood and Blood Forming Organs| Enzyme Inhibitors| Hematologic Agents| Peptides| Protease Inhibitors| Serine Protease Inhibitors| Thrombin Inhibitors"
505,DB00557,P35367,P10635,hsa:3269,9|10|11|12|14|15|18|19|37|178|180|181|182|185|189|192|283|284|285|286|294|308|332|333|338|340|342|344|345|346|351|352|355|356|362|365|366|370|371|384|390|391|405|406|416|430|434|441|446|464|470|490|501|503|516|520|524|540|549|550|552|556|564|566|567|569|570|571|578|582|584|591|592|595|598|599|603|607|608|611|613|614|615|618|628|633|634|640|656|659|660|662|663|664|668|677|678|679|683|688|696|697|708|709|710|717|780,Hydroxyzine,"Anti-Anxiety Agents| Antipruritics| Central Nervous System Depressants| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dermatologicals| Diphenylmethane Derivatives| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Histamine Receptor Antagonists| Miscellaneous Anxiolytics Sedatives and Hypnotics| Nervous System| Neurotransmitter Agents| P-glycoprotein substrates| Piperazines| Potential QTc-Prolonging Agents| Psycholeptics| QTc Prolonging Agents"
506,DB00281,Q9Y5Y9|Q15858|Q14524|P00533|P35499|P02763|P19652,P08684|P10635|P20815|P24462|P05177|P11712|P10632|P33260|P11509|P20813,hsa:6336|hsa:6335|hsa:6331|hsa:1956|hsa:6329|hsa:5004|hsa:5005,9|10|11|14|15|18|178|182|283|284|285|286|299|332|333|340|344|345|351|352|355|356|365|370|371|374|376|377|384|390|391|392|393|416|420|430|434|437|439|441|443|446|449|451|464|470|490|495|516|520|524|536|540|545|549|552|556|564|569|570|578|582|584|585|592|595|599|600|602|603|607|608|611|613|618|628|633|634|640|643|645|656|657|660|664|665|668|677|678|679|683|688|697|708|709|710|734|758|797|821,Lidocaine,"Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use| Agents that reduce seizure threshold| Amides| Amines| Analgesics and Anesthetics| Anesthetics| Anesthetics for Topical Use| Anesthetics, Local| Anilides| Aniline Compounds| Antiarrhythmic agents| Antiarrhythmics, Class I| Antiarrhythmics, Class Ib| Antipruritics and Local Anesthetics| Antipruritics, Incl. Antihistamines, Anesthetics, Etc.| Cardiac Therapy| Cardiovascular Agents| Cardiovascular System| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (moderate)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C18 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dermatologicals| Local Anesthesia| Local Anesthetics (Amide)| Membrane Transport Modulators| Methemoglobinemia Associated Agents| Nervous System| Neuraxial Anesthetics| Ophthalmologicals| Otologicals| P-glycoprotein inhibitors| Peripheral Nervous System Agents| Respiratory System| Sensory System Agents| Sodium Channel Blockers| Throat Preparations| Vasoprotectives| Voltage-Gated Sodium Channel Blockers"
507,DB01013,P04150,P04798|P05177,hsa:2908,9|10|11|12|18|19|20|23|37|143|144|178|179|182|185|186|192|283|284|286|287|294|308|332|333|334|335|337|339|341|342|343|344|346|352|361|366|374|380|405|406|416|420|430|432|434|440|441|443|446|452|462|490|516|524|535|537|550|553|556|561|571|579|582|591|599|605|614|617|637|640|660|671|672|678|679|680|681|684|688|689|692|693|696|697|698|699|704|705|708|709|710|711|712|776|777|797|798|818|819|839|840|860|861,Clobetasolpropionate,"Adrenal Cortex Hormones| Anti-Inflammatory Agents| Corticosteroids| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inducers| Cytochrome P-450 CYP3A5 Inducers (strength unknown)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Fused-Ring Compounds| Glucocorticoids| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Hyperglycemia-Associated Agents| Immunosuppressive Agents| Polycyclic Compounds| Pregnadienes| Pregnadienetriols| Pregnanes| Steroids| Steroids, Fluorinated| Thyroxine-binding globulin inhibitors"
508,DB01238,P28223|P14416|P08908|P28222|P28221|P28566|P28335|P46098|P50406|P34969|P21728|P21918|P35462|P21917|P35367|P35348|P35368|P08913|P18089|P18825|P11229|P08172|P20309|P08173|P08912,P20815|P24462|P10635|P08684,hsa:3356|hsa:1813|hsa:3350|hsa:3351|hsa:3352|hsa:3354|hsa:3358|hsa:3359|hsa:3362|hsa:3363|hsa:1812|hsa:1816|hsa:1814|hsa:1815|hsa:3269|hsa:148|hsa:147|hsa:150|hsa:151|hsa:152|hsa:1128|hsa:1129|hsa:1131|hsa:1132|hsa:1133,9|10|11|12|14|15|18|19|37|38|178|180|181|182|183|184|185|189|192|199|283|284|285|286|294|299|332|333|340|341|342|344|345|346|351|352|355|356|362|365|366|370|371|376|377|381|382|384|390|391|392|393|405|416|420|430|434|437|439|441|443|446|449|451|464|470|476|490|495|498|501|502|503|516|520|524|526|529|535|540|541|542|545|546|548|549|550|552|556|564|565|569|570|573|574|578|579|582|584|585|589|591|592|594|595|598|599|600|603|604|606|607|608|609|611|613|614|618|619|620|626|628|632|633|634|637|638|640|641|643|645|651|652|655|656|657|660|664|665|666|668|677|678|679|680|682|683|684|688|689|691|692|695|696|698|702|703|704|707|708|709|710|714|742|750|758|771|773|777|805|813|821|834|836,Aripiprazole,"Adrenergic alpha-1 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Agents producing tachycardia| Agents that produce hypertension| Anticholinergic Agents| Antidepressive Agents| Antidepressive Agents Indicated for Depression| Antipsychotic Agents| Antipsychotic Agents (Second Generation [Atypical])| Aripiprazole and prodrugs| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Substrates| Dopamine Agents| Dopamine Agonists| Dopamine Antagonists| Dopamine D2 Receptor Antagonists| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Histamine Antagonists| Histamine H1 Antagonists| Hyperglycemia-Associated Agents| Muscarinic Antagonists| Nervous System| Neurotoxic agents| Neurotransmitter Agents| P-glycoprotein inhibitors| Piperazines| Potential QTc-Prolonging Agents| Psycholeptics| Psychotropic Drugs| QTc Prolonging Agents| QTc shortening agents| Quinolines| Quinolones| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT1 Receptor Agonists| Serotonin 5-HT1 Receptor Antagonists| Serotonin 5-HT1D Receptor Antagonists| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin 5-HT2C Receptor Antagonists| Serotonin Agents| Serotonin Receptor Agonists| Serotonin Receptor Antagonists| Tranquilizing Agents"
509,DB01246,P35367,P08684,hsa:3269,9|10|11|12|14|15|33|178|180|181|182|185|189|192|283|284|285|293|332|333|335|340|344|345|351|353|355|365|370|371|374|376|377|383|384|390|391|412|416|434|437|441|446|449|464|470|490|495|500|502|507|516|520|524|531|532|533|540|545|546|549|552|556|564|570|577|578|582|584|585|586|592|593|595|599|600|603|607|608|613|618|628|633|634|640|656|657|658|660|664|665|668|677|678|679|683|767|830,Alimemazine,"Antihistamines for Systemic Use| Antipruritics| Antipsychotic Agents| Central Nervous System Depressants| Dermatologicals| Heterocyclic Compounds| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Neurotoxic agents| Neurotransmitter Agents| Phenothiazine Derivatives| Phenothiazines| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Respiratory System| Sulfur Compounds"
510,DB00490,P08908|P14416,P08684|P20815|P24462|P10635,hsa:3350|hsa:1813,9|10|11|12|14|15|16|18|19|143|144|178|180|181|183|184|185|187|188|192|283|284|285|286|332|333|334|344|345|351|352|355|358|365|370|371|372|373|375|376|379|384|387|389|390|391|396|403|416|418|420|434|435|439|441|442|443|445|446|447|449|450|451|453|464|472|482|484|487|491|495|502|504|506|516|519|521|523|530|535|538|539|540|545|546|549|555|560|569|572|576|579|582|585|592|593|596|599|601|611|613|621|628|636|645|646|650|654|656|657|674|679|683|684|688|692|694|695|704|708|709|710|711,Buspirone,"Agents that produce hypertension| Antidepressive Agents| Azaspirodecanedione Derivatives| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Substrates| Dopamine Antagonists| Dopamine D2 Receptor Antagonists| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hydrocarbons| Hydrocarbons, Cyclic| Miscellaneous Anxiolytics Sedatives and Hypnotics| Nervous System| Neurotransmitter Agents| P-glycoprotein inhibitors| Piperazines| Polycyclic Compounds| Psycholeptics| Pyrimidines| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin Agents| Spiro Compounds| Tranquilizing Agents"
511,DB00295,P35372|P41145|P41143|Q9Y6Y9,P10635|P10632|P08684|P16662|P22309|Q9HAW9|P54855|P06133|P35503,hsa:4988|hsa:4986|hsa:4985|hsa:23643,9|10|11|12|14|18|19|143|146|178|180|181|182|185|189|192|196|199|283|284|285|286|308|332|333|334|335|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|391|405|406|416|430|434|441|446|470|476|490|498|516|520|524|540|541|542|544|548|552|556|564|565|567|570|571|573|574|578|582|584|589|590|592|594|595|599|603|604|606|607|608|613|614|617|618|619|620|626|630|631|632|634|637|640|641|651|655|656|660|662|663|664|666|667|668|677|678|679|680|682|683|688|689|690|691|696|697|698|699|701|702|703|708|709|710|711|712|714|735|755|756|761|776|777|779|797|798|800|818|819|821|824,Morphine,"Alkaloids| Analgesics| Anesthetics| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Heterocyclic Compounds, Bridged-Ring| Heterocyclic Compounds, Fused-Ring| High-risk opioids| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hypotensive Agents| Narcotics| Natural Opium Alkaloids| Nervous System| Neuraxial Anesthetics| Opiate Agonists| Opiate Alkaloids| Opioid Agonist| Opioids| P-glycoprotein substrates| Peripheral Nervous System Agents| Phenanthrene opioids| Phenanthrenes| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Sensory System Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| UGT1A1 Substrates| UGT1A3 substrates| UGT2B7 substrates"
512,DB01437,P14867|BE0004797,P05108|P10635,hsa:2554,9|10|11|14|18|19|178|180|181|182|185|283|284|285|286|299|332|333|334|344|351|352|355|356|370|371|374|384|390|392|393|416|420|430|434|439|441|443|446|451|470|490|516|520|524|535|552|556|564|570|578|579|582|584|592|595|597|599|603|607|608|613|618|634|640|643|645|650|656|660|664|668|677|678|679|683|684|688|692|694|695|696|697|704|708|709|710|711|712,Glutethimide,"Central Nervous System Agents| Central Nervous System Depressants| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypnotics and Sedatives| Nervous System| Piperidinedione Derivatives| Piperidines| Piperidones| Psycholeptics"
513,DB01200,P14416|P35462|P28221|P08913|P08908|P18825|P18089|P41595|P21917|P28223|P28222|P28335|P21918|P21728|P35348|P35368|P25100|P34969,P08684|P05177,hsa:1813|hsa:1814|hsa:3352|hsa:150|hsa:3350|hsa:152|hsa:151|hsa:3357|hsa:1815|hsa:3356|hsa:3351|hsa:3358|hsa:1816|hsa:1812|hsa:148|hsa:147|hsa:146|hsa:3363,6|9|10|11|12|13|14|15|16|18|19|20|143|145|146|148|149|150|152|153|157|178|180|181|182|183|184|185|189|192|199|272|274|283|284|285|286|299|308|332|333|335|338|340|341|344|345|351|352|355|356|357|358|365|370|371|374|376|377|380|384|385|386|387|390|391|392|393|396|399|400|403|405|406|416|418|420|430|431|434|437|439|441|442|443|446|449|451|453|462|464|470|472|482|490|495|502|506|516|520|523|524|527|530|535|536|537|538|539|540|545|546|549|552|555|556|559|563|564|566|569|570|576|577|578|579|580|582|584|585|592|593|595|599|600|602|603|605|607|608|611|612|613|614|615|617|618|628|633|634|637|640|643|645|646|656|657|659|660|661|664|665|668|677|678|679|680|683|684|688|691|696|697|702|708|709|710|712|737|755|758|779|797|800|818|821,Bromocriptine,"Adrenergic Agonists| Adrenergic alpha-1 Receptor Agonists| Adrenergic alpha-1 Receptor Antagonists| Adrenergic alpha-2 Receptor Agonists| Adrenergic alpha-Agonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Agents producing tachycardia| Agents that produce hypertension| Alkaloids| Anti-Dyskinesia Agents| Anti-Parkinson Agents (Dopamine Agonist)| Anti-Parkinson Drugs| Antidepressive Agents| Blood Glucose Lowering Agents| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dopamine Agents| Dopamine Agonists| Ergolines| Ergot Alkaloids and Derivatives| Ergot-derivative Dopamine Receptor Agonists| Ergotamines| Genito Urinary System and Sex Hormones| Heterocyclic Compounds| Heterocyclic Compounds with 4 or More Rings| Heterocyclic Compounds, Fused-Ring| Hormone Antagonists| Hormones, Hormone Substitutes, and Hormone Antagonists| Hypotensive Agents| Nervous System| Neurotransmitter Agents| P-glycoprotein inhibitors| P-glycoprotein substrates| Prolactine Inhibitors| Serotonin 5-HT2 Receptor Agonists| Serotonin Agents| Serotonin Modulators| Serotonin Receptor Agonists"
514,DB01159,O14649|Q9NPC2|Q12791|Q8TCU5|O60391|Q12879|P23415|P08100|P48051|P48549|P03886|O15554|P30049|P98194|P14867|P59768|Q6W5P4|BE0004797,P05181|P08684|P11509|P20813|P11712|P10635,hsa:3777|hsa:51305|hsa:3778|hsa:116443|hsa:116444|hsa:2903|hsa:2741|hsa:6010|hsa:3763|hsa:3760|hsa:4535|hsa:3783|hsa:513|hsa:27032|hsa:2554|hsa:54331|hsa:387129,6|9|23|24|37|272|274|283|284|287|294|342|343|344|361|363,Halothane,"Agents that produce hypertension| Anesthetics| Anesthetics, General| Anesthetics, Inhalation| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Hydrocarbons| Hydrocarbons, Halogenated| Hypotensive Agents| Nervous System| NMDA Receptor Antagonists"
515,DB00523,P10276|P19793|P10826|P28702|P13631|P48443|P17936|Q15238|Q6V0L0,P05177,hsa:5914|hsa:6256|hsa:5915|hsa:6257|hsa:5916|hsa:6258|hsa:3486|hsa:5673|hsa:340665,9|10|11|12|18|19|178|182|283|284|286|308|332|333|334|344|352|374|380|406|416|420|430|434|440|441|443|446|452|490|516|524|553|556|564|573|582|599|619|640|660|664|667|671|678|679|688|696|697|708|709|710|711|818,Alitretinoin,"Agents for Dermatitis, Excluding Corticosteroids| Alkenes| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Biological Factors| Carotenoids| Cyclohexanes| Cyclohexenes| Cycloparaffins| Dermatologicals| Diterpenes| Hydrocarbons| Hydrocarbons, Acyclic| Hydrocarbons, Alicyclic| Hydrocarbons, Cyclic| Misc. Skin and Mucous Membrane Agents| P-glycoprotein substrates| Pigments, Biological| Polyenes| Retinoids| Retinoids for cancer treatment| Terpenes| Vitamin A| Vitamins| Vitamins (Fat Soluble)"
516,DB00916,O25608|P29166|Q16850,P11712|P08684|P10632,hsa:1595,9|10|14|15|18|19|143|148|149|283|284|285|286|301|308|344|345|346|351|352|358|359|365|366|370|372|373|374|375|376|378|379|387|389|390|391|395|396|397|401|403|406|416|418|423|435|438|442|445|446|447|449|450|453|454|455|472|482|484|485|487|491|495|499|502|504|506|514|519|521|539|540|546|547|558|560|566|569|571|572|596|611|636|648|654|656|659|674,Metronidazole,"Agents that reduce seizure threshold| Alimentary Tract and Metabolism| Anti-Bacterial Agents| Anti-Infective Agents| Antibacterials for Systemic Use| Antiinfectives and Antiseptics for Local Oral Treatment| Antiinfectives for Systemic Use| Antiparasitic Agents| Antiparasitic Products, Insecticides and Repellents| Antiprotozoals| Azoles| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dermatologicals| Drugs for Acid Related Disorders| Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)| Genito Urinary System and Sex Hormones| Gynecological Antiinfectives and Antiseptics| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Imidazole Derivatives| Imidazoles| Miscellaneous Antiprotozoals| Miscellaneous Local Anti-infectives| Nitro Compounds| Nitroimidazole Antimicrobial| Nitroimidazole Derivatives| Nitroimidazoles| P-glycoprotein inhibitors| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Stomatological Preparations| UGT1A1 Substrates"
517,DB09462,Q03181|O60760|P37700|P09211|Q9NZK7|Q9NPH2|P13632|P00325|Q14643|P09466|P17050|Q52369|Q93PP9|P37173|P0A6E4|Q8GR70|P84077|P52477|O43252|P06988|P23367|P0AER0|P69924|P17802|O14717,P00352|P05181,hsa:5467|hsa:27306|hsa:2950|hsa:30814|hsa:51477|hsa:125|hsa:3708|hsa:5047|hsa:4668|hsa:7048|hsa:375|hsa:9061|hsa:1787,9|18|19|283|284|286|308|332|339|341|344|346|352|366|406|567|571|617|639|663,Glycerin,"Alcohols| Alimentary Tract and Metabolism| Basic Ointments and Protectants| Carbohydrates| Cell-mediated Immunity| Compounds used in a research, industrial, or household setting| Cryoprotective Agents| Cytochrome P-450 CYP2E1 Inducers| Cytochrome P-450 CYP2E1 Inducers (strength unknown)| Cytochrome P-450 Enzyme Inducers| Drugs for Constipation| Enemas| Increased Histamine Release| Increased IgG Production| Irrigating Solutions| Laxatives| Non-Standardized Chemical Allergen| Osmotic Laxatives| Other Cold and Cough Preparations| Other Diagnostics| Protective Agents| Solvents| Sugar Alcohols| Triose Sugar Alcohols"
518,DB00647,P35372|P41143|P41145|P23141,P08684|P10635|P10632|P11712|P24462,hsa:4988|hsa:4985|hsa:4986|hsa:1066,9|10|11|12|14|18|19|178|182|185|189|283|284|285|286|332|333|335|337|341|344|345|351|352|355|356|365|370|371|374|380|384|390|391|405|416|420|430|434|440|441|443|446|452|470|490|516|520|524|535|540|548|552|556|564|570|573|574|578|582|584|592|594|595|599|603|604|608|613|614|618|619|634|637|638|640|641|655|660|664|666|668|677|678|679|680|683|688|689|696|697|698|708|709|710|712,Dextropropoxyphene,"Acids, Acyclic| Agents that reduce seizure threshold| Analgesics| Carboxylic Acids| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Diphenylheptane opioids| Diphenylpropylamine Derivatives| High-risk opioids| Narcotics| Nervous System| Opioid Agonist| Opioids| Peripheral Nervous System Agents| Propionates| Sensory System Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome"
519,DB11181,P11229|P08172|P20309|P08173|P08912,P23141,hsa:1128|hsa:1129|hsa:1131|hsa:1132|hsa:1133,9|10|11|12|14|18|19|143|145|146|178|180|181|182|185|283|284|285|286|308|332|333|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|380|384|390|391|405|406|416|420|430|434|440|441|443|446|452|462|470|490|516|520|524|535|537|540|548|552|556|564|567|570|571|573|574|578|579|582|584|592|595|597|599|603|608|613|614|617|618|619|634|637|638|640|641|655|656|660|662|663|664|667|668|677|678|679|680|683|684|688|689|692|696|698|704|708|709|710,Homatropine,"Alkaloids| Anticholinergic Agents| Autonomic Agents| Aza Compounds| Azabicyclo Compounds| Bicyclo Compounds, Heterocyclic| Heterocyclic Compounds| Heterocyclic Compounds, Bridged-Ring| Muscarinic Antagonists| Mydriatics and Cycloplegics| Ophthalmologicals| Parasympatholytics| Peripheral Nervous System Agents| Sensory Organs"
520,DB01101,P04818,P19971|P23141|Q12882|P32320|P11712,hsa:7298,9|10|11|14|15|18|19|20|23|143|146|178|183|184|283|284|285|286|287|299|308|332|339|341|344|345|346|351|352|355|358|364|365|366|370|372|373|374|375|376|378|379|380|384|387|389|390|391|392|393|396|397|403|405|406|416|418|420|435|438|441|442|445|446|447|449|450|451|452|453|464|472|482|484|487|491|495|504|506|519|521|523|530|538|540|545|549|555|559|560|566|567|571|572|576|582|585|592|593|596|601|612|613|614|617|621|628|636|637|638|639|645|646|647|654|656|657|659|662|663|674|680|682|683,Capecitabine,"Antimetabolites| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Cardiotoxic antineoplastic agents| Cytidine Deaminase Substrates| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strong)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Fluoropyrimidines| Fluorouracil and prodrugs| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Immunosuppressive Agents| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| Noxae| Nucleic Acid Synthesis Inhibitors| Nucleic Acids, Nucleotides, and Nucleosides| Nucleoside Metabolic Inhibitor| Pyrimidine Analogues| Toxic Actions"
521,DB00972,P35367,P05177|P08684|P33261|P04798|P20815|P11712|P10632|P10635|P11509|P20813|P05181,hsa:3269,9|10|11|12|14|15|18|37|178|182|183|184|185|189|192|213|215|216|283|284|285|286|294|300|332|333|338|340|342|344|345|351|352|355|356|357|358|362|365|370|371|374|376|381|384|385|387|390|391|396|416|418|420|422|430|431|434|437|439|441|442|443|446|449|451|453|464|467|470|477|490|493|495|496|501|503|515|516|518|520|521|523|524|530|535|538|539|540|545|549|550|552|553|555|556|564|570|576|578|579|582|584|585|591|592|593|595|597|598|599|600|603|607|608|613|616|618|623|628|633|634|640|644|645|646|656|657|660|664|665|668|671|672|677|678|679|683|684|685|688|692|696|697|704|708|709|710|712|717|755|780|818,Azelastine,"Anti-Allergic Agents| Antiallergic Agents, Excl. Corticosteroids| Antihistamines for Systemic Use| Autonomic Agents| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2A6 Inhibitors| Cytochrome P-450 CYP2A6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Decongestants and Antiallergics| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Histamine H1 Antagonists, Non-Sedating| Nasal Preparations| Neurotransmitter Agents| Ophthalmologicals| P-glycoprotein inhibitors| Pyridazines| Respiratory System| Respiratory System Agents| Sensory Organs"
522,DB01558,P14867|P47869|P34903|P48169|P31644|Q16445|P18505|P47870|P28472|Q8N1C3|P18507|Q99928|O14764|P78334|O00591|P24046|P28476|A8MPY1|Q9UN88,P08684|P05177|P33261|P05181,hsa:2554|hsa:2555|hsa:2556|hsa:2557|hsa:2558|hsa:2559|hsa:2560|hsa:2561|hsa:2562|hsa:2565|hsa:2566|hsa:2567|hsa:2563|hsa:2564|hsa:2568|hsa:2569|hsa:2570|hsa:200959|hsa:55879,6|9|10|11|14|15|18|178|182|183|184|185|213|218|219|272|274|283|284|285|286|299|332|333|340|344|345|351|352|355|356|357|358|365|370|371|372|373|376|377|384|387|390|392|393|396|403|416|418|420|430|431|434|435|437|439|441|442|443|445|446|447|449|451|453|464|470|472|482|490|491|495|502|506|516|520|521|523|524|530|536|538|539|540|545|546|549|552|555|556|564|569|570|576|577|578|582|584|585|592|595|599|600|603|607|608|611|613|618|628|633|634|640|643|645|656|657|660|664|665|668|677|678|679|683|688|696|697|708|709|710|758|821,Bromazepam,"Anti-Anxiety Agents| Benzazepines| Benzodiazepine hypnotics and sedatives| Benzodiazepines and benzodiazepine derivatives| Benzodiazepinones| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| GABA Agents| GABA Modulators| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hypnotics and Sedatives| Muscle Relaxants| Muscle Relaxants, Centrally Acting Agents| Nervous System| Neurotransmitter Agents| Psycholeptics| Psychotropic Drugs| Tranquilizing Agents"
523,DB00754,Q14524|O75469,P33261,hsa:6331|hsa:8856,9|10|11|14|15|18|19|143|145|146|178|182|283|284|285|286|299|332|333|338|340|344|345|351|352|355|356|365|370|371|374|375|384|390|391|392|393|416|420|430|434|439|441|443|446|451|464|470|490|516|520|524|528|535|536|540|549|552|556|560|564|569|570|578|579|582|584|592|595|597|599|602|603|607|608|611|613|618|628|633|634|636|640|645|646|647|650|654|656|660|664|668|677|678|679|683|684|688|692|696|704|708|709|710,Ethotoin,"Anti-epileptic Agent| Anticonvulsants| Azoles| Cardiovascular Agents| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 Enzyme Inducers| Decreased Central Nervous System Disorganized Electrical Activity| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hydantoins| Imidazoles| Imidazolidines| Membrane Transport Modulators| Nervous System| Sodium Channel Blockers| Thyroxine-binding globulin substrates| Voltage-Gated Sodium Channel Blockers"
524,DB06716,P47870|P28472,P05186,hsa:2561|hsa:2562,9|10|11|18|19|20|30|178|182|283|284|286|308|314|332|333|335|341|344|352|355|356|366|367|370|371|374|380|381|382|384|405|407|411|416|425|430|434|441|446|456|470|476|490|498|516|520|524|541|548|552|556|563|564|565|570|573|574|578|582|584|589|594|595|599|603|604|606|608|618|619|626|634|637|640|641|651|655|660|661|664|666|668|677|678|679|680|688|689|696|697|698|708|709|710|712|734|756|797|819,Fospropofol,"Agents that reduce seizure threshold| Anesthetics| Anesthetics, General| Benzene Derivatives| Central Nervous System Agents| Central Nervous System Depressants| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hypnotics and Sedatives| Phenols"
525,DB00907,Q01959|P23975|P31645|Q14524|Q9UI33|Q9Y5Y9|P11229|P08172|Q99720|P23141,P08684|P20815|P24462|P10635|P11712|P10632,hsa:6531|hsa:6530|hsa:6532|hsa:6331|hsa:11280|hsa:6336|hsa:1128|hsa:1129|hsa:10280|hsa:1066,9|10|11|12|14|18|19|20|143|145|146|178|180|181|182|185|283|284|285|286|332|333|335|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|380|384|390|391|405|416|420|430|434|440|441|443|446|452|470|490|493|516|520|524|535|540|548|552|553|556|564|570|573|574|578|579|580|581|582|584|592|594|595|597|599|603|604|608|613|614|618|619|623|634|637|638|639|640|641|642|655|656|660|664|666|668|671|672|677|678|679|680|683|684|688|689|691|692|695|696|697|698|702|703|704|707|708|709|710,Cocaine,"Agents producing tachycardia| Agents that reduce seizure threshold| Alkaloids| Analgesics and Anesthetics| Anesthetics| Anesthetics, Local| Anticholinergic Agents| Aza Compounds| Azabicyclo Compounds| Bicyclo Compounds, Heterocyclic| Cardiovascular Agents| Central Nervous System Agents| Central Nervous System Stimulants| Cholinesterase substrates| Cocaine, antagonists & inhibitors| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dopamine Agents| Dopamine Uptake Inhibitors| Esters of Benzoic Acid| Heterocyclic Compounds| Heterocyclic Compounds, Bridged-Ring| Highest Risk QTc-Prolonging Agents| Local Anesthetics (Ester)| Membrane Transport Modulators| Muscarinic Antagonists| Nervous System| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| OCT2 Inhibitors| Ophthalmologicals| QTc Prolonging Agents| Respiratory System| Sensory Organs| Sensory System Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Throat Preparations| Tropanes| Vasoconstrictor Agents"
526,DB00947,P03372,P08684,hsa:2099,9|10|11|12|13|18|19|23|24|25|33|143|144|178|179|182|185|186|192|283|284|286|287|293|308|332|333|334|335|339|341|344|346|349|352|353|355|356|363|366|368|370|371|374|381|382|384|406|412|414|416|430|434|441|446|457|465|470|490|498|507|516|520|524|541|542|548|552|556|564|570|571|573|574|578|582|584|586|590|595|599|603|606|608|617|618|619|634|637|640|641|651|655|658|660|664|667|668|677|678|679|680|688|689|696|697|698|699|708|709|710|711|712|714|735|755|776|777|797|798|818|840|860|861,Fulvestrant,"Anti-Estrogens| Antineoplastic Agents| Antineoplastic Agents, Hormonal| Antineoplastic and Immunomodulating Agents| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Endocrine Therapy| Estradiol Congeners| Estranes| Estrenes| Estrogen Antagonists| Estrogen Receptor Antagonists| Fused-Ring Compounds| Gonadal Hormones| Gonadal Steroid Hormones| Hormone Antagonists| Hormone Antagonists and Related Agents| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Polycyclic Compounds| Selective Estrogen Receptor Modulators| Steroids| UGT1A1 Substrates"
527,DB01227,P35372|P30926|P32297,P20815|P24462|P08684|P11511,hsa:4988|hsa:1143|hsa:1136,9|10|11|12|14|18|19|178|182|185|189|283|284|285|286|332|333|334|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|380|384|390|391|405|416|420|430|434|440|441|443|446|452|470|490|516|520|524|540|552|556|564|570|578|582|584|592|595|599|603|608|613|614|618|634|637|640|641|655|660|664|668|677|678|679|680|682|683|688|689|696|697|698|708|709|710|711|712,Levomethadylacetate,Analgesics| Anticholinergic Agents| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Substrates| Drugs Used in Addictive Disorders| Drugs Used in Opioid Dependence| Ketones| Moderate Risk QTc-Prolonging Agents| Narcotics| Narrow Therapeutic Index Drugs| Nervous System| Nicotinic Antagonists| Opioids| Peripheral Nervous System Agents| QTc Prolonging Agents| Sensory System Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
528,DB06292,P31639,P04798|P05177|P11509|P11712|P10635|P08684|O60656|P06133|P16662,hsa:6524,9|10|11|12|18|19|20|37|178|181|182|185|189|192|283|284|286|294|308|332|333|339|341|342|344|346|352|355|356|362|366|370|371|374|381|382|384|405|406|416|430|434|441|446|470|476|490|498|501|503|516|520|524|541|542|548|550|552|556|564|565|567|570|571|573|574|578|582|584|589|591|594|595|598|599|603|604|606|608|614|617|618|619|620|626|632|634|637|639|640|641|651|655|660|662|663|664|666|668|677|678|679|680|681|688|689|690|696|697|698|699|701|708|709|710|714|717|734|759|777|780|797|822,Dapagliflozin,"Alimentary Tract and Metabolism| Benzene Derivatives| Blood Glucose Lowering Agents| Carbohydrates| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Diuretics| Drugs Used in Diabetes| Glycosides| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hypotensive Agents| Oral Hypoglycemics| P-glycoprotein substrates| Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors| Sodium-Glucose Transport Proteins, antagonists & inhibitors| Sodium-Glucose Transporter 2 Inhibitors| UGT1A9 Substrates| UGT2B7 substrates"
529,DB01076,P04035|P27487|P35869,P08684|P20815|P24462|P10632|P10635|P11712|P33261|P20813|P22309|P35503|P16662,hsa:3156|hsa:1803|hsa:196,9|10|11|12|13|14|15|18|19|20|23|143|148|149|178|182|185|189|192|196|283|284|285|286|287|299|308|332|333|335|339|340|341|344|345|346|351|352|355|356|357|358|364|365|366|370|371|374|376|377|380|384|387|390|391|392|393|396|397|403|406|416|418|420|430|431|434|437|439|440|441|442|443|446|449|451|452|453|464|470|472|482|490|493|495|502|506|516|520|521|523|524|530|535|538|539|540|545|546|549|552|553|555|556|564|570|571|576|577|578|579|580|581|582|584|585|592|593|595|597|599|600|603|607|608|613|617|618|623|624|628|633|634|637|638|639|640|642|643|645|656|657|660|664|665|668|671|673|677|678|679|680|683|684|685|688|689|690|691|692|693|696|697|698|701|702|704|705|708|709|710|712,Atorvastatin,"Agents Causing Muscle Toxicity| Anticholesteremic Agents| Azoles| BSEP/ABCB11 Substrates| Cardiovascular System| Cytochrome P-450 CYP2B6 Inducers| Cytochrome P-450 CYP2B6 Inducers (strength unknown)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Enzyme Inhibitors| Fatty Acids| Heptanoic Acids| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hydroxymethylglutaryl-CoA Reductase Inhibitors| Hypolipidemic Agents| Hypolipidemic Agents Indicated for Hyperlipidemia| Lipid Modifying Agents| Lipid Modifying Agents, Plain| Lipid Regulating Agents| Lipids| OATP1B1/SLCO1B1 Inhibitors| OATP1B1/SLCO1B1 Substrates| OATP1B3 substrates| OATP2B1/SLCO2B1 substrates| P-glycoprotein inhibitors| P-glycoprotein substrates| Pyrroles| Toxic Actions| UGT1A1 Substrates| UGT1A3 substrates"
530,DB09053,Q06187,P08684|P20815|P10635,hsa:695,9|10|11|12|14|15|16|18|19|143|148|149|178|180|181|182|183|184|185|189|192|199|283|284|285|286|299|300|332|333|338|340|341|344|345|351|352|355|356|357|358|359|365|370|371|373|375|376|378|379|381|382|384|385|387|388|389|390|391|393|396|403|405|416|418|420|422|430|431|434|437|438|439|441|442|443|446|447|449|450|451|453|464|467|470|472|476|477|482|484|486|487|490|491|495|496|498|504|506|515|516|517|519|520|521|523|524|530|538|540|541|542|545|548|549|552|553|555|556|560|564|565|569|570|572|573|574|576|578|582|584|585|589|592|593|594|595|596|599|600|601|603|604|606|607|608|611|613|614|616|618|619|620|621|626|628|632|633|634|636|637|640|641|644|645|646|651|654|655|656|657|660|664|665|666|668|672|674|677|678|679|680|683|688|689|691|696|697|698|703|708|709|710|714|777,Ibrutinib,"Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Bruton's tyrosine kinase (BTK) inhibitors| Cancer immunotherapy| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Substrates| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Immunosuppressive Agents| Immunotherapy| Kinase Inhibitor| Myelosuppressive Agents| Protein Kinase Inhibitors| Purines| Tyrosine Kinase Inhibitors"
531,DB06800,P35372|P41145,P10635,hsa:4988|hsa:4986,9|10|11|12|14|18|19|20|115|116|143|146|178|179|180|181|182|185|189|192|199|283|284|285|286|308|332|333|334|335|337|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|391|405|406|416|420|430|432|434|441|443|446|462|470|476|490|498|516|520|524|535|537|540|541|542|544|548|552|556|564|565|566|567|570|573|574|578|579|582|584|589|590|592|594|595|599|603|604|605|606|607|608|613|614|617|618|619|620|626|630|631|632|634|637|639|640|641|651|655|656|659|660|662|663|664|666|667|668|677|678|679|680|681|682|683|684|686|688|689|690|691|692|693|695|696|697|698|699|700|701|702|703|704|705|707|708|709|710|711|712|714|735|755|756|761|776|777|779|797|798|800|803|818|819|821|824|826,Methylnaltrexone,"Alimentary Tract and Metabolism| Alkaloids| Amines| Ammonium Compounds| Central Nervous System Agents| Drugs for Constipation| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds with 4 or More Rings| Heterocyclic Compounds, Bridged-Ring| Heterocyclic Compounds, Fused-Ring| Miscellaneous GI Drugs| Morphinans| Nitrogen Compounds| Onium Compounds| Opiate Alkaloids| Opioid Antagonists| Opioids| Peripheral Nervous System Agents| Peripheral Opioid Receptor Antagonists| Phenanthrene opioids| Phenanthrenes| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Sensory System Agents"
532,DB00628,BE0004797|P30536,P08684,hsa:706,9|10|11|12|14|15|18|19|37|178|182|185|189|213|218|219|283|284|285|286|294|299|308|332|333|338|340|342|344|345|351|352|355|356|362|365|370|371|376|377|380|384|390|392|393|406|416|418|420|430|431|434|437|439|440|441|442|443|446|449|451|452|453|464|470|490|495|501|502|503|516|520|524|535|536|538|545|546|549|550|552|555|556|564|566|569|570|576|578|580|581|582|584|585|588|591|592|595|598|599|600|603|607|608|611|613|617|618|628|633|634|638|640|642|643|645|656|657|660|664|665|668|677|678|679|683|688|696|697|708|709|710|729|738|758|792|801|821,Clorazepate,"Anti-Anxiety Agents| Anticonvulsants| Benzazepines| Benzodiazepines and benzodiazepine derivatives| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| GABA Agents| GABA Modulators| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Nervous System| Neurotransmitter Agents| Psycholeptics| Psychotropic Drugs| Tranquilizing Agents"
533,DB00166,Q9Y234|O43766|Q9Y289,P16435,hsa:51601|hsa:11019|hsa:8884,9|10|11|18|19|33|34|143|146|283|284|286|293|308|332|344|349|352|353|368|380|406|420|440|443|452|535|579|582|617|637|679|680|684|688|689|692|696|698|704,Lipoicacid,"Alimentary Tract and Metabolism| Antioxidants| Biological Factors| Carboxylic Acids| Coenzymes| Compounds used in a research, industrial, or household setting| Dietary Supplements| Enzymes and Coenzymes| Fatty Acids| Hypoglycemia-Associated Agents| Lipids| Micronutrients| Protective Agents| Sulfur Compounds| Supplements| Thiophenes| Various Alimentary Tract and Metabolism Products| Vitamin B Complex| Vitamins"
534,DB06016,P35462|P14416|P08908|P41595|P28223|P35367,P08684|P10635,hsa:1814|hsa:1813|hsa:3350|hsa:3357|hsa:3356|hsa:3269,9|10|11|12|14|15|16|18|37|38|178|179|180|181|182|185|192|283|284|285|286|294|299|332|333|335|338|340|342|344|345|351|355|362|365|370|371|374|375|376|377|384|390|391|392|393|416|420|434|437|441|446|449|451|464|470|490|495|501|502|503|516|520|524|526|528|529|540|545|546|549|550|552|556|560|564|569|570|578|582|584|585|591|592|595|598|599|600|603|607|608|609|611|613|618|628|633|634|636|640|643|645|646|654|656|657|660|664|665|668|677|678|679|683|688|696|708|709|710|750|771|773|779|813|834|836,Cariprazine,"Agents that produce hypertension| Antidepressive Agents| Antipsychotic Agents| Antipsychotic Agents (Second Generation [Atypical])| Central Nervous System Agents| Central Nervous System Depressants| Chlorobenzenes| Cyclohexanes| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (weak)| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (weak)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (weak)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP2E1 Inhibitors| Cytochrome P-450 CYP2E1 Inhibitors (weak)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Inducers| Cytochrome P-450 CYP3A5 Inducers (strength unknown)| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Dopamine Agonists| Dopamine D2/D3 receptor modulators| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Histamine Antagonists| Histamine H1 Antagonists| Nervous System| Neurotoxic agents| P-glycoprotein inhibitors| Piperazines| Psycholeptics| Psychotropic Drugs| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT1 Receptor Agonists| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin 5-HT2C Receptor Antagonists| Serotonin Agents| Serotonin Receptor Agonists| Serotonin Receptor Antagonists| Tranquilizing Agents"
535,DB13952,P03372|O75469|Q92731|P43681|Q15596|Q99527|P00846|Q14457|P37059|P62508,P05177|P22309|P08684|P20815|P24462|P04798|Q16678|P33261|P10632|P11712,hsa:2099|hsa:8856|hsa:2100|hsa:1137|hsa:10499|hsa:2852|hsa:4508|hsa:8678|hsa:3294|hsa:2104,0|9|10|11|12|18|19|143|144|178|179|182|185|186|192|283|284|286|308|332|333|334|335|339|341|344|346|352|355|356|366|370|371|374|380|381|382|384|405|406|416|420|430|434|440|441|443|446|452|470|476|490|498|516|520|524|541|542|548|552|556|564|565|570|571|573|574|578|582|584|589|594|595|599|603|604|606|608|614|617|618|619|620|622|626|632|634|637|640|641|651|655|660|664|666|668|677|678|679|680|688|689|696|697|698|699|708|709|710|711|712|714|735|755|776|777|797|798|818|840|860|861,Estradiolacetate,BCRP/ABCG2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP1A2 Inhibitors (weak)| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Estrogens| OATP1B1/SLCO1B1 Inhibitors| OCT1 inhibitors| OCT2 Inhibitors| Organic Anion Transporting Polypeptide 2B1 Inhibitors| P-glycoprotein substrates| Thyroxine-binding globulin inducers| UGT1A1 Substrates
536,DB00491,O43451|P10253|Q14697|Q8TET4,P04746,hsa:8972|hsa:2548|hsa:23193|hsa:2595,9|10|11|14|18|19|20|178|180|181|283|284|285|286|308|332|338|339|340|341|344|345|346|351|352|365|366|390|391|406|540|566|567|571|582|592|613|617|637|638|639|656|659|663|679|680|681|682|683|689|690|701,Miglitol,"Alimentary Tract and Metabolism| Alkaloids| Blood Glucose Lowering Agents| Carbohydrates| Drugs Used in Diabetes| Enzyme Inhibitors| Glycoside Hydrolase Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypoglycemia-Associated Agents| Imines| Imino Pyranoses| Imino Sugars| Oral Hypoglycemics| Piperidines"
537,DB00555,Q15878|Q99250|P30542|P29274|P35348|P08913|P08588|BE0004889|P14416|BE0004797|BE0008668|P35367|P41145|BE0004890|P28223|P46098,P22310|P00374|P35503,hsa:777|hsa:6326|hsa:134|hsa:135|hsa:148|hsa:150|hsa:153|hsa:1813|hsa:3269|hsa:4986|hsa:3356|hsa:3359,9|10|11|14|15|16|37|38|178|182|183|184|185|283|284|285|294|299|300|332|333|340|342|344|351|355|356|357|358|362|370|371|375|376|378|379|384|387|389|390|393|396|403|416|418|422|430|431|434|437|438|441|442|446|449|450|453|464|467|470|472|477|482|484|485|486|487|490|495|499|501|503|504|506|515|516|517|519|520|523|524|526|529|530|538|545|547|549|550|552|555|556|560|564|569|570|572|576|578|582|584|585|591|592|595|596|598|599|603|607|608|611|613|616|618|633|634|635|640|644|654|657|660|664|665|668|674|677|678|679|683|688|696|708|709|710|738|759|773|801|822|836,Lamotrigine,"Agents causing hyperkalemia| Agents producing tachycardia| Anti-epileptic Agent| Antiarrhythmic agents| Anticholinergic Agents| Anticonvulsants| Bradycardia-Causing Agents| Calcium Channel Blockers| Calcium-Regulating Hormones and Agents| Central Nervous System Agents| Central Nervous System Depressants| Decreased Central Nervous System Disorganized Electrical Activity| Drugs causing inadvertant photosensitivity| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Membrane Transport Modulators| Miscellaneous Anticonvulsants| Mood Stabilizer| Muscarinic Antagonists| Nervous System| OCT1 substrates| OCT2 Inhibitors| P-glycoprotein inhibitors| P-glycoprotein substrates| Photosensitizing Agents| Potential QTc-Prolonging Agents| Psychotropic Drugs| QTc Prolonging Agents| Sodium Channel Blockers| Tranquilizing Agents| Triazines| UGT1A1 Inducers| UGT1A1 Substrates| UGT1A3 substrates| UGT1A4 substrates"
538,DB08875,P08581|P35968|P07949,P08684|P11712,hsa:4233|hsa:3791|hsa:5979,9|10|11|12|14|15|18|19|20|23|115|116|178|182|183|184|185|189|192|196|199|283|284|285|286|287|299|332|333|334|340|341|344|345|351|352|355|356|357|358|364|365|366|370|371|372|373|374|376|377|381|382|384|385|386|387|390|392|393|396|403|405|416|418|420|430|431|434|435|437|439|441|442|443|445|446|447|449|451|453|464|470|472|476|482|490|491|495|498|502|506|516|520|521|523|524|530|535|538|539|540|541|542|544|545|546|548|549|552|555|556|564|565|567|570|573|574|576|577|578|579|580|582|584|585|588|589|592|593|594|595|599|600|603|604|606|607|608|613|614|618|619|620|626|628|630|632|633|634|637|638|640|641|643|645|651|652|655|656|657|660|662|664|665|666|668|677|678|679|680|681|682|683|688|689|690|691|696|698|699|700|701|702|703|708|709|710|714|721|735|742|758|761|777|784|798|805|821|824,Cabozantinib,"Amides| Amines| Aniline Compounds| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (weak)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Kinase Inhibitor| Narrow Therapeutic Index Drugs| Protein Kinase Inhibitors| Receptor Protein-Tyrosine Kinases, antagonists & inhibitors| Tyrosine Kinase Inhibitors"
539,DB01033,P00492|Q06203|BE0004941,P51580|P47989|Q06278,hsa:3251|hsa:5471,9|10|14|15|16|33|143|148|149|178|183|184|283|284|285|293|299|332|340|351|353|355|357|358|359|365|373|375|376|377|378|379|383|384|386|387|388|389|390|392|393|396|399|400|403|416|418|421|431|437|438|441|442|447|449|450|453|464|472|482|484|485|487|488|491|495|499|504|506|508|519|521|523|527|528|530|538|540|545|547|549|555|560|569|572|585|593|596|601|611|613|621|628|636|654|657|674,Mercaptopurine,"Antimetabolites| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Drugs for Obstructive Airway Diseases| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Immunologic Factors| Immunosuppressive Agents| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| Noxae| Nucleic Acid Synthesis Inhibitors| Nucleoside Metabolic Inhibitor| OAT3/SLC22A8 Inhibitors| OAT3/SLC22A8 Substrates| OAT3/SLC22A8 Substrates with a Narrow Therapeutic Index| Purine Analogues| Purines| Respiratory System| Sulfhydryl Compounds| Sulfur Compounds| Thiopurine Analogs| Toxic Actions| Xanthine derivatives"
540,DB00714,P35462|P21917|P14416|P18825|P18089|P28335|P21918|P08908|P28223|P41595|P08913|P21728|P28221|P28222|Q9NYX4,P05177,hsa:1814|hsa:1815|hsa:1813|hsa:152|hsa:151|hsa:3358|hsa:1816|hsa:3350|hsa:3356|hsa:3357|hsa:150|hsa:1812|hsa:3352|hsa:3351|hsa:50632,9|10|11|12|14|18|19|178|182|183|184|185|189|192|196|199|283|284|285|286|308|332|333|338|340|341|344|345|351|352|355|356|365|370|371|374|381|382|384|390|391|406|416|430|434|441|446|464|470|490|498|516|520|524|540|541|542|544|548|549|552|556|564|567|570|573|574|578|582|584|590|592|595|599|603|606|607|608|613|617|618|619|628|631|633|634|637|640|641|651|655|656|660|663|664|667|668|677|678|679|680|683|688|689|691|696|697|698|699|702|703|708|709|710|712|714|734|735|755|756|761|776|777|779|797|798|800|818|819|821|824,Apomorphine,"Alkaloids| Anti-Parkinson Agents (Dopamine Agonist)| Anti-Parkinson Drugs| Antidepressive Agents| Aporphines| Autonomic Agents| Benzylisoquinolines| Central Nervous System Agents| Central Nervous System Depressants| COMT Substrates| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Substrates| Dopamine Agents| Dopamine Agonists| Drugs Used in Erectile Dysfunction| Emetics| Gastrointestinal Agents| Genito Urinary System and Sex Hormones| Heterocyclic Compounds| Heterocyclic Compounds with 4 or More Rings| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hypotensive Agents| Isoquinolines| Nervous System| Neurotransmitter Agents| Nonergot-derivative Dopamine Receptor Agonists| Opiate Agonists| Peripheral Nervous System Agents| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin Agents| Serotonin Receptor Antagonists| Urologicals"
541,DB12001,P11802|Q00534,P08684,hsa:1019|hsa:1021,9|10|11|12|14|15|16|17|23|24|143|148|149|178|180|181|182|183|184|185|190|191|192|199|283|284|285|287|299|332|333|338|340|344|345|351|355|356|357|358|359|364|365|370|371|372|373|374|375|376|377|378|379|384|386|387|389|390|391|392|393|396|397|403|416|418|430|431|434|435|437|438|441|442|445|446|447|449|450|453|464|470|472|482|484|485|487|490|491|495|499|502|504|506|516|519|520|521|523|524|530|538|539|540|545|546|547|549|552|555|556|560|564|569|570|572|576|577|578|582|584|585|592|593|595|596|599|600|601|603|607|608|611|613|618|621|628|633|634|636|640|643|654|656|657|660|664|665|668|674|677|678|679|683|688|696|708|709|710|716|737|770|779|800|833,Abemaciclib,"Amines| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| BCRP/ABCG2 Inhibitors| BCRP/ABCG2 Substrates| Cyclin-dependent kinase (CDK) inhibitors| Cytochrome P-450 CYP1A2 Inhibitors| Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Kinase Inhibitor| MATE 1 Inhibitors| MATE 1 Substrates| MATE 1 Substrates with a Narrow Therapeutic Index| MATE 2 Inhibitors| MATE inhibitors| MATE substrates| Narrow Therapeutic Index Drugs| OCT2 Inhibitors| P-glycoprotein inhibitors| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Protein Kinase Inhibitors| Pyridines"
542,DB09116,P48448,P04040,hsa:222,14|15|52|285|375|418,Calciumcarbimide,Carbodiimides| Cyanides| Drugs Used in Addictive Disorders| Drugs Used in Alcohol Dependence| Imines| Nervous System| Nitrogen Compounds
543,DB01094,P35610|O75908|P55157|P04278,P05177,hsa:6646|hsa:8435|hsa:4547|hsa:6462,9|10|11|12|18|19|20|178|181|182|185|189|192|283|284|286|308|332|333|339|341|344|346|352|355|356|366|370|371|374|381|382|384|405|406|416|420|430|432|434|441|443|446|470|476|490|493|498|516|520|524|535|541|542|544|548|552|553|556|564|565|567|570|573|574|575|578|579|581|582|584|589|590|594|595|597|599|603|604|606|608|614|617|618|619|620|623|625|626|630|631|632|634|637|639|640|641|642|651|653|655|660|662|663|664|666|667|668|671|677|678|679|680|681|684|688|689|690|692|693|696|697|698|699|700|701|704|705|708|709|710|714|735|740|756|761|777|798|803|819|824,Hesperetin,"BCRP/ABCG2 Inhibitors| Benzopyrans| Carbohydrates| Chromones| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 Substrates| Flavanones| Flavonoids| Glycosides| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Pyrans"
544,DB00245,P11229|Q01959|P35367,P33261|P10635,hsa:1128|hsa:6531|hsa:3269,9|10|11|12|14|18|143|145|146|178|180|181|182|185|189|192|283|284|285|286|332|333|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|384|390|391|405|416|430|434|441|446|470|490|516|520|524|540|548|552|556|564|570|573|574|578|582|584|592|594|595|599|603|604|608|613|614|618|619|634|637|638|640|641|655|656|660|664|666|668|677|678|679|680|683|688|689|696|697|698|708|709|710,Benzatropine,"Agents producing tachycardia| Alkaloids| Anti-Dyskinesia Agents| Anti-Parkinson Drugs| Anticholinergic Agents| Aza Compounds| Bicyclo Compounds| Bridged Compounds| Central Nervous System Agents| Cholinergic Agents| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 Substrates| Dopamine Agents| Dopamine Uptake Inhibitors| Drugs that are Mainly Renally Excreted| Ethers of Tropine or Tropine Derivatives| Histamine Antagonists| Histamine H1 Antagonists| Histamine Receptor Antagonists| Hydrocarbons| Hydrocarbons, Cyclic| Membrane Transport Modulators| Muscarinic Antagonists| Nervous System| Neurotransmitter Agents| Neurotransmitter Uptake Inhibitors| Peripheral Nervous System Agents| Polycyclic Compounds| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Tropanes"
545,DB09039,Q16739,P10635|P08684,hsa:7357,9|10|11|12|14|15|18|19|20|143|145|146|178|182|184|185|283|284|285|286|308|332|333|338|339|340|341|344|345|346|351|352|355|356|365|366|370|371|374|381|382|384|390|391|405|406|416|418|430|434|441|442|446|453|470|476|490|498|516|520|524|538|539|540|541|542|544|548|552|556|564|565|566|567|569|570|571|573|574|578|582|584|589|592|594|595|599|603|604|606|607|608|611|613|614|617|618|619|620|626|630|632|634|637|638|640|641|651|655|656|660|662|664|666|667|668|677|678|679|680|681|683|688|689|690|691|696|698|699|700|701|703|708|709|710|714|735|761|777|798|824,Eliglustat,"Alimentary Tract and Metabolism| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Enzyme Inhibitors| Gaucher Disease| Glucosylceramide Synthase Inhibitor| Glucosylceramide Synthase Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Highest Risk QTc-Prolonging Agents| Other Miscellaneous Therapeutic Agents| P-glycoprotein inhibitors| P-glycoprotein substrates| QTc Prolonging Agents| Various Alimentary Tract and Metabolism Products"
546,DB00204,Q12809|O95069|Q14500,P08684,hsa:3757|hsa:3776|hsa:3768,9|10|11|12|14|15|18|19|20|33|34|178|182|185|189|283|284|285|286|293|299|305|332|333|340|341|344|345|346|351|352|355|356|365|366|368|370|371|374|376|377|381|382|384|390|391|393|405|414|416|430|434|437|441|446|449|457|459|464|470|476|490|498|502|516|520|524|540|541|542|545|546|548|549|552|556|564|565|566|570|573|574|578|582|584|589|592|594|595|599|600|603|604|606|607|608|613|614|615|618|619|620|626|632|633|634|637|640|641|643|651|655|656|659|660|664|665|666|668|677|678|679|680|682|683|688|689|696|708|709|710|716|721|779|784,Dofetilide,"Amides| Amines| Antiarrhythmic agents| Antiarrhythmics, Class III| Cardiac Therapy| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Substrates| Ethylamines| Highest Risk QTc-Prolonging Agents| Membrane Transport Modulators| Narrow Therapeutic Index Drugs| OCT2 Substrates| OCT2 Substrates with a Narrow Therapeutic Index| Potassium Channel Blockers| QTc Prolonging Agents| Sulfones| Sulfur Compounds"
547,DB05039,P07550,P08684|P22309,hsa:154,9|10|11|12|14|15|18|19|143|144|178|182|183|184|185|189|192|283|284|285|286|299|308|332|333|338|339|340|341|344|345|346|351|352|355|356|357|358|365|366|370|371|374|376|377|381|382|384|385|386|387|390|392|393|396|399|400|403|406|416|418|420|430|431|434|437|439|441|442|443|446|449|451|453|461|464|470|472|482|490|493|495|497|498|502|506|516|520|523|524|527|528|530|535|538|539|540|541|542|543|545|546|548|549|552|553|555|556|564|566|570|571|573|574|576|577|578|579|582|584|585|587|590|592|595|597|599|600|603|606|607|608|613|617|618|619|623|628|633|634|637|640|641|643|645|651|655|656|657|659|660|664|665|667|668|671|672|677|678|679|680|682|683|684|688|689|690|692|695|696|697|698|699|701|704|707|708|709|710|712|713|714|734|735|737|755|758|763|776|777|797|798|800|818|821|826|842|860,Indacaterol,"Adrenergic Agonists| Adrenergic beta-2 Receptor Agonists| Adrenergic beta-Agonists| Adrenergics, Inhalants| Agents producing tachycardia| Agents that produce hypertension| Agents to Treat Airway Disease| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Drugs for Obstructive Airway Diseases| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Indenes| Long-acting beta-adrenoceptor agonists| P-glycoprotein substrates| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| Potential QTc-Prolonging Agents| QTc Prolonging Agents| Quinolines| Respiratory System| Selective Beta 2-adrenergic Agonists| UGT1A1 Substrates"
548,DB09232,Q00975|BE0008715,BE0004866,hsa:774,9|10|11|12|14|15|18|19|20|178|182|183|184|185|189|192|283|284|285|286|299|301|332|333|335|340|344|346|351|352|355|356|366|370|371|374|376|377|380|384|390|392|393|395|401|405|416|420|423|430|434|437|440|441|443|446|449|452|454|455|464|470|490|502|514|516|520|524|535|545|546|549|552|553|556|558|564|567|570|573|578|579|582|584|592|594|595|599|600|603|607|608|614|618|619|633|634|637|640|643|656|660|662|664|665|666|668|671|673|677|678|679|680|683|684|688|689|690|692|693|694|696|697|698|700|704|708|709|710|712|737|800,Cilnidipine,"Agents causing hyperkalemia| Antiarrhythmic agents| Bradycardia-Causing Agents| Calcium Channel Blockers| Calcium-Regulating Hormones and Agents| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Dihydropyridine Derivatives| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hypotensive Agents| Membrane Transport Modulators| Pyridines| Selective Calcium Channel Blockers With Mainly Vascular Effects| Vasodilating Agents"
549,DB01280,P09884,P00813|P27707|Q16854,hsa:5422,9|10|11|14|15|16|18|19|20|143|146|148|149|150|178|183|184|283|284|285|286|299|308|332|339|340|341|344|345|346|351|352|355|357|358|359|365|366|373|374|375|376|377|378|379|381|384|386|387|388|389|390|391|393|396|397|403|405|406|416|418|431|437|438|441|442|447|449|450|453|461|464|472|476|482|484|485|487|491|495|497|498|499|504|506|519|521|523|530|538|540|541|543|545|547|548|549|555|560|565|566|567|569|571|572|573|582|585|589|592|593|594|596|601|604|611|612|613|614|615|617|621|626|628|636|637|638|639|652|654|656|657|659|662|663|666|674|680|681|682|683|690|691|702,Nelarabine,"Antimetabolites| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Immunosuppressive Agents| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| Nucleic Acid Synthesis Inhibitors| Nucleic Acids, Nucleotides, and Nucleosides| Nucleoside Metabolic Inhibitor| Nucleosides| Purine Analogues"
550,DB01240,Q9H244|P43119|Q16647,P11712,hsa:64805|hsa:5739|hsa:5740,9|10|11|12|18|19|20|143|144|146|150|283|284|286|308|332|333|335|339|341|344|346|352|366|374|380|405|406|416|420|434|440|441|443|446|452|476|490|498|516|524|535|556|571|573|579|582|599|614|617|619|637|639|640|641|660|667|678|679|680|681|684|688|689|690|696|698|700|701|708|709|710|712|840|845|860|861,Epoprostenol,"Anticoagulants| Antihypertensive Agents| Antiplatelet agents| Autacoids| Biological Factors| Blood and Blood Forming Organs| Cardiovascular Agents| Drugs that are Mainly Renally Excreted| Eicosanoids| Fatty Acids| Fatty Acids, Unsaturated| Hematologic Agents| Hypotensive Agents| Inflammation Mediators| Lipids| Platelet Aggregation Inhibitors Excl. Heparin| Prostacyclin Analogues| Prostacycline Vasodilator| Prostaglandins| Prostaglandins I| Vasodilating Agents| Vasodilation"
551,DB01029,P30556|P05412,P10632|P11712|P35503|P23219|P05177|P10635|P08684,hsa:185|hsa:3725,9|10|11|12|14|15|16|18|143|144|148|149|150|155|156|157|178|182|185|189|283|284|285|286|299|300|332|333|336|340|344|345|351|352|355|356|358|359|365|370|371|374|375|379|384|389|390|391|398|416|418|420|422|430|434|438|439|441|442|443|446|450|451|453|464|470|486|487|490|515|516|517|519|520|522|524|530|535|536|538|539|540|549|552|555|556|564|569|570|576|578|579|582|584|592|595|596|599|603|607|608|611|613|618|628|633|634|640|645|646|656|660|664|668|677|678|679|683|684|688|692|696|697|708|709|710|712|713|755|776|818,Irbesartan,"Agents Acting on the Renin-Angiotensin System| Agents causing hyperkalemia| Angiotensin 2 Receptor Blocker| Angiotensin II receptor antagonists| Angiotensin II receptor blockers (ARBs) and calcium channel blockers| Angiotensin II receptor blockers (ARBs) and diuretics| Angiotensin II receptor blockers (ARBs), plain| Angiotensin II Type 2 Receptor Blockers| Angiotensin Receptor Antagonists| Antihypertensive Agents| Antihypertensive Agents Indicated for Hypertension| Azoles| Benzene Derivatives| Biphenyl Compounds| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2C8 Inhibitors| Cytochrome P-450 CYP2C8 Inhibitors (moderate)| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hypotensive Agents| Polycyclic Compounds| Spiro Compounds| Tetrazoles| UGT1A3 substrates"
552,DB00370,P28223|P46098|P08913|P28335|P41145|P35367|P18825|P34969|BE0004863|P14416|P35462|P23975|P31645|Q01959|P41595|BE0004889|Q9Y5N1|P35348|P08588|P07550,P08684|P10635|P05177|P11712|P10632,hsa:3356|hsa:3359|hsa:150|hsa:3358|hsa:4986|hsa:3269|hsa:152|hsa:3363|hsa:1813|hsa:1814|hsa:6530|hsa:6532|hsa:6531|hsa:3357|hsa:11255|hsa:148|hsa:153|hsa:154,9|10|11|12|14|15|178|180|181|182|183|184|185|192|213|218|219|283|284|285|332|333|338|340|344|345|351|355|356|358|365|370|371|372|373|374|375|376|378|379|384|387|390|391|396|403|416|418|430|434|435|438|441|442|445|446|447|449|450|453|464|470|472|482|484|487|490|491|495|502|506|516|519|520|521|523|524|530|538|539|540|545|546|549|552|555|556|560|564|569|570|576|577|578|582|584|585|592|595|596|599|600|603|607|608|611|613|618|628|633|634|636|640|654|656|657|660|664|665|668|674|677|678|679|683|688|696|697|708|709|710|712|755|818,Mirtazapine,"Adrenergic Agents| Adrenergic alpha-2 Receptor Antagonists| Adrenergic alpha-Antagonists| Adrenergic Antagonists| Agents that produce hypertension| Anti-Anxiety Agents| Antidepressive Agents| Antidepressive Agents Indicated for Depression| Antidepressive Agents, Second-Generation| Antidepressive Agents, Tetracyclic| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (weak)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Heterocyclic Compounds, Fused-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Miscellaneous Antidepressants| Nervous System| Neurotransmitter Agents| Potential QTc-Prolonging Agents| Psychoanaleptics| Psychotropic Drugs| QTc Prolonging Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin 5-HT2C Receptor Antagonists| Serotonin 5-HT3 Receptor Antagonists| Serotonin Agents| Serotonin Modulators| Serotonin Receptor Antagonists| Tranquilizing Agents"
553,DB11638,P63261|P49419|P07355|P25705|O75964|P48047|P20810|P49368|P23528|O00299|P21291|Q16555|P15924|P68104|P06733|P21333|Q9C0B1|P11413|O14556|P06744|P22626|Q14103|P61978|Q5SSJ5|P04792|P46940|Q92945|P00338|P07195|P09382|P27816|P40925|P55786|P07737|P00558|P14618|P62937|Q06830|P27635|P50914|Q07020|P62750|P42766|P36578|P62277|P08708|P62269|P39019|P62857|P46782|P62753|P62241|P46781|Q15637|P23246|P62316|P37108|Q08170|P37802|P60174|P09493|Q71U36|P08670|Q15942|P11142|Q9BUF5|P04350|P07437|P04075|P04406|P99999|P18669|P35579|P07237|P17844|P34897|Q13838|P06748|Q8I3Z5|Q5R2K6|Q6LFH8|Q00080|P13568|Q8IKW5|P86287|Q8IKK7|P14223|C6KT34|Q8IC05|Q8IKF0|C6KTA4|Q27743|C0H4Y6|Q8IDH5|Q8II73|Q8I2Z8|Q8ILF7|Q8I0V4|P20035|Q8IJN7|Q8IKH8|A0A143ZZK9|P14642|P13817|Q7K6A4|Q8IKR1|Q8I431|Q8IDQ9|O97313|Q8IJT2|Q8IJC6|C0H571|T1RTG8|C0H5C2|Q8I6U8|Q08853|Q76NM6|Q8I3T9|Q8I0X2|Q8IM16|Q7KQM4|Q9N623|C0H4V6|Q8I5G6|C6S3C7|Q7KQL5|Q8IKM5|Q8IL86|Q8IJR6|Q8I492|C0H4L1|Q76NN7|Q8IB72|P13827|Q8IDD3|O77323|P46925|C0H546|Q8I4R5|Q8IBN5|Q8I487|Q8I3X4|P50250|Q8IJA9|Q8IJ60|Q8IEN3|Q8IDP8|Q8I4W4|O77361|C6KSR5|Q02155|Q8IBI3|Q8IJ74|Q8III5|Q8IHS5|Q8IDP1|Q8I5Y3|Q8IEM3|Q8IE82|Q8IDI5|Q8IM15|C0H5H0|Q8ILV2|Q8IM74|Q8I5H4|Q8ID50|Q8IL80|O96221|A0A144A2G5|P13830|Q9TY94|Q8IBS5|P38545|Q8IB78|C0H4X5|C0H551|Q8IJK8|Q8IIR9|Q8IIA4|Q7KQK0|Q8IDV0|Q8IKL4|Q8ILK3|Q8ILE8|Q8IKM6|Q8IL88|C6KT50|P02768,O60656|P16662|P05177|P10635|P33261,hsa:71|hsa:501|hsa:302|hsa:498|hsa:10632|hsa:539|hsa:831|hsa:7203|hsa:1072|hsa:1192|hsa:1465|hsa:1808|hsa:1832|hsa:1915|hsa:2023|hsa:2316|hsa:79068|hsa:2539|hsa:26330|hsa:2821|hsa:3181|hsa:3184|hsa:3190|hsa:50809|hsa:3315|hsa:8826|hsa:8570|hsa:3939|hsa:3945|hsa:3956|hsa:4134|hsa:4190|hsa:9520|hsa:5216|hsa:5230|hsa:5315|hsa:5478|hsa:5052|hsa:9045|hsa:6141|hsa:6147|hsa:11224|hsa:6124|hsa:6207|hsa:6218|hsa:6222|hsa:6223|hsa:6234|hsa:6193|hsa:6194|hsa:6202|hsa:6203|hsa:7536|hsa:6421|hsa:6633|hsa:6727|hsa:6429|hsa:8407|hsa:7167|hsa:7168|hsa:7846|hsa:7431|hsa:7791|hsa:3312|hsa:84617|hsa:10382|hsa:203068|hsa:226|hsa:2597|hsa:54205|hsa:5223|hsa:4627|hsa:5034|hsa:1655|hsa:6472|hsa:7919|hsa:4869|hsa:213,0|9|10|11|18|19|20|178|179|181|185|188|192|213|216|283|284|286|308|309|332|333|335|337|341|344|346|347|352|366|367|374|380|405|406|563|567|571|582|610|614|617|637|661|662|679|680|681|688|689|690|696|697|698|699|700|701|708|709|710|712|776|797|798|818|819,Artenimol,"Anti-Infective Agents| Antimalarials| Antiparasitic Agents| Antiparasitic Products, Insecticides and Repellents| Antiprotozoals| Artemisia| Artemisinin and derivatives| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (weak)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 Enzyme Inhibitors| Free Radicals| Hydrocarbons| Peroxides| Reactive Oxygen Species| Sesquiterpenes| Terpenes| UGT1A9 Substrates| UGT2B7 substrates"
554,DB04845,Q13509,P08684,hsa:10381,9|10|11|12|14|15|18|19|20|33|115|118|143|148|149|283|284|285|286|293|299|308|332|333|334|335|337|338|339|340|341|344|345|346|349|351|352|353|355|357|358|365|366|368|370|374|376|383|387|390|392|393|396|403|405|406|412|416|418|420|421|430|431|432|434|437|439|441|442|443|446|449|451|453|464|470|472|473|474|475|480|482|489|490|495|500|502|506|507|508|520|524|528|531|533|535|539|540|546|555|556|564|571|579|581|582|584|586|592|599|613|614|617|637|638|640|642|643|645|646|656|658|660|664|677|678|679|680|682|683|684|688|689|690|692|694|695|696|697|698|699|701|704|706|708|709|710|711,Ixabepilone,Anti-Bacterial Agents| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Substrates| Cytotoxic Antibiotics and Related Substances| Immunosuppressive Agents| Lactones| Macrolides| Microtubule Inhibition| Microtubule Inhibitors| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| P-glycoprotein inhibitors| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Polyketides| Tubulin Modulators
555,DB05239,Q02750,BE0004866|P08183,hsa:5604,9|10|11|12|14|15|18|19|23|24|46|129|131|132|178|180|181|182|185|189|192|283|284|285|286|287|298|299|308|332|333|337|338|340|341|344|345|350|351|352|355|356|364|365|370|371|376|377|384|390|391|392|393|406|416|420|430|434|437|439|441|443|446|449|451|464|470|490|493|495|502|516|520|524|528|535|540|545|546|549|552|553|556|564|566|570|577|578|579|580|582|584|585|592|593|595|597|599|600|603|607|608|613|617|618|623|624|628|633|634|637|640|643|645|646|656|657|659|660|664|665|668|671|672|673|677|678|679|680|683|684|688|689|692|697|704|708|709|710|758|821,Cobimetinib,"Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates (strength unknown)| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs causing inadvertant photosensitivity| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Kinase Inhibitor| MAP Kinase Kinase 1, antagonists & inhibitors| MAP Kinase, antagonists & inhibitors| Mitogen-activated protein kinase (MEK) inhibitors| Narrow Therapeutic Index Drugs| OATP1B1/SLCO1B1 Substrates| OATP1B3 inhibitors| OATP1B3 substrates| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Photosensitizing Agents| Protein Kinase Inhibitors| UGT2B7 substrates| UGT2B7 Substrates with a Narrow Therapeutic Index"
556,DB12161,Q05940,P16152|O75828|P10635|P05177|P20815|P08684,hsa:6571,0|9|10|11|12|14|18|19|178|180|181|182|183|184|185|192|283|284|285|286|332|333|335|338|340|341|344|345|351|352|355|356|365|366|370|371|374|381|382|384|390|391|405|416|420|430|432|434|441|443|446|464|470|476|490|498|520|524|535|540|541|542|544|548|549|552|556|564|565|567|570|573|574|578|579|580|582|584|589|592|594|595|599|603|604|606|607|608|613|618|619|626|628|630|633|634|637|640|641|651|655|656|660|662|664|666|668|677|678|679|680|682|683|684|688|689|691|692|696|697|698|699|702|703|704|708|709|710|712|714|735|755|761|777|798|818|824,Deutetrabenazine,"Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Highest Risk QTc-Prolonging Agents| Nervous System| QTc Prolonging Agents| Quinolizines| Tetrabenazine and isomer| Vesicular Monoamine Transporter 2 Inhibitor| Vesicular Monoamine Transporter 2 Inhibitors"
557,DB11691,P35372|P41143|P41145,BE0004866|P35503,hsa:4988|hsa:4985|hsa:4986,9|10|11|12|13|14|15|16|18|19|20|115|116|143|148|149|150|156|178|179|180|181|182|185|189|192|196|199|206|283|284|285|286|299|301|308|332|333|334|335|336|337|338|339|340|341|344|345|346|351|352|355|356|358|359|365|366|370|371|374|375|379|381|382|384|389|390|391|392|393|395|396|403|405|406|416|418|420|423|430|434|438|439|441|442|443|446|450|451|453|454|464|470|472|476|484|487|490|498|504|506|514|516|519|520|524|530|535|536|538|540|541|542|544|548|549|552|553|555|556|560|564|565|566|567|569|570|572|573|574|576|578|579|582|584|589|590|592|594|595|596|599|602|603|604|606|607|608|611|613|614|617|618|619|620|626|628|630|631|632|633|634|637|639|640|641|643|645|647|651|654|655|656|659|660|662|663|664|666|667|668|671|677|678|679|680|681|682|683|684|686|688|689|690|691|692|695|696|697|698|699|701|702|703|704|707|708|709|710|711|712|714|735|755|756|761|776|777|779|782|797|798|800|818|819|821|824|826,Naldemedine,"Alimentary Tract and Metabolism| Alkaloids| Drugs for Constipation| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds with 4 or More Rings| Heterocyclic Compounds, Bridged-Ring| Heterocyclic Compounds, Fused-Ring| Morphinans| Opiate Alkaloids| Opioid Antagonists| Peripheral Opioid Receptor Antagonists| Phenanthrenes| Polycyclic Compounds| Polycyclic Hydrocarbons, Aromatic| UGT1A3 substrates"
558,DB06725,P23219|P35354,P11712,hsa:5742|hsa:5743,9|10|11|14|15|18|19|20|33|34|37|143|149|178|183|184|185|190|191|283|284|285|286|293|294|299|305|308|332|340|341|342|344|345|351|352|353|355|358|362|365|370|371|372|373|374|375|376|378|379|383|384|387|390|392|393|396|403|406|412|414|416|418|420|421|434|435|437|438|439|441|442|443|445|446|447|449|450|451|453|457|459|464|465|470|471|472|480|482|483|484|487|490|491|495|498|500|501|502|503|506|507|513|516|519|520|521|523|524|530|531|532|536|538|539|540|545|546|548|549|550|552|553|555|556|560|564|569|570|573|574|576|577|578|582|584|585|586|591|592|595|596|598|599|600|602|603|607|608|611|613|617|618|619|628|633|634|636|637|640|641|643|645|647|654|655|656|657|658|660|664|665|667|668|671|674|677|678|680|683,Lornoxicam,"Agents causing hyperkalemia| Agents that produce hypertension| Analgesics| Analgesics, Non-Narcotic| Anti-Inflammatory Agents| Anti-Inflammatory Agents, Non-Steroidal| Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)| Antiinflammatory and Antirheumatic Products| Antiinflammatory and Antirheumatic Products, Non-Steroids| Antirheumatic Agents| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 Substrates| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Musculo-Skeletal System| Nephrotoxic agents| Non COX-2 selective NSAIDS| Oxicams| Peripheral Nervous System Agents| Sensory System Agents| Sulfur Compounds| Thiazines"
559,DB09235,Q9P0X4|Q13936,P08684,hsa:8911|hsa:775,9|10|11|12|13|14|15|18|19|20|30|178|181|182|183|184|185|189|192|196|199|206|283|284|285|286|292|299|301|314|332|333|334|335|340|344|345|346|351|352|355|356|365|366|370|371|374|376|377|380|384|390|391|392|393|395|401|405|407|411|416|420|423|425|430|434|437|440|441|443|446|449|452|454|455|456|464|470|490|495|502|514|516|520|524|535|540|545|546|549|552|553|556|558|564|566|570|573|578|579|582|584|585|592|594|595|599|600|603|607|608|613|614|615|618|619|628|633|634|637|639|640|643|656|657|659|660|664|665|666|668|671|673|677|678|679|680|683|684|688|689|692|696|697|698|704|708|709|710|712|737|800,Efonidipine,"Agents causing hyperkalemia| Antiarrhythmic agents| Antihypertensive Agents| Benzene Derivatives| Bradycardia-Causing Agents| Calcium Channel Blockers| Calcium-Regulating Hormones and Agents| Cardiovascular Agents| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Diuretics| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Hypotensive Agents| Membrane Transport Modulators| Natriuretic Agents| Nitro Compounds| Phenols| Potential QTc-Prolonging Agents| Pyridines| QTc Prolonging Agents| Vasodilating Agents"
560,DB00604,Q13639|P46098|P28223|Q12809,P24462|P08684|P20815|P05177|P11509|P20813|P33261|P10632|P11712|P10635,hsa:3360|hsa:3359|hsa:3356|hsa:3757,9|10|11|12|14|15|18|19|20|23|37|178|180|181|182|185|189|192|283|284|285|286|287|294|299|332|333|338|339|340|341|342|344|345|346|351|352|355|356|362|364|365|366|370|371|374|376|377|381|382|384|390|391|392|393|405|416|420|430|434|437|439|441|443|446|449|451|464|470|476|490|493|498|501|502|503|516|520|524|528|535|540|541|542|545|546|548|549|550|552|553|556|564|565|566|570|573|574|578|579|581|582|584|589|591|592|593|594|595|597|598|599|600|603|604|606|607|608|613|614|615|618|619|620|623|625|626|628|632|633|634|637|638|640|641|642|643|645|646|651|652|655|656|659|660|664|665|666|668|671|672|677|678|679|680|682|683|684|688|689|691|692|695|698|703|704|707|708|709|710|716|722|738|742|756|771|779|785|801|805|819|834,Cisapride,"Acids, Carbocyclic| Alimentary Tract and Metabolism| Amides| Aminobenzoates| Anti-Ulcer Agents| Antidepressive Agents| Benzamides and benzamide derivatives| Benzene Derivatives| Benzoates| Carboxylic Acids| Central Nervous System Depressants| Chlorobenzoates| Cytochrome P-450 CYP2A6 Substrates| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (moderate)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (strong)| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates (strength unknown)| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A7 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs for Functional Gastrointestinal Disorders| Gastrointestinal Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Highest Risk QTc-Prolonging Agents| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| Neurotransmitter Agents| para-Aminobenzoates| Piperidines| Propulsives| QTc Prolonging Agents| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin Agents| Serotonin Receptor Agonists"
561,DB00851,Q14181|P52209,P04798|P05177|P05181,hsa:23649|hsa:5226,9|10|14|15|16|18|143|148|149|283|284|285|286|299|300|332|340|351|352|355|357|358|365|373|374|375|376|378|379|387|389|390|392|393|396|399|400|403|416|418|420|422|431|437|438|439|441|442|443|447|449|450|451|453|464|472|482|484|485|487|488|491|493|494|495|499|504|506|519|521|523|527|528|535|536|538|540|545|547|549|553|560|569|572|580|585|593|596|602|611|613|624|636|654|657|673|674,Dacarbazine,"ABVD chemotherapy regimen| Alkylating Activity| Alkylating Drugs| Antineoplastic Agents| Antineoplastic Agents, Alkylating| Antineoplastic and Immunomodulating Agents| Azoles| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP2E1 Substrates| Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Imidazoles| Immunosuppressive Agents| Myelosuppressive Agents| Narrow Therapeutic Index Drugs| Noxae| Toxic Actions| Triazenes"
562,DB01067,Q09428|P37231,P11712|P08684,hsa:6833|hsa:5468,9|10|11|12|14|15|16|18|19|20|33|178|179|182|183|184|185|192|283|284|285|286|293|299|305|332|333|338|340|344|345|351|352|353|355|356|357|358|365|370|371|372|373|374|375|376|383|384|387|390|392|393|396|403|414|416|418|420|430|431|434|435|437|439|441|442|443|445|446|447|449|451|453|457|459|464|465|470|472|482|483|485|490|491|493|494|495|499|502|506|516|520|521|523|524|528|531|532|535|536|538|539|540|545|546|547|549|552|553|556|560|564|569|570|577|578|580|582|584|585|592|593|595|599|602|603|607|608|611|613|618|624|628|634|640|643|645|646|654|656|657|660|664|668|672|673|677|678|679|683|688|696|708|709|710|715|778,Glipizide,Alimentary Tract and Metabolism| Blood Glucose Lowering Agents| BSEP/ABCB11 Substrates| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Drugs Used in Diabetes| Hypoglycemia-Associated Agents| Insulin Secretagogues| Oral Hypoglycemics| Sulfones| Sulfonylureas| Sulfur Compounds| UGT1A1 Substrates
563,DB09338,P05186|P29972|P53985,P19827|P35558,hsa:249|hsa:358|hsa:6566,9|10|11|14|18|19|20|95|178|182|283|284|285|286|299|308|332|333|339|341|344|345|346|351|352|355|356|365|366|370|371|374|380|381|382|384|390|392|393|405|406|416|420|430|434|439|440|441|443|446|451|452|462|464|470|476|490|493|498|516|520|524|528|535|537|540|541|542|548|549|552|553|556|564|565|566|567|570|573|574|578|579|581|582|584|589|592|594|595|597|599|603|604|605|606|607|608|613|614|615|618|619|620|623|625|626|628|632|633|634|637|638|640|641|642|643|645|646|651|655|656|659|660|662|663|664|666|668|671|672|677|678|679|680|683|684|688|689|692|698|704|708|709|710|756|819,Mersalyl,"Alkylmercury Compounds| Cardiovascular System| Diuretics| Drugs that are Mainly Renally Excreted| Enzyme Inhibitors| Low-Ceiling Diuretics, Excl. Thiazides| Mercurial Diuretics| Organomercury Compounds| Organometallic Compounds"
564,DB06148,P08913|P28223|P28335|P35367|P23975|P31645|Q9H3N8|P08908|P18825|P41595|P30939|P18089|P35462|P41145|Q01959|P34969|P14416|P50406|BE0004863|BE0004889,P10635|P08684|P05177|P20813,hsa:150|hsa:3356|hsa:3358|hsa:3269|hsa:6530|hsa:6532|hsa:59340|hsa:3350|hsa:152|hsa:3357|hsa:3355|hsa:151|hsa:1814|hsa:4986|hsa:6531|hsa:3363|hsa:1813|hsa:3362,9|10|11|12|14|15|178|180|181|182|185|189|192|213|215|216|283|284|285|332|333|338|340|344|345|351|355|356|365|370|371|374|376|377|384|390|391|416|430|434|437|441|446|449|464|470|490|495|502|516|520|524|540|545|546|549|552|556|564|569|570|578|582|584|585|592|595|599|600|603|607|608|611|613|618|628|633|634|640|656|657|660|664|665|668|677|678|679|683|688|696|697|708|709|710|712|755|758|818|821,Mianserin,"Adrenergic Agents| Agents that produce hypertension| Antidepressive Agents| Antidepressive Agents, Second-Generation| Antidepressive Agents, Tetracyclic| Central Nervous System Agents| Central Nervous System Depressants| Combined Inhibitors of Serotonin/Norepinephrine Reuptake| Cytochrome P-450 CYP1A2 Substrates| Cytochrome P-450 CYP2B6 Substrates| Cytochrome P-450 CYP2D6 Substrates| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Substrates| Dibenzazepines| Dopamine Antagonists| Dopamine D2 Receptor Antagonists| Heterocyclic Compounds| Heterocyclic Compounds, 3-Ring| Heterocyclic Compounds, Fused-Ring| Histamine Agents| Histamine Antagonists| Histamine H1 Antagonists| Nervous System| Neurotransmitter Agents| Psychoanaleptics| Psychotropic Drugs| Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome| Serotonin 5-HT2 Receptor Antagonists| Serotonin 5-HT2A Receptor Antagonists| Serotonin 5-HT2C Receptor Antagonists| Serotonin Agents| Serotonin Modulators| Serotonin Receptor Antagonists"
565,DB02300,P11473,P05164|Q07973,hsa:7421,9|10|11|12|18|19|115|116|143|144|178|179|185|186|283|284|286|308|332|333|334|335|339|341|344|346|352|366|374|406|416|430|434|441|446|490|516|524|556|564|571|573|582|599|617|619|637|639|640|641|660|664|667|678|679|680|688|689|690|696|697|701|708|709|710|711|712|803|818|839|860,Calcipotriol,Antipsoriatics| Antipsoriatics for Topical Use| Cholestanes| Cholestenes| Dermatologicals| Fused-Ring Compounds| Lipids| Membrane Lipids| Misc. Skin and Mucous Membrane Agents| Polycyclic Compounds| Secosteroids| Steroids| Sterols| Vitamin D and Analogues| Vitamins| Vitamins (Fat Soluble)
566,DB08804,P10275,P11511|P27338|P21397,hsa:367,9|10|11|12|18|19|143|144|178|179|182|185|186|192|283|284|286|332|333|334|335|339|341|344|346|352|366|374|380|405|416|420|430|432|434|440|441|443|446|452|490|524|535|553|556|579|582|599|614|637|640|660|671|678|679|680|684|688|689|692|696|697|698|699|704|708|709|710|711|712|776|797|818|840|860|861,Nandrolonedecanoate,"Anabolic Agents| Androgens| Bone Density Conservation Agents| Estranes| Estrenes| Fused-Ring Compounds| Gonadal Hormones| Gonadal Steroid Hormones| Hormones| Hormones, Hormone Substitutes, and Hormone Antagonists| Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates| Nandrolone and esters| Polycyclic Compounds| Steroids| Testosterone Congeners| Thyroxine-binding globulin inhibitors| UGT1A1 Substrates| UGT1A3 substrates| UGT1A4 substrates| UGT2B7 substrates"
567,DB01587,P30536|P14867|P18505|Q8N1C3|O14764|P78334,P08684,hsa:706|hsa:2554|hsa:2560|hsa:2565|hsa:2563|hsa:2564,9|10|11|12|14|15|18|19|37|178|182|183|184|185|189|192|213|218|219|283|284|285|286|294|332|333|340|341|342|344|345|351|352|355|356|362|365|370|371|374|376|377|384|390|391|405|416|420|430|434|437|439|441|443|446|449|451|464|470|476|490|495|498|501|502|503|516|520|524|536|540|545|546|548|549|550|552|553|556|564|569|570|573|574|578|582|584|585|591|592|593|594|595|598|599|600|602|603|604|607|608|611|612|613|614|618|619|628|633|634|637|638|640|641|645|646|655|656|657|660|664|665|666|668|671|677|678|679|680|683|688|689|696|697|698|708|709|710|729|738|758|792|801|821,Ketazolam,"Anti-Anxiety Agents| Benzazepines| Benzodiazepines and benzodiazepine derivatives| Central Nervous System Agents| Central Nervous System Depressants| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs that are Mainly Renally Excreted| Heterocyclic Compounds| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Nervous System| P-glycoprotein substrates| Psycholeptics| Psychotropic Drugs| Tranquilizing Agents"
568,DB00448,P20648|P10636,P33261|P11712|P08684|P04798|P05177|Q16678|P33260|P10632|P10635|Q02928,hsa:495|hsa:4137,9|10|11|12|14|15|18|19|23|24|33|143|148|149|178|182|183|184|185|283|284|285|286|287|293|299|332|333|340|341|344|345|346|349|351|352|353|355|356|357|358|363|365|366|368|370|371|372|373|374|375|376|377|379|381|382|384|386|387|389|390|392|393|396|399|400|403|405|412|414|416|418|430|431|434|435|437|441|442|445|446|447|449|450|453|457|464|465|468|470|472|473|475|476|478|482|484|485|487|488|489|490|491|495|498|499|502|504|506|507|516|519|520|521|523|524|527|530|538|539|540|541|542|545|546|547|548|549|552|555|556|560|564|565|569|570|572|573|574|576|577|578|582|584|585|586|589|592|594|595|596|599|600|603|604|606|607|608|611|613|614|618|619|620|626|628|632|633|634|636|637|638|640|643|651|652|654|656|657|660|664|665|666|668|674|677|678|679|683|708|709|710|770|833,Lansoprazole,"Acid Reducers| Alimentary Tract and Metabolism| Anti-Ulcer Agents| BCRP/ABCG2 Inhibitors| Benzimidazoles| Cytochrome P-450 CYP2C18 Substrates| Cytochrome P-450 CYP2C19 Inhibitors| Cytochrome P-450 CYP2C19 Inhibitors (strong)| Cytochrome P-450 CYP2C19 Substrates| Cytochrome P-450 CYP2C8 Substrates| Cytochrome P-450 CYP2C9 Inducers| Cytochrome P-450 CYP2C9 Inducers (strength unknown)| Cytochrome P-450 CYP2C9 Inhibitors| Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP2D6 Inhibitors| Cytochrome P-450 CYP2D6 Inhibitors (weak)| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (strength unknown)| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Drugs for Acid Related Disorders| Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)| Gastric Acid Lowering Agents| Gastrointestinal Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Heterocyclic Compounds, 2-Ring| Heterocyclic Compounds, Fused-Ring| Inhibition Gastric Acid Secretion| OAT3/SLC22A8 Inhibitors| P-glycoprotein inhibitors| P-glycoprotein substrates| Proton Pump Inhibitors| Proton-pump Inhibitors| Pyridines| Sulfoxides| Sulfur Compounds"
569,DB00559,P25101|P24530,P08684|P11712,hsa:1909|hsa:1910,9|10|11|12|14|15|16|18|19|20|33|178|182|183|184|185|189|190|191|192|199|283|284|285|286|293|299|305|308|332|333|334|341|344|345|346|351|352|353|355|356|358|359|365|366|370|371|372|373|374|375|376|378|379|381|382|383|384|387|389|390|393|396|403|405|406|414|416|418|430|434|435|438|441|442|445|446|447|449|450|453|457|459|461|464|465|470|472|476|482|483|484|487|490|491|495|497|498|502|504|506|516|519|520|521|523|524|530|531|532|538|539|540|541|542|543|544|545|546|548|549|552|555|556|560|564|565|566|567|569|570|571|572|573|574|576|578|582|584|585|589|593|594|595|596|599|601|603|604|606|608|611|612|613|614|615|618|619|620|621|626|628|630|632|634|636|637|638|640|641|651|652|654|655|656|657|659|660|662|663|664|666|668|674|677|678|679|680|688|689|696|697|708|709|710|711|712|715|761|778|824,Bosentan,"Amides| Antihypertensive Agents| Antihypertensives for Pulmonary Arterial Hypertension| Benzene Derivatives| Benzenesulfonamides| BSEP/ABCB11 Inhibitors| Cardiovascular Agents| Cardiovascular System| Cytochrome P-450 CYP2C9 Inducers| Cytochrome P-450 CYP2C9 Inducers (moderate)| Cytochrome P-450 CYP2C9 Substrates| Cytochrome P-450 CYP3A Inducers| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inducers| Cytochrome P-450 CYP3A4 Inducers (moderate)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 Enzyme Inducers| Cytochrome P-450 Substrates| Endothelin Receptor Antagonists| Genito Urinary System and Sex Hormones| Gynecological Antiinfectives and Antiseptics| Hepatotoxic Agents| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Hydrocarbons| Hydrocarbons, Aromatic| Hydrocarbons, Cyclic| OATP1B1/SLCO1B1 Substrates| Pyrimidines| Sulfonamides| Sulfones| Sulfur Compounds| Vasodilating Agents"
570,DB04953,O43526|O43525|P56696|Q9NR82,P22309|P35503|P22310|O60656|P11509|P11245,hsa:3785|hsa:3786|hsa:9132|hsa:56479,9|10|11|12|14|15|18|19|23|178|182|185|189|283|284|285|286|287|299|332|333|340|344|345|346|351|352|355|356|364|365|366|370|371|374|376|377|380|384|390|392|393|405|416|420|430|434|437|441|446|449|451|452|464|470|490|495|502|516|520|524|528|540|545|546|547|549|552|556|559|564|569|570|578|582|584|585|592|593|595|599|600|601|603|607|608|611|612|613|618|628|633|634|640|643|645|656|657|660|664|665|668|677|678|679|683|688|708|709|710|728|749|770|791|812|833,Ezogabine,"Acids, Acyclic| Amines| Aniline Compounds| Anticonvulsants| Carboxylic Acids| Central Nervous System Agents| Central Nervous System Depressants| Diamines| Drugs that are Mainly Renally Excreted| Membrane Transport Modulators| Nervous System| Polyamines| Potassium Channel Opener| Potential QTc-Prolonging Agents| QTc Prolonging Agents| UGT1A1 Substrates| UGT1A3 substrates| UGT1A4 substrates| UGT1A9 Substrates"
571,DB08865,Q9UM73|P08581,P08684|P20815|P20813,hsa:238|hsa:4233,9|10|11|12|14|15|16|18|23|37|38|143|148|149|178|180|181|182|183|184|185|192|283|284|285|286|287|294|299|300|332|333|338|339|340|341|342|344|345|346|351|352|355|356|358|362|364|365|366|370|371|372|373|374|375|376|378|379|381|382|384|387|390|392|393|396|403|405|416|418|422|430|434|435|438|441|442|445|446|447|449|450|453|461|464|467|470|472|476|477|482|484|487|490|491|495|496|497|498|501|503|506|515|516|520|521|523|524|528|530|538|540|541|542|543|545|548|549|550|552|555|556|560|564|565|566|570|573|574|576|577|578|582|584|585|589|591|592|593|594|595|598|599|600|601|603|604|606|607|608|613|614|615|616|618|619|620|621|626|628|632|633|634|637|640|641|643|644|651|654|655|656|657|659|660|664|665|666|668|674|677|678|679|680|682|683|688|689|691|696|698|702|708|709|710|712|752|759|815|822,Crizotinib,"Aminopyridines| Anaplastic lymphoma kinase (ALK) inhibitors| Antineoplastic Agents| Antineoplastic and Immunomodulating Agents| Bradycardia-Causing Agents| Cytochrome P-450 CYP2B6 Inhibitors| Cytochrome P-450 CYP2B6 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A Inhibitors| Cytochrome P-450 CYP3A Substrates| Cytochrome P-450 CYP3A4 Inhibitors| Cytochrome P-450 CYP3A4 Inhibitors (moderate)| Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A4 Substrates| Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 CYP3A5 Inhibitors| Cytochrome P-450 CYP3A5 Inhibitors (strength unknown)| Cytochrome P-450 CYP3A5 Substrates| Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index| Cytochrome P-450 Enzyme Inhibitors| Cytochrome P-450 Substrates| Enzyme Inhibitors| Heterocyclic Compounds| Heterocyclic Compounds, 1-Ring| Kinase Inhibitor| Moderate Risk QTc-Prolonging Agents| Narrow Therapeutic Index Drugs| OCT2 Inhibitors| Organic Cation Transporter 1 Inhibitors| P-glycoprotein inhibitors| P-glycoprotein substrates| P-glycoprotein substrates with a Narrow Therapeutic Index| Piperidines| Protein Kinase Inhibitors| Pyridines| QTc Prolonging Agents| Receptor Tyrosine Kinase Inhibitors| ROS1 tyrosine kinase inhibitors| Tyrosine Kinase Inhibitors"
